---
document_datetime: 2023-09-21 20:55:56
document_pages: 141
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/raylumis-epar-refusal-public-assessment-report_en.pdf
document_name: raylumis-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 132.6951314
conversion_datetime: 2025-12-24 21:33:28.473977
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 September 2021 EMA/CHMP/556162/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Raylumis

International non-proprietary name: tanezumab

Procedure No. EMEA/H/C/005189/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                              |                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 6                                                                                                    |
| 1.2. Steps taken for the assessment of the product .......................................................              | 9                                                                                                    |
| 2. Scientific discussion ..............................................................................10               |                                                                                                      |
| 2.1. Problem statement...........................................................................................       | 10                                                                                                   |
| 2.1.1. Disease or condition.......................................................................................      | 10                                                                                                   |
| 2.1.2. Epidemiology                                                                                                     | ................................................................................................ 11  |
| 2.1.3. Clinical presentation, diagnosis........................................................................         | 11                                                                                                   |
| 2.1.4. Management.................................................................................................      | 12                                                                                                   |
| 2.2. Quality aspects ................................................................................................   | 14                                                                                                   |
| 2.2.1. Introduction                                                                                                     | ................................................................................................. 14 |
| 2.2.2. Active Substance...........................................................................................      | 14                                                                                                   |
| 2.2.3. Finished Medicinal Product ..............................................................................        | 20                                                                                                   |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 24                                                                                                   |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 24                                                                             |
| 2.2.6. Recommendation(s) for future quality development............................................                     | 24                                                                                                   |
| 2.3. Non-clinical aspects..........................................................................................     | 24                                                                                                   |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 24 |
| 2.3.2. Pharmacology...............................................................................................      | 25                                                                                                   |
| 2.3.3. Pharmacokinetics ..........................................................................................      | 27                                                                                                   |
| 2.3.4. Toxicology....................................................................................................   | 29                                                                                                   |
| 2.3.5. Ecotoxicity/environmental risk assessment........................................................                | 36                                                                                                   |
| 2.3.6. Discussion on non-clinical aspects....................................................................           | 36                                                                                                   |
| 2.3.7. Conclusion on the non-clinical aspects..............................................................             | 38                                                                                                   |
| 2.4. Clinical aspects                                                                                                   | ................................................................................................ 38  |
| 2.4.1. Introduction .................................................................................................   | 38                                                                                                   |
| 2.4.2. Pharmacokinetics ..........................................................................................      | 39                                                                                                   |
| 2.4.3. Pharmacodynamics........................................................................................         | 43                                                                                                   |
| 2.4.4. Discussion on clinical pharmacology .................................................................            | 46                                                                                                   |
| 2.4.5. Conclusions on clinical pharmacology                                                                             | ............................................................... 47                                   |
| 2.4.6. Clinical efficacy                                                                                                | ............................................................................................. 47     |
| 2.4.7. Dose response studies....................................................................................        | 49                                                                                                   |
| 2.4.8. Main studies .................................................................................................   | 50                                                                                                   |
| 2.4.9. Discussion on clinical efficacy ..........................................................................       | 92                                                                                                   |
| 2.4.10. Conclusions on the clinical efficacy .................................................................          | 97                                                                                                   |
| 2.5. Clinical safety .................................................................................................. | 97                                                                                                   |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................122                       |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................126                         |
| 2.6. Risk Management                                                                                                    | Plan.....................................................................................127         |
| 2.7. Pharmacovigilance...........................................................................................127    |                                                                                                      |
| 2.8. Product information.........................................................................................127    |                                                                                                      |
| 2.8.1. User consultation..........................................................................................127   |                                                                                                      |

<div style=\"page-break-after: always\"></div>

3. Benefit-Risk Balance............................................................................  128

3.1. Therapeutic Context ........................................................................................  128

3.1.1. Available therapies and unmet medical need ....................................................  128

3.1.2. Main clinical studies  ......................................................................................  128

3.2. Favourable effects  ...........................................................................................  130

3.3. Uncertainties and limitations about favourable effects ..........................................  131

3.4. Unfavourable effects  ........................................................................................  131

3.5. Uncertainties and limitations about unfavourable effects .......................................  133

3.6. Effects Table ..................................................................................................  134

3.7. Benefit-risk assessment and discussion ..............................................................  136

3.7.1. Importance of favourable and unfavourable effects ...........................................  136

3.7.2. Balance of benefits and risks  ..........................................................................  138

3.7.3. Additional considerations on the benefit-risk balance .........................................  139

3.8. Conclusions  ....................................................................................................  141

4. Recommendations ...............................................................................  141

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Term

ADA

anti-drug antibodies

ADR

adverse drug reaction

AE

adverse event

ANCOVA

analysis of covariance model

APAP

acetaminophen/paracetamol

APS

abnormal peripheral sensation

BID

bis in diem (twice a day)

BMI

body mass index

BOCF

baseline observation carried forward

BR

benefit-risk

BUN

blood urea nitrogen

BWS

best-worst scaling

Cavg

average plasma concentration

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CLBP

chronic low back pain

Cmax

maximum plasma concentration

Cmax, ss

maximum plasma concentration at steady-state

COX-2

cyclooxygenase-2 inhibitors

CR

controlled release

CSF

cerebrospinal fluid

CSR

clinical study report

DB

double-blind

DCE

discrete-choice experiment

Diff

difference

DILI

drug-induced liver injury

ECG

electrocardiogram

eGFR

estimated glomerular filtration rate

EQ-5D-5L

Euro Quality of Life - 5 Dimension, 5 Level

EU

European Union

Ex

extension study

FDA

Food and Drug Administration

IgG2

immunoglobulin G Type 2

IPR

inadequate pain relief

ITT

intent-to-treat

IAC

intra-articular corticosteroids

IENF

intra epidermal nerve fiber

IV

intravenous

JSW

Joint Space Width

KL

Kellgren-Lawrence

LOCF

last observation carried forward

LS

least squares

MACE

major adverse cardiac events

MCDA

multi-criteria decision analysis

MedDRA

Medical Dictionary for Regulatory Activities

mg

milligram

MI

myocardial infarction

MRI

magnetic resonance imaging

N

number of patients (denominator)

NA

not applicable

NGF

nerve growth factor

NSAIDs

nonsteroidal anti-inflammatory drugs

OA

osteoarthritis

OARSI

Osteoarthritis Research Society International

OIC

opioid induced constipation

ON

osteonecrosis

PBO

placebo

PD

pharmacodynamic(s)

PGA-OA

Patient Global Assessment of Osteoarthritis

PK

pharmacokinetics

## Abbreviation Term

PT

preferred term

q8wks

every 8 weeks

qBR

quantitative BR

QST

quantitative sensory testing

QTc

In electrocardiography, the time corresponding to the beginning of depolarisation to repolarisation of the ventricles, corrected for heart rate

QTcB

QT corrected for heart rate using Bazett's formula

QTcF

QT corrected for heart rate using Fridericia's formula

RMP

risk management plan

RPOA

rapidly progressive osteoarthritis

RPOA1

rapidly progressive osteoarthritis type 1

RPOA2

rapidly progressive osteoarthritis type 2

SAE

serious adverse event

SC

subcutaneous

SE

standard error

SIF

subchondral insufficiency fracture

SMAA

stochastic multi-criteria acceptability analysis

SMQ

Standardised MedDRA Queries

SOC

System Organ Class

SR

slow release

TE

treatment-emergent

TJR

total joint replacement

TKR

total knee replacement

trkA

tropomyosin receptor kinase A

UK

United Kingdom

US

United States

WOMAC

Western Ontario and McMaster Universities Osteoarthritis Index

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pfizer Europe MA EEIG submitted on 5 March 2020 an application for marketing authorisation to the European Medicines Agency (EMA) for Raylumis, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 18 October 2018.

The applicant initially applied for the following indication:

Raylumis is indicated for treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate.

Over the course of the assessment, the applicant proposed revised versions of the indication, the assessment of which is discussed in the Clinical efficacy and Clinical safety sections of the assessment report.

In the last step round of the procedure, the applicant proposed the following updated indication:

Raylumis is indicated for treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0070/2018 on the agreement of a paediatric investigation plan (PIP), the granting of a (productspecific) waiver and on the granting of a class waiver.

At the time of submission of the application, the PIP EMEA-001635-PIP03-17 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## New active Substance status

The applicant requested the active substance tanezumab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## Scientific advice

The applicant received the following Scientific advice on the development relevant for the indication subject to the present application:

| Date             | Reference                              | SAWP co-ordinators                 |
|------------------|----------------------------------------|------------------------------------|
| 26 June 2008     | EMEA/H/SA/1111/1/2008/II               | Beatriz Silva Lima, Markku Pasanen |
| 19 November 2008 | EMEA/H/SA/1111/1/2008/II clarification | Beatriz Silva Lima, Markku Pasanen |
| 20 November 2008 | EMEA/H/SA/1111/2/2008/II               | Cristina Sampaia, Minne Casteels   |
| 21 January 2009  | EMEA/H/SA/1111/2/2008/II clarification | Cristina Sampaia, Minne Casteels   |
| 25 June 2009     | EMEA/H/SA/1111/3/2009/II               | Ferran Torres. Cristina Sampaio    |
| 7 October 2009   | EMEA/H/SA/1111/3/2009/II clarification | Ferran Torres. Cristina Sampaio    |
| 21 March 2013    | EMEA/H/SA/1111/3/FU/1/2012/II          | Luca Pani, Mario Miguel Rosa       |

The Scientific advice pertained to the following aspects:

The applicant received Scientific Advice on the development from the CHMP on 26 June 2008 ( Procedure No.: EMEA/H/SA/1111/1/2008/II ). The Scientific Advice pertained to the following quality and non clinical aspects:

- The   agreement with Comparability/qualification studies for pivotal clinical trials and ICH.
- The agreement with Pfizer's approach to Quality by Design (QbD) for PF-04383119.
- The Agreement on the extent of non-clinical information required for  the  registration  of  PF04383119.

The applicant received Scientific Advice from the CHMP on 20 November 2008 ( Procedure No.: Procedure No.: EMEA/H/SA/1111/2/2008/II ). The Scientific Advice pertained to the following clinical aspects:

- the adequacy of the proposed overall clinical pharmacology package to support a MAA 'for the treatment of moderate to severe pain in osteoarthritis of the knee and hip in patients for whom NSAIDs provide inadequate pain relief'
- The   agreement with the proposed fixed dose regimen (given intravenously every 8 weeks) and with the use of 2.5 mg, 5 mg and 10 mg as doses for the Phase 3 programme.
- The agreement on the use of the WOMAC Pain Subscale, the WOMAC Physical Function Subscale and the Patient Global Assessment of Osteoarthritis as the three co-primaries for Phase 3.

<div style=\"page-break-after: always\"></div>

- The agreement with the proposed statistical analysis plan for the primary and secondary endpoints and the justification of sample size for the pivotal efficacy studies
- The  agreement  that  tanezumab  exposure  data  from  the  proposed  Phase  3  osteoarthritis programme  would  fulfill  ICH  long-term  safety  requirements  and  is  adequate  to  support  the indication
- Agreement  on Risk Management Strategy : a) agreement with the proposed risk management strategy for the Phase 3 clinical programme; b) agreement that the conduct of the nonhuman primate embryofoetal development (EFD) study can occur in parallel with Phase 3 programme and  that  women  of  child  bearing  potential  (WOCP)  may  be  included  in  the  Phase  3  studies provided they are using double contraceptive methods
- Agreement on Moderate to Severe Chronic Pain : a) that with demonstrated efficacy and safety in  the  studies outlined in this package, osteoarthritis would provide data for one pain model supporting a subsequent indication 'for the treatment of moderate to severe chronic pain' for tanezumab; b) that together with the osteoarthritis programme described above, a single pivotal study  in  an  appropriate  visceral  pain  model  (such  as  interstitial  cystitis,  prostatitis,  or endometriosis) and an additional single short term study in a severe pain model (such as a four week cancer pain study) would be sufficient to grant a subsequent indication 'for the treatment of moderate to severe chronic pain' for tanezumab?

The applicant received Scientific Advice from the CHMP  on  25  June  2009  (Procedure No.: EMEA/H/SA/1111/3/2009/II). The Scientific Advice pertained to the following clinical aspects:

- the proposed overall clinical pharmacology plan adequate to support a MAA 'for the treatment of chronic low back pain
- The agreement that that the proposed 16-week efficacy studies, A4091012 and A4091038, are adequate to support the efficacy review of a MAA for the indication 'treatment of chronic low back pain' provided the primary objective of both studies is met
- The agreement with the proposed tanezumab doses of 5 mg, 10 mg and 20 mg (administered IV every 8 weeks) for the chronic low back pain Phase 3 programme
- The acceptance of the escalating dose regimen adequate for the proposed Phase III studies, avoiding the usual dose-range finding study in parallel groups.
- The agreement with the use of Low Back Pain Intensity (11-point NRS) as the primary endpoint and Roland Morris Disability Questionnaire and Patient Global Assessment of Low Back Pain as key secondary efficacy endpoints in the two 16-week efficacy studies of patients with chronic low back pain (Studies A4091012 and A4091038
- The agreement with the proposed statistical analysis plan for the primary and secondary endpoints and the justification of sample size for the pivotal efficacy studies.
- The agreement that the tanezumab exposure data from the proposed chronic low back pain development programme (Studies A4091012, A4091039, A4091038 and A4091037) along with the exposure expected in the Phase 3 osteoarthritis programme are sufficient to support the indication as follows: 'Tanezumab is indicated for the treatment of chronic low back pain.
- Agreement with the proposed risk management strategy for the chronic low back pain clinical development programme.

<div style=\"page-break-after: always\"></div>

The applicant received Scientific Advice from the CHMP on 21 March 2013 ( Procedure No.: Procedure No.: EMEA/H/SA/1111/3/FU/1/2012/II). The Scientific Advice pertained to the following clinical aspects:

- The proposed risk minimisation, identification, management, and characterisation measures are supported by available data and carefully designed. Use of isolated low dose aspirin as a platelet aggregation inhibitor is also acceptable.
- The  risk  for  neurological  toxicity  on  the  long  term  remains  partly  unknown  and  therefore, particular care should be put on peripheral neurologic examination on long term follow up and end of studies.
- The label should reflect in detail how the population that is intended to benefit from the new product was selected during the efficacy trials.
- The proposed indication of moderate to severe chronic nociceptive pain is preferred over the single diagnosis indications.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Johann Lodewijk Hillege Co-Rapporteur:  Ewa Balkowiec Iskra

The appointed co-rapporteur had no such prominent role in Scientific advice relevant for the indication subject to the present application.

| The application was received by the EMA on                                                                              | 5 March 2020     |
|-------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                | 26 March 2020    |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                          | 15 June 2020     |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                       | 15 June 2020     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                     | 25 June 2020     |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                 | 23 July 2020     |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                     | 23 November 2020 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on | 04 January 2021  |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                | 14 January 2021  |
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                          | 28 January 2021  |
| The applicant submitted the responses to the CHMP List of Outstanding                                                   | 15 April 2021    |

<div style=\"page-break-after: always\"></div>

| Issues on                                                                                                                                                                                |                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                         | 05 May 2021       |
| The Rapporteurs circulated the updated Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                 | 14 May 2021       |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                  | 18 May 2021       |
| The CHMP agreed on a second list of outstanding issues to be sent to the applicant on                                                                                                    | 20 May 2021       |
| The applicant submitted the responses to the second CHMP List of Outstanding Issues on                                                                                                   | 21 June 2021      |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the second List of Outstanding Issues to all CHMP members on                                                  | 07 July 2021      |
| The CHMP agreed on a third list of outstanding issues to be sent to the applicant on                                                                                                     | 22 July 2021      |
| The applicant submitted the responses to the third CHMP List of Outstanding Issues on                                                                                                    | 13 August 2021    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the third List of Outstanding Issues to all CHMP members on                                                   | 03 September 2021 |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a marketing authorisation to Raylumis on | 16 September 2021 |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Osteoarthritis (OA) is a progressive degenerative joint disease precipitated by the loss of cartilage leading to compensatory hypertrophy (osteophytes or bone spurs) of bone structure at the joint margins, areas of abnormal bone hardening (subchondral sclerosis), and fluid-filled pockets in the marrow known as subchondral cysts. Over time, the joint may become misaligned, and bone or cartilage fragments may float free in the joint space resulting in an inflammatory response which increases pain and the likelihood of further joint damage. The hallmark signs and symptoms of OA are joint pain, stiffness, and reduced range of motion.

OA is no longer regarded as mainly a degenerative process of the cartilage. While the main feature is an imbalance between catabolism and anabolism of the extracellular matrix in the cartilage, in essence, it

<div style=\"page-break-after: always\"></div>

is a disorder of the complete joint and surrounding tissues (EULAR Textbook of the Rheumatic Diseases, 2018). The disease manifests first as abnormal joint tissue metabolism followed by cartilage degradation, bone remodelling, osteophyte formation, joint inflammation and loss of normal joint function, that can culminate in illness (www.oarsi.org).

As the cartilage is not innervated, pain from OA is the result of nociception in other joint tissues and from tissues surrounding the joints (ligaments, tendons, muscle). Apart from peripheral nociception, pain sensitisation by neuropathic pain mechanisms or by central pain mechanisms may play a role in a considerable proportion of patients (Hunter 2019).

The course of OA varies widely between patients, according to the joints affected and the degree of erosiveness (EULAR Textbook 2018). Differences in the functionality of joints (e.g. hip/knee, spine, hand) and differences in phenotype (notably for hand OA) may complicate extrapolation of evidence within OA as an entity (Kloppenburg et al. 2018; CHMP Guideline on OA CPMP/EWP/784/97 Rev. 1).

An OA subtype of rapid progressive/rapid destructive OA has been first described by Forestier in 1957 (Lequesne 1970) and is understood as an uncommon, rapidly destructive subset of OA (Rosenberg et al. 2012). A typical history and radiographic features for RPOA are described for the hip joint, though RPOA may also occur in the shoulder (Flemming 2017).

## 2.1.2. Epidemiology

Osteoarthritis  is  a  common  disorder  in  the  population,  its  occurrence  increases  with  age,  and  it  is generally more common in females than in males (Silman and Hochberg, Epidemiology of the Rheumatic Diseases, 2001). The prevalence of OA varies according to the definition used (notably: radiographic or symptomatic  +  radiographic),  the  specific  joints  under  study,  and  the  characteristics  of  the  study population (Zhang 2010). Clinically defined, the knee is the most common site of OA, followed by the hand and hip (Hunter 2019), many patients have OA in more than one joint.

For the US it has been estimated that OA has a lifetime risk of 45% for knee OA and 25% for hip OA (Murphy et al. 2008; Murphy et al. 2010). For Europe, the prevalence of symptomatic OA in middle-aged and older people was estimated for knee OA to be 23% in women and 8% in men, and for hip OA to be 8% in women and 7% in men (Hunter 2019). Overall, it has been estimated that OA affects &gt;40 million adults across Europe (WHO report, in Kingsbury et al. 2014). A retrospective cross-sectional study using data from the 2011 National Health and Wellness survey in 5 European countries estimated that ~60% of OA patients have moderate to severe pain and that ~70% of patients had OA in more than one joint which may include the spine (Kingsbury et al. 2014).

Risk factors for the occurrence of OA may differ per joint, e.g. whether weight-bearing or not. Common risk  factors  for  OA  include  increased  age,  being  female,  obesity,  joint  injury  and  physical  overload, malalignment and joint deformity, muscle strength and physical fitness, family history/genetics (EULAR Textbook 2018). This implies that with increasing average age and increasing prevalence of obesity in the population, the prevalence of OA can be expected to increase.

## 2.1.3. Clinical presentation, diagnosis

OA usually results in joint pain, stiffness, deformity and loss of function, ultimately leading to chronic disability (EULAR textbook 2018). Pain is the dominant symptom and is a major driver of clinical decision making and health service use (Hunter 2019). While signs of OA can be made visible on X-rays or MRI, those  are  not  well  correlated  to  the  presence  of  pain  and  other  symptoms,  and  vice  versa.  Clinical diagnosis usually is made using the combination of the presence of typical symptoms, physical findings and imaging (EULAR textbook 2018).

<div style=\"page-break-after: always\"></div>

For the inclusion of patients in clinical trials, classification criteria have been designed. The classification criteria of the American College of Rheumatology for hip and knee OA are based on clinical criteria or combined clinical and radiographic criteria (EULAR Textbook 2018). The severity based on radiographically visible signs is usually based on the grading system by Kellgren. It is referred to the methods section in the Day 80 Clinical AR for more details.

To include patients with at least a moderate to severe extent of symptoms in studies, the level of pain can be used, e.g. pain of at least 40 mm as measured on the 100-mm Visual Analogue Scale (CHMP Guideline on OA, CPMP/EWP/784/97 Rev.1).

## 2.1.4. Management

International  treatment  guidelines  are  in  line  with  each  other  regarding  the  recommendations  for management (OARSI, Bannuru et al. 2019; ACR, Kolansinski et al. 2020; EULAR, Kloppenburg et al. 2019; www.Up-to-date.com).

Education about the nature and consequences of osteoarthritis, self-management, exercise, and weight loss are common elements of first-line management. Surgery is reserved for patients for whom nonpharmacological and pharmacological treatments are not helpful or no option.

Currently,  there  are  no  pharmacological  treatment  options  with  disease-modifying  properties;  thus pharmacological treatment of osteoarthritis  is  symptomatic.  The  most  relevant  treatment  options  to discuss  for  the  symptomatic  treatment  of  osteoarthritis  are  paracetamol,  NSAIDs,  intra-articular corticosteroids, and opioids.

Paracetamol has  long  been  regarded  as  the  first-line  treatment  of  choice,  but  is  not  widely recommended  anymore  (ACR,  OARSI,  EULAR).  From  meta-analyses,  it  appeared  that  NSAIDs  are superior to paracetamol for knee and hip OA (Cochrane, Towheed et al. 2006) and that paracetamol provides only minimal improvements in pain and function for hip or knee OA as compared to placebo (Cochrane, Leopoldino et al. 2019).

Topical NSAIDs are  regarded  as  an  effective  treatment,  and  as  a  safe  treatment  due  to  its  lower systemic exposure as compared to oral NSAIDs. Topical NSAIDs are strongly recommended if not many joints are involved at the same time and if the joint to be treated is not too deep, such as knee OA (OARSI, ACR) and hand OA (EULAR, ACR).

Oral non-selective NSAIDs and Cox-2 inhibitors are the mainstays of treatment if topical NSAIDs are not applicable (OARSI, ACR). Their use, however, depends on their respective safety profile and the presence of GI and CV comorbidities and general frailty in the patient. Cox-2 inhibitors are not strongly recommended in patients with CV risk factors; non-selective NSAIDs are not recommended without gastric protection in patients with risk factors for GI bleeding (OARSI). It is recommended that NSAID doses  should  be  as  low  as  possible,  and  treatment  duration  should  be  as  short  as  possible  (ACR), especially in the presence of risk factors (OARSI).

Oral or transdermal opioids were strongly recommended against (OARSI, ACR), except as a 'last-resort' option while preferring tramadol over non-tramadol opioids (ACR). Results of a meta-analysis indicated that  compared  to  placebo,  tramadol  alone  or  in  combination  with  acetaminophen  probably  has  no important benefit on mean pain or function in people with osteoarthritis (Cochrane, Toupin et al. 2019). Also, according to the meta-analysis, the small average benefit of non -tramadol opioids is contrasted by significant increases in the risk of adverse events (Cochrane, Da Costa et al. 2014).

Intra-articular  corticosteroids are  regarded  to  be  effective  (ACR,  OARSI),  though  they  are  only applicable if not many joints are involved, and also the effects are not long-lasting (Cochrane, Jüni et al.

<div style=\"page-break-after: always\"></div>

2015). Serial use of intra-articular CS is not universally recommended due to probable side effects on joint tissues (Up-to-date).

Duloxetine,  a  serotonin  and  norepinephrine  reuptake  inhibitor  with  antidepressant,  central  pain inhibitory, and anxiolytic activities, may have a place for treatment of OA patients with wide-spread pain (Hunter 2019, ACR, OARSI).

The EULAR issued specific treatment recommendations on hand OA (EULAR, Kloppenburg et al. 2019). Accordingly, topical NSAIDs are recommended as a first pharmacological treatment option, oral NSAIDs are recommended for a limited duration; also chondroitin sulfate is recommended to treat pain, and corticosteroids may be used for the treatment of painful interphalangeal joints.

## About the product

Tanezumab is a humanised immunoglobulin G Type 2 monoclonal antibody that binds to human nerve growth factor (NGF) with high affinity and specificity, thus preventing its interaction with the tropomyosin receptor kinase-A (TrkA) or p75 receptors. Tanezumab is produced by recombinant DNA technology in a mammalian cell line.

Tanezumab was initially developed as IV solution and now is proposed as 2.5 mg solution in a pre-filled syringe, for SC injection every eight weeks (Q8W), to be administered by a health care professional.

The role of NGF in adults appears to principally be a modulator of nociceptive neuronal activity (Mantyh et al. 2011; Denk et al. 2017; Schmelz et al. 2019). According to the applicant, in adults TrkA receptors are  expressed  in  a  subset  of  nociceptive  primary  sensory  neurons  in  the  dorsal  root  ganglia  and trigeminal ganglia and in neurons of the sympathetic ganglia. NGF is upregulated in response to injury and inflammatory conditions. Based on preclinical data (see below), NGF appears to play an important role in pain signalling by inducing peripheral and central sensitisation. Tanezumab acts peripherally to reduce sensitisation and pain by inhibiting the interaction of NGF with the TrkA receptors located on the peripheral terminals of peptidergic unmyelinated C-fibres and Aδ fibres.

NGF is supposed to affect the development and maintenance of pain in adults in the following ways:

- -NGF  has  a  role  in  the  development  and  maintenance  of  peripheral  sensitisation:  Following peripheral injury or inflammation, immune cells and other cells release NGF and other stimulatory factors which bind to receptors on peripheral nociceptors to induce a local sensitisation of the nociceptive response.
- -NGF is retrogradely transported back to the neuronal cell somata in the dorsal root ganglion (DRG) where it can induce changes in expression of many pain transduction related genes.
- -NGF might cause increased pain sensitivity by promoting the sprouting of nociceptive fibres in peripheral tissues.

## Type of Application and aspects on development

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as sterile, preservative free, solution for injection in pre-filled syringe (PFS) containing 2.5 mg of tanezumab as active substance.

Other  ingredients  are:  histidine,  histidine  hydrochloride  monohydrate,  trehalose  dihydrate,  disodium edetate, polysorbate 20 and water for injections.

The product is available in a single-use 1 mL glass (type I) pre-filled syringe with a coated latex-free butyl  rubber  plunger  stopper  and  Luer  lock  closure  with  a  thermoplastic  elastomer  (TPE)  tip  cap containing an elastomeric rubber insert.

## 2.2.2. Active Substance

## General Information

Tanezumab (INN - international non-proprietary name) is a humanised IgG2 monoclonal antibody with two heavy chains (HC) and two kappa light chains (LC), covalently linked through six inter-chain disulfide bonds.  The  N  terminus  of  the  H  chain  is  mainly  in  pyroglutamate  form  (pQ),  which  is  known  to spontaneously form in monoclonal antibodies (mAbs) when the N-terminal residue is glutamine (Q).

The N-linked glycosylation consensus sequence, NST, in the CH2 region is predominantly occupied with asialo, core-fucosylated, complex-type biantennary oligosaccharides with zero or one terminal galactose residues (abbreviated as G0F or G1F, respectively). The C-terminal lysine (K) is encoded by the H chain expression vector cDNA sequence but is observed only at trace levels in the mature, secreted form of tanezumab,  presumably  due  to  intracellular  processing  by  CHO  cellular  proteases.  Therefore,  the penultimate glycine (G) residue is the predominant H chain C terminus in tanezumab. Tanzumab is an IgG2 Δ a mutant, selected to reduce Fc effector function. The theoretical molecular mass is 146 kDa. Tanezumab binds to human nerve growth factor (NGF) and then block NGF interaction with its receptors tropomyosin receptor kinase A (TrkA) and the p75 neurotropin receptor (p75 NTR).

## Manufacture, process controls and characterisation

## Description of the active substance manufacturing process

The manufacturing process for tanezumab active substance uses a recombinant Chinese hamster ovary (CHO) cell line that contains the DNA encoding the sequence for tanezumab and is grown in suspension culture  using  chemically-defined  (CD),  animal-derived  component-free  (ACF)  media.  The  active substance manufacturing process comprises an upstream and a downstream process.

The upstream manufacturing process begins with thawing of a WCB vial and serial cell culture expansion in cell culture flasks and/or culture bags followed by progressive expansion in seed bioreactors.

A 2500 L production bioreactor is used for production. Multiple tanezumab batches may result from a single thaw from a WCB, as long as the total number of cell generations is not exceeded. The harvest procedure involves clarification by continuous centrifugation followed by depth and clarifying filtration and addition of the buffer. In the downstream process, the harvested cell culture fluid is purified by affinity chromatography followed by virus inactivation, followed by ion exchange chromatography steps and virus reduction by filtration.

<div style=\"page-break-after: always\"></div>

The purification process is followed by concentration of the active substance and buffer exchange, final formulation, filtration,  filling,  freezing  and  storage.  Prior  to  finished  product  manufacture,  the  active substance is transported frozen to the finished product manufacturing site.

The manufacturing process, with process controls and main process parameters has been clearly outlined and additional information on e.g. solutions and operational details have been adequately provided for each step.

The maximum number of cycles (for resins) and uses (for membranes) is stated and has been adequately supported by small scale data for resins and by vendor specifications and concurrent validation protocol for membranes.

The information provided is sufficient and adequate.

## Control of materials

The only raw material of biological or recombinant origin used for the manufacture of tanezumab active substance is fetal bovine serum (FBS), sourced from New Zealand and USA, which was used in the development of the recombinant master cell bank (MCB).

Raw materials used in the manufacture of tanezumab active substance are either of compendial quality or released using in-house specifications / methods.

A tiered cell banking system for MCB, WCB and end of production cells (EOP) is in place. The CHO-cells are well characterised and are in general established according to ICH Q5A, ICH Q5B and Q5D guidelines. The cell banks are tested to be free from adventitious agents. The limit of in vitro cell age (LIVCA) is determined  and  the  genetic  stability  is  demonstrated.  The  protocol  presented  for  the  preparation, qualification and storage of renewal working cell banks, is acceptable. Data and information on cell banks have been presented in adequate and sufficient detail.

## Control of Critical steps and intermediates

In-process  controls  (IPC)  have  been  adequately  defined  for  each  step  of  the  active  substance manufacturing process. The IPCs defined and their corresponding action limits or acceptance criteria are considered appropriate. Summary of validation data for non-compendial methods used for in-process tests has also been provided.

## Process validation and/or evaluation

The  commercial  manufacturing  process  for  tanezumab  active  substance  has  been  validated  at  the commercial scale using consecutive batches. EOP cells were obtained for evaluation.

The validation covered all the manufacturing steps as defined in the description of the manufacturing process and process controls. All process parameters / material attributes and in process controls with their respective limits if applicable have been included in the validation.

Performance of all unit operations was as expected and met all the acceptance criteria. All validation results meet their respective criteria.

It  can  be  concluded  that  the  tanezumab  active  substance  manufacturing  process  can  consistently produce active substance fulfilling the commercial acceptance criteria.

<div style=\"page-break-after: always\"></div>

## Validation of removal of impurities

Clearance of process-related impurities was evaluated on chromatography pools and active substance samples at manufacturing scale and additional information was derived at laboratory scale as part of process characterisation studies. The presented data demonstrate that the tanezumab active substance manufacturing  process  for  commercial  production  adequately  clears  process-related  impurities  to acceptable levels.

## Validation of hold times

Hold  time  validation  studies  were  conducted  at  small  scale  under  conditions  and  in  containers representative of the full-scale manufacturing process and anticipated worst-case scenarios. Stability was evaluated by several assays to reveal possible degradation or loss of bioactivity. Clear summaries of the test results including the maximum validated hold times were provided.

## Additional process evaluation

Resin/membrane  lifetime  and  shipping  validation  was  also  presented.  The  applicant's  approach  to establish the resin and membrane lifetimes is acceptable as well as the more detailed protocols provided for the validation at the commercial scale.

Shipping qualification included operational qualification testing (OQ), performance qualification testing (PQ) and mechanical performance studies. The results provided demonstrated that under anticipated extreme temperature conditions, the shipping configuration maintained the required temperatures under maximum and minimum fill conditions.

## Manufacturing process development

The tanezumab active substance manufacturing process was developed using Pfizer's platform CHO host cell line and mAb cell culture and purification processes. Prior knowledge obtained from past process development  and  characterisation  studies  as  well  as  experience  gained  from  numerous  Pfizer  mAb products served as an important basis for understanding the Pfizer mAb platform process.

Four  different  strengths  (2.5,  5,  10  and  20  mg/mL)  of  tanezumab  administered  by  two  routes (intravenous and subcutaneous) were investigated in several different indications throughout development.

Additionally, there were a number of manufacturing process changes, including different manufacturing sites  as  described  in  the  dossier.  These  have  resulted  in  a  number  of  batches  manufactured  and investigated in different combination of manufacturing process, strength, route of administration and indication.  Combinations  different  from  the  proposed  one  were  considered  as  supportive  only  in  the assessment, unless otherwise justified.

The development history has been presented with a clear chronological order and a discussion of the significant changes made to the manufacturing process accompanied by an assessment of its potential to impact the quality of the active substance.

Comprehensive  analytical  comparability  exercises  in  line  with  ICH  Q5E  principles  were  executed throughout tanezumab process development to support the active substance manufacturing process changes. The applicant's approach is endorsed.

Based on the results of the comparability exercise, it could be concluded that the quality attributes were maintained  throughout  the  entire  development  and  comparability  between  'relevant'  clinical  and commercial batches was demonstrated.

<div style=\"page-break-after: always\"></div>

Evolution of the analytical methods during development has been presented and bridging studies were performed  for  all  non-compendial  methods.  The  approach  is  acceptable,  and  the  results  presented support comparability or show improvements in method performances.

## Control strategy

The applicant has provided a general discussion on how criticality assessment was performed, using Cause &amp; Effect Matrix, experimentation and failure mode and effects analysis (FMEA) approach. The applicant's approach is acceptable and in accordance to relevant ICH guidelines (ICH Q8-11). A list of quality attributes, along with process performance attributes, process parameters and material attributes that could impact them, was established based on a risk assessment. The relative risk score resulted in a ranked list of process parameters and material attributes to be further investigated. In addition, to considering manufacturing experience throughout development of the tanezumab active substance and relevant platform experience, scale-down models were developed and used for process steps where feasible and appropriate.

Experimental  strategies  using  a  combination  of  approaches  including  univariate  and  multivariate experiments  to  generate  comprehensive  understanding  of  the  effect  of  the  process  parameters  and material  attributes  on  the  active  substance  quality  attributes  and  process  performance  were  used. Appropriate descriptions of the scale-down models used were provided and the results of the univariate and multivariate experiments were summarised in the dossier.

The in-process controls, including process parameters and material attributes with acceptable ranges and in-process tests with control limits as well as the targets and normal operating ranges (NORs) for tanezumab active substance manufacturing are listed with their classification as critical or non-critical. Overall, the presented process controls seem appropriate.

Summary and conclusions of extractables and leachables studies from contact material during active substance manufacturing for high risk components have been provided as well as the verification protocol for reprocessing at commercial scale.

## Characterisation

## Elucidation of Structure and Other Characteristics

Characterisation of tanezumab involved primary structure, post-translational modifications, charge and size heterogeneity, higher order structure, and biological activity. Broad and adequate panel of analytical techniques and methodologies was applied and sufficient proof of their qualification showing these are qualified for the intended use, has been provided.

Degradation pathways have been satisfactorily studied and potential degradation products are monitored through release and stability studies and regulated by tanezumab control strategy.

Overall,  the  results  demonstrate  that  tanezumab  has  the  expected  structure  and  target  binding properties.

## Biological Activity

Tanezumab is designed to bind to human nerve growth factor (NGF, same as beta-NGF) and then block NGF interaction with its receptors tropomyosin receptor kinase A (TrkA) and the p75 neurotropin receptor (p75 NTR). Tanezumab is a recombinant humanised IgG2 ∆ a monoclonal antibody (mAb) designed to have no effector function and directed against NGF. NGF is a well-established important mediator in the pain  signalling  process.  The  bioassay  development  focused  on  assessing  the  primary  binding  event between tanezumab and the antigen NGF and confirmation that this prevents its interaction with the TrkA receptor.

<div style=\"page-break-after: always\"></div>

## Impurities

All process-related impurities were observed in constant low levels and the presented data demonstrate that the tanezumab active substance manufacturing process for the commercial production clears the process-related impurities to acceptable levels.

Based on the demonstrated consistent removal of the process-related impurities, routine in-process tests or active substance specification for the control of these process-related impurities are not proposed and this is acceptable.

Removal of the evaluated product-related impurities has been demonstrated to be both effective and consistent.

## Specification,  analytical  procedures,  reference  standards,  batch  analysis, and container closure

The  tanezumab  active  substance  release  and  shelf  life  specification  includes  parameters  that  cover physico-chemical  properties,  content/protein  concentration,  charge  heterogeneity,  identity,  potency, purity, impurities and microbial assurance, as required, including respective analytical methods.

The test parameters included in the specification are considered adequate and in line with the current guidance.

The proposed specification limits are set taking into account release and stability results for tanezumab active substance batches. The proposed acceptance criteria are considered appropriately justified.

## Analytical procedures and reference standards

Appropriate method descriptions have been provided for all methods.

The biological activity assay has been developed as the intended commercial biological activity assay for release and stability testing to mimic the bind and block MoA.

In  general,  all  non-compendial  methods  are  validated  in  accordance  with  ICHQ2  (R1).  Since predetermined  validation  acceptance  criteria  were  met,  methods  are  considered  validated  for  their intended use. Additionally, individual validation results in tabularised form have are provided to support the validation summaries. Summaries for general robustness studies have been also provided. For all method validation studies more details on preparation of samples as well as proof that the material used in the validation studies represents both active substance and finished product have been provided.

## Reference standards

The reference standards used throughout the product development have been adequately described.

The applicant has established a two-tiered system for in-house reference material involving primary and working reference standards, which is in line with the relevant guidelines. The primary reference material is intended to last throughout the commercial product lifetime and will be used for qualification of future working reference materials (WRM). The PRM, and WRM were prepared from the same batch.

Quality attributes and analytical procedures for the qualification of future tanezumab WRM as well as the characterisation  tests  and  analytical  procedures  for  establishing  a  new  WRM  have  been  provided. Acceptance criteria for the qualification of future WRM will be based on product specification at the time of  manufacture.  Traceability  between  current  and  future  working  standards  is  ensured  by  qualifying future working standards against the existing primary standard. The applicant described the actions that will be taken in case a discrepancy between potency results of a new reference standard against the current PRM is observed and these are acceptable.

<div style=\"page-break-after: always\"></div>

## Batch analysis

The batch analyses data have been provided for tanezumab active substance batches manufactured during development (toxicology/nonclinical studies, clinical studies, stability and process validation).

Batch analyses from all the batches were provided and results met the acceptance criteria in force at the time  of  testing. The  analytical  results  for  all  batches  are  also  in  compliance  with  the  proposed specifications, where appropriate. The provided batch analysis data seem to confirm consistency of the manufacturing process and the quality of the active substance.

## Container closure system

Bags are used as the container closure system for tanezumab active substance. The bags are sterile, single-use,  flexible,  disposable  containers  specifically  designed  for  controlled  freezing,  thawing  and frozen storage of biopharmaceuticals.

The compatibility of the tanezumab active substance with the containers has been evaluated through stability  studies  of  the  tanezumab  active  substance.  Extractable  and  leachable  studies  have  been performed. The applicant also states that each batch of bags is certified to comply with Ph. Eur. and USA requirements.

Appropriate and acceptable documentation was provided including specifications for the active substance container  closure  system,  based  on  the  Certificate  of  Analysis  (CoA),  and  data  on  the  method  of sterilisation of active substance container closure system.

## Stability

To support the active substance shelf life claim, a stability programme was designed to follow the relevant ICH  guidelines  for  the  stability  of  the  active  substance  (ICH  Q1A  and  ICH  Q5C).  Stability  studies consequently include a photostability study designed in accordance with the conditions as per ICH Q1B guideline. Stability data has been provided for long-term, accelerated, thermal stress and thermal cycling conditions, followed by storage at the target storage condition.

Real-time data at the long-term conditions at the upper half of the proposed temperature range has been provided for tanezumab active substance batches. For process validation (PV) tanezumab active substance batches, produced at commercial scale and stored at the target storage condition results are provided.

Stability indicating properties of analytical procedures have been confirmed. Therefore, the proposed active substance shelf life claim is acceptable.

The applicant has evaluated the data obtained during the stability programme against clinical stability acceptance criteria (in place at the time of the studies) and the commercial stability acceptance criteria (in place at the time of the studies). Results from all the presented long-term stability studies were within the acceptance criteria.

For  stability  testing  at  temperatures  different  from  the  proposed  storage  conditions  the  applicant provided justification, which is endorsed, and in further support to this, data on additional stability studies conducted on lower temperature were provided. Results show that the critical quality attributes of the active substance are maintained.

Data for primary tanezumab active substance PV batches stored in accelerated conditions and thermal stress conditions are also presented. For thermal stress conditions, data for additional tanezumab active substance batches have been provided. Results at accelerated and thermal stress conditions showed that excursions above the recommended storage conditions are acceptable.

<div style=\"page-break-after: always\"></div>

Overall, the presented stability data is considered appropriate and the tanezumab active substance shelflife  claim  when  stored  protected  from  light  at  the  recommended  temperature  in  bags  is  considered acceptable. The post-approval stability protocol is considered acceptable.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical Development

The tanezumab finished product (FP) is a 2.5 mg/mL sterile, single-use, preservative-free solution for injection intended for subcutaneous injection. It is supplied in a 1 mL glass syringe with a Luer-lock closure. The finished product is presented as sterile, preservative free, solution for injection in pre-filled syringe (PFS) containing 2.5 mg of tanezumab as active substance. Other ingredients are: histidine, histidine hydrochloride monohydrate, trehalose dihydrate, disodium edetate, polysorbate 20 and water for injections.

To ensure that a 1.0 mL nominal volume can be delivered from the pre-filled syringe, there is an overfill. There are no manufacturing overages.

## Pharmaceutical development

The aim of the formulation development studies was to identify an appropriate formulation that provides adequate stability, safety/compatibility for dosing. The initial formulation contained excipients commonly used  in  commercial  biologic  products  and  was  based  on  experience  with  formulation  of  monoclonal antibody  finished  products.  Changes  in  the  tanezumab  formulation  excipients  were  made  based  on formulation development studies and led to the commercial formulation.

This  formulation  was  introduced  at  the  start  of  pivotal  clinical  trials.  The  tanezumab  formulation development programme evaluated the effects of pH, buffer type and concentrations of the various stabilizers on the chemical and physical stability of the active molecule. The study results support the appropriate choice of a robust formulation, appropriate for the intended use.

A summary of all tanezumab finished product formulation, dosage form and manufacturing changes in development  studies  has  been  provided  in  a  clear  way  and  with  sufficient  level  of  details.  Lists  of tanezumab  finished  product  lots  manufactured  for  clinical  studies,  nonclinical  studies,  stability, development purposes and process validation have been presented. Through the development of the finished product, two finished product formulations were produced in two different presentations (glass vial and PFS) and across three manufacturing sites. The changes to the manufacturing process have been driven by operational efficiency, and during facility transfer, driven by fit-to-facility equipment, leading to the proposed commercial process. Four different strengths (2.5, 5, 10 and 20 mg/mL) of tanezumab administered by two routes (intravenous and subcutaneous) were investigated in several different  indications.  To  support  the  finished  product  manufacturing  changes  during  the  process development, data on analytical comparability studies, conducted by evaluating the release and stability data of the pivotal clinical and process validation finished product lots has been provided. The results provided support the applicant's conclusion that the process changes did not impact the overall quality of the resulting product lots.

The  process  development  and  characterisation  studies  were  performed  to  understand  the  effect  of process parameters on product quality attributes. Development studies results have been presented in sufficient detail.

Principles outlined in ICH Q8, ICH Q9 and ICH Q10 were applied to the development of the tanezumab finished product manufacturing process. A science- and risk-based approach was used to develop the

<div style=\"page-break-after: always\"></div>

understanding of tanezumab critical quality attributes (CQAs) and a robust manufacturing process to consistently deliver the desired quality for this product. A holistic approach to the control strategy has been taken, and the control strategy has been constructed in order to support the achievement of the quality  target  product  profile  (QTPP),  in  line  with  the  relevant  guidelines.  Process  risk  assessment strategy has been clearly defined with sufficient level of details. The applicant has adequately discussed the QAs, which have been categorised as critical and non-critical, and the output of the criticality risk assessments was considered when defining the control strategy applied to the individual attributes. The approach to defining the CQAs and the rationale for the criticality decisions is endorsed.

Development  studies  were  performed  on  the  container  closure  system  to  confirm  that  tanezumab finished product is compatible with the proposed container. Extractables and leachables studies were performed  on  the  product  contact  elastomeric  closure  materials.  The  applicant's  statement  that  no further toxicological assessment was considered necessary for any of the solvent leachables is sufficiently substantiated  with  appropriate  data.  From  the  design  and  functional  attributes  tested  during  design verification, it was demonstrated that the design input requirements, and specifically those attributable to  essential  performance,  are  suitably  controlled  for  this  product.  Statements  of  compliance  of  the container closure materials, including the syringe lubricant, with the relevant Ph. Eur., USP and ISO requirements have been provided.

## Manufacture of the product and process controls

## Description of manufacturing process and process controls

The manufacturing process and process controls have been clearly described. The manufacturing process consists of thawing the active substance, followed by transfer to a manufacturing vessel to begin bulk finished product compounding. A formulation buffer is prepared and used to dilute the active substance to the target protein concentration of 2.5 mg/mL.

The formulated bulk finished product is then filtered and aseptically filled into syringes. A plunger stopper is inserted into each syringe immediately after filling. Following this filling operation, the syringes are visually  inspected,  assembled,  labelled  and  packed  into  trays.  Manufacturing  process  and  process controls have been adequately presented.

The process parameters are considered acceptable. All process controls with their control limits for critical manufacturing steps are adequately controlled and acceptable, in line with the proposed control strategy for tanezumab finished product.

## Process validation

Tanezumab finished product has been validated.

All release results met acceptance criteria in place at the time of the process validation and additionally meet the commercial specification. Furthermore, all required process controls (i.e. process parameters and  in-process  tests)  were  met  by  all  process  validation  lots.  Therefore,  the  finished  product manufacturing process can be considered successfully validated. The maximum in-process hold times for the tanezumab finished product manufacturing process were confirmed.

The  data  provided  for  sterilising  filter  membrane  validation  are  in  line  with  the  'Guideline  on  the sterilisation  of  the  medicinal  product,  active  substance,  excipient  and  primary  container'  and  are considered acceptable. The results from validation study of product-specific media fills confirm that the tanezumab  finished  product  manufacturing  process,  from  filling  the  syringes  to  plunger  placement activities is performed aseptically.

<div style=\"page-break-after: always\"></div>

Shipping  validation  studies,  which  consisted  of  operational  qualification  testing  (OQ),  performance qualification  testing  (PQ)  and  supportive  studies,  demonstrated  that  the  process  can  maintain  the required temperature range for the duration of the transportation within the intended shipping lanes. Tanezumab finished product and container closure systems are not adversely impacted by the shipping hazard conditions expected to be encountered during transportation.

## Product specification, analytical procedures, batch analysis

The  proposed  release  and  stability  testing  specification  for  tanezumab  finished  product  includes characteristics tests, identity tests, purity tests, product related impurity tests, potency test for biological activity and tests for safety.

The analytical procedures that are common to the active substance and finished product are described and discussed in the active substance part. Since there are different/multiple testing/validation sites for the  finished  product  which  also  differ  from  the  active  substance  site,  transfer  validation  reports  for biological/immunological/immunochemical tests methods used for the finished product batch release are provided and considered appropriate.

The proposed specification complies with Ph. Eur. Monographs MAb for Human Use (2031) and Parenteral preparations (0520) and covers most of the relevant characteristics of monoclonal antibodies, in line with  the  Guideline  on  development,  production,  characterisation  and  specification  for  monoclonal antibodies  and  related  products  and  ICH  Q6B.  Justification  for  the  acceptance  criteria,  is  in  general endorsed. For some parameters, the acceptance criteria set are much wider than the actual batch results presented. Considering there is no impact of wider specifications for these parameters on the quality, safety and efficacy of the product, and taking into account the limited number of batches available during development, the applicant's approach is considered acceptable.

An elemental impurities risk assessment was performed on tanezumab finished product, in line with ICH Q3D Guideline.  All  elements  included  in  the  assessment  were  below  the  control  threshold.  The  risk assessment  on  overall  contribution  of  elemental  impurities  to  the  finished  product  is  amended  with potential impurity sources from excipients, water, manufacturing equipment and packaging material. No further assessment or control is required, which is endorsed.

A discussion on degradation products potentially arising during shelf life was provided. The summary of the assessment of the potential nitrosamine risk factors associated with the active substance, finished product and primary packaging components has been provided. Based on this assessment the applicant concluded that there is low risk associated with nitrosamines for Raylumis finished product, and this conclusion can be agreed.

## Analytical procedures

Compendial  analytical  procedures  are  performed  in  accordance  with  its  respective  compendial monographs and no validation data have been provided. Non-compendial analytical procedures were confirmed suitable for their intended use by assessing all relevant validation elements described in ICH Q2 (R1).

## Batch analyses

Batch analyses results for several tanezumab finished product lots used for clinical trials, stability and process validation met the acceptance criteria used at the time of lot release. The applicant's justification on selection of finished product lots used in setting the specifications is acceptable.

## Container closure system

<div style=\"page-break-after: always\"></div>

The primary container closure system (PFS) consists of the following components:

- Type I borosilicate 1 ml glass syringe barrel with a silicone coating, intended for single use
- Polycarbonate Luer lock closure with a polycarbonate luer lock adapter and a tip cap composed of a gray thermoplastic elastomer (TPE)
- product contact plunger stopper composed of butyl rubber with a fluoropolymer film and crosslinked silicone coating
- polypropylene finger grip and a plunger rod.

The  components  have  been  sufficiently  described.  The  justification  provided  for  the  selection  of sterilisation methods is acceptable.

## Stability of the product

To support the finished product shelf life claim, the stability programme was designed to follow the relevant ICH guidelines. Stability data has been provided for long-term, accelerated, high thermal stress, low thermal stress, and thermal cycling conditions.

Additionally, photostability data has been also provided, in accordance with conditions as per ICH Q1B guideline.

The shelf life claim is based on ongoing primary stability programs and completed supportive stability programme.

Tanezumab finished product lots were packaged in glass syringes, which is the same material as the commercial packaging.

The applicant has evaluated the data obtained during the stability programme against the clinical stability acceptance criteria, in place at the time of the studies, and the commercial stability acceptance criteria.

Real time data at long-term conditions remained within the acceptance criteria at the time of testing and meet the commercial acceptance criteria. Completed data in accelerated conditions demonstrated that excursions  above  the  recommended  storage  condition  are  acceptable.  Additional  confirmation  of excursions above the recommended storage conditions was demonstrated.

The stability  data  available  supports  the  proposed  tanezumab  finished  product  shelf  life  claim  when stored at the recommended temperature in pre-filled syringes. The post-approval stability protocol is also considered acceptable.

The product information statements on storage conditions are supported by stability studies, in line with the Guideline on declaration of storage conditions.

## Adventitious agents

## Non-viral adventitious agents

Control of mycoplasma, bacteria and fungi have been included for all materials used in the development of the recombinant cell line, establishment of the MCB and WCB and in the tanezumab manufacturing process. The unprocessed bulk from the day of harvest is tested for mycoplasma and bioburden prior to downstream  purification.  Results  from  several  batches  are  presented.  Non-viral  adventitious  agents safety have been adequately addressed.

Risk of contamination with animal TSE/BSE

<div style=\"page-break-after: always\"></div>

All  materials  used  in  the  establishment  of  MCB,  WCB  and  in  tanezumab  manufacturing  have  been evaluated for the origin of the animal material and have been determined to comply with the 'EMEA Note for  Guidance  on  Minimizing  the  Risk  of  Transmitting  Animal  Spongiform  Encephalopathy  Agents  via Human and Veterinary Medicinal Products' (EMEA/410/01.current version).

Foetal bovine serum was used in the development of the recombinant cell line. Information on supplier, source (foetal bovine blood), origin, use of material and number of Certificate of Suitability (CEP) issued by EDQM is presented. Control of all materials regarding TSE/BSE have been adequately addressed.

## Adventitious viruses

A multifaceted programme has been established to ensure the viral safety of the active substance which includes selection and control of raw materials, platform knowledge, characterisation and control of the cell banking system, employment of viral removal and inactivation steps and evaluation of the overall process capability to remove and inactivate adventitious viruses.

Programme and testing as presented in the dossier are in line with the relevant guidelines. Based on the data  provided  it  can  be  concluded  that  the  manufacturing  process  is  adequately  validated  for  viral removing/inactivation capacity.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The overall quality standard of the Module 3 Quality dossier presented in support of this application for tanezumab is adequate with the descriptions of the manufacture and control of the active substance and finished product containing sufficient detail. The results of tests carried out indicate consistency and uniformity of important product quality characteristics.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The  overall  quality  of  Raylumis  is  considered  to  be  acceptable  when  used  in  accordance  with  the conditions as defined in the SmPC.

The different aspects of the chemical, pharmaceutical and biological documentation comply with existing guidelines. The manufacturing process of the active substance is adequately described, controlled and validated.  The  active  substance  is  well  characterised  and  appropriate  specifications  are  set.  The manufacturing process of the finished product has been satisfactorily described and validated.

The quality of the finished product is controlled by adequate test methods and specifications. Adventitious agents' safety including TSE have been sufficiently assured.

## 2.2.6. Recommendation(s) for future quality development

Not Applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The applicant submitted full set of non-clinical studies to support this Initial Marketing Application.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

On an amino acid sequence level, NGF sequence identity is not full conserved across species. Amino acid sequence alignment of the mouse, rat, cynomolgus monkey, and human NGF is 66.8%, 70.6%, and 99.2%, respectively and was assessed in UNIPROT. However, the amino acid sequence of the tanezumab binding epitope on NGF is remarkably similar to the monkey NGF amino acid sequence at the anticipated tanezumab  binding  epitope.  It  is  actually  100%  homologous  to  the  human  NGF  binding  epitope. Tanezumab binding epitopes in rat and mouse differ only minimally from the human tanezumab binding epitope,  respectively  one  or  two  amino  acids.  This  indicates  that  NHP,  rat  and  mice  are  considered pharmacologically relevant animal models. In silico evaluation suggests that mRNA expression levels of NGF receptor genes (TrkAR and NGFR) is relatively similar between these species. It is unknown how this correlates to the functional translation of the protein although the applicant discusses that Trk A receptor may be more highly expressed in the skin of rats compared with monkeys or humans which may explain why more severe skin effects are observed in rats after administration of tanezumab but not in monkeys or in the clinic.

Tanezumab binds to human NGF with very high affinity, and no dissociation was detected over 8 hours (KD &lt;2pM). Shorter dissociation times show that binding affinity in human, rat and mouse remains high (KD &lt;40pM). Given the identical sequence of human and monkey NGF, it is assumed that the binding affinity will be the same. Tanezumab binding to human neurotrophin 3 and neurotrophin 4 are lower, in the low nanomolar range (41-60 nM and 6-8 nM, respectively), suggesting that NT3 and NT4 may be bound in vivo as well.

An evaluation of in vivo effects of exogenous NT3 and/or NT4 in human trials; in vivo effects of a pantrk inhibitor approved for use in oncology; and estimates of the degree of NT3, NT4 sequestration that might be seen in the clinic did not find evidence of adverse events as a result of NT3 or NT4 inhibition by  tanezumab.  At  the  estimated  clinical  serum  concentrations  NT3  inhibition  is  anticipated  to  be negligible. NT4 is minimally inhibited (30%) but this is not anticipated to have a clinically meaningful effect. Based on species cross-reactivity, the effects in animals can be considered indicative of clinical findings.

Taken together, it is not anticipated that tanezumab mediated inhibition of NT3 or NT4 will occur at such levels as to be of clinical relevance. Tanezumab (up to 10 µg/mL) failed to bind to human brain-derived neurotrophic factor (BNDF), suggesting that neuronal homeostasis will not be disrupted via inhibition of BNDF.

In a functional in vitro assay where bioactivity of NGF was measured as a function of embryonic neuron survival (EC50 = 1.5 pM), tanezumab inhibited NGF resulting in increased neuronal survival. Tanezumab was investigated in tandem with affinity maturation antibody variants, including fab fragments. In this experiment, tanezumab was the most potent in the ability to block NGF activity. It would have been informative if an IC50 was calculated. Based on the plotted NGF activity data, the IC50 of tanezumab likely lays between 1.28 and 6.40 x10 -3  nM. Nevertheless, this experiment shows that tanezumab is a potent blocker of NGF function. The ability of tanezumab to alleviate pain was assessed in Sprague Dawley rats receiving a surgical incision in the hind paw. Animals received a single dose of tanezumab (dose range 0.003-1.0 mg/kg) 12 or 16 hours prior to surgery. In addition, timing of dosing was investigated in rats receiving  1  mg/kg  tanezumab  after  1,  2,  6  or  10  hours  after  surgery.  Furthermore,  IV  and  IP administration was evaluated in these experimental conditions. The primary endpoint, weight-bearing on  a  plastic  mesh  grid,  is  a  rather  crude  assessment  since  there  are  only  3  points  of  assessment. Additional endpoints such as the rat grimace scale (e.g. Sotocinal et al. 2011) could have been included

<div style=\"page-break-after: always\"></div>

to  provide  a  more  refined  evaluation  of  efficacy.  Nevertheless,  increasing  doses  of  IV  administered tanezumab  had  a  modest  effect  in  reducing  post-surgical  pain  score,  with  statistically  significant decreases in pain scores reached above 0.1 mg/kg and 1 mg/kg but not 0.3 mg/kg doses due to inter animal variability in this group. The dosing prior to surgery was more effective in relieving pain than dosing after surgery, where no statistically significant improvements were noted although there was a trend  towards  improvement.  IP  administration  of  tanezumab  prior  to  surgery  resulted  in  a  dosedependent decrease of pain score from 0.02 mg/kg onwards with a maximum effect being reached after administration of 1 mg/kg. Overall, this study shows that tanezumab is able to modestly reduce postoperative pain when administered prior to surgery.

In a rat model of chronic arthritis, IV administration of tanezumab significantly and dose-dependently decreased pain relief measured as vocalisation following flexion of the hindpaw up to 99% compared to controls in the highest dose tested (5 mg/kg) and after 24 days. In the 1 and 5 mg/kg dosing groups on Day 24, there was no vocalisation observed in 8/10 and 9/10 rats, respectively, thus demonstrating that blockade of NGF by tanezumab is effective in alleviating arthritic pain and therefore demonstrates the proof of concept of tanezumab therapy in OA.

Tanezumab does not bind to FcγR1 and weakly to other FcγR isoforms. It is therefore unlikely that there is ADCC or ADCP activity. Tanezumab does not bind complement C1q. CDC is therefore not anticipated.

## Secondary pharmacodynamic studies

The  potential  for  tanezumab  to  have  ADCC  (Fcγ  receptor  binding)  and  CDC  (C1q  binding)  effector functions was evaluated in vitro . Tanezumab binds with high affinity to NGF, which is a soluble target and blocks binding of NGF to its cognate receptors. Therefore, tanezumab is unlikely to accumulate and subsequently localize on the surface of cells. Tissue cross reactivity studies using human, monkey and rat tissues confirm that there was no binding of tanezumab to tissues, and tissue distribution studies in rat showed no significant localisation to any specific tissue. These data support the lack of binding of tanezumab to cell surface proteins. Since binding of an antibody to cell surface receptors prior to Fc receptor engagement is a critical step for inducing antibody-dependent cellular cytotoxicity (ADCC), the lack of cell surface binding of tanezumab suggests a low potential for it to mediate ADCC. In addition, tanezumab has been engineered into a hIgG2∆a framework. Human IgG2 is known to have reduced affin ities, relative to other subclasses, for human Fc receptors and hIgG2∆a is reported to have even further reduced affinities from IgG2 for Fcγ receptors.

To evaluate tanezumab for potential ADCC or antibody-dependent cellular phagocytosis (ADCP) effector f unction, binding to the Fcγ RI, Fcγ RIIa (131H and 131R), Fcγ RIIb, Fcγ RIIIa (158F and 158V), and Fcγ RIIIb receptors was measured using surface plasmon resonance (SPR) and was shown to be very weak or non-existent. Rituxan, a wild-type IgG1, was used as a positive control.

To evaluate tanezumab for potential complement-dependent cytotoxicity (CDC), binding to human C1q was measured using an enzyme-linked immunosorbent assay (ELISA). Results showed that tanezumab binding to C1q was undetectable at concentrations as high as 10 μg/mL. The negative control antibody, mAb 8.8 (a wild-type human IgG2), also lacks C1q binding, whereas the positive control, Rituxan (a wild-type IgG1 that binds to C1q), bound C1q to saturation at similar concentrations. In conclusion, there  was  no  detectable  binding  of  tanezumab  to  C1q,  which  suggests  that  tanezumab  lacks  C1qmediated effector function and therefore the potential for CDC.

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

Repeat dose toxicity studies with tanezumab in rats and cynomolgus monkeys revealed changes to the sympathetic  nervous  system  (for  an  assessment  of  these  changes,  see  the  toxicology  section).  No histopathological changes were observed in the heart during these studies. However, because neuronal changes could potentially affect cardiovascular function, a dedicated 6-month safety pharmacology study evaluated the effects of subcutaneous administration of tanezumab (1.2mg/kg Q8w and 30 mg/kg Q1w, 4/s/g) when administered over a 6-month period to telemetered cynomolgus monkeys. There were no tanezumab related changes in blood pressure, heart rate, body temperature or activity at any time and at any dose during the study for the ambulatory CV assessment. However, 80) according to guideline ICHS7,  the  respiratory  rate  and  other  measures  of  respiratory  function  (e.g.,  tidal  volume  or haemoglobin oxygen saturation) should be evaluated. However, a thorough evaluation of the available data did not suggest evidence of a negative effect of tanezumab on the respiratory system or respiratory function. Moreover, no imbalance in respiratory, thoracic and mediastinal disorder AEs was observed in clinical trials. During orthostatic tilt challenges, tanezumab did not produce any overall effects on mean systolic blood pressure and heart rate, calculated as change from supine levels. Orthostatic hypotension was observed once on day 73 in a single animal in the 1,2 mg/kg group and twice (on day 142 and 156) in an animal in the 30 mg/kg animal. The findings resolved in the recovery period. AUC at the lowest dose tested was 6160 µg.h/ml, which is approximately 28x above the intended clinical exposure. At the highest dose tested, exposure in the animals far exceeded that in the clinic ( ≥ 5000x).

While the orthostatic hypotension is considered incidental and of limited toxicological relevance, it is not known whether life-long treatment with tanezumab would not result in disruption of neuronal signalling as  a  result  of  prolonged  neuronal  atrophy  (as  observed  in  the  repeat  dose  studies  in  monkeys  and mechanistic studies in monkeys) in the heart.

## Pharmacodynamic drug interactions

No pharmacodynamic drug interactions are expected and are not required.

## 2.3.3. Pharmacokinetics

Enzyme-linked  immunosorbent  assays  (ELISAs)  were  used  for  the  quantification  of  tanezumab  and detection of ADA in rats, rabbits, and monkeys. The rat plasma, monkey plasma and ADA assays are considered sufficiently validated and fit for purpose to quantify tanezumab or ADA titre in non-clinical samples. No assays were developed to distinguish between neutralizing or clearing anti-tanezumabantibodies.

As  the  target  of  tanezumab  is  a  soluble  protein  and  as  it  interferes  with  binding  of  the  target  to  a (membrane-bound) receptor, elimination will be determined by FcRN mediated clearance of the antibody complexed with the target. This will result in single-phase clearance of the antibody, which is expected to be slow as it is fully FcRN mediated. Indeed, intravenous administration of a single dose of tanezumab was characterised by long half-lives and low clearance in rats, rabbits and monkeys. The volume of distribution at steady state was low in these species as well, suggesting that tanezumab remains largely in  plasma.  There  were  no  apparent  gender  differences  in  exposure.  Subcutaneous  administration  of tanezumab in monkeys at doses of 1 or 10 mg/kg resulted in a bioavailability in plasma of 67.7% ± 10.5%  in  the  1mg/kg  animals  and  72.2%  ±  13.3%  in  the  10  mg/kg  group.  Maximum  plasma concentrations were reached between 68 and 108 hours, and exposure increased dose proportionally. Further comparisons in cynomolgus monkeys were made with an original drug product formulation and the proposed commercial formulation. Animals received a single dose of 1 mg/kg tanezumab formulated

<div style=\"page-break-after: always\"></div>

with either the original formulation or the commercial formulation. Apart from a modestly lower half-life (373  hours  ±  55  vs  251  hours  ±  58),  there  were  no  meaningful  differences  when  tanezumab  was prepared  in  the  proposed  commercial  formulation.  With  over  10  days,  the  lower  half-life  remains sufficiently long.

According to the study report no: WIL-471003: The thyroid radioactivity levels were possibly a result of concentrated free 125I released from the labelled antibodies or an artefact of the 125I-labeling process.

After IV or SC repeat dose administration of tanezumab in rats at doses of 1 or 10 mg/kg for 2 weeks in a dedicated GLP compliant PK study. ADAs were detected in all dose groups. The incidence of ADA was 25% (3/12 animals), 58% (7/12 animals), 50% (6/12 animals), and 50% (6/12 animals) in rats dosed at 1 mg/kg (IV), 10 mg/kg (IV), 1 mg/kg (SC), and 10 mg/kg (SC), respectively. Independent of ADA status,  Cmax  and  exposure  to  tanezumab  increased  in  a  dose-proportional  manner.  Subcutaneous injection resulted in lower dose-proportional increases in Cmax (roughly a factor of 2) and a later Tmax (168 hours vs 73 hours) compared to intravenous administration.

Toxicokinetics and the presence of ADA was also assessed as part of the repeat dose toxicity studies in rats  and  cynomolgus  monkeys.  In  two  of  these  studies  (the  1-month  rat  and  the  6-month  adult cynomolgus monkey study), it appears that the control animals were exposed to tanezumab because control group animals had quantifiable concentrations of tanezumab or were positive for ADA. However, in none of these animals, ADA- or tanezumab related effects were apparent or were within normal limits reported in literature. Historical control data were not submitted. It is accepted that ADA formation in controls and (potential) tanezumab exposure in these animals did not confound the overall interpretation of the studies.

In rats, ADA occurred in up to 88% of the animals in the repeat dose toxicity studies. However, the toxicokinetic  profile  in  ADA  positive  animals  was  not  changed,  and  functional  effects  of  tanezumab exposure (e.g. skin lesions) noted in the study reflecting tanezumab exposure. The ADA status of the animals, therefore, did not affect the interpretation of the rat data. In cynomolgus monkeys, ADA was observed in up to 23% of the animals in the repeat dose toxicity studies. ADA positive animals tended to have lower exposure to tanezumab. Nevertheless, animals were sufficiently exposed to tanezumab throughout the study to allow interpretation of the data.

In rats, systemic exposure generally increased in a dose-proportional manner and was higher on later study days when compared to day 1 of the repeat dose studies. Similarly, tanezumab dose-dependently increased in exposure and Cmax after repeated IV administration in monkeys. Exposure on day 22 of the study was higher than on day 1. In this study, control animals also had quantifiable levels of tanezumab. No  ADA  were  detected  in  monkeys  given  tanezumab  in  this  study.  The  mean  accumulation  ratios (AUC168 (Day 22)/ AUC168 (Day 1)) were generally similar across doses and ranged from 1.9 to 2.2 after  repeat  IV  dosing.  In  a  six-month  study  with  a  2-month  recovery  period  in  monkeys  receiving tanezumab, the overall incidence of ADA in treated animals was low (21% or 6/28 animals). ADA positive animals  had  lower  exposure  to  tanezumab,  but  within  the  group,  animals  were  sufficiently  exposed throughout the study to allow an adequate assessment of the safety profile of tanezumab. The mean systemic exposure (as assessed by Cmax and AUC168; includes all animals regardless of ADA status) increased in a generally dose-proportional manner with increasing dose. The systemic exposure was higher  after  repeat  dosing  in  the  1,  10  and  30  mg/kg  dose  groups  with  similar  accumulation  ratios (AUC168 (Day 155 or 176)/AUC168 (Day 1)) of 2.6, 2.8 and 3.2, respectively. In a second 6-month study in monkeys receiving SC or IV doses of tanezumab, tanezumab increased in a dose-dependent manner. The overall incidence of ADA in tanezumab treated animals was 5% or 2/44 animals. However, ADA was detected  in  65%  of  animals  receiving  control  vehicle,  suggesting  that  animals  were  exposed  to tanezumab as well.

<div style=\"page-break-after: always\"></div>

In the PPND studies in monkeys, more animals were positive for ADA (30% maternal animals in study SNBL 252 48 and 37% of maternal animals in study SNBL 252 55). In addition, ADAs were quantified in offspring  as  well  (17%  and  32%,  respectively).  In  the  first  study  (SNBL  252  48),  quantifiable concentrations  of  tanezumab  were  measured  in  control  animals  (see  the  section  on  antigenicity  for further discussion). Quantifiable concentrations of tanezumab were detected in maternal milk until LD66, LD15 and LD60 in samples from the 0.5 mg/kg, 4 mg/kg and 30 mg/kg dose groups, respectively. Quantifiable concentrations of tanezumab were detectable in neonates in the 0.5, 4, and 30 mg/kg dose groups until the day after birth (DB) 30, DB120 and DB127 respectively, following birth.

Tanezumab is distributed across the placenta and is detected in milk. A tissue distribution study showed that tanezumab is distributed to mainly highly perfused organs, primarily liver and kidney. In addition, lung heart and spleen also contained tanezumab. With respect to CNS tissues, all brain samples had  125 I concentrations near the lower limit of quantitation for both tanezumab and control antibody.

Because  of  the  intrinsic  nature  of  IgG  antibodies,  no  metabolism  studies  or  excretion  studies  were conducted since antibodies are primarily catabolised. No drug-drug interaction studies were performed.

## 2.3.4. Toxicology

## Single dose toxicity

A single dose of 20 mg/kg did not result in any noteworthy findings.

## Repeat dose toxicity

## Repeat dose studies in rats

In a short-term repeat dose study, doses of 0.2, 2 or 20 mg/kg tanezumab were administered IV to rats. In all groups receiving tanezumab, skin changes were observed which manifested as crusted and reddish skin, which correlated histopathologically with mixed cell inflammation, ulceration and serocellular crust. These changes did not resolve during the recovery period. These lesions were considered self-inflicted and considered adverse. Rat females appeared to be more sensitive the to the skin effects of tanezumab in  the  separate  male  and  female  fertility  and  early  embryonic  development  studies.  Variability  in nonclinical toxicokinetic data could be explained by variability in the animal populations, small number of animals and/or immunogenicity. Based on the absence of tanezumab-related skin effects in clinical trials, there appears to be no clinical relevance for these skin observations in rats regardless of sex. Serum osteocalcin was mildly increased in all animals receiving tanezumab, without other correlating findings.

There were no morphologic changes to CNS or PNS. However, average neuron size in the dorsal root ganglia was decreased in animals receiving 20mg/kg tanezumab and average neuron area of a superior cervical  ganglion was decreased at all tested doses and was partially recoverable. Average ganglion volume was decreased in all males receiving tanezumab and in all females receiving 2mg/kg tanezumab and above. Average total estimated neuron counts were decreased in all animals receiving tanezumab with  partial  recovery.  These  observations  were  followed  up  by  a  series  of  experiments  which  are described  in  the  section  on  mechanistic  toxicity  evaluations,  which  disclose  this  finding  to  be  an exaggerated pharmacological effect. The NOAEL could not be determined as a result of the observed skin lesions. The mean Cmax and AUC168 values during Week 4 of the study for the 0.2 mg/kg/dose (0.4 mg/kg/week) level were 10.2 µg/mL and 969 µg·h/mL, respectively, which was 35 times higher

<div style=\"page-break-after: always\"></div>

than the clinical exposure (based on Cav). ADA disposition of the animals (36% positive in the treatment groups) did not affect the interpretation of the results.

## Repeat dose studies in cynomolgus monkeys.

A  1-month IV,  1-month SC, a 6-month IV and a 6-month combined IV/SC study was conducted in cynomolgus monkeys. In the 1-month IV study, there were no remarkable tanezumab-related adverse effects at any dose tested. No ADA positive animals were identified. The NOAEL was 30 mg/kg/week, with associated Cmax and AUC168 of 950 µg/mL and 90300 µg·h/mL, respectively, which was 3298 times higher than the clinical exposure (based on Cav).

In the 1-month SC study there were similarly no remarkable findings with the exception that in animals receiving 10mg/kg tanezumab and up, minimal to mild injection site reactions were observed which correlated  histopathologically  with  dermal  and  muscle  inflammation.  This  finding  is  not  considered adverse. The overall incidence of ADA across dose groups was 23% (5/22 animals) but is not considered to have affected the interpretation of the study.  The NOAEL was 30 mg/kg/week, with associated Cmax and AUC168 of 474 µg/mL and 65300 µg·h/mL, respectively, which was 2385 times higher than the clinical exposure (based on Cav).

In the first 6-month study (study 03034), IV doses of tanezumab up to 30mg/kg were administered weekly to young adult cynomolgus monkeys for 26 weeks with a recovery period of 2 months (lots H3001 and H3005 were used in this study). One female was found dead, with the possible cause of death attributed to severe pulmonary haemorrhage, likely due to an ADA mediated infusion reaction. Other animals in this study had the dosing halted nearing the end of the study due to an adverse ADA response and  either  removed  from  the  study  or  assigned  to  the  recovery  group.  ADA  positive  animals  were associated  with  a  marked  reduction  in  systemic  exposure  to  tanezumab.  In  this  study  the  overall incidence of ADA in treated animals was 21% (6/28 animals). There were no remarkable findings in the remaining study animals, which included clinical observations, body weights or body weight changes, food consumption, blood pressure, respiratory rate, body temperature, ophthalmology, electrocardiograms (including measured heart rate and QTc interval), clinical pathology, gross findings, or organ weights. There were no apparent effects upon eosinophils, platelets, fibrinogen, complement, or  C-reactive  protein,  nor  were  changes  seen  that  could  be  attributed  to  tanezumab  following comprehensive examination of the central, peripheral and autonomic nervous systems (brain; spinal cord; sciatic, tibial, sural and optic nerves; trigeminal, SMG, CTG and SCG; dorsal roots; ventral roots and ganglia). The NOAEL was 30 mg/kg/week, with associated Cmax and AUC168 of 1390 µg/mL and 151000 µg·h/mL, respectively, which was 5514 times higher than the intended clinical exposure (based on Cav).

In  a  second  6-month  study,  mature  cynomolgus  monkeys  received  doses  of  tanezumab  up  to  30 mg/kg/week for 26 weeks followed by a 2-month recovery period. There were no remarkable changes in  mortality,  clinical  signs,  body  weight,  food  consumption,  menstrual  cycle  evaluation,  neurological evaluation, haematology, clinical chemistry, coagulation, ECG, echocardiography, blood pressure, body temperature, ophthalmology, testicular volume, semen analysis, immunophenotyping, cell proliferation markers  (Ki67,  PCNA),  organ  weights,  macroscopic  and  microscopic  changes.  A  comprehensive evaluation of bone/joint homeostasis, including radiographic (X-ray) and magnetic resonance imaging (MRI) examination of the coxofemoral (hip) joint, analysis of serum bone biomarkers (C-telopeptide fragments of collagen Type 1 [CTX1], osteocalcin, and type 1 collagen N-terminal propeptide [P1NP]), bone micro computed tomography (microCT) and decalcified and undecalcified bone histopathology of the hip and knee joint also did not reveal any test-article related changes. There were no tanezumab effects on the central nervous system, the peripheral nerves, the DRG, or the parasympathetic ganglia. In females given tanezumab, slightly decreased intraepidermal nerve fibre density was observed. In males, decreased neuron size in the cervicothoracic ganglion was observed without further corollary

<div style=\"page-break-after: always\"></div>

findings. The findings were only partially reversible as in males and females exposed to tanezumab in the high dose group, decreased nerve fibre density (F) and ganglion size (M) was not fully resolved. It should be noted that due to the half-life of tanezumab, a 2-month recovery may not have been sufficient duration to fully evaluate reversal of the study observations in an exposure-free window. The NOAEL for IV administration of tanezumab was 30 mg/kg/week, with associated Cmax and AUC168 of 1480 µg/mL and 160000 µg·h/mL, respectively. The NOAEL for SC administration of tanezumab was 30 mg/kg/week, with associated Cmax and AUC168 of 1080 µg/mL and 162000 µg·h/mL, respectively, which was 5916 times higher than the intended clinical exposure (based on Cav).

In one 6-month IV study in young adult animals, no neuronal effects were seen. In the other 6-month IV study in adult animals, decreases in neuronal fibre density or neuronal size were observed. It is not clear what causes these differences. Notable variables between these studies were the age of the animals at the time of study initiation and tanezumab batch used in the study. The differences in observations between the two 6-month repeat dose toxicity studies are striking, because neuronal effects would be expected in the young-adult animals as well. Particularly since neuronal toxicity was observed in in the cynomolgus PPND study. Though no definitive answer can be given that explains these differences in outcomes, they can be attributed to methodological rather than true age-related differences. Possible causes are the methods used to evaluate ganglia in these two studies, the date of initiation (in the older juvenile study, less was known about potential NGF effects), and experience with evaluating NHP ganglia pathology. Finally, the number of animals in the adult study was also higher, providing more confidence in the interpretation of the data. While these arguments are all accepted, it must be considered that the effects seen in adult monkeys would have also been seen in young adult animals when performed under the same conditions. This would be in line with the overall PD effects of tanezumab and observations in mechanistic studies in other species as well as reproductive toxicity studies.

## Mechanistic studies

Neuronal observations including small neurons, decreased neuron area, decreased ganglion volume and observations  suggesting  neuronal  loss,  resulted  in  an  extensive  investigation  on  the  potential  for tanezumab mediated neurotoxicity in adult animals. The mechanistic studies consisted of three studies: one study in rats was conducted to evaluate differences between young and adult animals using a rodent anti-NGF antibody (muMab911); a single dose study in monkeys to evaluate the effects on the peripheral nervous  system  when  followed  for  28  days  and  was  optimised  for  the  detection  of  neuronal  cell necrosis/apoptosis; and a 3-6 month study in monkeys to evaluate tanezumab related effects on the peripheral  sympathetic  nervous  system  when  administered  once  every  8  weeks  via  subcutaneous injection to cynomolgus monkeys for 3 months (two doses total) or 6 months (three doses total) and to assess the reversibility or persistence of any effects through recovery up to 10 months following the last dose.

These studies confirmed that inhibition of NGF function results in a decreased in neuron size, neuron area,  average  ganglion  volume  and,  initially,  lower  estimated  neuron  counts.  In  rats,  lower  neuron volumes were observed in young rats (6-8 weeks), but not in adult animals and did not reveal notable changes in ganglion volume or neuron number. The observed differences are likely due to the chosen methodology to process tissue in the stereological evaluation. In the mechanistic studies, tissue was embedded prior to processing. This reduced tissue shrinkage (up to 10% shrinkage was observed). In contrast, the toxicology study used frozen sections of the SCG resulting in significant tissue shrinkage up to 74%. The trend towards smaller ganglia, smaller and fewer neurons is considered to be attributed to this shrinkage. In monkeys, neuronal changes were observed at doses of 1.2mg/kg either given once or after repeated dosing and the onset of these changes was observed as early as 2 weeks after the first administration. All changes were fully reversible after discontinuation of treatment by the end of the 10

<div style=\"page-break-after: always\"></div>

months  recovery  period.  Regarding  the  lower  estimated  neuron  counts  observed  in  monkey,  the applicant states that while these lower counts were observed in the mechanistic studies, this is not considered to be due to neuronal cell death or neuronal necrosis, but due to atrophy leading to a lack of recognition of neurons in the paraffin embedded sections used for the stereologic evaluation. This is accepted. Furthermore, none of the tanezumab-related neuronal changes appeared to have an effect on normal functioning of adult animals. Therefore, these changes are not likely to be toxicologically relevant. The current hypothesis is that tanezumab causes morphological changes to sympathetic neurons that leads (some of) these to become unrecognizable with the current stereology methodology. It is noted that the estimated neuron count returned to baseline after recovery, which also supports that there is no cell death. An additional cardiovascular safety study was conducted in monkeys (see section on safety pharmacology). No overt tanezumab related effects were revealed, although in isolated cases incidental orthostatic hypotension was observed. Given the transient nature and low severity of the finding this is not considered to be toxicologically relevant although long term cardiovascular risk cannot be completely ruled out and is a potential risk.

A further set of (non-GLP) studies was conducted after observations of rapidly progressive osteoarthritis (RPOA) in the clinic to evaluate bone and joint safety in rodents. In a 12-week observatory study in female mice, there were no test article-related findings on any bone endpoints, including osteonecrosis. A one-month rat study was conducted in which female rats received weekly doses of either tanezumab, muMab911, naproxen or a combination of tanezumab and naproxen or muMab911 and naproxen for one month. Naproxen was dosed daily. There were no test-article related effects on any evaluated bone parameters, including osteonecrosis. An expected increase in skin lesions was observed in all groups receiving antibody. In presence of naproxen, the severity of the lesions was increased and in the case of muMab911 the incidence of the findings was also increased. The applicant considers that this may be due to delayed wound healing and fracture healing in rats given NSAIDS, which is a plausible explanation of the findings. A series of studies with tanezumab was conducted in the medial meniscal tear (MMT)induced joint damage rat model, which is an established model for arthritis. A one-month study in the MMT rat model was conducted in which animals received muMab911 or tanezumab or either antibody combined with naproxen. After one month, animals receiving either antibody showed increased severity of MMT-induced joint damage as a result of adaptive responses to mechanical loading or joint instability. Co-administration  with  naproxen  did  not  increase  joint  damage  although  it  was  considered  by  the applicant that the duration of the study may not have been sufficient to demonstrate an additive effect of naproxen. In another 1-month study, male rats with MMT-induced joint damage were given tanezumab in increasing doses (0.1, 1 or 10 mg/kg/week) for one month. At the lowest dose tested, tanezumab induced an increase in joint damage as measured by cartilage damage observations, bone changes and osteophyte formation values. Similar to the previous study, these changes are considered to be related to  an  adaptive  response  to  altered  load  bearing,  which  was  supported  by  observations  of  early  gait deficiency in isotype and vehicle controls compared to sham and tanezumab treated groups. Similar results were obtained in another study when initiating treatment 21 days after induction of the lesion. Overall,  the  data  suggest  that  tanezumab  increases  joint  lesion  severity  in  the  MMT  rat  model  by encouraging  normal  weight  bearing,  rather  than  through  any  direct  enhancement  of  cartilage/joint damage. No evidence was found related to atrophic bone destruction associated with RPOA. Finally, in a study to evaluate the effects of muMAb011 on peripheral (sciatic) nerve regeneration following nerve crush injury, no evidence was found that anti-NGF treatment affects axonal regeneration or functional recovery.

In  conclusion,  repeated  dosing  of  tanezumab  resulted  in  adverse  skin  reactions  in  rat.  In  monkeys, tanezumab was relatively well tolerated but ADA mediated toxicity resulting in death was noted in 1 monkey. In both species, neuronal effects were observed in line with the anticipated pharmacological action of tanezumab. These findings were ultimately not considered adverse by the applicant because there is no neuronal loss, the findings were completely reversible (in the mechanistic studies) and no

<div style=\"page-break-after: always\"></div>

overt  signs  of  neuronal  toxicity  were  observed.  Because  the  findings  are  considered  related  to  the pharmacology of tanezumab, they are clinically relevant, despite being observed at exposures exceeding the clinical exposure. No specific behavioural endpoints were included in non-clinical studies. However, clinical observations did not reveal any evidence of tanezumab related behavioural effects. Similarly, an evaluation of the cardiovascular system in monkeys did not reveal any meaningful changes. Animals in the 6-month repeat dose toxicity study were exposed for 8 months, which included the duration of the recovery due to the long half-life  of  tanezumab.  These  data  did  not  suggest  that  neuronal  changes progressed in this time period. The totality of evidence - lack of behavioural changes, no progression of neuronal findings, high exposure multiples- would not suggest that functional changes would become clinically relevant after 6-8 months. There was no evidence of axonal effects suggestive of retraction. Furthermore, data from the 2-month nerve regeneration study showed that axonal regeneration and functional  recovery  was  not  affected  by  NGF  inhibition.  Finally,  investigations  to  evaluate  whether tanezumab can induce rapidly progressive osteoarthritis showed that tanezumab induced bone and joint damage was an adaptive response secondary to normal load bearing on that joint.

## Genotoxicity

Genotoxicity was not assessed in line with ICH S6(R1). An evidence-based approach did not identify any risks that would suggest that tanezumab has carcinogenic potential.

## Carcinogenicity

## Reproduction Toxicity

In a rat fertility and early embryonic development study, no tanezumab related effects were observed on any fertility or development parameters. Skin lesions were apparent in all doses tested, appeared self-inflicted and were considered adverse. One male animal in the 6mg/kg/week dose was euthanised on day 25 due to a deteriorating condition which was considered treatment related. As a result, a NOAEL for male systemic toxicity was not identified. A NOAEL for male and female fertility is considered to be the highest dose tested, 6 mg/kg/week, with associated Cmax and AUC96 of 143 µg/mL and 10400 µg·h/mL, respectively, which was 665 times higher than the intended clinical exposure (based on Cav). As in other tanezumab studies in rats, adverse skin lesions were observed in all tanezumab treated animals  and  were  accompanied  by  hair  loss  and  isolated  incidences  of  desquamation,  discoloration, discharge and swelling. There were no tanezumab-related effects on body weight, food consumption, oestrous cyclicity, female fertility, reproductive indices, or Caesarean section parameters including early embryo  viability,  prenatal  and  postnatal  development,  including  maternal  function.  The  NOAEL  for developmental toxicity was 6 mg/kg/week, with associated Cmax and AUC72 of 109 µg/mL and 4360 µg·h/mL, respectively, which was 372 times higher than the intended clinical exposure (based on Cav). A NOAEL for systemic toxicity was the highest dose tested.

Two  PPND  studies  were  conducted  in  cynomolgus  monkeys:  one  IV  study  where  tanezumab  was administered between GD20 to parturition (initiated in 2008) and a second study where tanezumab was administered from GD20 to GD48 (initiated in 2010).

In the study where pregnant females received doses of tanezumab between GD20 and GD48 there were no remarkable maternal observations in clinical observations, abortion/in utero embryo-foetal death, food  consumption,  body  weight,  gestation  length,  or  haematology,  coagulation,  or  serum  chemistry parameters. The NOAEL for maternal toxicity was the highest dose tested (30mg/kg/week).

<div style=\"page-break-after: always\"></div>

Stillbirth and early infant loss were increased in all tanezumab treated groups. Stillbirth was at the high end of historical control limits, but infant loss was above normal background ranges. While a definitive cause of death could not be determined, bacterial infection was confirmed in most (5/6) of these cases. Skin lesions in infants were observed across the study, including in control group animals, but were slightly  more  frequent  and  took  longer  to  heal  in  the  drug  treated  group.  These  findings  included abnormal skin colour, abrasions (high dose animals) loss of fur, swollen skin (high dose animals) and scabbing/crust formation and likely comparable to the skin lesions observed in adult rats. Skin lesions were observed in all study groups including controls. Incidence and severity were higher in treatment animals  and  was  considered  a  secondary  effect  since  the  observations  were  made  after  systemic clearance of tanezumab. However, the applicant states that although it is not certain whether rodent findings are fully translatable to NHP, it remains a possibility that the skin effects are mechanistically similar to the rat findings. Of note, no skin-related effects were observed in adult animals, which can be explained by age-dependent NGF requirements. Skin-related AEs were not seen in clinical trials.

The NOAEL is considered to be not determined based on the increased stillbirth rates in tanezumab treated animals and skin lesions in the 30 mg/kg/week group. 0.5 mg/kg/week is therefore the LOAEL and corresponds to maternal GD48 Cmax and AUC168 of 18.4 µg/mL and 1810 µg·h/mL, respectively, which is 37 times higher than the intended clinical exposure (based on Cav).

All maternal plasma samples and milk samples collected during the lactation phase were below the lower limit of quantitation (BLQ). Neonate plasma samples were BLQ. It should be noted that in this study, as in the 1-month rat study, tanezumab could be quantified in 1 control group animal. The overall incidence of ADA in treated animals in maternal serum across dose groups was 37% (15/41 animals) and was 33% (7/21 animals) and 40% (8/20 animals) in dams dosed at 0.5 and 30 mg/kg/week, respectively. The overall  incidence  of  ADA  in  milk  and  neonate  serum  was  16%  and  32%,  respectively.  The  immune response against tanezumab did not affect the interpretation of this study.

A  study  in  cynomolgus  monkeys  where  pregnant  females  received  tanezumab  between  GD20  to parturition showed a slight increase in abortion and embryofoetal loss (within historical control) and revealed a dose dependent increase in stillbirth from the lowest tested dose (0.5mg/kg/week) onward. Infant death was observed in the mid dose (4mg/kg/week) in the same incidence but at a later time point than controls, and was increased in the highest dose tested (30mg/kg/d). Surviving animals in the mid and high dose groups had lower body weights compared to control animals from birth. Body weight gain was slightly lower in high dose group animals. The growth rate in mid and high dose animals was lower compared to controls. In these groups, animals also showed clinical signs of hunched posture, lowered activity/lethargy and shivering.

Skin lesions were observed in all groups including controls and comparable in incidence. However the severity increased in animals receiving tanezumab. In the high dose group, haematology parameters were suggestive of inflammation, which the applicant attributes to the skin lesions and reduced clinical condition  in  some  animals.  This  is  endorsed.  Immune  system  depression  was  assessed  via  a  KLH challenge and showed that infants could successfully mount an antibody response against KLH although the primary response (IgG and IgM) was lower in the tanezumab group compared to control animals.

The pronounced developmental effects in cynomolgus monkey offspring are considered to be the result of the intended pharmacology resulting in neurotoxicity and skin toxicity. Furthermore, the dampened initial  immune  response  is  noted,  but  its  toxicological  relevance  is  limited.  The  NOAEL  for  maternal toxicity is the highest dose tested, 30 mg/kg/week. A NOAEL for offspring could not be determined. Based  on  the  effects  observed  in  the  infants,  the  lowest-observed-adverse-effect  level  (LOAEL)  for developmental toxicity was 0.5 mg/kg. Th e maternal AUC at infant LOAEL was 1090 μg·hours/mL at GD139.

<div style=\"page-break-after: always\"></div>

Concluding, tanezumab clearly has an adverse effect on the developing foetus in monkeys at all doses tested because of the mode of action of tanezumab. Tanezumab is contraindicated during pregnancy as reflected in the SPC.

## Local Tolerance

Repeated tanezumab administration resulted in manageable (histopathological) suggestive of injection site reactions in a 1-month study in monkeys, but was not observed in subsequent longer term studies. Skin irritation was observed in rats and offspring of monkeys treated with tanezumab and is considered adverse.  Nevertheless,  the  potential  for  tanezumab  to  result  in  local  tolerance  issues  is  considered limited.

## Other toxicity studies

## Antigenicity

ADA have been observed in most repeat dose studies in rat and monkey. While ADA incidence in the rat studies was high (88%), this was not accompanied with an increase in clearance and exposure in ADA positive animals was comparable to ADA negative animals. In contrast, the overall incidence of ADA in repeat-dose  monkey  toxicity  studies  ranged  from  0%  to  23%  and  ADA  positive  animals  had  lower exposure to tanezumab than ADA negative animals. However, the lower exposure in individual animals did not affect the interpretation of the data generated in these studies as there was no appreciable effect on group mean TK parameters.

Surprisingly, ADA and tanezumab were measured in control animals in the 1 month repeat dose study in rats ADA was measured in the 6-month repeat dose study in monkeys. The applicant considers that one  of  the  vehicle-control  article  formulations  (after  Day  12)  may  have  been  contaminated  with tanezumab. In the monkey study, quantifiable concentrations of tanezumab were not detected in vehicle control samples, but ADA was detected in approximately 65% of animals from the vehicle control group and the ADA titre values in these animals increased over the duration of the study. While the applicant suggests that the increase could be attributed to control animals being housed in the same room as tanezumab-treated animals may have been indirectly exposed to tanezumab or human IgG through aerosolisation, the air exchange system or through handling. Given that tanezumab was also quantified in controls in a developmental toxicity study in monkeys at this facility, it seems that this could have been the source of the issue. Therefore, the provided rationale is a possible root cause. In none of these animals, ADA- or tanezumab related effects were apparent or were within normal limits reported in literature. Historical control data, while implicitly requested, has not been submitted. It is accepted that ADA formation in controls and (potential) tanezumab exposure in these animals did not confound the overall interpretation of the studies. It is agreed with the applicant that ADA observed in the vehiclecontrol animals did not affect the interpretation or conclusions of either study.

## Immunotoxicity

A weight of evidence approach does not suggest that inhibition of NGF will have an adverse effect on the immune system. No influence of tanezumab on peripheral lymphocytes (and subsets) of infant monkeys exposed  to  tanezumab  in  utero  were  observed,  although  the  initial  immune  response  to  KLH  was dampened.  There  was  no  evidence  of  immune  system  modulation  observed  in  patients  exposed  to tanezumab. The weight of evidence suggests that there is no toxicologically relevant effect of tanezumab on the immune system, which is endorsed. Nevertheless we identified one publication that suggests that a NGF null-mutation results in immune system dysfunction in humans (Carvalho et al. 2010). Loss of

<div style=\"page-break-after: always\"></div>

function mutations in the NGF gene is often associated with adverse pathologies. This is not the case for patients treated with tanezumab, where NGF/trkA is not disrupted. Therefore, the pathologies resulting from loss of function mutations are not relevant for the effects of temporal NGF inhibition. This is also reflected in the absence of overt toxicity in animal studies. However, it should be noted that the inhibition of NGF in reproductive toxicity studies suggests that NGF signalling is important in development.

## Haemocompatibility and tissue cross reactivity

Compatibility of tanezumab with human blood and binding of tanezumab to a standard tissue panel was also assessed. Tanezumab did not bind to any tissues in a standard panel of rat, monkey and human tissues. Tanezumab was compatible with human blood.

## 2.3.5. Ecotoxicity/environmental risk assessment

Tanezumab is a humanised immunoglobulin G Type 2 (IgG2) monoclonal antibody consisting of two heavy and two light amino  acid chains. Therefore, in accordance with the  CHMP  guidance EMEA/CHMP/SWP/4447/00,  an  environmental  risk  assessment  is  not  provided  with  this  marketing authorisation application.

## 2.3.6. Discussion on non-clinical aspects

Safety  pharmacology  studies  with  tanezumab  in  monkeys  revealed  only  a  minor  and  incidental occurrence  of  orthostatic  hypotension.  However,  it  is  not  known  whether  lifelong  treatment  with tanezumab would not result in disruption of neuronal signalling as a result of prolonged neuronal atrophy (as observed in the repeat dose studies in monkeys and mechanistic studies in monkeys) in the heart. It is considered that this is a potential unknown risk.

ADAs have been observed in most repeat-dose studies in rat and monkey. While ADA incidence in the rat studies was high (88%), this was not accompanied by an increase in clearance and exposure in ADA positive animals was comparable to ADA negative animals. In contrast, the overall incidence of ADA in repeat-dose  monkey  toxicity  studies  ranged  from  0%  to  23%  and  ADA  positive  animals  had  lower exposure to tanezumab than ADA negative animals. However, the lower exposure in individual animals did not affect the interpretation of the data generated in these studies as there was no appreciable effect on group mean TK parameters. Surprisingly, ADA and tanezumab were measured in control animals in the 1-month repeat dose study in rats ADA was measured in the 6-month repeat dose study in monkeys. The applicant considers that one of the vehicle-control article formulations (after Day 12) may have been contaminated with tanezumab. In the monkey study, quantifiable concentrations of tanezumab were not detected in vehicle control samples, but ADA was detected in approximately 65% of animals from the vehicle control group, and the ADA titre values in these animals increased over the duration of the study. While the applicant suggests that the increase could be attributed to control animals being housed in the same room as tanezumab-treated animals may have been indirectly exposed to tanezumab or human IgG through aerosolisation, the air exchange system or through handling. Given that tanezumab was also quantified in controls in a developmental toxicity study in monkeys at this facility, it seems that this could have been the source of the issue. Therefore, the provided rationale is a possible root cause. It is agreed  with  the  applicant  that  ADA  observed  in  the  vehicle-control  animals  did  not  affect  the interpretation or conclusions of either study.

In one 6-month IV study in young adult animals, no neuronal effects were seen. In the other 6-months IV study in adult animals, decreases in neuronal fibre density or neuronal size were observed. It is not clear what causes these differences. Notable variables between these studies were the age of the animals at the time of study initiation and tanezumab batch used in the study. The differences in observations

<div style=\"page-break-after: always\"></div>

between the two 6-month repeat-dose toxicity studies are striking because neuronal effects would be expected in the young-adult animals as well. Particularly since neuronal toxicity was observed in in the cynomolgus PPND study. Even though no definitive answer can be given that explains these differences in outcomes, they can be attributed to methodological rather than true age-related differences. Possible causes are the methods used to evaluate ganglia in these two studies, the date of initiation (in the older juvenile study, less was known about potential NGF effects), and experience with evaluating NHP ganglia pathology. Finally, the number of animals in the adult study was also higher, providing more confidence in the interpretation of the data. While these arguments are all accepted, it must be considered that the effects seen in adult monkeys would have also been seen in young adult animals when performed under the same conditions. This would be in line with the overall PD effects of tanezumab and observations in mechanistic studies in other species as well as reproductive toxicity studies.

In monkeys, neuronal changes were observed at doses of 1.2mg/kg either given once or after repeated dosing and the onset of these changes was observed as early as 2 weeks after the first administration. All changes were fully reversible after discontinuation of treatment by the end of the 10 months recovery period. Regarding the lower estimated neuron counts observed in monkey, the applicant states that while these lower counts were observed in the mechanistic studies, this is not considered to be due to neuronal cell death or neuronal necrosis, but due to atrophy leading to a lack of recognition of neurons in  the  paraffin-embedded  sections  used  for  the  stereologic  evaluation.  To  explain  this,  the  current (undemonstrated) hypothesis is that tanezmab causes morphological changes to sympathetic neurons that leads (some of) these to become unrecognizable with the current stereology methodology. It is noted that the estimated neuron count returned to baseline after recovery, which also supports that there is no cell death. Furthermore, none of the tanezumab-related neuronal changes appeared to have an  effect  on  normal  functioning  of  adult  animals.  Therefore,  these  changes  are  not  likely  to  be toxicologically relevant. No specific behavioural endpoints were included in non-clinical studies. However, clinical observations did not reveal any evidence of tanezumab related behavioural effects. Similarly, an evaluation of the cardiovascular system in monkeys did not reveal any meaningful changes. Animals in the 6-month repeat dose toxicity study were exposed for 8 months, which included the duration of the recovery due to the long half-life  of  tanezumab.  These  data  did  not  suggest  that  neuronal  changes progressed in this time period. The totality of evidence - lack of behavioural changes, no progression of neuronal findings, high exposure multiples- would not suggest that functional changes would become clinically relevant after 6-8 months. There was no evidence of axonal effects suggestive of retraction. Furthermore, data from the 2-month nerve regeneration study showed that axonal regeneration and functional recovery was not affected by NGF inhibition.

The weight of evidence suggests that there is no toxicologically relevant effect of tanezumab on the immune system. Nevertheless, we identified one publication that suggests that a NGF null-mutation results in immune system dysfunction in humans (Carvalho et al. 2010). Loss of function mutations in the NGF gene are often associated with adverse pathologies. This is not the case for patients treated with  tanezumab,  where NGF/trkA is  not  disrupted.  Therefore,  the  pathologies  resulting  from  loss  of function mutations are not relevant for the effects of temporal NGF inhibition. This is also reflected in the absence of overt toxicity in animal studies. However, it should be noted that the inhibition of NGF in reproductive toxicity studies suggests that NGF signalling is important in development.

In a monkey PPND study, Stillbirth and early infant loss were increased in all tanezumab treated groups. Stillbirth was at the high end of historical control limits, but infant loss was above normal background ranges. While a definitive cause of death could not be determined, bacterial infection was confirmed in most (5/6) of these cases. Skin lesions in infants were observed across the study, including in control group animals, but were slightly more frequent and took longer to heal in the drug-treated group. These findings included abnormal skin colour, abrasions (high dose animals) loss of fur, swollen skin (high dose animals) and scabbing/crust formation and likely comparable to the skin lesions observed in rats. While

<div style=\"page-break-after: always\"></div>

skin lesions were observed in all study groups including controls, incidence and severity was higher in treatment  animals  and  was  considered  a  secondary  effect  since  the  observations  were  made  after systemic clearance of tanezumab. However, the applicant states that although it is not certain whether rodent  findings  are  fully  translatable  to  NHP,  it  remains  a  possibility  that  the  skin  effects  are mechanistically  similar  to  the  rat  findings.  Of  note,  no  skin-related  effects  were  observed  in  adult animals, which can be explained by age-dependent NGF requirements. Skin-related AEs were not seen in clinical trials.

## 2.3.7. Conclusion on the non-clinical aspects

The non-clinical part of this Marketing Authorisation Application is satisfactory.

## 2.4. Clinical aspects

## 2.4.1. Introduction

The development programs of all anti-NGF monoclonal antibodies (tanezumab, fasinumab, fulranumab) were put on clinical hold by the FDA from 2010 - 2012 due to the occurrence of severe adverse effects to synovial joints, and further from 2012 - 2015 due to a risk of adverse events to the sympathetic nervous system based on findings from non-clinical studies. The period during the clinical hold was used to devise phase 3 studies with SC administration and implementation of precautionary measures, in  patients  with  moderate  to  severe  OA  of  hip/knee  who  were  required  to  have  insufficient efficacy/inappropriateness of standard pharmacological therapies, while the 10 mg dose was not included anymore. As a result, there are 7 'pre-2015' and 3 'post-2015' phase 3 studies on OA that provide efficacy data with different design features.

Of the 'pre-2015' studies, three studies (1025, 1043, and 1016) were fully enrolled when terminated early and are included in integrated efficacy and safety analyses. Another three studies (1026, 1027 and 1030) had enrolled approximately 50 to 75% of the planned number of patients and provide supportive efficacy data. The 'pre-2015' studies were all performed in patients with moderate to severe OA of the hip or knee.

The 'post-2015' studies included three phase 3 studies (1056, 1057, 1058) in OA evaluating tanezumab 2.5 mg and 5 mg SC. Studies 1056 and 1057 were placebo-controlled of 16 weeks and of 24 weeks duration. Study 1058 was NSAID controlled and of 56 weeks duration, the patients in this study did not have a contra-indication for NSAIDs.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1 Tabular overview of clinical trials

| Efficacy Study Category/ Categories          | Study (To be linked to Module 5.2)   | N    | Index Joint   | UnsatisfactoryPrior Analgesicsa (Inclusion Criteria)   | Study. Designb   | Comparator   | Comparator   | Treatment Duration [1°Efficacy Analysis] in Weeks (No. Doses)   | Route of Admin   | Tanezumab Doses (mg8 Weeksd)   | Tanezumab Doses (mg8 Weeksd)   | Tanezumab Doses (mg8 Weeksd)   |
|----------------------------------------------|--------------------------------------|------|---------------|--------------------------------------------------------|------------------|--------------|--------------|-----------------------------------------------------------------|------------------|--------------------------------|--------------------------------|--------------------------------|
| Efficacy Study Category/ Categories          | Study (To be linked to Module 5.2)   | N    | Index Joint   | UnsatisfactoryPrior Analgesicsa (Inclusion Criteria)   | Study. Designb   | PBO          | Activec      | Treatment Duration [1°Efficacy Analysis] in Weeks (No. Doses)   | Route of Admin   | 2.5                            | 5                              | 10                             |
| Placebo-Controlled                           | 1056                                 | 696  | KH            | APAP,NSAID,Opioid                                      | RDB              | Y            |              | 16 [16] (2)                                                     | SC               | Y                              | T                              |                                |
| Placebo-Controlled                           | 1057                                 | 849  | K/H           | APAP, NSAID,Opioid                                     | RDB              | Y            |              | 24 [24] (3)                                                     | SC               | Y                              | Y                              |                                |
| Placebo-Controlled                           | 1011                                 | 690  | K             | Non-opioid                                             | RDB              | Y            |              | 24 [16] (3)                                                     | IV               | Y                              | Y                              | Y                              |
| Placebo-Controlled                           | 1014                                 | 621  | H             | Non-opioid                                             | RDB              | Y            |              | 24 [16] (3)                                                     | IV               | Y                              | Y                              | Y                              |
| Placebo-Controlled Active-Controlled         | 1015                                 | 828  | K             | No criteria                                            | RDB              | 人            | Y            | 16 [16] (2)                                                     | IV               |                                | Y                              | Y                              |
| Placebo-Controlled Active-Controlled         | 1018                                 | 840  | KH            | No criteria                                            | R,DB             | Y            | Y            | (2) [91]91                                                      | IV               |                                | Y                              | Y                              |
| Active-Controlled Long-TermActiveControlled  | 1058                                 | 3021 | KH            | APAP, Opioid                                           | R, DB            |              | Y            | 56 [16] (7)                                                     | SC               | Y                              | Y                              |                                |
| Active-Controlled Long-Term ActiveControlled | 1025e                                | 2700 | K/H           | No criteria                                            | R DB             |              | Y            | 56 [16] (7)                                                     | IV               |                                | Y                              | Y                              |
| Long-Term Uncontrolled                       | 1016e                                | 2142 | K/H           | No criteria/Non-opioid                                 | RB, Ex + StOC    |              |              | 104 [24,48] (13)                                                | IV               | Y                              | Y                              | Y                              |
| Long-Term Uncontrolled                       | 1043e                                | 678  | K/H           | No criteria                                            | RB +StOC         |              |              | 56 [8,16] (7)                                                   | SC               | Y                              | Y                              | Y                              |

## 2.4.2. Pharmacokinetics

## Methods

PK characterisation is supported by:

- Non-compartmental analysis from across 2 healthy volunteer studies and 4 studies in patients with OA, CLBP, or undergoing bunionectomy across doses of 10 to 1000 μg/kg following IV administration and fixed doses of 5 to 20 mg following IV or SC administration

## PopPK model

Pharmacokinetics of tanezumab at steady state were estimated based on the popPK model. The model is considered suitable for characterising the PK after a single dose and the steady-state PK of tanezumab. Regarding possibly dependency of PK at steady state on NGF, the applicant stated that it was not possible to measure free NGF over time, but that consistent with the MOA and standard PK of mAbs, BNGF is found to be a covariate on Vmax and has a small impact on the nonlinear CL of tanezumab related to binding to its target. The limited impact is related to molar concentrations of tanezumab being 200-900fold higher than BNGF over the steady state dosing interval following 2.5 mg SC administered every 8 weeks.  Further, the applicant stated that the total NGF concentrations increase during tanezumab dosing due to the formation of tanezumab-NGF complexes. Upon termination of tanezumab treatment, the total NGF concentrations begin approaching baseline concentrations with an effective half-life similar to that of tanezumab. The lack of change in proNGF over time also supports this conclusion. Therefore, while free NGF could not be measured over time, the indirect evidence supports that it remains suppressed as predicted by the PK-NGF model over the time course of the tanezumab treatment.

Although the estimated KM (31.2 ng/mL) for the non-linear clearance pathway is below the LLOQ (35 ng/mL) for the post-2015 samples based on the updated assay, it is above the LLOQ (12 ng/mL) for the pre-2015 samples. There were &gt;11,000 observations from &gt;2500 patients across pre-2015 Studies 1011, 1012, 1014, 1015, 1018, 1027, constituting all the concentration data following IV administration

<div style=\"page-break-after: always\"></div>

and some following SC administration (1027), with KM = 27.7 (Relative SE 37%). Therefore, the current estimated  KM=  31.2  ng/mL,  based  on  combined  pre-  and  post-2015  IV/SC  analysis  is  considered acceptable.

Post-hoc comparison of a simple one compartment model vs a simple two compartment model to the IV data resulted in a 1736-point increase in -2LL (Objective Function Value) justifying the need for the second compartment to appropriately describe these data. The two-compartment nature of tanezumab PK following IV infusion is also in line with literature data for other mAbs.

## Bioavailability

The SC bioavailability (F) of tanezumab is estimated, based on popPK analysis, to range from 62% to 76%. In males and females, respectively, F was estimated to be 73% and 76% in the more intensively sampled Phase 2 study (1027) compared to 62% and 65% in the more sparsely sampled studies (1056, 1057 and 1059). The range of these PopPK estimates of F is consistent with the NCA estimate of 68% (90% CI 62% to 75%) from the HV study 1013.

## Iv vs SC administration

The  applicant  concluded  that  steady-state  simulations  from  the  combined  IV/SC  popPK  analyses indicated  that  despite  the  lower  bioavailability  and  Cmax  after  SC  administration,  the  tanezumab concentrations measured from Week 4 postdose were similar between the IV and SC routes.

There  were  noticeable  differences  in  almost  all  analysed  PK  parameters  after  administration  of tanezumab IV in identical doses comparing results obtained in study A4091006 and study A4091007.

The main reasons for such differences were the small sample size and the fact that in the study 1006, the PK parameter estimates for the 100 μg/kg and 300 μg/kg dose groups in Study 1006 were based on the combined sample size. In addition, there were differences in the first post-dose PK sampling time point (study 1006 - 0.1h+/-15 min; study 1007 - 1 h+/-15 min). This would be a cause of differences in the Cmax parameter estimates across the two studies.

The  estimated  half-lives  were  similar  for  corresponding  doses  across  the  two  studies  and  generally increased with increasing dose as would be expected for a drug with a non-linear PK.

## Distribution

The volume of distribution (Vz) NCA estimates from HV study 1013 was 5.39 L (10 mg IV treatment group Vz of 76.4 mL/kg, mean body weight of the treatment group of 70.5 kg). The popPK analyses estimates for the central volume of distribution (Vc), the peripheral volume of distribution (Vp) and volume of distribution at steady state (Vss) were 2.6 L, 1.77 L and 4.37 L, respectively. Normalised for dose, the AUCinf values were similar (104.2 and 109.3 μg.hr /mL/mg, respectively and a ratio of 0.953).

This limited extravascular distribution suggests that tanezumab is restricted to the interstitial space.

## Excretion

Excretion studies were not conducted with tanezumab. A two-compartment PK model with parallel linear and  non-linear  eliminations  and  first-order  absorption  adequately  described  the  plasma  tanezumab concentration versus time data following tanezumab IV and SC administration in patients with OA or CLBP. The estimated elimination parameter CL in the final popPK analysis was 0.133 (0.961) L/day. In

<div style=\"page-break-after: always\"></div>

comparison, the NCA clearance estimate based on study 1013 for the 10 mg IV dose was 0.163 L/day (mean Weight of subjects treated with tanezumab 10 mg IV was 70.5 kg). The fraction of the dose that is eliminated via the non-linear pathway decreased with increasing dose from 2.5 to 10 mg tanezumab and was estimated to be 18% for 2.5 mg tanezumab dose following IV administration to a typical patient. The mean effective half-life was estimated to be approximately 22 days following a 2.5 mg tanezumab SC dose.

## Metabolism

Metabolism  studies  were  not  conducted  with  tanezumab.  Similar  to  other  therapeutic  proteins  with molecular  weights  above  the  glomerular  filtration  cut-off,  tanezumab  is  expected  to  be  metabolised primarily by catabolic degradation following endocytosis by the mononuclear phagocytic system.

Excretion studies were not conducted with tanezumab. A two-compartment PK model with parallel linear and  non-linear  eliminations  and  first-order  absorption  adequately  described  the  plasma  tanezumab concentration versus time data following tanezumab IV and SC administration in patients with OA or CLBP. There is a good agreement between the observed and simulated data concerning the concentration of tanezumab administered at 5 and 10 mg with or without NSAIDs.

## Dose proportionality

PopPK model-predictions indicate that tanezumab PK has a small degree of nonlinearity that decreases with  an  increase  in  dose.  This  resulted  in  an  additional  increase  in  Cmaxss,  Cavgss,  and  Cminss approximately 5%, 8%, and 20%, respectively, on doubling the SC dose from 2.5 mg to 5 mg. This is expected for a target mediated drug disposition.

## Time dependency

After  2.5  mg  subcutaneous  dose  administered  every  8  weeks,  the  systemic  accumulation  ratio  for tanezumab was approximately 1.2, based on popPK model.  Steady-state concentrations of tanezumab are expected to be achieved after the second subcutaneous dose when administered every 8 weeks.

## Pharmacokinetics in the target population

Following 2.5 mg subcutaneous dose of tanezumab, the steady-state Cmax, Cmin, Cavg and AUCtau estimates  in  patients  with  OA  were  259  ng/mL,  60.2  ng/mL,  163  ng/mL  and  9150  ng.day/mL, respectively.

## Effect of ADA on tanezumab plasma concentrations

In  OA placebo-controlled trials of 40 to 48 weeks duration (1056, 1057), the incidence of TE ADA+ patients in those receiving 2 or 3 doses of tanezumab 2.5 mg at eight-week intervals was 7.1% (36/509) compared to 3.2% (16/498) in patients receiving placebo.

Overall, the plasma concentrations were similar between TE ADA- and TE ADA+ patients between week 8 and 32. Only at week 24, in TE ADA+ patients, exposure was 20 % lower as compared to TE ADApatients.  Based  on  popPK  model,  CL  was  slightly  increased  6-7%  higher  in  the  TE  ADA+  patient population in contrast to patients who did not produce ADA to tanezumab.

## Impaired renal function

Renal clearance is not considered important for the elimination of monoclonal antibodies due to their large  size  and  inefficient  filtration  through  the  glomerulus.  The  renal  clearance  of  tanezumab  was

<div style=\"page-break-after: always\"></div>

estimated  to  be  &lt;15%  of  total  tanezumab  clearance.  Based  on  population  PK  analysis,  no  dose adjustment is required in patients with mild to moderate renal impairment. Tanezumab PK has not been studied in patients with severe renal impairment.

## Impaired hepatic function

Clinical  studies  have  not  been  conducted  to  evaluate  the  effect  of  hepatic  impairment  on  the  PK  of tanezumab. As tanezumab is expected to be metabolised primarily by catabolic degradation following endocytosis by the mononuclear phagocytic system, it is expected that hepatic impairment will not have a clinically relevant effect on the PK of tanezumab.

## Race, Gender, Age, Weight

The individual impact race, sex and age on predicted changes in Cmaxss, Cminss and Cavgss (across the 5th to 95th percentile of their covariate distributions) were within ±20% of the expected value for the typical patient.

The individual impact of body weight (WT) on predicted changes in Cmaxss, Cminss, Cavgss, resulted in a -18% to -20% decrease at the 95th percentile (108 kg) to a +45 to +49% increase at the 5th percentile (55.3 kg) across these steady-state parameters estimates compared to the typical patient.

The  analysis  of  individual  covariates  indicates  a  significant  impact  of  injection  site  (thigh  versus abdomen), age, sex, and body weight on the extent of absorption. And age, sex, and body weight were also estimated to impact the rate of absorption following SC administration. The results of the analysis indicate a particularly significant effect of body weight and in lesser extent injection site on Cmax and Cmin. The applicant performed an additional analysis to explore the importance of the covariates of interest, which revealed that there is no significant difference in BMI, body weight and CLCR by injection site. The chosen injection site is not related to underlying demographics, but could be related to relative preference  for  injection  into  the  abdomen  compared  to  the  thigh,  reducing  the  power  for  covariate identification associated with injection into the thigh compared to the abdomen. The additional analysis showed that BMI (using the proposed 'typical ranges' eg, &lt;19, 19-25, 25-30, &gt;30) split by Sex, Age and Injection site had no significant influence on the predicted individual Cavg, Cmin and Cmax.

In addition, the analysis for the potential for an interaction for a sub-population of females with low BMI (&lt;25) and injection into the thigh (N=37) indicated that this combination of factors in the final model would have a non-significant increase 6% [95%CI -2.3, 14.3]) in bioavailability. This does not identify this population as being at significant additional risk of higher than expected exposure. Moreover, results of subgroup analyses for WOMAC pain Scale for placebo-controlled trials across IV and SC studies were irrespective of: gender, age (&lt;65 vs 65 years and importantly in elderly patients &lt;75 vs ≥ 75 years), BMI categories ≥ 25 kg/m2 (25-&lt;30, 30-&lt;35 vs ≥ 35 kg/m2).

Finally, a review of tanezumab safety data in discrete patient populations based on age ( ≥ 65 and ≥ 75 years old), gender, race, ethnicity, body mass index, baseline eGFR category, geographic region and concomitant (intermittent) NSAID use, revealed that no special precautions regarding the safe use of tanezumab in any of the above patient subpopulations are needed.

## Pharmacokinetic interaction studies

No formal drug interaction studies have been conducted with tanezumab. Since the elimination of mAbs does not occur through noncatabolic pathways such as hepatic metabolic enzymes (i.e., cytochrome P450 enzymes) or via small molecule renal/hepatic drug transporters, PK interactions with concomitant medications that are eliminated via these pathways are unlikely. Although there is a potential for a DDI between immunosuppressants and a mAb, this is not expected to be clinically meaningful for tanezumab

<div style=\"page-break-after: always\"></div>

since co-administration of an immunosuppressant would likely result in lowering ADA production and thereby minimize an increase in tanezumab clearance by ADA.

Many therapeutic proteins belonging to the cytokine class appear to differentially affect CYP activities. Cytokine modulators may affect CYP enzyme activities by altering cytokine effects on CYP enzymes. Tanezumab  does  not  belong  to  the  cytokine  class  and  binds  to  human  NGF  with  high  affinity  and specificity. Tanezumab is therefore not expected to bind to cytokines and modulate their concentrations. Due to the lack of tanezumab interaction with cytokines, changes in cytokine-dependent expression of CYP enzymes is not anticipated.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Tanezumab is a humanised IgG2 monoclonal antibody targeting  NGF  (nerve  growth  factor).  NGF  is expressed at a higher level in patients with chronic pain, such as osteoarthritis and other disorders, like rheumatoid arthritis. In animal experiments, administration of NGF triggers pain. Following tissue injury or  inflammation,  immune  and  other  cells  release  NGF  and  other  stimulatory  factors  which  bind  to receptors on peripheral nociceptors, to induce a local sensitisation of the nociceptive response. It is thought that signalling of NGF via the TrkA (Tropomyosin receptor kinase receptor A) plays a major role in modifying pain perception, but there is some evidence that signalling through the p75 receptor may also be relevant.

NGF is retrogradely transported back to the neuronal cell soma in the dorsal root ganglion (DRG) where it can induce changes in expression of multiple pain transduction related genes (e.g. genes involved in voltage and ligand-gated ion channels), leading to increased excitability of nociceptors and peripheral sensitisation.

## Primary and Secondary pharmacology

## Primary PD effect of tanezumab on target molecule NGF

Although  tanezumab  inhibits  NGF  activity,  the  total  serum  total  NGF  concentrations  increase  during tanezumab treatment, in a dose-dependent way. There is an approximately 30- to 47-fold increase in total NGF concentrations from baseline to steady-state following 8 weekly administration of tanezumab 2.5 mg SC. This is due to the accumulation of (inactive) tanezumab-NGF complexes, which have a much slower elimination rate than free human NGF. However, the total free fraction NGF in serum, which is biological active in the pain process, decreases in the presence of tanezumab. Notably, tanezumab did not alter serum concentrations of soluble NGF-receptor Sp75.

Upon termination of tanezumab treatment, the total NGF concentrations begin approaching baseline concentrations with an effective half-life similar to that of tanezumab (i.e. 21 days). Thus, it takes several months before the (inactive) NGF-tanezumab complexes are cleared from the body.

## Secondary PD effects on the nervous system

The effect of tanezumab on peripheral nerve system was studied in two placebo-controlled studies: one Phase I trial in healthy volunteers (N=22, single-dose 20 mg), and one multiple-dose Phase II trial in OA patients.

No meaningful changes in IENF density were observed between treatment groups versus placebo in the Phase I study. Study 1026 was designed to evaluate in detail the effect of tanezumab (5 and 10 mg IV)

<div style=\"page-break-after: always\"></div>

on peripheral nerve system in OA patients, such as alterations of intra-epidermal nerve fibre (IENF) density, peripheral nerve conductance tests and autonomic function tests. The dosing schedule was 3 doses with a 8 weeks interval. This study was preliminary interrupted and finished because of the clinical hold by the FDA. From the 219 OA patients of Study 1026 who received at least one dose, only 26 completed the study. It was concluded that administration of tanezumab 5 mg or 10 mg IV did not meaningfully affect sensory-motor NC, autonomic nerve function, or cutaneous small fibre nerve density as compared to placebo treatment. However, the incidence rates of paresthesia that was reported as Adverse Event were considerably increased for tanezumab versus placebo (16.4% (12/73), 12.2 (9/74) and 2.8% (2/72), for tanezumab 5 mg, 10 mg and placebo, respectively.

The risk of central neurological effects was claimed to be small, based on PK data from non-human primates showing very low tanezumab levels in the CSF. As can be read in the clinical safety part of this report, there were indeed no relevant signals of central toxicity.

## Secondary PD effects on QTc

The effects of tanezumab IV on QTc were tested with tanezumab dosages till 1000 μg/kg IV , leading to tanezumab peak drug concentrations that are approximately 100-fold higher than obtained with the regular tanezumab 2.5 mg dose. Even at these extreme doses, there were no relevant effects for QTc. Neither in the Phase III studies, any aberrant on QTc was noticed as compared to controls.

## Secondary PD effects on the joint.

Rapidly  progressive  osteoarthritis  is  an  identified  risk  of  tanezumab  (see  Clinical  Safety  section). Exploratory joint-safety related biomarkers of inflammation or collagen degradation were collected in the post-2015 OA studies, on request of the FDA. No clear correlations were found between these biomarkers and the occurrence of RPOA.

## PD interactions

The  previous  studies  were  put  on  hold  because  of  signals  of  rapidly  progressive  osteoarthritis  and osteonecrosis, which were increased a concurrent use of NSAIDs. In the post-2015 studies, chronic comedication with NSAIDs was not allowed. Only low-dose aspirin and short rescue use of therapeutic analgesic doses of NSAIDs (10 days in an 8-week period) was allowed.

## PK-PD relationship

The relationship between plasma exposure and WPS (weekly Pain Scale) was estimated using NONMEM. Data from 3985 OA patients were used in the analysis.

As shown in the panels in Figure 1 below, there were no relevant effects on WPS from differences in body weight, age, creatinine clearance, gender, prior response to NSAIDs, site of the OA (hip or knee). There was a swallow dose-response relationship for tanezumab doses ranging between the 2.5 and 10 mg (lower right panel). The responses to equivalent IV and SC dose were overlapping.

<div style=\"page-break-after: always\"></div>

Figure 1 Co-variate analyses of the PK-PD relationship model (WPS, Weekly Pain Score)

<!-- image -->

Neutralising antibodies (Nab) were present in about 5% of the subjects. The effect NAb on either Emax or EC50 was not statistically significant.

## Dose-response relationships

The dose-response relationship of tanezumab in the treatment of OA for WOMAC pain scores is illustrated in  Figure  2  below.  In  this  analysis,  data  were  included  from  the  dose-finding studies from pre-2015 (tanezumab IV, Studies 1011, 1014, 1015 and 1018), as well as the dose-finding studies post-2015 studies with SC tanezumab (Study 1056/57).

The outcomes of the IV band SC studies (post-2015, the pivotal studies for this application for marketing authorisation) overlapped. Tanezumab generally distinguished from placebo. With eye-ball screening, the optimum effect seems to be 5 mg. The 10 mg dose (IV) did not appear to add more efficacy.

Whereas in the pre-2015 studies with the IV dosing tanezumab tended to be superior to naproxen (see Figure 2), this was not confirmed in the post-2015 trial 1058, where tanezumab was not superior to NSAIDs (not included in the figure below). This will be further discussed in the efficacy section of this report.

<div style=\"page-break-after: always\"></div>

Figure 2 Mean (95% CI) WOMAC pPain subscale change from baseline at Week 16 by tanezumab dose and naproxen by study (OA)

<!-- image -->

Source: Module 5.3.3.5 PMAR-900 Figure 8.

Based on endpoint data using mixed LOCF/BOCF imputation without uncertainty (fixed imputation) Abbreviations: CFB = change from baseline; CI = confidence interval; OA = osteoarthritis; WOMAC = Western Ontario and McMaster Universities OsteoarthritisIndex

## 2.4.4. Discussion on clinical pharmacology

Pharmacokinetics of tanezumab at steady state were estimated based on the popPK model. The model is considered suitable for characterising the PK after a single dose but cannot yet be used for simulations at steady state as PK is most likely heavily dependent on NGF and the target-mediated disposition was not incorporated in the model. Therefore, the predicted data at steady-state cannot yet be considered trusted.

The proof of concept of tanezumab, a monoclonal antibody targeting NGF for the reduction of pain, has been adequately shown in models of nociceptive pain. The PK-PD model and the dose-response analyses indicate a shallow dose-response relationship of tanezumab in the treatment of OA, with an optimum for a  tanezumab  dose  of  5  mg.  The  recommended  dose  is  lower,  namely,  2.5  mg  every  eight  weeks. However, safety concerns preclude a higher dose (see discussion in the Clinical Safety part of this report).

Other covariates like body weight, age, gender, neutralising drug antibodies, localisation of the OA (hip or knee), route of administration (IV or SC), and creatinine clearance did not significantly alter the doseresponse relationship. Thus, no dose adjustments are required for special populations from an efficacy perspective.

Although the use of tanezumab was clearly associated with increased risk of peripheral neurological damage and progressive joint damage in the clinical studies, there are no further PD biomarkers available to further clarify these adverse drug reactions.

One large study that was designed to evaluate the effect of tanezumab on nerve conductance in detail was interrupted prematurely because of the clinical hold by the FDA -for other reasons not related to peripheral nerve damage-. No conclusion could be drawn from this study, as less than 10% of the ITT population  could  complete  this  study.  Although  it  is  considered  an  omission  that  the  study  was  not repeated, this issue is not further pursued -the SAWP agreed that neurological safety could be further monitored in the Phase III study programme by scoring Neuropathy Impairment Score routinely. As

<div style=\"page-break-after: always\"></div>

discussed  in  the  Clinical  Safety  part,  the  NIS  outcomes  confirmed  that  there  is  a  risk  of  peripheral neuropathy -and possible autonomic effects as well- for tanezumab.

Although the clinical data clearly indicate an increased risk of joint damage of tanezumab at concurrent chronic use of NSAIDs, the possible underlying mechanism remains unknown.

Limited number of patents were also exposed to intra-articular (IA) corticosteroids during the treatment with tanezumab. Also IA corticosteroids may cause harm to the joint, such as osteonecrosis. No clear correlation was found between concurrent IA corticosteroid use and the occurrence of RPOA events. However, it was difficult to draw a conclusion regarding any interaction between both treatments given the limited data.

There was no relevant effect of tanezumab on QTc. Other cardiac outcomes were not studied in PD studies.

## 2.4.5. Conclusions on clinical pharmacology

PD and PK-PD relationships were adequately described. The proof of concept of tanezumab, a monoclonal antibody targeting NGF for the reduction of pain, has been adequately shown in models of nociceptive pain. The PK-PD model and the dose-response analyses indicate a shallow dose-response relationship of tanezumab in the treatment of OA, with an optimum for a tanezumab dose of 5 mg. The recommended dose is lower, namely 2.5 mg every eight weeks due to safety concerns.

## 2.4.6. Clinical efficacy

The  applicant  has  performed  4  phase  2  studies  for  dose-finding  in  OA,  but  dose-finding  was  based primarily on PK/PD modelling combining the data of one phase 2 study in OA (1008), one in chronic low back pain (1004) and one in healthy volunteers (1003).

In total, there are 10 phase 3 studies in OA with available efficacy data (Figure 3). Because the 'post2015' studies are best aligned with the proposed indication regarding dose, administration and population (but not hand OA), these three studies (1056, 1057, 1058) are regarded as 'pivotal'. The 'pre-2015' usually are IV studies and are regarded as providing supportive information only.

<div style=\"page-break-after: always\"></div>

Figure 3 An overview of the main OA studies, with the 'post-2015' studies with 2.5 mg SC

<!-- image -->

N = Number of patients (Intent-to-treat (ITT))

- a. Studies shown as underlined included sub-cutaneous tanezuumab dosing. Studies not underlined used only IV dosing of tanezumab. Studies shown in bold were conducted post-2015.
- b. Studies affected by 2010 partial clinical hold, fully enmrolled, and with sufficient data for efficacy analysis.
- c. Study 1016 was a dose-blinded extension to placebo-controlled Studies 1011, 1014, 1015 and 1018. A total of 827 patients received tanezumab for the first time in Study 1016.

The three 'post-2015' studies (1056, 1057, 1058) evaluated tanezumab 2.5 mg and 5 mg SC (Table 2). These studies were all performed in patients with moderate to severe OA of the hip or knee who had an inadequate response, or could not tolerate, or had a contraindication for paracetamol/ NSAIDs/opioids or were not willing to take opioids. Studies 1056 and 1057 were placebo-controlled of 16 weeks and of 24 weeks duration. Study 1058 was NSAID controlled, and of 56 weeks duration, the patients in this study did not have a contra-indication for NSAIDs (Table 2).

<div style=\"page-break-after: always\"></div>

Table 2 Design of the 'post-2015' studies, including tanezumab 2.5 mg SC

| Study ID Locations                                  | Design                                                                                                                                                                                                | Subjects                                                                                                                                                                                                                                                                                                           | Treatment groups                                                                                                                                                                                    | N (included/ completed)     | Primary Endpoints                                                                                                         |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------|
| 1056 North America                                  | Phase 3 (16- week treatment) Randomised, DB, PBO- controlled, multicentre study of the analgesic efficacy and safety of a dose up-titration regimen of TAN SC in subjects with OA of the hip or knee. | Moderate to severe hip/knee OA, with: 1) APAP: insufficient pain relief; and 2) NSAIDs: insufficient pain relief/ contra-indication/ intolerance; and 3) TRA or opioids: insufficient pain relief/ contraindication/ intolerance (or for opioids only, unwilling to take).                                         | TAN 2.5 mg SC (Day 1), TAN 2.5 mg SC (wk8) TAN 2.5 mg SC (Day 1), TAN 5 mg SC (wk8) PBO SC (Day 1 and wk8)                                                                                          | 231/ 208 233/ 209 232/ 192  | Co-primary efficacy endpoints were change from baseline to Week 16 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |
| 1057 Europe, Japan                                  | Phase 3 (24- week treatment) randomised, DB, PBO- controlled, multicentre study of the analgesic efficacy and safety of TAN SC in subjects with OA of the hip or knee.                                | Moderate to severe hip/knee OA, with: 1) APAP: insufficient pain relief; and 2) NSAIDs: insufficient pain relief/ contra-indication/ intolerance; and 3) TRA or opioids: insufficient pain relief/ contraindication/ intolerance (or for opioids only, unwilling to take).                                         | TAN 2.5 mg SC Every-8-wks (3 doses) TAN 5 mg SC every-8-wks (3 doses) PBO SC every-8-wks (3 doses)                                                                                                  | 283/ 257 284/ 255 282/ 283  | Co-primary efficacy endpoints were change from baseline to Week 24 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |
| 1058 North/South America, Asia, Australasia, Europe | Phase 3 (56- Week treatment), Randomised, DB, Active- Controlled Multicentre Study of the long term Safety and Efficacy of SC Administration of TAN in Subjects with OA of the Hip or Knee            | Moderate to severe hip/knee OA, and: 1) tolerating and on a stable NSAID dose regimen; and 2) APAP: insufficient pain relief; and at least 1 of the following: a) TRA: inadequate pain relief/contra- indication/intolerable; b) Opioid: inadequate pain relief/contra- indication/intolerance/unwilli ng to take. | TAN 2.5 mg SC every-8-wks (7 doses) + PBO to match NSAID TAN 5 mg SC every-8-wks (7 doses) + PBO to match NSAID NSAID PO (NAP 500 mg BID, CEL 100 mg BID, or DIC 75 mg BID) + SC PBO (to match TAN) | 1002/ 447 998/ 419 996/ 446 | Co-primary efficacy endpoints were change from baseline to Week 16 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |

TAN=Tanezumab; NAP=Naproxen; CEL=Celecoxib; DIC=Diclofenac; APAP=paracetamol; TRA=tramadol; PBO=placebo; SC=subcutaneous; PO=oral.

## 2.4.7. Dose response studies

The doses for the phase 3 clinical studies in OA were based on PK/PD modelling using the results of a phase 2 study in OA (1008) and a phase 2 study in chronic low back pain (1004), aimed at IV dosing. Accordingly, it was decided that a dosing interval of 8 weeks would be appropriate, and it was estimated

<div style=\"page-break-after: always\"></div>

that 5 mg would be about 30% more effective than 2.5 mg in OA. It also was deduced that the doseresponse would be linear up to 2.5 mg and that lower doses would reduce efficacy.

A  comparison  of  tanezumab  SC  versus  IV  was  performed  in  study  1013  with  healthy  volunteers. According to PK/PD simulations and population PK modelling also including data from above studies 1008 and 1004, the onset of effect was predicted to be slower with SC compared with IV, but was predicted to be largely similar after 2-4 weeks up to week 8 (also see pharmacokinetics section).

The applicant has performed pooled analysis of the 'pre-2015' IV studies. Accordingly, there was only a marginal dose-response relationship over the 2.5 mg, 5 mg and 10 mg doses. In the 'post-2015' pivotal SC studies, only the 2.5 mg and the 5 mg doses were included.

Figure 4 Pooled analysis of difference against placebo in WOMAC Pain at week 16 in 'pre2015' placebo-controlled IV studies with tanezumab in OA

<!-- image -->

Treatment Difference (95%CIl)

Trealment Difere ne =IS mrn change for trnealrmert group msires LS msns change for placebo proep. A negatire ireaiment differenloe represenis an improvemcmt erver placebo.

PFIZER OONFIDENTLAL Output FIlkc /a409 xol/A409pool OA pbcntrlffig adwm pxim num1 Date of Gunmomation: 03/UN2019 (07:92)

Source: SCE Appendix Figure 11.1.a

## 2.4.8. Main studies

The main studies that provide efficacy data are:

Study A409 1056 : A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic  Efficacy  and  Safety  of  A  Dose  Titration  Regimen  for  the  Subcutaneous  Administration  of Tanezumab in Subjects with Osteoarthritis of the Hip or Knee.

Study A409 1057 : A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic  Efficacy  and  Safety  of  the  Subcutaneous  Administration  of  Tanezumab  in  Subjects  with Osteoarthritis of the Hip or Knee.

Study A409 1058 :  A  Phase  3,  Randomized,  Double-Blind,  Active-Controlled  Multicenter  Study  of  the Long-Term  Safety  and  Efficacy  of  Subcutaneous  Administration  of  Tanezumab  in  Subjects  with Osteoarthritis of the Hip or Knee.

## Objectives

Study 1056

<div style=\"page-break-after: always\"></div>

The primary objective was to demonstrate superior efficacy of tanezumab 2.5 mg SC and tanezumab 2.5 mg SC to 5 mg SC titration ('tanezumab 2.5/5 mg' SC) versus placebo at Week 16. Secondary efficacy  objective  was  to  evaluate  the  efficacy  and  safety  of  tanezumab  2.5/5  mg  SC  relative  to tanezumab 2.5 mg SC.

## Study 1057

The primary objective was to demonstrate superior efficacy of tanezumab 2.5 mg SC and tanezumab 5 mg SC every 8 weeks versus placebo at Week 24.

## Study 1058

The primary efficacy objective was to demonstrate superior efficacy of tanezumab 2.5 mg and tanezumab 5 mg SC versus NSAID treatment (naproxen 500 mg BID, celecoxib 100 mg BID, or diclofenac ER 75 mg BID) at Week 16. A secondary efficacy objective was to demonstrate the efficacy of tanezumab 2.5 mg and tanezumab 5 mg SC versus NSAID (combined) treatment at all time points to week 56.

This study also had a primary safety objective: to characterize the long-term risk of joint safety events (including  rapidly progressive OA type 1 or type 2) in patients with OA of the knee or hip who receive tanezumab 2.5 mg or tanezumab 5 mg subcutaneous (SC) versus NSAID treatment over 56 weeks of treatment.

## Design

## Study 1056

This  was  a  randomised,  placebo-controlled  double-blinded  trial  (Figure  5).  The  study  consisted  of  a screening period, an initial pain assessment period, a treatment period of 16 weeks and a safety followup period of 24 weeks. Patients received 2 doses of blinded SC study medication at week 0 and week 8. Patients (N=698) with moderate to severe OA and insufficient pain relief despite, or inappropriateness of,  standard pharmacological treatment were randomised (1:1:1) to tanezumab 2.5 mg, tanezumab 2.5/5 mg (2.5 mg at week 0 and 5 mg at week 8), or placebo. The three co-primary outcomes were: change from baseline to week 16 in the WOMAC Pain Subscale, the WOMAC Physical Function Subscale, and the PGA-OA. Paracetamol was used as rescue medication.

## Study 1057

This was a randomised, placebo-controlled double-blinded trial. The study consisted of a screening period (including an initial pain assessment), a treatment period of 24 weeks and a safety follow-up period of 24 weeks. Patients received 3 doses of blinded SC study medication at week 0, week 8, and week 16. Patients (N=849) with moderate to severe OA and insufficient pain relief despite, or inappropriateness of, standard pharmacological treatment were randomised (1:1:1) to tanezumab 2.5 mg, tanezumab 5 mg, or placebo. The three co-primary outcomes were: change from baseline to week 24 in the WOMAC Pain Subscale, the WOMAC Physical Function Subscale, and the PGA-OA. Paracetamol was used as rescue medication.

## Study 1058

This was a randomised, active-controlled double-blinded trial (Figure 5, Figure 7). The study consisted of a screening period (including a washout, NSAID stabilisation and an initial pain assessment period), a double-blind treatment period of 56 weeks, and a safety follow-up of 24 weeks. Patients (N=3021) with moderate to severe OA and insufficient pain relief despite being on a stable NSAID dose, and insufficient pain  relief,  or  inappropriateness  of,  paracetamol  and  tramadol/opioids,  were  randomised  (1:1:1)  to tanezumab  2.5  mg,  tanezumab  5  mg,  or  NSAID.  Randomised  patients  received  tanezumab  SC  or

<div style=\"page-break-after: always\"></div>

matching placebo every-8-weeks for a total of 7 doses. NSAID treatment (naproxen 500 mg, celecoxib 100 mg, or diclofenac 75 mg) or matching placebo was taken orally BID up to Week 56. Patients had not been randomised to a specific NSAID: they continued their previous NSAID or if it was not one of the three, the choice was at the discretion of the treating physician. At week 16, patients needed to be a ' partial responder ' to continue on treatment, according to an improvement in WOMAC Pain ≥ 30% AND an improvement ≥ 15% in WOMAC pain at either week 2, 4 or 8. At week 24, radiographic eligibility (see in/exclusion criteria) was reassessed and patients not meeting the criteria also were excluded from further experimental treatment. The three co-primary outcomes were: change from baseline to week 16 in the WOMAC Pain Subscale, the WOMAC Physical Function Subscale, and the PGA-OA. Paracetamol was used as rescue medication. Patients who underwent or planned to undergo total joint replacement or other arthroplasty during the study, were discontinued from study treatment. (Patients who underwent total knee/hip/shoulder replacement surgery were separately followed, in study 1064).

## Pre-2015 phase 3 studies

The seven 'pre-2015' supportive phase 3 studies, were basically similarly designed as the 'post-2015' studies. WOMAC Pain, WOMAC Physical Function, and Patient Global Assessment were common primary outcomes.

- Two placebo-controlled studies (1011 and 1014) of 24-week duration, comparing tanezumab 2.5 mg, 5 mg and 10 mg IV with placebo, were performed in patients with OA of the knee (1011) or of the hip (1014) who were not willing to take opioids or for whom opioids were contra-indicated or insufficiently effective.
- Two placebo- and active-controlled studies (1015 and 1018) of 16 weeks duration, comparing tanezumab 5 mg and 10 mg IV with placebo and with naproxen 500 mg BID, were performed in patients with OA of the knee (1015) or hip or knee (1018) with no requirement of past treatment history.
- A long-term active-controlled study (1025) of planned 56-weeks duration that was terminated early ('clinical hold'), comparing tanezumab 5 mg and 10 mg IV with naproxen 500 mg BID, celecoxib 100 mg BID, or placebo, performed in patients with OA of the hip or knee having some benefit of NSAIDs.
- A long-term dose-controlled study (1016) that was terminated early ('clinical hold'), comparing tanezumab 2.5 mg, 5 mg, and 10 mg IV, as follow-up in patients who participated in parent studies (1011, 1014, 1015 or 1018).
- A long-term dose-controlled study (1043) that was terminated early ('clinical hold'), comparing tanezumab 2.5 mg, 5 mg, and 10 mg SC, in patients with OA of the hip or knee who were regularly (≥4 days/week) users of opioid or non -opioid analgesics because of OA.

<div style=\"page-break-after: always\"></div>

## Figure 5 Design scheme of randomised double-blind 16-week placebo-controlled study 1056.

<!-- image -->

Source: Protocol (Section 16.1.1, Section 3)

Figure 6 Design scheme of randomised double-blind 24-week placebo-controlled study 1057

Source:Protoco1 Figure 1 (Section 16.1.1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7 Design scheme of randomised double-blind long-term active-controlled study 1058

<!-- image -->

Source: Appendix 16.1.1, Protocol Figure 1

## Study Participants

The participants of study 1056 were primarily enrolled through sites in the United States. Study 1057 was  performed  primarily  at  sites  in  14  European  countries.  Study  1058  was  conducted  at  sites  in Australasia, North and South America, Asia, Europe, but patients were primarily included in sites in the United States.

The main inclusion criteria of the studies were:

- Male or female ≥18 years of age, and a BMI≤39.
- Diagnosis of OA of the knee or hip based on the ACR criteria with a Kellgren-Lawrence X-ray grade ≥2. In 'post -2015' studies 1056, 1057 and 1058 this was based on X-rays collected at screening and central scoring by a radiologist. In the case of bilateral knee or hip OA, the more painful joint was selected as index joint.
- A WOMAC Pain score ≥5 for the index joint at screening and baseline; a WOMAC Physical Function score ≥ 5 for the index joint at baseline; a Patient Global Assessment of 'fair', 'poor', or 'very poor' at baseline.

## Studies 1056 and 1057

- Paracetamol had not provided sufficient pain relief AND oral NSAID therapy had not provided adequate pain relief or patient was unable to take NSAIDs due to contraindication or inability to tolerate,

<div style=\"page-break-after: always\"></div>

- AND Tramadol or opioids had not provided adequate pain relief or patient was unable to take tramadol or opioids due to contraindication or inability to tolerate; or patient was unwilling to take opioids.

## Study 1058

- The same criteria for paracetamol and for tramadol and opioids as for 1056 and 1057 AND
- Was on a stable dose regimen of oral NSAID therapy (specified selection of 10 with dose ranges), was tolerating this NSAID and taking it regularly (on average ≥5 days per week during the 30 -day period prior to screening).
- Was compliant to a stabilised dose regimen of either naproxen 500 mg BID, celecoxib 100 mg BID or diclofenac ER 75 mg BID (provided at screening) with a minimum compliance of 5 of 7 days per week for the final 2 or 3 weeks before baseline.

## The main exclusion criteria were:

- Other disease that may involve the index joint including  inflammatory joint disease such as rheumatoid arthritis, seronegative spondyloarthropathy, crystalline disease, etc.
- Radiographic  evidence  of  disorders  such  as:  excessive  malalignment  of  the  knee,  severe chondrocalcinosis;  joint  disorders  other  than  OA,  large  cystic  lesions,  primary  or  metastatic tumour lesions, stress or traumatic fracture.
- History of osteonecrosis or osteoporotic fracture
- Planned surgery (any) during duration of the study
- Patients considered unfit for surgery (ASA&gt;3) or patients who were not willing to undergo joint replacement surgery if required.
- A score &gt;7 on the Survey of Autonomic Symptoms (SAS).

## Studies 1057 and 1058

- Radiographic  evidence  of:  1)  Rapidly  progressive  OA,  2)  atrophic  or  hypotrophic  OA,  3) subchondral insufficiency fractures, 4) spontaneous osteonecrosis of the knee, 5) osteonecrosis, or 6) pathologic fracture; assessed by central reading using a reference atlas.

## Treatments

## Study treatment

Tanezumab 2.5 mg and 5 mg were presented as a sterile solution for SC administration, in a glass prefilled syringe of 2.5 mg/ml and 5 mg/ml. Each PFS was individually packed and numbered.

Placebo for tanezumab was presented as a sterile solution for SC administration in a matching glass PFS. Each PFS was individually packed and numbered.

Three NSAIDs were comparator in study 1058 (Table 3). Celecoxib 100 mg, Naproxen 500 mg, or Diclofenac 75 mg ER, was provided as oral capsules in high-density polyethylene bottles (double-blind supply). Matching placebos for each of the three NSAIDs were provided using the same bottles also used for verum. Compliance with NSAIDs (placebo) was reviewed and reconciled at each study visit. Patient

<div style=\"page-break-after: always\"></div>

compliance was encouraged by investigators, and counselling was applied if compliance fell to &lt;70% in an 8-week dosing interval.

Table 3 Study treatments by treatment arm in study 1058

| Treatment Group   | Subeutaneous Investigational Product (SC)          | Oral Investigational Produet (PO)*                                                   |
|-------------------|----------------------------------------------------|--------------------------------------------------------------------------------------|
|                   | Placebo for tanezumab once every S weeks x 7 doses | Naproxen 500 mg BID, celecoxib 100 mg BID, or diclofenac ER 75 mg BID through Week56 |
| 2                 | Tanezumab 2.5 mg once every 8 weeks x 7 doses      | Placebo for BID naproxen, BID diclofenac ER orBID celecoxib through Week 56          |
| m                 | Tanezumab 5 mg once every 8 weeks X 7 doses        | Placebo for BID naproxen, BID diclofenac ER. or BID celecoxib through Week 56        |

Souurce: Appendix 16.1.1, Protocol Table 8

*In Japan, the oral investigational product consisted of celecoxib 100 mg BlD or matching placebo for celecoxib BID

## Concomitant treatments

Included patients were required to discontinue all non-study pain medications for OA. Use of analgesics except paracetamol (for rescue) was prohibited. Use of concomitant treatment was recorded.

Occasional use of medication, including NSAIDs to relieve the pain was permitted in certain situations (e.g. painful procedure, accidental injury, self-limiting non-OA condition) but not for OA. Concomitant NSAIDs were not allowed in study 1058.  Analgesics/NSAIDs should not have been used 48 hours before an efficacy assessment in studies 1057 and 1058. Patients exceeding occasional use of NSAIDs for nonOA reasons (not more than 30 days before week 24 in 1056, not more than 40 days before week 32 in 1057) were withdrawn from study medication in study 1056 and 1057.

Daily low dose aspirin (≤325 mg or per local prescribing practice) therapy for cardiovascular prophylaxis was permitted.

## Rescue treatment

Paracetamol was issued to the patient by the study sites in an approved marketed product dress (carton, bottle, documents) for use as rescue medication.

In the event of inadequate pain relief for OA during the double-blind treatment period, patients could take up to a maximum permitted daily dose of 3000 to 4000 mg, but only up to three to five days per week (depends on study protocol). All rescue medication was discontinued at least 24 hours prior to any scheduled study visit at which efficacy data was collected. Patients were to bring back rescue medication bottles at each study visit for assessment of compliance.

## Outcomes/endpoints

## Primary outcomes

There were three co-primary efficacy endpoints, similar in all three main studies: Change in WOMAC Pain, WOMAC Physical Function, and PGA-OA scores, from baseline to Week 16 in studies 1056 and 1058,  and  baseline  to  Week  24  in  Study  1057  (Table  4).  The  WOMAC  Pain  and  Physical  Function subscales (there also is a Stiffness subscale) are composed of NRS scaled items and run from 0 to 10, with higher numbers indicating higher levels of Pain or impaired Physical Function. The Pain subscale is the average from 5 items, and the Physical Function subscale is the average from 17 items.

<div style=\"page-break-after: always\"></div>

## Secondary outcomes

To  evaluate  the  clinical  relevance  of  treatment  effects,  change  from  baseline  in  WOMAC  Pain  was categorised as an improvement ≥30% to denote 'moderate improvement' and an improvement '≥50% to denote 'substantial improvement'.

The WOMAC Stiffness subscale is composed of NRS scaled items from 0 to 10, with higher numbers indicating higher levels of joint stiffness on movement. The Stiffness subscale is the average from 2 items.

In the main study periods, pain of the target joint was also assessed on a daily basis using an electronic patient diary. Use was made of a 0 ('no pain') to 10 ('worst possible pain') NRS, describing the average pain level of over the past 24 hours.

Use of rescue medication (paracetamol use in the number of pills and strength) was recorded daily, using an electronic patient diary.

## Table 4 Description of the three main clinical efficacy outcomes: WOMAC Pain, WOMAC Physical Function, Patient Global Assessment

| Endpoint                           | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WOMAC Pain Subscale5.6,7           | regarding the amount of pain experienced due to OA in the index joint (selected study knee or hip) in the past 48 hours. The WOMAC Pain Subscale is calculated as the mean of the scores from the five individual questions, which may not be a whole (integer) number. The WOMAC Pain Subscale numerical rating scale (INRS) scores for each question, and the WOMAC Pain Subscale score, range from 0 to 10, with higher scores indicating higher                                                                                                                                                                                                     | regarding the amount of pain experienced due to OA in the index joint (selected study knee or hip) in the past 48 hours. The WOMAC Pain Subscale is calculated as the mean of the scores from the five individual questions, which may not be a whole (integer) number. The WOMAC Pain Subscale numerical rating scale (INRS) scores for each question, and the WOMAC Pain Subscale score, range from 0 to 10, with higher scores indicating higher                                                                                                                                                                                                     |
| WOMAC Physical Function Subscale   | The WOMAC Physical Function Subscale (5.3.5.3 SCE Appendix 3.2.3) is comprised of 17 questions regarding the degree of difficulty experienced due to OA in the index joint in the past 48 hours. The WOMAC Physical Function Subscale is calculated as the mean of the scores from the seventeen individual questions, which may not be a whole (integer) number. The WOMAC Physical Function Subscale NRS scores for each question, and the WOMAC Physical Function Subscale score, range from 0 to 10 with higher scores indicating worse function. This refers to the patient's ability to move around and perform usual activities of daily living. | The WOMAC Physical Function Subscale (5.3.5.3 SCE Appendix 3.2.3) is comprised of 17 questions regarding the degree of difficulty experienced due to OA in the index joint in the past 48 hours. The WOMAC Physical Function Subscale is calculated as the mean of the scores from the seventeen individual questions, which may not be a whole (integer) number. The WOMAC Physical Function Subscale NRS scores for each question, and the WOMAC Physical Function Subscale score, range from 0 to 10 with higher scores indicating worse function. This refers to the patient's ability to move around and perform usual activities of daily living. |
| Patient Global Assessment (PGA)8.9 | For the PGA, depending on the index joint, patients answered the following question: \"Considering all the ways your osteoarthritis in your knee/hip affects you, how are you doing today?\"F Patients rated their condition using the following scale:                                                                                                                                                                                                                                                                                                                                                                                                   | For the PGA, depending on the index joint, patients answered the following question: \"Considering all the ways your osteoarthritis in your knee/hip affects you, how are you doing today?\"F Patients rated their condition using the following scale:                                                                                                                                                                                                                                                                                                                                                                                                   |
| Patient Global Assessment (PGA)8.9 | 1 - Very Good                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Asymptomatic and no limitation of normal activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Patient Global Assessment (PGA)8.9 | 2-Good                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Mild symptoms and no limitation of normal activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Patient Global Assessment (PGA)8.9 | 3-Fair                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Moderate symptoms and limitation of some normal activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Patient Global Assessment (PGA)8.9 | 4-Poor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Severe symptoms and inability to carry out most normal activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Patient Global Assessment (PGA)8.9 | 5 - Very Poor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Very severe symptoms which are intolerable and inability to carry out all normal activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

## Randomisation and blinding (masking)

In Studies 1056 and 1057, patients were randomly assigned in a 1:1:1 ratio to the treatment regimens according to a computer-generated randomisation code. Randomisation was stratified by index joint and most severe KL grade (of any knee or hip joint). Randomisation was coordinated centrally through IRT.

In  Study  1058,  patients  were  randomly  assigned  in  a  1:1:1  ratio  to  one  of  the  treatment  groups, according to a computer-generated randomisation schedule. Randomisation was stratified by index joint, most severe KL grade (of any knee or hip joint) and NSAID treatment at study entry Randomisation was coordinated centrally through a web-based interactive response system.

Subjects who were receiving celecoxib, diclofenac or naproxen prior to Screening will receive this same oral  NSAID.  Subjects  who  were  receiving  other  NSAIDS  will  be  assigned  to  celecoxib,  naproxen  or diclofenac, this will be the choice of the investigator.

Studies 1056, 1057 and 1058 were double-blind studies. The patients, Investigators, study coordinators, clinical site staff, Clinical Research Associates, and staff directly involved with the study at the Sponsor and its designees were blinded to patient assignment. Blinding was only broken in emergency situations for reasons of patient safety.

## Statistical methods

In Study 1056, a sample size of  at  least  230  patients  per  treatment group was needed to provide approximately 90% power to achieve statistical significance (at the 5% two-sided level) for the two comparisons of tanezumab 2.5 mg and tanezumab 2.5/5 mg SC versus placebo, over all three co-primary endpoints. The assumed treatment differences for this calculation comes from a combined analysis of Studies A4091011 and A4091014.

In Study 1057, a sample size of 270 patients per treatment group was needed to provide approximately 80% power to achieve statistical significance (at the 5% two-sided level) for the two comparisons of tanezumab 2.5 and tanezumab 5 mg SC versus placebo, over all three co-primary endpoints. The total sample size was planned to be approximately 810 patients. The assumed treatment differences for this calculation came from a combined analysis of Studies A4091011 and A4091014.

In Study 1058, a sample size of approximately 1000 patients for each of the treatment groups of NSAID, tanezumab 2.5 mg, and tanezumab 5 mg were used in this study. This sample size allowed for a high probability of observing patients with any component of the composite safety endpoint where the event rate  over  this  study  was  very  small.  If  the  event  rate  were  0.25%,  then  there  would  be  a  &gt;90% probability of observing at least one patient with an event in any single treatment group.

The intent to treat (ITT) analysis set was the primary analysis set for efficacy analyses. It consisted of all randomised subjects who received at least one dose of study medication. This analysis set was used in the presentations of all efficacy data. The per-protocol (PP) analysis set was the secondary efficacy analysis set. It was defined as all subjects in the ITT analysis set who are not major protocol deviators. The safety analysis set was defined as all subjects treated with tanezumab or placebo.

A  modified  treatment-policy estimands  strategy was  applied  as  the  main  strategy  to  assess  the effectiveness of tanezumab. Data collected were included for efficacy assessment regardless of rescue medication being used or not.

The co-primary efficacy endpoints were analysed using an ANCOVA model, with model terms for baseline score, baseline diary average pain, index joint (knee or hip), highest Kellgren-Lawrence grade, and treatment group, and study site as a random effect. An additional (main effects ANCOVA) analysis

<div style=\"page-break-after: always\"></div>

for each of the co-primary efficacy endpoints used a per-protocol analysis set, which excluded subjects who were major protocol deviators.

The primary analysis of the co-primary endpoints used multiple imputations for missing data , to account for uncertainty around the subject response. The basis for imputing missing values was dependent on the reasons for missing data. For subjects with missing data due to discontinuation prior to Week 16 for lack of efficacy or for an adverse event or death, imputation was based on sampling from a normal distribution using a mean value equal to the subject's baseline efficacy value and the standard deviation (over all treatment groups) of the observed efficacy data at Week 16. For subjects with missing data for any other reason, imputation was based on sampling from a normal distribution using a mean value of the subject's last  observed efficacy value and standard deviation (over all treatment groups) of the observed efficacy data at Week 16. Imputed values for the Patient's Global Assessment of Osteoarthritis were rounded to integer values from 1 to 5. Imputed values for WOMAC Pain and Physical Function were truncated at 0 and 10.

A number of sensitivity analyses were performed on the primary efficacy endpoints in order to assess the robustness of the conclusions for the primary objective. These related to the analyses for missing data and the analysis population.

The primary analysis using multiple imputation described above was repeated but using the Per-Protocol analysis set in place of the ITT analysis set. There were four additional analyses to assess the robustness of the efficacy conclusions to the choice of multiple imputation as the primary method for accounting for missing data. In the first and second analyses, the primary ANCOVA analysis model described above was repeated, but using BOCF and LOCF respectively for missing data (note these were single imputation analyses).  The  third  sensitivity  analysis  for  the  primary  endpoints  used  a  mixed  model  repeated measures analysis  using  the  observed  and  imputed  data  up  to  Week  16  from  the  primary  multiple imputation analysis. This sensitivity analysis was not performed in study 1058. The fourth sensitivity analysis for the primary endpoints used a mixed model repeated measures analysis using all observed data up to Week 16 (i.e. retrieved dropout). Interaction analyses was performed for the co-primary endpoints, exploring the effect of Study site and Country. For the three co-primary endpoints, the ANOVA model unadjusted for covariates was used as an alternative to the primary analysis. During the conduct of the study 1058, it was identified that there may be GCP compliance issues at Sites 1714 and 1730. A sensitivity analysis was performed excluding the patients from both sites. For study 1058, the CMH test stratified by the combined levels of the three stratification factors was performed for the PGA.

Binary  response  parameters , and the incidence of rescue medication use and treatment discontinuation  due  to  lack  of  efficacy  were  analysed  using  logistic  regression  for  binary  data,  with covariates described for continues data above.

Multiplicity is handled differently in the three studies. In Study 1056, the assessment of significance for the tanezumab versus placebo treatment contrasts will use a step-down testing strategy within each of the co-primary efficacy endpoints. The stepdown testing will first test tanezumab 2.5/5 mg versus placebo, and if statistically significant will then test tanezumab 2.5 mg versus placebo. The secondary endpoint of subjects with ≥ 50% reduction from baseline in WOMAC Pain at Week 16 is identified as a key secondary endpoint and will be included in the testing strategy. If both tanezumab regimens are found to be statistically significantly better than placebo in the primary comparisons described above, the two comparisons of this secondary endpoint will be adjusted for multiple comparisons using the Hochberg procedure.

In Study 1057, in addition to three co-primary endpoints, three secondary endpoints of subjects with ≥ 50% reduction from baseline in WOMAC Pain at Week 24, change from baseline to Week 2 in the WOMAC Pain subscale, and change from baseline to Week 1 in average pain score in the index knee or hip, are identified as key secondary endpoints. The testing of these co-primary endpoints and key secondary

<div style=\"page-break-after: always\"></div>

endpoints will follow the graphical approach of gate keeping strategy proposed by Bretz et al (2011) and is a closed testing procedure.

In Study 1058, in addition to the three co-primary endpoints, the percentage of subjects with ≥ 50% reduction from baseline in WOMAC Pain at Week 16 is identified as a key secondary endpoint. The testing of these co-primary endpoints and key secondary endpoint will follow the graphical approach of gate keeping strategy proposed by Bretz et al (2011) and is a closed testing procedure.

## Participant flow

In  all  three  studies,  many  more  patients  were  screened  than  could  be  included.  Patients  were  not included if there was X-ray evidence for RPOA or other devastating joint disorders, or joint disorders other than OA. Screening failures for these reasons were 14% in study 1056, 26% in study 1057, 8% in study 1058.

In study 1056 ,  N=698 patients were included and randomised to tanezumab 2.5 mg, 2.5/5 mg, or placebo, 2 patients were randomised but not treated (Figure 8). The PP population was ~88% of patients in each group. The double-blind 16-week treatment period was completed by ~90% in the tanezumab groups and 83% in the placebo group. The most common reasons for drop-out were 'withdrawal by subject'  and  'insufficient  clinical  response'  in  all  treatment  groups,  though  numerically  lower  for tanezumab. Few patients discontinued due to adverse events. About 84% in all three treatment groups completed the safety follow-up.

In study 1057 , N=849 patients were included and randomised to tanezumab 2.5 mg, 5 mg, or placebo, all patients randomised were treated (Figure 9). The PP population was ~73% of patients in each group. The double-blind 24-week treatment period was completed by ~90% in the tanezumab groups and 85% in  the  placebo  group.  The  most  common  reasons  for  drop-out  were  'withdrawal  by  subject'  in  all treatment groups, 'insufficient clinical response' especially in the placebo group, and 'adverse event' in all groups but least in the tanezumab 5 mg group. About 86% in all three treatment groups completed the safety follow-up.

In study 1058 , N=3021 patients were included and randomised to tanezumab 2.5 mg, 5 mg, or NSAID. Six to 12 patients per allocated group were randomised but not treated (Figure 10). The PP population was ~88% of patients in each group. The double-blind 56-week treatment period was completed by ~44% in the tanezumab and NSAID groups. The most common reason for drop-out was 'patient meets protocol-specified  pain  criterion  for  discontinuation'  which  occurred  in  ~22%  in  all  three  treatment groups. Discontinuation due to adverse events occurred in 10% of the tanezumab 5 mg group, 7% in the 2.5 mg group, and 6% in the NSAID group. There were 5 deaths, all patients allocated to tanezumab. Discontinuation due to 'insufficient clinical response' occurred in 6% of the tanezumab groups and 9% of the NSAID group.

<div style=\"page-break-after: always\"></div>

Figure 8 Disposition of patients in study 1056

<!-- image -->

Figure 9 Disposition of patients in study 1057

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 10 Disposition of patients in study 1058

<!-- image -->

Source: Table 14.1.1.1, Table 14.1.1.2

## Baseline data

In studies 1056, 1057 and 1058, the mean age of the patients fell between 60 and 65 years, about 35% in studies 1056 and 1058 and 55% in study 1057 were &gt;65 years. With 65% to 70% the majority of the included patients were females. The mean (SD) BMI was ~30 and ranged up to 39. Age, gender and BMI were equally distributed over treatment groups (not shown).

The time since the first diagnosis of OA was on average 7 - 9 years, but ranged between less than 1 year up to &gt;50 years. The majority of patients had OA in ≥2 joints, according to the Kellgren score. In all studies, &lt;10% of patients did have had a total joint replacement before baseline.

For about 15% of the patients the index joint was the hip, and for about 85% of patients the index joint was the knee.

In studies 1056 and 1058, the mean (SD) WOMAC pain score at baseline was similar and about 7 in the three treatment groups (Table 5, Table 7) and the mean (SD) WOMAC Physical Function scores also were about 7. In study 1057, the mean (SD) WOMAC Pain score and Physical Function score at baseline were about 6.5 points in the three treatment groups (Table 6). In all studies, baseline WOMAC scores &lt;5 are protocol violations. Most of the included patients had rated their Global Assessment of OA as 'fair' or 'poor'.

<div style=\"page-break-after: always\"></div>

Table 5 Disease variables at baseline of study 1056

|                                                             | Placebo     | Tanezumab     | Tanezumab      |
|-------------------------------------------------------------|-------------|---------------|----------------|
|                                                             | N=232       | 2.5 mg N= 231 | 2.5/5 mg N=233 |
| Total                                                       | 232 (100.0) | 231 (100.0)   | 233 (100.0)    |
| Number of Joints per Subject withKellgren-Lawrence Grade ≥2 |             |               |                |
| 0                                                           | 0           | 0             | 0              |
| 1                                                           | 48 (20.7)   | 62 (26.8)     | 47 (20.2)      |
| 2                                                           | 118 (50.9)  | 111 (48.1)    | 124 (53.2)     |
| 3                                                           | 44 (19.0)   | 32 (13.9)     | 34 (14.6)      |
| 4                                                           | 22 (9.5)    | 26 (11.3)     | 28 (12.0)      |
| Total                                                       | 232 (100.0) | 231 (100.0)   | 233 (100.0)    |
| WOMAC Pain Subscale Score at Screening                      |             |               |                |
| N                                                           | 229         | 228           | 232            |
| Mean (SD)                                                   | 7.02 (1.20) | 6.87 (1.15)   | 7.02 (1.18)    |
| Median                                                      | 7.0         | 6.8           | 6.9            |
| Min, Max                                                    | (0.0, 9.8)  | (5.0, 10.0)   | (3.4, 10.0)    |
| WOMAC Pain Subscale Score at Baseline                       |             |               |                |
| N                                                           | 232         | 231           | 233            |
| Mean (SD)                                                   | 7.30 (1.15) | 7.08 (1.16)   | 7.33 (1.26)    |
| Median                                                      | 7.4         | 7.0           | 7.2            |
| Min, Max                                                    | (4.2,10.0)  | (4.8, 10.0)   | (5.0, 10.0)    |
| WOMAC Physical Function Subscale Score at                   |             |               |                |
| Baseline                                                    |             |               |                |
| N                                                           | 232         | 231           | 233            |
| Mean (SD)                                                   | 7.38 (1.12) | 7.18 (1.11)   | 7.39 (1.18)    |
| Median                                                      | 7.5         | 7.2           | 7.2            |
| Min, Max                                                    | (4.4, 10.0) | (5.1, 9.9)    | (3.2, 9.9)     |
| Patient Global Assessment of Osteoarthritis atBaseline      |             |               |                |
| Very Good                                                   | 0           | 0             | 0              |
| Good                                                        | 0           | 1 (0.4)       | 0              |
| Fair                                                        | 134 (57.8)  | 144 (62.3)    | 125 (53.6)     |
| Poor                                                        | 89 (38.4)   | 74 (32.0)     | 92 (39.5)      |
| Very Poor                                                   | 9 (3.9)     | 12 (5.2)      | 16 (6.9)       |
| Total                                                       | 232 (100.0) | 231 (100.0)   | 233 (100.0)    |

Source:Table14.1.2.1.1.1

Kellgren-Lawrence grade is evaluated for each subject for 4 joints, left/right hip and left/right knee. Abbreviations: max = maximum; min = minimum; SD = standard deviation; WOMAC =Westem Ontario and McMaster Universities Osteoarthritis Index.

<div style=\"page-break-after: always\"></div>

Table 6 Disease variables at baseline of study 1057

|                                                              | Placebo (N=282)   | Tanezumab 2.5 mg (N=283)   | Tanezumab 5 mg (N=284)   |
|--------------------------------------------------------------|-------------------|----------------------------|--------------------------|
| Number of Joints per Subject with Kellgren-Lawrence Grade =2 |                   |                            |                          |
| 0                                                            | 0                 | 0                          | 0                        |
| 1                                                            | 53 (18.8)         | 62 (21.9)                  | 48 (16.9)                |
| 2                                                            | 160 (56.7)        | 167 (59.0)                 | 166 (58.5)               |
| m                                                            | 43 (15.2)         | 36 (12.7)                  | 48 (16.9)                |
| 4                                                            | 26 (9.2)          | 18 (6.4)                   | 22 (7.7)                 |
| Total                                                        | 282 (100.0)       | 283 (100.0)                | 284 (100.0)              |
| WOMAC Pain Subscale Score at Screening                       |                   |                            |                          |
| N                                                            | 277               | 281                        | 283                      |
| Mean(SD)                                                     | 6.49 (1.06)       | 6.54 (0.97)                | 6.54 (0.93)              |
| Median                                                       | 6.4               | 6.4                        | 6.4                      |
| Min, Max                                                     | (2.2, 10.0)       | (2.8, 9.4)                 | (2.6, 9.4)               |
| WOMAC Pain Subscale Score atBaseline                         |                   |                            |                          |
| N                                                            | 281               | 282                        | 284                      |
| Mean(SD)                                                     | 6.59 (0.94)       | 6.70 (0.94)                | 6.60 ( 0.89)             |
| Median                                                       | 6.6               | 6.6                        | 6.4                      |
| Min, Max                                                     | (4.4, 9.4)        | (2.8, 10.0)                | (4.6, 9.6)               |
| WOMAC Physical Function Subscale Score at Baseline           |                   |                            |                          |
| N                                                            | 281               | 282                        | 284                      |
| Mean(SD)                                                     | 6.67 (0.87)       | 6.77 (0.87)                | 6.76 (0.88)              |
| Median                                                       | 6.6               | 6.6                        | 6.6                      |
| Min, Max                                                     | (5.1, 9.4)        | (4.9,9.8)                  | (4.6, 9.4)               |
| Patient Global Assessment of Osteoarthritis at Baseline      |                   |                            |                          |
| VERY GOOD                                                    | 0                 | 0                          | 1 (0.4)                  |
| GOOD                                                         | 0                 | 0                          | 1 (0.4)                  |
| FAIR.                                                        | 145 (51.6)        | 132 (46.8)                 | 136 (47.9)               |
| POOR.                                                        | 117 (41.6)        | 129 (45.7)                 | 129 (45.4)               |
| VERY POOR                                                    | 19 (6.8)          | 21 (7.4)                   | 17 (6.0)                 |
| Total                                                        | 281 (100.0)       | 282 (100.0)                | 284 (100.0)              |

Kellgren-Lawrence grade was evaluated for each subject for 4 joints: left'right hip and left/right kuee.

/ndal/A4091057/adsl\\_base\\_char\\_i Date of Generation: 07FEB2019 (09:53)

Table 14.1.2.1.1.1.iis for Pfizer intermal use.

PFIZER CONFIDENTIAL SDTM Creation: 26DEC2018 (05:14) Source Data: 16.2.4.1.1, 16.2.6.1, 16.2.6.2 Output File:

<div style=\"page-break-after: always\"></div>

Table 7 Disease variables at baseline of study 1058

|                                                              | Tanezumab 2.5 mg (N=1002)   | Tanezumab5 mg (866=ND   | NSAID (N=996)   |
|--------------------------------------------------------------|-----------------------------|-------------------------|-----------------|
| Total                                                        | 1002 (100.0)                | 998 (100.0)             | 996 (100.0)     |
| Number of Joints per Subject with Kellgren-Lawrence Grade =2 |                             |                         |                 |
| 0                                                            | 1 (0.1)                     | 0                       | 0               |
| 1                                                            | 232 (23.2)                  | 214 (21.4)              | 219 (22.0)      |
| 2                                                            | 538 (53.7)                  | 556 (55.7)              | 560 (56.2)      |
|                                                              | 134 (13.4)                  | 138 (13.8)              | 124 (12.4)      |
| 4                                                            | 97 (9.7)                    | 90 (9.0)                | 93 (9.3)        |
| Total                                                        | 1002 (100.0)                | 998 (100.0)             | 996 (100.0)     |
| WOMAC Pain subscale score at Screening                       |                             |                         |                 |
| N                                                            | 997                         | 996                     | 994             |
| Mean(SD)                                                     | 6.95 (1.10)                 | 7.04 (1.19)             | 6.95 (1.10)     |
| Median                                                       | 6.8                         | 7.0                     | 6.8             |
| Min,Max                                                      | (3.8, 10.0)                 | (0.0, 10.0)             | (4.8, 10.0)     |
| WoMAC Pain subscale score at Baseline                        |                             |                         |                 |
| N                                                            | 1000                        | 566                     | 994             |
| Mean(SD)                                                     | 7.01 (1.12)                 | 7.02 (1.12)             | 6.96 (1.08)     |
| Median                                                       | 7.0                         | 7.0                     | 7.0             |
| Min,Max                                                      | (3.6, 10.0)                 | (1.6, 10.0)             | (2.6, 10.0)     |
| WOMAC Physical Fumction subscale score at Baseline           |                             |                         |                 |
| N                                                            | 1000                        | 995                     | 994             |
| Mean(SD)                                                     | 7.09 (1.07)                 | 7.08 (1.11)             | 6.99 (1.09)     |
| Median                                                       | 7.1                         | 7.1                     | 6.9             |
| Min,Max                                                      | (1.5, 10.0)                 | (1.1, 10.0)             | (2.4, 10.0)     |
| Patient Global Assessment of Osteoarthritis at Baseline      |                             |                         |                 |
| VERY GOOD                                                    | 1 (0.1)                     | 0                       | 1 (0.1)         |
| GOOD                                                         | 5 (0.5)                     | 7 (0.7)                 | 3 (0.3)         |
| FAIR                                                         | 557 (55.7)                  | 569 (57.2)              | 592 (59.6)      |
| POOR.                                                        | 381 (38.1)                  | 369 (37.1)              | 355 (35.7)      |
| VERY POOR                                                    | 56 (5.6)                    | 50 (5.0)                | 43 (4.3)        |
| Total                                                        | 1000 (100.0)                | 995 (100.0)             | 994 (100.0)     |

Kellgren-Lawrence grade is evaluated for each subject for 4 joints, left/right hip and left/right knee. PFIZER CONFIDENTLAL SDTM Creafion: 03APR2019 (02:27) Source Data: Listings 16.2.4.1.1 16.2.6.1 and 16.2.6.2 Output File:./ndal/A4091058\\_IM\\_Efficacy/adsl\\_base\\_char\\_iDate of Generation: 22MAY2019 (10:18) Table 14.1.2.1.1.1.i is for Pfizer intemal use.

According to the inclusion criteria, patients should have a documented history of an inadequate response to, be intolerant to or have a contraindication to acetaminophen, NSAIDs and opioids/ tramadol or be unwilling to take opioids to be eligible. In NSAID-controlled study 1058, contra-indication or tolerability issue with NSAIDs were exclusion criteria.

At baseline of studies 1056, 1057, 65% and 79% of included patients had used at least 3 of the four treatment classes (paracetamol, NSAIDs, opioids, tramadol).  In study 1058, all included patients had insufficient  relief/inappropriateness  of  at  least  2  of  the  3  treatment  classes  (paracetamol,  opioids, tramadol).

In  the  studies,  virtually  all  patients  had  used  paracetamol  and  found  it  gave  inadequate  pain  relief. Similarly, virtually all patients had used NSAIDS and for the vast majorities in studies 1056 and 1057 it gave inadequate pain relief, but contra-indications and intolerability also occurred.

In studies 1056 and 1058, a large majority of patients had used opioids and/or were unwilling to take opioids, and a large minority had used tramadol. In study 1057 (with most patients from European centres), this was reversed: a large minority of patients had used opioids and/or were unwilling to take opioids, and a majority of patients had used tramadol. Tramadol usually gave inadequate pain relief in

<div style=\"page-break-after: always\"></div>

these patients and in patients who had used opioids, inadequate pain relief but also intolerability had been common issues.

Table 8 History of OA treatment at baseline of study 1056

|                                                            | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                            | Placebo                  | Tanezumab                | Tanezumab                | Total                    |
|                                                            | N=232                    | 2.5 mg N=231             | 2.5/5 mg N=233           | N = 696                  |
| Number (%) of subjects with any qualifying pain medication | 232 (100.0)              | 231 (100.0)              | 233 (100.0)              | 696 (100.0)              |
| Acetaminophen /Paracetamol                                 | 232 (100)                | 230 (99.6)               | 232 (99.6)               | 694 (99.7)               |
| Inadequate pain relief                                     | 232 (100)                | 230 (99.6)               | 231 (99.1)               | 693 (99.6)               |
| Intolerability                                             | 0                        | 0                        | 1 (0.4)                  | 1 (0.1)                  |
| NSAIDs-oral                                                | 232 (100)                | 230 (99.6)               | 233 (100)                | 695 (99.9)               |
| Contraindication                                           | 5 (2.2)                  | 12 (5.2)                 | 7 (3.0)                  | 24 (3.4)                 |
| Inadequate pain relief                                     | 211 (90.9)               | 209 (90.5)               | 211 (90.6)               | 631 (90.7)               |
| Intolerability                                             | 23 (9.9)                 | 16 (6.9)                 | 22 (9.4)                 | 61 (8.8)                 |
| Opioids                                                    | 179 (77.2)               | 172 (74.5)               | 180 (77.3)               | 531 (76.3)               |
| Contraindication                                           | 1 (0.4)                  | 5 (2.2)                  | 3 (1.3)                  | 9 (1.3)                  |
| Inadequate pain relief                                     | 58 (25.0)                | 69 (29.9)                | 58 (24.9)                | 185 (26.6)               |
| Intolerability                                             | 33 (14.2)                | 28 (12.1)                | 33 (14.2)                | 94 (13.5)                |
| Unwilling to take                                          | 90 (38.8)                | 78 (33.8)                | 89 (38.2)                | 257 (36.9)               |
| Tramadol                                                   | 71 (30.6)                | 73 (31.6)                | 79 (33.9)                | 223 (32.0)               |
| Contraindication                                           | 0                        | 1 (0.4)                  | 0                        | 1 (0.1)                  |
| Inadequate pain relief                                     | 62 (26.7)                | 53 (22.9)                | 65 (27.9)                | 180 (25.9)               |
| Intolerability                                             | 9 (3.9)                  | 19 (8.2)                 | 14 (6.0)                 | 42 (6.0)                 |

Source: Table 14.4.2.7.2

Totals for the number of subjects at a higher level are not necessarily the sum of those at the lower levels since a subject may report two or more different medications within the higher-level category.

<div style=\"page-break-after: always\"></div>

Table 9 History of OA treatment at baseline of study 1057

|                                                            | Placebo (N=282) n (%)   | Tanezumab 2.5 mg (N=283) n (%)   | Tanezumab 5mg (N=284) n (%)   | Total (N=849) n (%)   |
|------------------------------------------------------------|-------------------------|----------------------------------|-------------------------------|-----------------------|
| Number (%) of subjects with any qualifying pain medication | 282 (100.0)             | 283 (100.0)                      | 284 (100.0)                   | 849 (100.0)           |
| **Uncoded Subcategory for Medication                       | 13 (4.6)                | 7 (2.5)                          | 15 (5.3)                      | 35 (4.1)              |
| **Uncoded Reason for D                                     | 13 (4.6)                | 7 (2.5)                          | 15 (5.3)                      | 35 (4.1)              |
| ACETAMINOPHEN/PARACETAMOL                                  | 282 (100)               | 283 (100)                        | 284 (100)                     | 849 (100)             |
| INADEQUATE PAIN RELIEF                                     | 282 (100)               | 283 (100)                        | 284 (100)                     | 849 (100)             |
| NSAIDS-ORAL                                                | 282 (100)               | 283 (100)                        | 283 (99.6)                    | 848 (99.9)            |
| CONTRAINDICATION                                           | 11 (3.9)                | 9 (3.2)                          | 14 (4.9)                      | 34 (4.0)              |
| INADEQUATE PAIN RELIEF                                     | 254 (90.1)              | 247 (87.3)                       | 240 (84.5)                    | 741 (87.3)            |
| INTOLERABILITY                                             | 31 (11.0)               | 34 (12.0)                        | 30 (10.6)                     | 95 (11.2)             |
| OPIOIDS                                                    | 102 (36.2)              | 98 (34.6)                        | 91 (32.0)                     | 291 (34.3)            |
| CONTRAINDICATION                                           | 1 (0.4)                 | 0                                | 1 (0.4)                       | 2 (0.2)               |
| INADEQUATE PAIN RELIEF                                     | 30 (10.6)               | 34 (12.0)                        | 34 (12.0)                     | 98 (11.5)             |
| INTOLERABILITY                                             | 26 (9.2)                | 14 (4.9)                         | 17 (6.0)                      | 57 (6.7)              |
| UNWILLING TO TAKE                                          | 45 (16.0)               | 51 (18.0)                        | 40 (14.1)                     | 136 (16.0)            |
| TRAMADOL                                                   | 207 (73.4)              | 208 (73.5)                       | 218 (76.8)                    | 633 (74.6)            |
| CONTRAINDICATION                                           | 0                       | 0                                | 1 (0.4)                       | 1 (0.1)               |
| INADEQUATE PAIN RELIEF                                     | 157 (55.7)              | 139 (49.1)                       | 159 (56.0)                    | 455 (53.6)            |
| INTOLERABILITY                                             | 48 (17.0)               | 65 (23.0)                        | 59 (20.8)                     | 172 (20.3)            |
| UNWILLING TO TAKE                                          | 6 (2.1)                 | 4 (1.4)                          | 1 (0.4)                       | 11 (1.3)              |

Totals for the number of subjects at a higher level are not necessarily the sum of those at the lower levels since a subject may have reported two or more different medications within the higher level category. PFIZER CONFIDENTIAL SDTM Creation: 31DEC2018 (04:26) Source Data: Listing 16.2.5.2.5 Output File: /nda1/A4091057/adcm\\_s004\\_pqi Date of Generation: 08MAR2019 (13:22) Table 14.4.2.7.2.i is for Pfizer intermal use.

<div style=\"page-break-after: always\"></div>

Table 10 History of OA treatment at baseline of study 1058

|                                                            | Tanezumab 2.5 mg (N=1002) n (%)   | Tanezumab 5mg (N=998) n (%)   | NSAID (N=996) n (%)   | Total (N=2996) n (%)    |
|------------------------------------------------------------|-----------------------------------|-------------------------------|-----------------------|-------------------------|
| Number (%) of subjects with any qualifying pain medication | 1002 (100.0)                      | 998 (100.0)                   |                       | 996 (100.0)2996 (100.0) |
| **Uncoded Subcategory for Medication                       | 111 (11.1)                        | 97 (9.7)                      | 104 (10.4)            | 312 (10.4)              |
| **Uncoded Reason for D                                     | 111 (11.1)                        | 97 (9.7)                      | 103 (10.3)            | 311 (10.4)              |
| INTOLERABILITY                                             | 0                                 | 0                             | 1 (0.1)               | 1 (0.0)                 |
| ACETAMINOPHEN/PARACETAMOL                                  | 1002 (100)                        | 998 (100)                     | 995 (99.9)            | 2995 (100)              |
| CONTRAINDICATION                                           | 0                                 | 0                             | 1 (0.1)               | 1 (0.0)                 |
| INADEQUATE PAIN RELIEF                                     | 1002 (100)                        | 998 (100)                     | 995 (99.9)            | 2995 (100)              |
| INTOLERABILITY                                             | 1 (0.1)                           | 1 (0.1)                       | 1 (0.1)               | 3 (0.1)                 |
| OPIOID                                                     | 0                                 | 0                             | 1 (0.1)               | 1 (0.0)                 |
| **Uncoded Reason for D                                     | 0                                 | 0                             | 1 (0.1)               | 1 (0.0)                 |
| OPIOIDS                                                    | 701 (70.0)                        | 709 (71.0)                    | 669 (67.2)            | 2079 (69.4)             |
| CONTRAINDICATION                                           | 4 (0.4)                           | 6 (0.6)                       | 5 (0.5)               | 15 (0.5)                |
| INADEQUATE PAIN RELIEF                                     | 231 (23.1)                        | 244 (24.4)                    | 215 (21.6)            | 690 (23.0)              |
| INTOLERABILITY                                             | 129 (12.9)                        | 141 (14.1)                    | 142 (14.3)            | 412 (13.8)              |
| UNWILLING TO TAKE                                          | 352 (35.1)                        | 327 (32.8)                    | 318 (31.9)            | 997 (33.3)              |
| TRAMADOL                                                   | 443 (44.2)                        | 423 (42.4)                    | 462 (46.4)            | 1328 (44.3)             |
| **Uncoded Reason for D                                     | 0                                 | 1 (0.1)                       | 0                     | 1 (0.0)                 |
| CONTRAINDICATION                                           | 1 (0.1)                           | 5 (0.5)                       | 3 (0.3)               | 9 (0.3)                 |
| INADEQUATE PAIN RELIEF                                     | 296 (29.5)                        | 288 (28.9)                    | 309 (31.0)            | 893 (29.8)              |
| INTOLERABILITY                                             | 145 (14.5)                        | 130 (13.0)                    | 151 (15.2)            | 426 (14.2)              |
| UNWILLING TO TAKE                                          | 1 (0.1)                           | 0                             | 0                     | 1 (0.0)                 |

PFIZER CONFIDENTIAL SDTM Creation: 03APR2019 (05:28) Source Data: Listing 16.2.5.2.5 Output File:

/nda1/A4091058\\_IM\\_Safety/adcm\\_s004\\_pqi Date of Generation: 13MAY2019 (16:23)

Table 14.4.2.7.2.i is for Pfizer internal use.

## Numbers analysed

The ITT analysis set was the primary analysis set for efficacy analyses. It consisted of all randomised patients who received at least 1 dose of SC medication (tanezumab or placebo). The PP analysis set was defined as all patients from the ITT set without major protocol violations. Major protocol violations were predefined as violations which would potentially affect efficacy.

In study 1056 , 698 patients were randomised, 2 of them were not treated, and the ITT population thus consisted of 696 patients: 232 were allocated to placebo, 231 allocated to tanezumab 2.5 mg, and 233 allocated to tanezumab 5 mg. The PP population consisted of 618 patients: 204 (88%) were allocated to placebo, 208 (90%) allocated to tanezumab 2.5 mg, and 206 (88%) allocated to tanezumab 5 mg.

In study 1057 , 849 patients were randomised, and all were treated, the ITT population thus consisted of 849 patients: 282 were allocated to placebo, 283 allocated to tanezumab 2.5 mg, and 284 allocated to tanezumab 5 mg. The PP population consisted of 619 patients: 200 (71%) were allocated to placebo, 209 (74%) allocated to tanezumab 2.5 mg, and 210 (74%) allocated to tanezumab 5 mg.

<div style=\"page-break-after: always\"></div>

In study 1058 , 3021 patients were randomised, 25 of them were not treated and the ITT population thus consisted of 2996 patients: 996 were allocated to NSAID, 1002 allocated to tanezumab 2.5 mg, and 998  allocated  to  tanezumab  5  mg.  The  PP  population  consisted  of  2657  patients:  885  (88%)  were allocated to NSAID, 876 (87%) allocated to tanezumab 2.5 mg, and 885 (88%) allocated to tanezumab 5 mg.

## Use of concomitant and rescue medication

Paracetamol rescue medication was used by most (80% - 85%) patients in the three trails, usually a bit more  patients  in  the  placebo  group  and  less  in  the  tanezumab  5  mg  group,  and  with  decreasing proportions to about 35% - 45% after 10-16 weeks and beyond. The average number of days using rescue was &lt;1.5/week, with no differences between the treatment groups.

Concomitant NSAIDs (allowed if occasional and for non-OA) was used by about 25% in the studies without clear differences between treatment groups. Protocol violations by exceeding the NSAID limit occurred in ≤5% of the tanezumab treated groups.

## Outcomes and estimation

## Tanezumab versus placebo

The primary objective of study 1056 was met. For all three co-primary outcomes (WOMAC Pain, WOMAC Physical Function, Patient Global Assessment) the changes from baseline to week 16 were statistical significantly different (p&lt;0.05) from placebo for both dose regimens (2.5 mg and 2.5/5 mg), (Table 11 ). For all three co-primary outcomes, the improvements at week 16 were numerically slightly higher in the 2.5/5 mg group as compared to the 2.5 mg, which is also reflected in the size of the treatment effects of tanezumab versus placebo.

The primary objective of study 1057 was not met for the 2.5 mg dose and met for the 5 mg dose. For tanezumab 5 mg, for all three co-primary outcomes (WOMAC Pain, WOMAC Physical Function, Patient Global  Assessment)  the  changes  from  baseline  to  week  24  were  statistically  significantly  different (p&lt;0.05) from placebo (Table 11). For tanezumab 2.5 mg, for two of the three co-primary outcomes (WOMAC Pain,  WOMAC  Physical  Function)  the  changes  from  baseline  to  week  24  were  statistically significantly different (p&lt;0.05) from placebo, but not for Patient Global Assessment (Table 12), which was statistically significant at week 16. For all three co-primary outcomes, the improvements at weeks 16 and 24 were numerically slightly higher in the 5 mg group as compared to the 2.5 mg, which is also reflected in the size of the treatment effects of tanezumab versus placebo.

The between-group results and statistical conclusions for the three co-primary outcomes were generally similar when in sensitivity analyses missing data were handled according to BOCF, LOCF and MRMM, or when the PP set was analysed (not shown).

<div style=\"page-break-after: always\"></div>

Table 11 Results of co-primary outcomes at week 16 in study 1056

|                                          | Placebo        | Tanezumab      | Tanezumab      |
|------------------------------------------|----------------|----------------|----------------|
| Primary Efficacy Endpoint                | N=232          | 2.5 mg N=231   | 2.5/5 mg N=233 |
| WOMAC Pain Subscale                      |                |                |                |
| LS Mean (SE)                             | -2.64 (0.23)   | -3.23 (0.23)   | -3.37 (0.22)   |
| 95% CI for LS Mean                       | (-3.08, -2.19) | (-3.67, -2.79) | (-3.81, -2.93) |
| Versus Placebo                           |                |                |                |
| LS Mean Difference (SE)                  |                | -0.60 (0.24)   | -0.73 (0.24)   |
| 95% CI for LS Mean                       |                | (-1.07, -0.13) | (-1.20, -0.26) |
| p-value                                  |                | 0.0129         | 0.0023         |
| WOMACPhysical FunctionSubscale           |                |                |                |
| LS Mean (SE)                             | -2.56 (0.22)   | -3.22 (0.22)   | -3.45 (0.22)   |
| 95% CI for LS Mean                       | (-3.00, -2.12) | (-3.66, -2.79) | (-3.88, -3.03) |
| Versus Placebo                           |                |                |                |
| LS Mean Difference (SE)                  |                | -0.66 (0.24)   | -0.89 (0.24)   |
| 95% CIfor LS Mean                        |                | (-1.14, -0.19) | (-1.37, -0.42) |
| p-value                                  |                | 0.0065         | 0.0002         |
| PatientGlobalAssessmentof Osteoarthritis |                |                |                |
| LS Mean (SE)                             | -0.65 (0.08)   | -0.87 (0.08)   | -0.90 (0.08)   |
| 95%CI for LS Mean                        | (-0.80, -0.50) | (-1.02, -0.72) | (-1.05, -0.75) |
| Versus Placebo                           |                |                |                |
| LS Mean Difference (SE)                  |                | -0.22 (0.09)   | -0.25 (0.09)   |
| 95% CI for LS Mean                       |                | (-0.39, -0.05) | (-0.41, -0.08) |
| p-value                                  |                | 0.0109         | 0.0038         |

Source:Table 14.2.1.3,Table14.2.1.9,andTable 14.2.2.3.

A changefromBaseline&lt;O was an improvement.

Abbreviations: CI = confidence interval; LS = least squares; SE = standard error; WOMAC = Westem Ontario and McMaster Universities Osteoarthritis Index.

<div style=\"page-break-after: always\"></div>

Table 12 Results of co-primary outcomes at week 24 in study 1057

|                                               |                               | Placebo (N=282)   | Tanezumab 2.5 mg (N=283)   | Tanezumab 5 (N=284)   |
|-----------------------------------------------|-------------------------------|-------------------|----------------------------|-----------------------|
| WOMAC Pain Subscale                           | LS Mean (SE)                  | -2.24 (0.17)      | -2.70 (0.17)               | -2.85 (0.17)          |
|                                               | 95% CI for LS Mean            | (-2.58,-1.90)     | (-3.03,-2.37)              | (-3.19,-2.52)         |
|                                               | Versus Placebo                |                   |                            |                       |
|                                               | LS Mean Difference (SE)       |                   | -0.46 (0.18)               | -0.62 (0.18)          |
|                                               | 95% CI for LS Mean Difference |                   | (-0.81,-0.12)              | (-0.97,-0.26)         |
|                                               | p-value                       |                   | 0.0088                     | 0.0006                |
| WOMAC Physical Function Subscale LS Mean (SE) |                               | -2.11 (0.17)      | -2.70 (0.17)               | -2.82 (0.17)          |
|                                               | 95% CI for LS Mean            | (-2.45,-1.77)     | (-3.03,-2.37)              | (-3.15,-2.49)         |
|                                               | Versus Placebo                |                   |                            |                       |
|                                               | LS Mean Difference (SE)       |                   | -0.59 (0.18)               | -0.71 (0.17)          |
|                                               | 95% CI for LS Mean Difference |                   | (-0.93,-0.24)              | (-1.05,-0.36)         |
|                                               | p-value                       |                   | 0.0008                     | <.0001                |
| Patient Global Assessment of                  | LS Mean (SE)                  | -0.72 (0.06)      | -0.82 (0.06)               | -0.90 (0.06)          |
| Osteoarthritis                                | 95% CI for LS Mean            | (-0.84,-0.59)     | (-0.94,-0.70)              | (-1.02,-0.78)         |
|                                               | Versus Placebo                |                   |                            |                       |
|                                               | LS Mean Difference (SE)       |                   | -0.11 (0.07)               | -0.19 (0.07)          |
|                                               | 95% CI for LS Mean Difference |                   | (-0.24,0.02)               | (-0.32,-0.06)         |
|                                               | p-value                       |                   | 0.1092                     | 0.0051                |

Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, Baseline Patient Global Assessment of Osteoarthritis and Baseline diary average pain as covariates, and study site as a random effect.

Results were taken from a combined analysis of the individual imputed dataset ANCOVA results. PFIZER CONFIDENTIAL SDTM Creation: 02JAN2019 (14:20) Source Data: Listing 16.2.6.1 Output File: /nda1/A4091057/adwn\\_sg\\_infr\\_chg\\_ancova\\_mi Date of Generation: 06JUN2019 (10:41) Table 14.2.1.3.1.i is for Pfizer intermal use.

The  largest  improvements  in  WOMAC  Pain,  WOMAC  Physical  Function,  but  also  of  Patient  Global Assessment of Osteoarthritis, in the tanezumab groups as well as the placebo group is seen in the first 2 weeks (Figure 11, Figure 12), with a similar response in the two tanezumab groups. After the first 2 weeks, the course over time in WOMAC Pain and the other 2 co-primary outcomes was similar for both dose groups, with globally a similar difference to placebo which appears to be largest between dosing visits (see Clinical AR for the course of PGA).

<div style=\"page-break-after: always\"></div>

Figure 11 Course of WOMAC Pain over time in studies 1056 and 1057

<!-- image -->

Source:Figure14.2.1.1.1.2,Tab1e14.2.1.3

Significantly differentfromplacebo(p≤0.05)

Significantlydifferentfromplacebo(p≤0.001)

A changefromBaseline&lt;Owas animprovement.

Abbreviations:LS=least squares;SE=standard error;WOMAC=Westem Ontario and McMaster UniversitiesOsteoarthritisIndex.

<!-- image -->

PFIZERCONFIDENTIAL SDTM Creation:02JAN2019(13:20)SourceData:Listing16.2.6.1OutputFile: /ndal/A4091057/plot\\_adwnmi pain\\_descDateofGeneration:17JAN2019(10:03)

Source: Figure 14.2.1.1.1.2, Table 14.2.1.3

* Significantly different from placebo (p≤0.05)

↑Significantly different from placebo (p≤0.0001)

A change fromBaseline &lt;O was an improvement.

<div style=\"page-break-after: always\"></div>

Figure 12 Course of WOMAC physical function over time in studies 1056 and 1057

<!-- image -->

Source:Figure 14.2.1.1.4.2, Table 14.2.1.9.

- *Significantly different from placebo (p≤0.05).

↑Significantly different from placebo (p≤0.001)

A change fromBaseline&lt;O was an improvement.

Abbreviations: LS = least squares; SE = standard error; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

<!-- image -->

PFIZERCONFIDENTIAL SDTMCreation:02JAN2019(13:20)SourceData:Listing16.2.6.1OutputFile:. /ndal/A4091057/plotadwnmiphy\\_descDateofGeneration:17JAN2019(10:03)

Source:Figure 14.2.1.1.4.2,Tab1e 14.2.1.9

Significantly differentfromplacebo(p≤0.05)

Significantlydifferentfromplacebo(p≤O.0oo1)

AchangefromBaseline&lt;Owasanimprovement.

<div style=\"page-break-after: always\"></div>

To reflect the clinical relevance of effects, an improvement in WOMAC Pain from baseline ≥50% was one of the secondary outcomes. In study 1056 the proportion of patients with an improvement in WOMAC Pain ≥ 50% at week 16 was 55% in the group of patients treated with tanezumab 2.5 mg and 38% (p ≤ 0.001) in the group of patients treated with placebo with 38%. In study 1057 these proportions at week 24 were 45% in the tanezumab 2.5 mg and 34% in placebo (p&lt;0.05). The responses in both trials were also quite similar at week 16 and have been pooled.

Figure 13 WOMAC Pain response at week 16 in studies 1056 and 1057

<!-- image -->

p-value&lt;=0.05;*→p-value&lt;=0.01;**+p&lt;=0.001vs.placebo PFIZERCONFIDENTIALOutputFile:/a409\\_poolA409pool\\_OA\\_pbcntrl/fig\\_adwn\\_pain\\_num41DateofGcneration: 03JUN2019 (07:02)

Source:Figure 11.2.2.a

Pain assessment was also performed using a patient diary with more dense assessments. In these results from  study  1057  (Figure  14)  it  is  illustrated  that  the  treatment  effect  is  somewhat  larger  between infusions to be slightly 'U shaped' after week 2-4.

<div style=\"page-break-after: always\"></div>

Figure 14 Course of average pain in the index joint over time in study 1057

<!-- image -->

PFIZERCONFIDENTIAL SDTMCreation:02JAN2019(13:11)SourceData:Listing16.2.6.3.2OutputFile: /ndal/A4091057/plot\\_adnrmi\\_descDateofGeneration:17JAN2019(10:07)

Source:Figure 14.2.1.1.10.2,Table 14.2.7.2

- *Significantly differentfromplacebo(p≤0.05)

AchangefromBaseline&lt;Owasanimprovement.

- ↑ Significantly different from placebo (p≤0.oo01)

The WOMAC also consists of a Stiffness scale, which is the average of 2 items. In studies 1056 and 1057, effects of the 2.5 mg dose against placebo were statistically significant. At week 16 in study 1056, the mean change in WOMAC Stiffness in the tanezumab 2.5 mg groups was -3.2 versus -2.4 in the placebo group; with a mean (95%CI) difference of -0.8 (-1.3 - -0.4) and (p=0.0007). At week 24 in study 1057, the mean change in WOMAC Stiffness in the tanezumab 2.5 mg group was -2.6 versus -2.0 in the placebo group; with a mean (95%CI) difference of -0.6 (-0.99 - -0.2) for 2.5 mg (p=0.0013). The results for 5 mg were similar as for 2.5 mg.

## Tanezumab versus NSAIDs

The primary objective of study 1058: superiority of both tanezumab doses in three co-primary outcomes at week 16, was not met.  For tanezumab 5 mg, for two of the three co-primary outcomes (WOMAC Pain, WOMAC Physical Function) the changes from baseline to week 16 were statistically significantly superior (p&lt;0.05) to NSAIDs, but not for PGA (Table 13).

For tanezumab 2.5 mg, the changes from baseline up to week 16 in all three co-primary outcomes were not statistically significantly different (p&lt;0.05) from placebo. For all three co-primary outcomes, the improvements at week 16 were numerically slightly higher in the 5 mg group as compared to 2.5 mg, and changes in the 2.5 mg group were numerically slightly higher than in NSAIDs, which is also reflected in the size of the treatment effects of tanezumab versus placebo (Table 13).

The between-group results and statistical conclusions for the three co-primary outcomes were generally similar when in sensitivity analyses missing data were handled according to BOCF, LOCF and MRMM, or when the PP set was analysed (not shown). There was no large differences between the three NSAIDs in comparative effectiveness compared to tanezumab 2.5 mg SC (Figure 15).

Seen graphically (Figure 16), the effects in the NSAID group appear to be smaller as compared to the tanezumab groups, especially in the first 16 weeks. (By protocol, only patients with an improvement in WOMAC Pain ≥ 30% were allowed to continue after week 16.) After week 16 the effects diminished and became more similar in all three treatment groups. At week 24 and thereafter, differences from baseline

<div style=\"page-break-after: always\"></div>

in tanezumab 2.5 mg and 5 mg groups in WOMAC Pain, WOMAC Physical Function, and PGA are not statistically  significantly  different  from  NSAIDs.  The  effects  remain  more  or  less  stable,  with  a  slow decrease, up to week 56 (Figure 16).

At week 16, the proportions of patients with an improvement of ≥ 30% or ≥ 50% in WOMAC Pain were numerically slightly higher in the tanezumab 2.5 mg and 5 mg groups, as compared to NSAIDs (Figure 17). At week 16, the proportions with an improvement in WOMAC Pain ≥ 50% were 55% in the tanezumab 2.5 mg and 57% (p&lt;0.05) in the 5 mg groups, as compared to 52% in placebo.

Figure 15 The effect of tanezumab versus the three individual NSAIDs on WOMAC pain at week 16 in study 1058

<!-- image -->

Treatment Difference =LS mean change for tanezumab treatment group minusLSmean change for indicated comparator. Anegative treatmentdifferencerepresents differencesinfavorof tanezumab. PFIZER CONFIDENTIAL Output File:/a409 scs requests/scsa4090121a/plot adwnpn trt diff Date of Generation:21SEP2020 (17:11)

<div style=\"page-break-after: always\"></div>

Table 13 Results of co-primary outcomes at week 16 in study 1058

|                              |                               | Tanezumab 2.5 mg (N=1002)   | Tanezumab 5 (N=998)   | NSAID (N=996)   |
|------------------------------|-------------------------------|-----------------------------|-----------------------|-----------------|
| WOMAC Pain Subscale          | LS Mean (SE)                  | -3.22 (0.11)                | -3.33 (0.11)          | -3.07 (0.11)    |
|                              | 95% CI for LS Mean            | (-3.43,-3.01)               | (-3.54, -3.12)        | (-3.29, -2.86)  |
|                              | Versus NSAID                  |                             |                       |                 |
|                              | LS Mean Difference (SE)       | -0.15 (0.11)                | -0.26 (0.11)          |                 |
|                              | 95% CIfor LS Mean Difference  | (-0.36, 0.06)               | (-0.46, -0.05)        |                 |
|                              | p-value                       | 0.1597                      | 0.0148                |                 |
| WOMAC Physical Fumcation     | LS Mean (SE)                  | -3.27 (0.11)                | -3.39 (0.11)          | -3.08 (0.11)    |
| Subscale                     | 95% CI for LS Mean            | (-3.48, -3.05)              | (-3.60, -3.17)        | (-3.29, -2.86)  |
|                              | Versus NSAID                  |                             |                       |                 |
|                              | LS Mean Difference (SE)       | -0.19 (0.11)                | -0.31 (0.10)          |                 |
|                              | 95% CI for LS Mean Difference | (-0.40, 0.02)               | (-0.52, -0.11)        |                 |
|                              | p-value                       | 0.0691                      | 0.0030                |                 |
| Patient Global Assessment of | LS Mean (SE)                  | -0.96 (0.04)                | -0.97 (0.04)          | -0.94 (0.04)    |
| Osteoarthritis               | 95% CI for LS Mean            | (-1.03, -0.88)              | (-1.05, -0.90)        | (-1.01, -0.86)  |
|                              | Versus NSAID                  |                             |                       |                 |
|                              | LS Mean Difference (SE)       | -0.02 (0.04)                | -0.04 (0.04)          |                 |
|                              | 95% CI for LS Mean            | (-0.09,0.06)                | (-0.11, 0.04)         |                 |
|                              | Difference p-value            | 0.6332                      | 0.3431                |                 |

Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint, highest Kellgren-Lawrence grade, and NSAID) as fixed effects, Baseline value and Baseline diary average pain as covariates, and study site as a random effect.

Results were taken from a combined analysis of the individual imputed dataset ANCOVA results.

PFIZER CONFIDENTIAL SDTM Creation: 07APR2019 (22:38) Source Data:Listing 16.2.6.1 Output File: /nda1/A4091058 IM Efficacy/adwn sg infr chg ancova mi Date of Generation: 08JUL2019 (11:32) Table 14.2.1.3.1.iis for Pfizer intermal use.

<div style=\"page-break-after: always\"></div>

Figure 16 Course of WOMAC pain over time in study 1058

<!-- image -->

PFIZER CONFIDENTIAL SDTM CroMion: 07APR20I9 (22:29) SoENe Dax Lirtieg 16.2.6.1 Crtpu File: . /nda1/A4091058 Emicacyiplot adwnmi pain \\_dese56 Date of Generation: 13APR2019 (12:42)

Souce: Figwe 14.2.1.1.3

Abbreviations: LS = least squares; SE = standard eror

Figure 17 Proportions of patients with a response in WOMAC pain at week 16 in study 1058

<!-- image -->

PFIZER CONFIDENTIAL SDTM Crcation: 07AIR2019 (22:38) Sowrcc Datn: Listing I6.2.6.1 Outut Filc . /ndal/A4091058\\_Effcary/adws\\_res\\_f101 Date of Generation: 12JUL2019 (16:16)

Source: Figure 14.2.1.1.17

*Signifieantly different from NSAID (p\\_0.05)

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Rebound

Rebound can be analysed because treatment was stopped and followed by a safety follow-up period with efficacy assessment in studies 1056, 1057, and 1058. Rebound is defined by a revival of disease activity to higher-than-baseline levels, upon stop of treatment.

In studies 1056 , 1057 and 1058 , 16 weeks after treatment stop, the mean changes in WOMAC Pain were less than assessed 8 weeks after the last dose. In week 16, and were approaching the levels at week 2-4, with standard deviations that were about as large as the mean changes (see section 'Ancillary analyses' in Clinical AR for more details). Occurrence of rebound after cessation of tanezumab (study medication) was also analysed using categorisations of WOMAC pain at week 16 after cessation and using average e-diary pain scores from weeks 13 to 16. The number of initial responders who had an increase  to ≥ 30% of  baseline  values  was  small  for  all  treatment  groups,  with  a  tendency  that  the proportions were numerically larger in the tanezumab 2.5 mg group as compared to placebo (see Clinical AR, response to OC 134).

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 14 Summary of efficacy for trial 1056

| Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                         | Study A409 1056                                                                                                                                                                                                                                          | Study A409 1056                                                                                                                                                                                                                                          | Study A409 1056                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                                   | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 16 weeks (2 doses).                                                                                                                                    | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 16 weeks (2 doses).                                                                                                                                    | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 16 weeks (2 doses).                                                                                                                                    |
| Design                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                           | 16 weeks -- --                                                                                                                                                                                                                                           |
| Hypothesis                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                                        | Placebo SC eo8w                                                                                                                                                                                                                                          | Placebo SC eo8w                                                                                                                                                                                                                                          | n=232                                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                        | Tanezumab 2.5 mg eo8w                                                                                                                                                                                                                                    | Tanezumab 2.5 mg eo8w                                                                                                                                                                                                                                    | n=231                                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                        | Tanezumab 2.5/5 mg                                                                                                                                                                                                                                       | Tanezumab 2.5/5 mg                                                                                                                                                                                                                                       | n=233, first dose 2.5 mg, 8-week dose 5 mg.                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                | Co-Primary endpoints:                                                                                                                                                                                                                                    | WOMAC pain                                                                                                                                                                                                                                               | Change in WOMAC Pain from baseline to week 16. Calculated as the average of 5 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more pain.                                                         |

<div style=\"page-break-after: always\"></div>

|                                                 |                                          | WOMAC Physical Function                  | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations.   | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations.   | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations.   |
|-------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                          | PGA                                      | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                       | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                       | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                       |
|                                                 | Secondary endpoint:                      | WOMAC Pain ≥50%                          | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                                | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                                | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                                |
| Database lock                                   | Last patient last visit was in May 2018. | Last patient last visit was in May 2018. | Last patient last visit was in May 2018.                                                                                                                                                                                           | Last patient last visit was in May 2018.                                                                                                                                                                                           | Last patient last visit was in May 2018.                                                                                                                                                                                           |
| Results and Analysis                            | Results and Analysis                     | Results and Analysis                     | Results and Analysis                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                               |
| Analysis description                            | Primary Analysis                         | Primary Analysis                         | Primary Analysis                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                   |
| Analysis population and time point              | ITT population at week 16.               | ITT population at week 16.               | ITT population at week 16.                                                                                                                                                                                                         | ITT population at week 16.                                                                                                                                                                                                         | ITT population at week 16.                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Treatment group                          | Treatment group                          | Placebo                                                                                                                                                                                                                            | Tanezumab 2.5 mg SC                                                                                                                                                                                                                | Tanezumab 2.5/5 mg SC                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects                       | Number of subjects                       | 232                                                                                                                                                                                                                                | 231                                                                                                                                                                                                                                | 233                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | WOMAC Pain Mean (SE)                     | WOMAC Pain Mean (SE)                     | -2.64 (0.23)                                                                                                                                                                                                                       | -3.23 (0.23)                                                                                                                                                                                                                       | -3.37 (0.22)                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | WOMAC Physical Mean (SE)                 | WOMAC Physical Mean (SE)                 | -2.56 (0.22)                                                                                                                                                                                                                       | -3.23 (0.22)                                                                                                                                                                                                                       | -3.45 (0.22)                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | PGA Mean (SE)                            | PGA Mean (SE)                            | -0.65 (0.08)                                                                                                                                                                                                                       | -0.87 (0.08)                                                                                                                                                                                                                       | -0.90 (0.08)                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | WOMAC Pain ≥50% n (%)                    | WOMAC Pain ≥50% n (%)                    | 88 (38%)                                                                                                                                                                                                                           | 126 (55%)                                                                                                                                                                                                                          | 133 (57%)                                                                                                                                                                                                                          |
| Comparison groups                               |                                          |                                          |                                                                                                                                                                                                                                    | Tanezumab 2.5 mg versus Placebo                                                                                                                                                                                                    | Tanezumab 2.5/5 mg vs. Placebo                                                                                                                                                                                                     |
| Effect estimate per comparison                  | Co-primary outcomes:                     | Co-primary outcomes:                     | Co-primary outcomes:                                                                                                                                                                                                               | Co-primary outcomes:                                                                                                                                                                                                               | Co-primary outcomes:                                                                                                                                                                                                               |
| Effect estimate per comparison                  | WOMAC Pain                               | Mean                                     | difference                                                                                                                                                                                                                         | -0.60                                                                                                                                                                                                                              | -0.73                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | WOMAC Pain                               |                                          | (95%CI)                                                                                                                                                                                                                            | (-1.07 - -0.13)                                                                                                                                                                                                                    | (-1.20 - -0.26)                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | WOMAC Pain                               |                                          | P-value                                                                                                                                                                                                                            | 0.0129                                                                                                                                                                                                                             | 0.0023                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | WOMAC Physical Function                  | Mean                                     | difference                                                                                                                                                                                                                         | -0.66                                                                                                                                                                                                                              | -0.89                                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                          |                                          | (95%CI)                                                                                                                                                                                                                            | (-1.14 - -0.19)                                                                                                                                                                                                                    | (-1.37 - -0.42)                                                                                                                                                                                                                    |
| Effect estimate per comparison                  |                                          |                                          | P-value                                                                                                                                                                                                                            | 0.0065                                                                                                                                                                                                                             | 0.0002                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | PGA                                      | Mean                                     | difference                                                                                                                                                                                                                         | -0.22                                                                                                                                                                                                                              | -0.25                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|       |                           | (95%CI)            | (-0.39 - -0.05)    | (-0.41 - -0.08)    |
|-------|---------------------------|--------------------|--------------------|--------------------|
|       |                           | P-value            | 0.0109             | 0.0038             |
|       | Secondary outcome:        | Secondary outcome: | Secondary outcome: | Secondary outcome: |
|       | Change in WOMAC Pain ≥50% | OR                 | 1.9                | 2.2                |
|       |                           | (95%CI)            | (1.3 - 2.8)        | (1.5 - 3.2)        |
|       |                           | P-value            | 0.0010             | <0.001             |
| Notes | --                        | --                 | --                 | --                 |

Table 15 Summary of efficacy for trial 1057

| Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.   | Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                            | Study A409 1057                                                                                                                                                                                                             | Study A409 1057                                                                                                                                                                                                             | Study A409 1057                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                      | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 24 weeks (3 doses).                                                                                                       | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 24 weeks (3 doses).                                                                                                       | This was a randomised (1:1:1), placebo-controlled double-blinded trial with a treatment period of 24 weeks (3 doses).                                                                                                            |
| Design                                                                                                                                                                                                                      | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                              | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                              | 24 weeks -- --                                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                                  | Superiority                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                           | Placebo SC eo8w                                                                                                                                                                                                             | Placebo SC eo8w                                                                                                                                                                                                             | n=282                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                           | Tanezumab 2.5 mg eo8w                                                                                                                                                                                                       | Tanezumab 2.5 mg eo8w                                                                                                                                                                                                       | n=283                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                           | Tanezumab 5 mg eo8w                                                                                                                                                                                                         | Tanezumab 5 mg eo8w                                                                                                                                                                                                         | n=284                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                   | Co-Primary endpoints:                                                                                                                                                                                                       | WOMAC pain                                                                                                                                                                                                                  | Change in WOMAC Pain from baseline to week 24. Calculated as the average of 5 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more pain.                                 |
| Endpoints and definitions                                                                                                                                                                                                   |                                                                                                                                                                                                                             | WOMAC Physical Function                                                                                                                                                                                                     | Change in WOMAC Physical Function from baseline to week 24. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations. |
| Endpoints and definitions                                                                                                                                                                                                   |                                                                                                                                                                                                                             | PGA                                                                                                                                                                                                                         | Change in Patient Global Assessment of OA, from baseline to week 24. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                   | Secondary endpoint:                                                                                                                                                                                                         | WOMAC Pain ≥50%                                                                                                                                                                                                             | Improvement of at least 50% in WOMAC Pain from baseline to week 24.                                                                                                                                                              |
| Database lock                                                                                                                                                                                                               | Last patient last visit was in June 2018.                                                                                                                                                                                   | Last patient last visit was in June 2018.                                                                                                                                                                                   | Last patient last visit was in June 2018.                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                            | Results and Analysis       | Results and Analysis       | Results and Analysis            | Results and Analysis          |
|-------------------------------------------------|----------------------------|----------------------------|---------------------------------|-------------------------------|
| Analysis description                            | Primary Analysis           | Primary Analysis           | Primary Analysis                | Primary Analysis              |
| Analysis population and time point              | ITT population at week 24. | ITT population at week 24. | ITT population at week 24.      | ITT population at week 24.    |
| Descriptive statistics and estimate variability | Treatment group            | Placebo                    | Tanezumab 2.5 mg SC             | Tanezumab 5 mg SC             |
| Descriptive statistics and estimate variability | Number of subjects         | 282                        | 283                             | 284                           |
| Descriptive statistics and estimate variability | WOMAC Pain Mean (SE)       | -2.24 (0.17)               | -2.70 (0.17)                    | -2.85 (0.17)                  |
| Descriptive statistics and estimate variability | WOMAC Physical Mean (SE)   | -2.11 (0.17)               | -2.70 (0.17)                    | -2.82 (0.17)                  |
| Descriptive statistics and estimate variability | PGA Mean (SE)              | -0.72 (0.06)               | -0.82 (0.06)                    | -0.90 (0.06)                  |
| Descriptive statistics and estimate variability | WOMAC Pain ≥50% n (%)      | 159 (57%)                  | 185 (66%)                       | 195 (69%)                     |
| Comparison groups                               |                            |                            | Tanezumab 2.5 mg versus Placebo | Tanezumab 5 mg versus Placebo |
| Effect estimate per comparison                  | Co-primary outcomes:       | Co-primary outcomes:       | Co-primary outcomes:            | Co-primary outcomes:          |
| Effect estimate per comparison                  | WOMAC Pain                 | Mean difference            | -0.46                           | -0.62                         |
| Effect estimate per comparison                  | WOMAC Pain                 | (95%CI)                    | (-0.81 - - 0.12)                | (-0.97 - -0.26)               |
| Effect estimate per comparison                  | WOMAC Pain                 | P-value                    | 0.0088                          | 0.0006                        |
| Effect estimate per comparison                  | WOMAC Physical Function    | Mean difference            | -0.59                           | -0.71                         |
| Effect estimate per comparison                  | WOMAC Physical Function    | (95%CI)                    | (-0.93 - -0.24)                 | (-1.05 - -0.36)               |
| Effect estimate per comparison                  | WOMAC Physical Function    | P-value                    | 0.0008                          | <0.0001                       |
| Effect estimate per comparison                  | PGA                        | Mean difference            | -0.11                           | -0.19                         |
| Effect estimate per comparison                  | PGA                        | (95%CI)                    | (-0.24 - 0.02)                  | (-0.32 - - 0.06)              |
| Effect estimate per comparison                  | PGA                        | P-value                    | 0.11                            | 0.0051                        |
| Effect estimate per comparison                  | Secondary outcome:         | Secondary outcome:         | Secondary outcome:              | Secondary outcome:            |
| Effect estimate per comparison                  | Change in WOMAC Pain ≥50%  | OR                         | 1.9                             | 2.2                           |
| Effect estimate per comparison                  | Change in WOMAC Pain ≥50%  | (95%CI)                    | (1.3 - 2.8)                     | (1.5 - 3.2)                   |
| Effect estimate per comparison                  | Change in WOMAC Pain ≥50%  | P-value                    | 0.0010                          | <0.001                        |
| Notes                                           | --                         | --                         | --                              | --                            |

<div style=\"page-break-after: always\"></div>

Table 16 Summary of efficacy for trial 1058

| Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects   | Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects   | Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects   | Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects                                                     | Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects                                                     | Title: A Phase 3, Randomized, Double-Blind, Active-Controlled MultiCenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                               | Study A409 1058                                                                                                                                                                | Study A409 1058                                                                                                                                                                | Study A409 1058                                                                                                                                                                                                                  | Study A409 1058                                                                                                                                                                                                                  | Study A409 1058                                                                                                                                                                                                                  |
| Design                                                                                                                                                                         | This was a randomised (1:1:1), active-controlled double-blinded trial with a treatment period of 56 weeks.                                                                     | This was a randomised (1:1:1), active-controlled double-blinded trial with a treatment period of 56 weeks.                                                                     | This was a randomised (1:1:1), active-controlled double-blinded trial with a treatment period of 56 weeks.                                                                                                                       | This was a randomised (1:1:1), active-controlled double-blinded trial with a treatment period of 56 weeks.                                                                                                                       | This was a randomised (1:1:1), active-controlled double-blinded trial with a treatment period of 56 weeks.                                                                                                                       |
| Design                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                 | 56 weeks -- --                                                                                                                                                                                                                   | 56 weeks -- --                                                                                                                                                                                                                   | 56 weeks -- --                                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                     | Superiority at week 16                                                                                                                                                         | Superiority at week 16                                                                                                                                                         | Superiority at week 16                                                                                                                                                                                                           | Superiority at week 16                                                                                                                                                                                                           | Superiority at week 16                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                              | Oral NSAID BID                                                                                                                                                                 | Oral NSAID BID                                                                                                                                                                 | n=996                                                                                                                                                                                                                            | n=996                                                                                                                                                                                                                            | n=996                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                              | Tanezumab 2.5 mg eo8w                                                                                                                                                          | Tanezumab 2.5 mg eo8w                                                                                                                                                          | n=1002                                                                                                                                                                                                                           | n=1002                                                                                                                                                                                                                           | n=1002                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                              | Tanezumab 5 mg eo8w                                                                                                                                                            | Tanezumab 5 mg eo8w                                                                                                                                                            | n=998                                                                                                                                                                                                                            | n=998                                                                                                                                                                                                                            | n=998                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                      | Co-Primary endpoints:                                                                                                                                                          | WOMAC pain                                                                                                                                                                     | Change in WOMAC Pain from baseline to week 16. Calculated as the average of 5 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more pain.                                 | Change in WOMAC Pain from baseline to week 16. Calculated as the average of 5 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more pain.                                 | Change in WOMAC Pain from baseline to week 16. Calculated as the average of 5 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more pain.                                 |
| Endpoints and definitions                                                                                                                                                      |                                                                                                                                                                                | WOMAC Physical Function                                                                                                                                                        | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations. | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations. | Change in WOMAC Physical Function from baseline to week 16. Calculated as the average of 17 NRS items (0-10) concerning the index joint (hip or knee) for the past 48 hours, higher scores indicate more functional limitations. |
| Endpoints and definitions                                                                                                                                                      |                                                                                                                                                                                | PGA                                                                                                                                                                            | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                     | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                     | Change in Patient Global Assessment of OA, from baseline to week 16. Rated as a single item ranging from 1 ('very good') to 5 ('very poor').                                                                                     |
| Endpoints and definitions                                                                                                                                                      | Secondary endpoint:                                                                                                                                                            | WOMAC Pain ≥50%                                                                                                                                                                | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                              | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                              | Improvement of at least 50% in WOMAC Pain from baseline to week 16.                                                                                                                                                              |
| Database lock                                                                                                                                                                  | Last patient last visit was in February 2019.                                                                                                                                  | Last patient last visit was in February 2019.                                                                                                                                  | Last patient last visit was in February 2019.                                                                                                                                                                                    | Last patient last visit was in February 2019.                                                                                                                                                                                    | Last patient last visit was in February 2019.                                                                                                                                                                                    |
| Results and Analysis                                                                                                                                                           | Results and Analysis                                                                                                                                                           | Results and Analysis                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                             |
| Analysis description                                                                                                                                                           | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                 |
| Analysis population and time point                                                                                                                                             | ITT population at week 16.                                                                                                                                                     | ITT population at week 16.                                                                                                                                                     | ITT population at week 16.                                                                                                                                                                                                       | ITT population at week 16.                                                                                                                                                                                                       | ITT population at week 16.                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                                                | Treatment group                                                                                                                                                                | Treatment group                                                                                                                                                                | NSAID                                                                                                                                                                                                                            | Tanezumab 2.5 mg SC                                                                                                                                                                                                              | Tanezumab 5 mg SC                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                | Number of subjects                                                                                                                                                             | Number of subjects                                                                                                                                                             | 996                                                                                                                                                                                                                              | 1002                                                                                                                                                                                                                             | 998                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                | WOMAC Pain Mean (SE)                                                                                                                                                           | WOMAC Pain Mean (SE)                                                                                                                                                           | -3.07 (0.11)                                                                                                                                                                                                                     | -3.22 (0.11)                                                                                                                                                                                                                     | -3.33 (0.11)                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                | WOMAC Physical Mean (SE)                                                                                                                                                       | WOMAC Physical Mean (SE)                                                                                                                                                       | -3.08 (0.11)                                                                                                                                                                                                                     | -3.27 (0.11)                                                                                                                                                                                                                     | -3.39 (0.11)                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                | PGA Mean (SE)             | -0.94 (0.04)         | -0.96 (0.04)                  | -0.97 (0.04)                |
|--------------------------------|---------------------------|----------------------|-------------------------------|-----------------------------|
|                                | WOMAC Pain ≥50% n (%)     | 498 (50%)            | 531 (53%)                     | 555 (56%)                   |
| Comparison groups              |                           |                      | Tanezumab 2.5 mg versus NSAID | Tanezumab 5 mg versus NSAID |
| Effect estimate per comparison | Co-primary outcomes:      | Co-primary outcomes: | Co-primary outcomes:          | Co-primary outcomes:        |
| Effect estimate per comparison | WOMAC Pain                | Mean difference      | -0.15                         | -0.26                       |
| Effect estimate per comparison |                           | (95%CI)              | (-0.36 - 0.06)                | (-0.46 - 0.05)              |
| Effect estimate per comparison |                           | P-value              | 0.0129                        | 0.0023                      |
| Effect estimate per comparison | WOMAC Physical Function   | Mean difference      | -0.19                         | -0.31                       |
| Effect estimate per comparison |                           | (95%CI)              | (-0.40 - 0.02)                | (-0.52 - -0.11)             |
| Effect estimate per comparison |                           | P-value              | 0.0691                        | 0.0030                      |
| Effect estimate per comparison | PGA                       | Mean difference      | -0.02                         | -0.04                       |
| Effect estimate per comparison |                           | (95%CI)              | (-0.09 - 0.06)                | (-0.11 - 0.04)              |
| Effect estimate per comparison |                           | P-value              | 0.63                          | 0.34                        |
|                                | Secondary outcome:        | Secondary outcome:   | Secondary outcome:            | Secondary outcome:          |
|                                | Change in WOMAC Pain ≥50% | OR                   | 1.15                          | 1.2                         |
|                                |                           | (95%CI)              | (0.96 - 1.4)                  | (1.02 - 1.46)               |
|                                |                           | P-value              | 0.13                          | <0.026                      |
| Notes                          | --                        | --                   | --                            | --                          |

<div style=\"page-break-after: always\"></div>

## Supportive studies

The seven 'pre-2015' phase 3 studies are regarded as being supportive (Table 17). The studies were performed in hip and/or knee OA, were placebo-controlled or active-controlled, and had different entry criteria for treatment history, using SC or IV tanezumab administration, and doses of 2.5 mg, 5 mg and 10 mg.

These studies were used for pooled analyses with IV and SC studies, for more precision of the effect estimate in co-primary outcomes, and to perform subgroup analyses.

All 16 or 24-week phase 3 studies included a placebo control (1011, 1014, 1015, 1018, 1056 and 1057). Two of the 16-week placebo-controlled studies additionally included active comparator arms (1015 and 1018). The long-term studies (1025 and 1058) did not include placebo but included an NSAID active controlled arm. The NSAIDS used in studies 1015, 1018, 1025, and 1058 were:

- Naproxen 500 mg BID in Studies 1015, 1018, 1025, and 1058
- Celecoxib 100 mg BID in Studies 1025 and 1058
- Diclofenac extended-release (ER) 75 mg BID in Study 1058.

Table 17 Overview of efficacy studies and main design features

| Efficacy Study Category/ Categories           | Study (To be linked to Module 5.2)   | N    | Index Joint   | UnsatisfactoryPrior Analgesicsa (Inclusion Criteria)   | Study. Designb   | Comparator   | Comparator   | Treatment Duration [1°Efficacy Analysis] in Weeks (No. Doses)   | Route of Admin   | Tanezumab Doses (mg8 Weeksd)   | Tanezumab Doses (mg8 Weeksd)   | Tanezumab Doses (mg8 Weeksd)   |
|-----------------------------------------------|--------------------------------------|------|---------------|--------------------------------------------------------|------------------|--------------|--------------|-----------------------------------------------------------------|------------------|--------------------------------|--------------------------------|--------------------------------|
| Efficacy Study Category/ Categories           | Study (To be linked to Module 5.2)   | N    | Index Joint   | UnsatisfactoryPrior Analgesicsa (Inclusion Criteria)   | Study. Designb   | PBO          | Activec      | Treatment Duration [1°Efficacy Analysis] in Weeks (No. Doses)   | Route of Admin   | 2.5                            |                                | 10                             |
| Placebo-Controlled                            | 1056                                 | 696  | KH            | APAP, NSAID, Opioid                                    | RDB              | Y            |              | 16 [16] (2)                                                     | SC               | Y                              | T                              |                                |
| Placebo-Controlled                            | 1057                                 | 849  | K/H           | APAP, NSAID,Opioid                                     | RDB              | Y            |              | 24 [24] (3)                                                     | SC               | Y                              | Y                              |                                |
| Placebo-Controlled                            | 1011                                 | 690  | K             | Non-opioid                                             | R DB             | Y            |              | 24 [16] (3)                                                     | IV               | Y                              | Y                              | Y                              |
| Placebo-Controlled                            | 1014                                 | 621  | H             | Non-opioid                                             | R DB             | Y            |              | 24 [16] (3)                                                     | IV               | Y                              | Y                              | Y                              |
| Placebo-Controlled Active-Controlled          | 1015                                 | 828  | K             | No criteria                                            | RDB              | 人            | 人            | 16 [16] (2)                                                     | IV               |                                | Y                              | Y                              |
| Placebo-Controlled Active-Controlled          | 1018                                 | 840  | KH            | No criteria                                            | R, DB            | Y            | Y            | () [91]91                                                       | IV               |                                | Y                              | Y                              |
| Active-Controlled Long-TermActiveControlled   | 1058                                 | 3021 | K/H           | APAP, Opioid                                           | RDB              |              | Y            | 56 [16] (7)                                                     | SC               | Y                              | Y                              |                                |
| Active-Controlled Long-Term Active Controlled | 1025e                                | 2700 | KH            | No criteria                                            | R DB             |              | Y            | 56 [16] (7)                                                     | IV               |                                | Y                              | Y                              |
| Long-Term Uncontrolled                        | 1016e                                | 2142 | K/H           | No criteria/Non-opioid                                 | RB, Ex + StOC    |              |              | 104 [24,48] (13)                                                | IV               | Y                              | Y                              | Y                              |
| Long-Term Uncontrolled                        | 1043e                                | 678  | KH            | No criteria                                            | RB +StOC         |              |              | 56 [8,16] (7)                                                   | SC               | Y                              | 人                              | Y                              |

Source:IndividualStudyCSRs

B =Dose blinded; H=Hip; K =Knee; N=Number of patients (ITT);Ex =Extension study; StOC+Standard of Care; T=Titrated; Y=Variable included in the study. Blankcellsindicate that the variablewasnot used in that study

b.Balancedrandomizationbetweentreatmentgroups.

a.Prioranalgesicsthatprovidedinsufficientpainreliefand/orthat thepatientwas unwillingtotake,orunabletotakedue tocontraindications orinabilitytotolerate.

c.Naproxen 500mg BID(Studies 1015,1018,1025,and1058),Celecoxib100 mg BID(Studies 1025 and1058),Diclofenac Extended Release75 mgBID (Study 1058)

d.Unlessotherwisestated.

e.Studies affectedby the partial clinical holdbut included in the integrated efficacy analysis.

## Analysis performed across trials (pooled analyses and meta-analysis)

## Pooled comparisons against placebo

When analysing the treatment effects (against placebo) of tanezumab 2.5 mg on change from baseline in WOMAC Pain at week 16 (Figure 18), it can be seen that for all studies the effects are statistically significant. This can also be observed for WOMAC Physical Function (Figure 19) and for Patient Global Assessment of OA (not shown here).

The mean (95% CI) treatment effect of 2.5 mg SC on WOMAC Pain was -0.7 (-0.95 - -0.37) for the pooled SC studies (1056 and 1057) and -0.9 (-1.3 - -0.5) for the pooled IV studies (1011, 1014, 1015,

<div style=\"page-break-after: always\"></div>

1018) (Table 18). There was no or a small increase in treatment effect at higher doses of SC or IV. Similarly, the mean (95%CI) treatment effect of 2.5 mg SC on WOMAC Physical Function was -0.7 (-1.0 - -0.42) for the pooled SC studies, and a bit larger in the pooled IV studies (Figure 19).

Using the pooled data of the placebo-controlled SC studies 1056 and 1057, the responses in WOMAC Pain&gt;50% were 52% on tanezumab 2.5 mg and 37% on placebo (Table 19). The treatment effect can be derived as being 15% (p&lt;0.0001).

Table 18 Changes in WOMAC Pain from baseline at week 16 in studies 1011, 1014, 1015, 1018, 1056, 1057

|    |                                                | Placebo (N=1258)   | Tanezumab 2.5mg (N=841)                     | Tanezumab 5m (N=1260)                       | Tanezumab 10 mg (N=748)                     | Naproren 500 mg BID (N=417)                |
|----|------------------------------------------------|--------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|
| SC | LS Mean (SE) Diff of LS Means (95% CI) p-value | 513 -2.5 (0.12)    | 513 -3.1 (0.12) -0.7 (-0.95, -0.37) 1000'00 | 517 -3.2 (0.12) -0.7 (-0.99, -0.41) c0.0001 |                                             |                                            |
|    | LS Mean (SE) Diff of LS Means (95% CI) p-value | 744 -2.3 (0.12)    | 327 -3.2 (0.18) -0.9 (-1.33, -0.52) 1000'0> | 743 -3.5 (0.12) -1.2 (-1.54, -0.94) ≤0.0001 | 747 -3.5 (0.12) -1.2 (-1.50, -0.91) ≤0.0001 | 416 -2.9 (0.16) -0.7 (-1.03, -0.30) 0.0004 |
|    | LS Mean (SE) Diff of LS Means (95% CI) p-value | 1257 -2.4 (0.09)   | 840 -3.2 (0.11) -0.8 (-1.06, -0.57) 1000'0= | 1260 -3.4 (0.08) -1.0 (-1.23,-0.81) 0.0001  | 747 -3.5 (0.11) -1.1 (-1.36, -0.83) 0.0001  | 416 -2.9 (0.16) -0.6 (-0.89, -0.22) 0.0013 |

A change from baseline&lt;Ois an improvement.

Difference of LS means is for treatment versus placebo.

SC: 1056 and 1057 p0oled; IV: 1011, 1014, 1015, 1018 p0oled; SC+IV: 1011, 1014, 1015, 1018, 1056, 1057 p0oled.

PFIZER CONFIDENTLAL Output File: /a409\\_pool/A409pool\\_OA\\_pbcntrl/adwn\\_inf\\_chg\\_ancova\\_pain\\_mi Date of Generation: 02JUN2019 (23:00)

Table 2.1.p.a is for Pfizer internal use.

Table 19 Change in WOMAC Pain &gt;50% from baseline at week 16 in studies 1011, 1014, 1015, 1018, 1056, 1057

|       |                                                 | Placebo (N=1258)   | Tanezumab 2.5 mg (N=841)                  | Tanezumab 5mg (N=1260)                     | Tanezumab 10 mg (N=748)                   | Naproxen 500 mg BID (N=417)               |
|-------|-------------------------------------------------|--------------------|-------------------------------------------|--------------------------------------------|-------------------------------------------|-------------------------------------------|
| SC    | n >=50%improvement Odds Ratio (95% CI) p-value  | 513 189 (36.8%)    | 513 266 (51.9%) 1.88 (1.46, 2.42) <0.0001 | 517 268 (51.8%) 1.88 (1.46, 2.41) <0.0001  |                                           |                                           |
| IV    | n >=50%improvement Odds Ratio (95% CI) p-value  | 744 243 (32.7%)    | 327 157 (48.0%) 1.89 (1.42, 2.52) <0.0001 | 743 403 (54.2%) 2.55 (2.06, 3.16) <0.0001  | 747 403 (53.9%) 2.52 (2.04, 3.13) <0.0001 | 416 184 (44.2%) 1.78 (1.36, 2.31) <0.0001 |
| SC+IV | n >=50% improvement Odds Ratio (95% CI) p-value | 1257 432 (34.4%)   | 840 423 (50.4%) 1.94 (1.61, 2.34) <0.0001 | 1260 671 (53.3%) 2.24 (1.90, 2.64) <0.0001 | 747 403 (53.9%) 2.39 (1.96, 2.92) <0.0001 | 416 184 (44.2%) 1.67 (1.30, 2.15) <0.0001 |

Odds ratio and 95% CI are estimated from logistic regression model.

Oddsratioisfor treatmentversusplacebo.

SC:1056 and1057p0oled;IV:1011,1014,1015,1018p0oled;SC+IV:1011,1014,1015,1018,1056,1057po0led

PFIZER CONFIDENTIAL Output File: /a409 pool/A409poo1 OA pbcntrl/adwn cat infr resp multi mix1 Date of Generation: 04JUN2019 (18:32)

Table 2.4.p.a is for Pfizer intermal use.

<div style=\"page-break-after: always\"></div>

Figure 18 Treatment effects of tanezumab against placebo in WOMAC Pain from baseline at week 16 in studies 1011, 1014, 1015, 1018, 1056, 1057

<!-- image -->

TreatmentDifference (95%CI)

Treatment Difference =LS mean change for treatment group minus LS mean change for placebo group. A negative treatment difference represents an improverment over placebo.

PFIZER CONFIDENTLAL Cutput File: /a409 pool/A409pool OA pbcntrl/fig adwn pain numl Date of Generation: 03JUN2019 (07:02)

Figure 19 Treatment effects of tanezumab against placebo in WOMAC Physical Function from baseline at week 16 in studies 1011, 1014, 1015, 1018, 1056, 1057

<!-- image -->

Treatment Difference (95% CI)

Treatment Difference =LS mean change for treatment group minus LS mean change for placebo group. A negative treatment difference represents an improvement over placebo. PFIZER CONFIDENTIAL Output File: /a409 pool/A409pool OA pbxntrl/fig adwn phy num2 Date of Generation: 03JUN2019 (07:50)

<div style=\"page-break-after: always\"></div>

## Pooled comparisons against NSAID

In the active-controlled IV studies, 2.5 mg was not included as a treatment arm. Hence, for the 2.5 mg dose, only study 1058 is available for comparison with NSAID. According to the results, tanezumab 2.5 mg was not shown to be superior to NSAIDs (Figure 20).

When pooling the SC and IV studies including an NSAID comparator, it appears that the treatment effect on WOMAC pain of Naproxen 500 mg BID falls between tanezumab 2.5 mg (SC or IV) and placebo (Figure 21).

Figure 20 Treatment effects of tanezumab against NSAID in WOMAC Pain from baseline at week 16 in studies 1015, 1018, 1025 and 1058

<!-- image -->

A negative treatment difference represents an improvement.

Treatment Difference=LS mean change for Tanezumab treatment group minus LS mean change for NSAIDs Pooled group. PFIZER CONFIDENTIAL Output File: -a409\\_pool/A409pool\\_OA\\_ISE\\_Actcntr\\_ShT/adwnpn\\_diff\\_trt\\_plot Date of Generation: 13JUN2019 (21:20)

Source: Figure 1l.1.b

<div style=\"page-break-after: always\"></div>

Figure 21 Responses in WOMAC Pain at week 16 in studies 1011, 1014, 105, 1018, 1056, 1057

<!-- image -->

*p-value &lt;= 0.05;**p-value &lt;= 0.01;***p &lt;= 0.001 vs. placebo PFIZER CONFIDENTIAL Output File: /a409\\_pool/A409pool\\_OA\\_pbcntrlfig\\_adwn\\_pain\\_num4 Date ofGeneration: 03JUN2019 (07:02)

Souce: Figwre 11.2.1.a

## Subgroup analyses

Subgroup analyses across trials were performed for: male/female; age with 65 years and 75 years as cut-offs; BMI; index joint (hip or knee); KL-grade of index joint; disease duration; disease severity; depression/anxiety/insomnia; and region.

According to the results for tanezumab 2.5 mg, it appeared that the treatment effects on WOMAC Pain were positive for males and females and for different age groups (Figure 22). There was no tendency of decreasing treatment effects with increasing weight, for different regions, and when the index joint was the hip or the knee (Figure 23). There was no tendency for differential treatment effects in patients with moderate or severe disease (Figure 24). Also, the presence of depression, anxiety, and insomnia did not appear to lead to differential treatment effects on WOMAC pain.

<div style=\"page-break-after: always\"></div>

Figure 22 Subgroup analysis of treatment effects of tanezumab versus placebo on WOMAC pain in studies 1011, 1014, 1015, 1018, 1-56, 1057: age and gender

<!-- image -->

Treatment Difference (95% CI)

Treatment Difference =LS mean change for treatment group minus LS mean change for placebo group. A negative treatment difference represents an improvement over placebo. (07:50)

Source: Figure 11.8.a

<div style=\"page-break-after: always\"></div>

Figure 23 Subgroup analysis of treatment effects of tanezumab versus placebo on WOMAC pain in studies 1011, 1014, 1015, 1018, 1056, 1057: index joint and region

<!-- image -->

TreatmentDifference(95%CI)

Treatment Difference =LS mean change for treatment group minus LS mean change for placebo group. Anegative treatment differencerepresents animprovement over placebo. PFIZER CONFIDENTIAL Output File:./a409\\_pool/A409pool\\_OA\\_pbcntrl/fig\\_adwn\\_pain\\_num31 Date of Generation:03JUN2019 (07:50)

Source:Figure 11.8.a

Figure 24 Subgroup analysis of treatment effects of tanezumab versus placebo on WOMAC pain in studies 1011, 1014, 1015, 1018, 1-56, 1057: disease severity

<!-- image -->

TreatmentDifference (95%CI)

Treatment Differen ce =LS mean change for treatment group minus LS mean change for placebo group. A negative treatment difference represents an improvement over placebo. (07:50)

Source: Figure 1l.8.a

<div style=\"page-break-after: always\"></div>

## 2.4.9. Discussion on clinical efficacy

## Design and conduct of clinical studies

The clinical programme was extensive. All OA studies were performed in patients with moderate to severe OA of the hip or the knee. In that sense, the study populations of the 10 phase 3 studies are similar. The main differences between the 'pre-2015' and 'post-2015' studies in OA are that the latter: have more  strict  criteria  for  failure/inappropriateness  of  standard  of  care  pharmacological  treatment (paracetamol, NSAIDs, tramadol and opioids); do not include the 10 mg dose; have more strict exclusion criteria  serving  risk  minimisation  (ineligibility  for  joint  replacement  surgery,  Xray  signs  of  RPOA  and similar destructive joint disorders).

All  studies  have  been  performed  in  hip  or  knee  OA.  Initially  the  applicant  proposed  a  general  OA indication, including hand OA. However, according to the EMA Guideline for products for the treatment of OA (CPMP/EWP/784/97 Rev. 1), studies in hand OA should be performed as well for the acceptance of such a broad OA indication. During the procedure, the applicant agreed to restrict the indication to hip/knee OA.

Based on PK/PD modelling, the exposure of SC and IV are expected to be largely similar after 2-4 weeks and based on quality information, the substances for SC and IV are the same. This would support that the 'pre-2015' data can be used as supportive data.

## Main studies

Because  the  'post-2015'  studies  are  best  aligned  with  the  proposed  indication  regarding  dose, administration and population, these three studies are regarded as 'pivotal'. The 'pre-2015' studies are regarded as providing supportive information. The design of these seven phase 3 'pre-2015' studies is in line with what is expected and globally have similar designs as the 'post-2015' studies.

The study designs of the three main clinical studies 1056, 1057 and 1058 follow the objectives and overall are adequate, all included the 2.5 mg SC dose given every-8-weeks that is proposed by the applicant, and also include the next higher dose of 5 mg. Studies 1056 and 1057 are placebo-controlled, which is adequate to assess the treatment effect of tanezumab. While study 1056 with 16 weeks is quite short (2 doses), study 1057 is longer with 24 weeks (3 doses). This should be long enough to assess clinically meaningful treatment effects.

Study 1058 was long term and therefore did not include placebo but was NSAID controlled. The efficacy objective was at week 16; it was hypothesised that tanezumab would be superior to oral NSAIDs (pool of celecoxib, diclofenac, naproxen). After 16 weeks, only patients with at least a 'partial' response in WOMAC  pain  (≥30%  change  at  week  16  and  already  some  improvement  before)  could  continue. Therefore, the design is suited to evaluate maintenance of effects.

## Population

The inclusion criteria are in line with a target population as proposed in the indication regarding location of OA, disease severity and regarding treatment history. The inclusion criteria with a WOMAC Pain ≥ 5 at screening  and  baseline  is  sufficient  to  ensure  that  the  included  patients  comply  with  a  definition  of moderate  to  severe  pain ' (in  general  NRS ≥ 4)  [EMA/CHMP/970057/2011].  Fulfilment  of  the  ACR diagnostic criteria and a Kellgren-Lawrence ≥ 2 are appropriate to define patients with clinically relevant OA, of hip or knee (target joint). It is considered that treatment history is well defined and according to the protocol is based on a documented history of past use/appropriateness. This is in line with previous Scientific Advice.

<div style=\"page-break-after: always\"></div>

Patients from studies 1056 and 1058 were in the majority enrolled in the US and in study 1057 nearly all patients were enrolled in Europe, but baseline demographic and clinical variables were quite similar to studies 1056 and 1058, with only 0.5 lower WOMAC scores and on average 1 year shorter disease duration. Hence, it seems that study populations are comparable, except that patients in study 1058 had no  contra-indications  or  intolerability  issues  for  NSAIDs.  However,  this  subgroup  was  small  and  no meaningful subgroup analysis can be performed. There was no difference in treatment effect between patients with/without analgesic use at baseline. In all studies the large majority had insufficient effect of NSAID, therefore these populations are sufficiently similar to extrapolate the long-term effects to the population in the short-term studies. EU patients were well represented in study 1057, that also had 24weeks of follow-up. This makes study 1057 a most relevant study from the European perspective.

The pattern of past medication use was quite similar for studies 1056 and 1058 for whom a lot of patients from the US were contributing data, compared to study 1057 with the vast majority of patients from European countries. Most notably, in study 1057, opioid use was lower, and tramadol use was higher as compared to studies 1056 and 1058. It is considered that regarding overall treatment history, patients from study 1058 in essentially are stemming from the same source population as studies 1056 and 1057, except for contra-indications/tolerability for NSAIDs.

For all three main studies, many more patients had been screened than could be included. A considerable number of patients were ineligible due to the presence of radiographic evidence of concomitant joint disorders or having radiographic signs of RPOA or other joint manifestations that could be a risk for a devastating joint outcome. Also, planned surgery (any) during duration of the study' was an exclusion criterion in all three pivotal studies. These were exclusion criteria with the aim to mitigate the occurrence of adverse events for the autonomic nervous system or the joint. For the presence of RPOA and related joint manifestations a contra-indication is included in the SmPC.

## Outcomes

The co-primary outcomes (WOMAC pain, Physical Function, Patient Global Assessment of OA) are in line with the CHMP guideline for medicinal products for the treatment of OA of the hip and knee [Doc. Ref. CPMP/EWP/  784/97  Rev.  1],  given  that  tanezumab  is  intended  for  the  treatment  of  pain  (and  not intended  as  a  disease-modifier).  Responder  analyses  of  pain  improvements ≥ 30%  and ≥ 50%  are considered  appropriate  for  chronic  pain  conditions  such  as  OA,  in  line  with  the  CHMP  Guideline  for medicinal products for the treatment of pain [EMA/CHMP/970057/2011]. The guideline does not request that PGA is the co-primary outcome.

## Sample size, randomisation and blinding

The sample size calculation of studies 1056 and 1057 was based on treatment effects observed for the IV formulation in the phase 3 studies, which is acceptable. For study 1058 it is less clear what the efficacy assumptions were based on, this study is mainly powered detecting safety signals.

Randomisation and blinding are considered adequate. In study 1058, patients were randomly allocated to tanezumab 2.5 mg, 5 mg or NSAIDs. But within NSAIDs (celecoxib, diclofenac, naproxen) the specific treatment was not randomly allocated: patients could continue on their NSAID if it was one of the three, or  the  physician  could  make  a  preference.  Because  of  the  presence  of  contra-indications/tolerability issues, this is considered reasonable and may not necessarily have led to overt selection biased efficacy assessment through confounding-by-contra-indication.

## Statistical analysis

The  estimand  proposed,  is  a  mix  between  treatment  policy  and  hypothetical  strategy  for  handling intercurrent events and resulting missing data, and generally, it is well thought out.

<div style=\"page-break-after: always\"></div>

The statistical analysis populations and primary analysis methods are considered acceptable. Sensitivity analyses for the co-primary endpoints were defined testing the robustness of the results for the missing data assumptions and the analysis population.

Multiplicity  was  handled  by  stepdown  strategies  and/or  alpha-splitting  and  reallocation,  according  to Bretz et al., which will preserve the overall type I error in the studies.

## Completion

The completion rates in both the placebo-controlled studies were reasonably high. Completion was ~90% in the tanezumab 2.5 and 5 mg groups, which was with 83%-85% only somewhat lower in the placebo groups. In NSAID-controlled study 1058, only 44% of patients in the three treatment groups completed the 56-week study, which is low. This, however, appears to be the design feature that patient should be 'partial responder' (improvement in WOMAC Pain ≥30% at week 16 and ≥15% in the period before) to continue in the treatment part of the study. A treatment stop if there is no apparent effect after two doses (week 16) is also included in the SmPC.

## Rescue and concomitant medication

Rescue medication (paracetamol) was used by a large proportion of patients, which however became lower towards the end of the trial. The amount of paracetamol taken was limited in the number of days and in amount, with a tendency for more paracetamol use in the NSAID group. If of any influence, it may have diluted differences of tanezumab with NSAIDs, which is conservative and therefore no issue. From meta-analysis, it appeared that it is unlikely that paracetamol is beneficial for the treatment of OA [Cochrane, Leopoldino et al. 2019] and therefore, there neither is an issue of external validity. Hence, the issue of frequent use of rescue medication was not pursued.

Concomitant NSAID was allowed for occasional purpose, and in all studies, somewhat more than 20% used NSAIDs, mostly in the placebo group. While the number of days of use was low, and highest in the placebo group, this is not considered to lead to bias in favour of tanezumab.

## Efficacy data and additional analyses

According to the results of the 16-week (2 doses) and the 24-week (3 doses) placebo-controlled studies and the 16-week results of the NSAID-controlled study, there is evidence that tanezumab 2.5 mg SC has a statistically significant effect on pain and function, similar in size as the treatment effect of NSAIDs. Despite that, due to the size of the treatment effects the clinical relevance of these treatment effects is limited.  Treatment  effects  appear  to  be  maintained  over  time,  without  evidence  of  rebound  after treatment stop. The results in the SC studies are supported by the results of the previous IV studies.

## Against placebo

For tanezumab, 2.5 mg, which is the proposed dose, statistically significant differences against placebo were found in the three co-primary outcomes (WOMAC pain, WOMAC Physical Function, Patient Global Assessment) in the 16-week study, and for the WOMAC Pain and Physical Function but not Patient Global Assessment in the 24-week study. For 5 mg, all endpoints were met in both placebo-controlled trials. Primarily based on the number of patients who become responders (change in WOMAC pain ≥50%) after 16 weeks or 24 weeks of treatment, the clinical relevance of the treatment effects of tanezumab is small: between 11% and 17% of patients on 2.5 mg in the placebo-controlled studies had a reduction in WOMAC pain≥50%. The effects are supported by similar effe cts being found in patient pain ratings using the ediary and by the WOMAC Stiffness subscale.

It is a limitation that for 2.5 mg PGA was not statistically significantly different from placebo at week 24 in study 1057. However, of the three co-primary outcomes, pain and physical function are considered

<div style=\"page-break-after: always\"></div>

more important than PGA, in line with the EMA guideline on products intended for the treatment of OA. In the presence of small effects, pain and function showed significant differences with placebo in study 1057. Because PGA is an ordinal scale from 1-5, it is a priori less sensitive to detect change as compared to the WOMAC scales. Overall, the effects in PGA were of the same magnitude, and statistically significant at week 16 in studies 1056 and 1057. A slightly lower disease severity at baseline in study 1057, as compared to study 1056, may have contributed to the small and non-significant effect in PGA.

There is some support for clinical relevance of the moderate treatment effect. An improvement in pain score  of  at  least  50%  is  considered  a  clinically  relevant  change  (EMA  guideline  for  development  of products for the treatment of pain). However, the difference in pain responders between tanezumab and placebo is small: 15% in the pivotal SC studies and 16% in the pooled placebo controlled IV+SC studies. It is supportive that for WOMAC Pain responses larger than at least 50% (70% and 90%), the numerical difference of tanezumab and placebo does not totally disappear. Differences between tanezumab and placebo for sustained response and reaching a Patient Acceptable Symptom State (&lt;3 points in WOMAC Pain or Function), changes larger than the MCII (&gt;2 points in WOMAC Pain or Function), OARSI response, are quite consistently small with 10-12%. Similar patterns and differences as for WOMAC Pain are found for  WOMAC  Physical  Function.  Relevantly,  the  overall  treatment  effects  are  conserved  in  the subpopulation with severe OA.

## Against NSAID

In  comparison  with  NSAID  treatment,  for  the  2.5  mg  dose  none  of  the  three  co-primary  outcomes (WOMAC pain,  WOMAC Physical  Function,  PGA)  the  improvements  over  16  weeks  were  statistically significantly superior to NSAID treatment, but there was no evidence that tanezumab 2.5 mg would be worse. For the 5 mg dose, the improvements over 16 weeks were statistically significant for two of three co-primary outcomes (WOMAC Pain, WOMAC Physical Function), but not for PGA. In patients who are partial responders by week 16, the effects of treatment with tanezumab are basically maintained, similar as with NSAIDs.

The  comparison  of  NSAIDs  with  tanezumab  2.5  mg  SC  is  most  relevant  to  understand  the  clinical relevance of treatment effects. According to the analysis, including forest plots, of the comparison of tanezumab 2.5 mg and 5 mg with the three individual NSAIDs (celecoxib, naproxen, diclofenac),  it appeared  that  there  were  no  relevant  differences  between  NSAIDs.  This  is  relevant  because  of generalisation of the evidence of efficacy from study 1058 to the concept 'NSAID'.

It appeared that switching to tanezumab 2.5 mg SC was similarly effective as continuing NSAIDs, mainly from study 1058. The notion of the applicant that in the pooled (SC+IV) studies, tanezumab 2.5 mg was more effective than NSAIDs is not agreed. The size of these differences (p&lt;0.05) was -0.2 for WOMAC Pain and -0.3 for WOMAC Physical Function, which is considered as small effects without notable clinical relevance.

## Choice of dose

The choice for 2.5 mg as the proposed dose is driven by safety issues. The effect of tanezumab 5 mg is only incrementally higher than 2.5 mg; thus the choice for 2.5 mg as the preferred dose can also be understood from an efficacy perspective.  This  dose-relationship  was  also  found  in  the  'pre-2015'  IV studies in which 2.5, 5, and 10 mg were studied.

The proposed dose interval is 8 weeks. From the individual studies, it appears that the dose-response curve is a bit 'U' shaped with a length of 8 weeks: the effect is largest in the middle of the dosing interval, and by 8 weeks on average the start value has been reached again. This means that on average, the next dose is 'just in time'.

## Results in pooled analyses

<div style=\"page-break-after: always\"></div>

While the effects were small, pooling over the IV and SC studies showed that the treatment effects in WOMAC pain, WOMAC Physical Function and PGA were small and of the same size across studies. While precision increases with pooling, this supports that a small treatment effect has robustly been found, including the small incremental increase in efficacy with increasing dose of tanezumab.

## Post-hoc selected population

The proposed indication was post-hoc revised to an indication of adult patients with moderate to severe chronic hip or knee pain associated with advanced radiographic osteoarthritis (OA), defined as KellgrenLawrence (KL) grade 3 or grade 4, who have exhausted analgesic treatment options and are candidates or scheduled for total joint replacement.

For that purpose, the applicant post-hoc selected a subpopulation from the original trial population, with a WOMAC pain score ≥5 and a Kellg ren-Lawrence score grade 3 or 4 of the index joint. It is considered that none of the patients in the studies had an intention for TJR within foreseeable time, as 'Planned surgery  (any)  during  duration  of  the  study'  was  an  exclusion  criterion  in  all  three  pivotal  studies. However, according to the description of the sample and the study tables of disease characteristics at baseline (not shown), it can be agreed that as far as efficacy is concerned, the selected subgroup in principle is reflective of the target population described in the newly proposed indication.

The treatment effects in WOMAC pain and function in the selected treatment population are similar to the  treatment  effects  obtained  in  the  original  treatment  population.  In  the  selected  population,  the absolute changes in WOMAC pain and WOMAC function are lower than in the original population, but the between-group differences (the size of the treatment effects) are conserved, as are the percentages of responders. Also, the statistical null-hypothesis tests (of no difference between treatment groups) lead to the same conclusions in the restricted and original populations. Therefore, the efficacy conclusion for the original complete study population is confirmed for the post-hoc selected patient group with KL 3/4 and WOMAC pain ≥ 5 at baseline. Thus, tanezumab 2.5 mg SC has a statistically significant effect on pain and function, not better than continuation of NSAIDs in patients with insufficient response to NSAIDs, but  with  no  indication  that  it  would  be  worse.  Due  to  the  size  of  the  treatment  effects  the  clinical relevance of these treatment effects as compared to placebo (no treatment) appears small.

Tanezumab has been developed for chronic treatment. However, with the newly proposed indication to bridge the waiting period to TJR surgery, it is considered that short-term favourable effects are becoming more important as compared to the original chronic treatment goal. It is apparent that the average, modest, effect of tanezumab is maximal at 4 weeks and does not increase further. The time to onset of effect is 2 days on average.

In addition, use of NSAIDs during treatment with tanezumab and for 16 weeks after the last dose is not recommended, as it could potentially increase the risk for rapidly progressive OA in some patients. If NSAID  use  is  necessary,  for  the  treatment  of  acute  pain  or  inflammation  during  treatment  with tanezumab, the lowest effective dosage should be used for the shortest duration, but this should not exceed 10 days of NSAID treatment in an 8-week period. This precaution, however, interferes with the usual pre- and post-surgical use of NSAIDs, needed for TJR.

Therefore, the suitability of tanezumab as 'rescue' medication for patients on a waiting list for TJR is questioned.  It  is  clear  that  patients  who  are  scheduled  for  a  TJR  principally  have  exhausted  their analgesic options for chronic treatment due to insufficient effect on pain and progress of the disease. However, while waiting for a TJR the available treatment options include: 1) continuation of NSAIDs in patients experiencing at least some benefit; 2) intra-articular injections with corticosteroids in the target joint; 3) short course of tramadol as 'last resort' treatment.

<div style=\"page-break-after: always\"></div>

## Effects in subgroups

Overall  there  appears  to  be  no  indication  of  clinically  relevant  subgroup  effects.  It  is  relevant  that treatment effects appear to be similar for hip and knee, even if the subgroup of patients with hip OA was a minority (15%) it is considered that the sample was large enough to estimate with sufficient precision. A  subgroup  analysis  over  treatment  history,  especially  of  having  contra-indications/intolerability issues/lack  of  effect  for  NSAIDs  was  lacking.  However,  the  subgroup  with  contra-indications  to NSAIDs/opioids  was  small  and  no  meaningful  subgroup  analysis  can  be  performed.  There  was  no difference in treatment effect between patients with/without analgesic use at baseline. In all three studies the large majority had insufficient effect of NSAID, therefore these populations are sufficiently similar to extrapolate the long-term effects to the population in the short-term studies. The occurrence of ADA was low, but in comparative analysis there appeared to be no tendency that positivity of ADA and nAB would decrease treatment effect on Pain.

## Rebound

On average level, there is no strong indication for rebound effects. After treatment stopped past 16 weeks, the average values of WOMAC pain in the tanezumab groups (and control groups) had increased to approach the levels at week 2 (disregarding the baseline levels and the steep decrease in all groups post-baseline up to week 2). The number of initial responders who had an increase to ≥ 30% of baseline values was small for all treatment groups, with a tendency that the proportions were numerically larger in the tanezumab 2.5 mg group as compared to placebo. It is considered that a clinically relevant size of rebound in a relevant number of patients does not occur.

## 2.4.10. Conclusions on the clinical efficacy

According to the results of the 16-week (2 doses) and the 24-week (3 doses) placebo-controlled studies and the 16-week results of the NSAID-controlled study, there is evidence that tanezumab 2.5 mg SC has a statistically significant effect on pain and function, not better than NSAIDs but with no indication that it would be worse. Due to the size of the treatment effects, their clinical relevance is limited, and does not outweigh the adverse events. Treatment effects are maintained over time, currently without evidence of rebound after treatment stops. The results in the SC studies are supported by the results of the previous IV studies.

It considered that the clinical relevance of the moderate effects of tanezumab 2.5 mg SC versus placebo, in the co-primary outcomes (Pain, Function, Patient Global Assessment) is best supported by responder analysis of primary outcomes. However, in line with the results for the co-primary outcomes, differences of tanezumab against placebo are small. For a good response of at least 50%, for tanezumab versus no treatment the NNT is 7-8 for pain and function (risk differences from Effects Table). Tanezumab and NSAIDs are similarly effective, for a good response of at least 50% in pain (see Effect Table), 33 patients have to be treated with tanezumab, instead of NSAID, for 1 additional patient with a good response (NNT=33). Consequently, solely from the efficacy point of view, tanezumab 2.5 mg SC can be preferred over placebo (no treatment) in the target 3rd line population, but there is no clear efficacy advantage of tanezumab over NSAID.

Additional restricted indication of patients who are candidates or scheduled for TJR was proposed but was not considered acceptable.

## 2.5. Clinical safety

The clinical development programme of tanezumab is extensive, see Figure 25. It compromises of studies in osteoarthritis  (OA),  and  chronic  low  back  pain  (CLBP)  and  tanezumab  was  administrated

<div style=\"page-break-after: always\"></div>

subcutaneously (SC) and intravenously (IV). The clinical development programme has been affected by two partial clinical holds imposed by the United States Food and Drug Administration (FDA): 1) from June/July 2010 - 28 August 2012 due to investigator-reported AEs of osteonecrosis (ON), and 2) from December 2012 - 20 March 2015 due to concerns of possible adverse effects on the sympathetic nervous system based on preclinical toxicology findings.

The ON-findings were reason to include risk mitigation measures (identification of high-risk patients with rapid progressive OA and minimisation, such as preventing concurrent NSAIDs use) and surveillance focused on joint safety in the subsequent studies.

Figure 25 Overview of tanezumab clinical studies for safety assessments

<!-- image -->

N = number of unique randomised and treated patients

The 19 Supportive studies include patients with other forms of pain than osteoarthritis (chronic low back pain, cancer) or healthy volunteers)

- a. Studies shown as underlined included sub-cutaneous tanezumab dosing. Studies not underlined used only IV dosing of tanezumab;

b. Study 1055 and Study 1065 were observational infant safety follow-up studies and did not include treatment with tanezumab.

c. These are extension or observational studies (Study 1064 is an observational study and did not include treatment with tanezumab), Patients enrolled in extension or observational follow-up Study 1064 were counted once, only in the parent study totals.

Total values are based on number of randomised and treated patients reported in the respective clinical study reports.

The placebo-controlled studies phase III investigated tanezumab in several doses: 2.5mg, 5mg, 10mg versus  placebo  or  an  active  control  (e.g.  NSAIDs,  oxycodone).  Some  pre-2015  studies  investigated tanezumab as an add-on to an NSAID, or next to standard-of-care.

The post-2015 phase 3 OA studies (Studies 1056, 1057) evaluated SC administration of tanezumab (2.5 and 5mg doses) in patients with moderate to severe chronic pain associated with osteoarthritis (OA) for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate. Studies 1056 and 1057 are shorter-term placebo-controlled studies. Study 1058 is a long-term active-controlled study and allows a direct comparison of the safety profiles of tanezumab with NSAIDs. These studies are considered pivotal as these studies were not affected by the partial clinical holds, and include the proposed dose regimen (2.5 mg SC)

Placebo-controlled  study  1027  in  moderate-severe  OA  with  or  tanezumab  2.5mg,  5mg  or  10mg administered SC or tanezumab 10mg IV every 8 weeks dose is also considered pivotal by the applicant.

<div style=\"page-break-after: always\"></div>

It is agreed that the study includes the sought indication, proposed route of administration and dose. This study is therefore considered relevant, but not pivotal since this study was terminated prematurely because of the partial clinical hold.

The other clinical studies, e.g. the studies in chronic low back pain (CLBP) and healthy volunteers are considered as supportive and will be discussed only in more detail whenever relevant.

## Patient exposure

The safety database in OA is considered sufficiently large to establish common -and even not so commonadverse events associated with tanezumab treatment and to compare the safety profile of tanezumab with NSAIDs which are standard of care in OA.

In the Phase 3 OA studies, in total 9732 patients received at least one dose of tanezumab (SC or IV) every 8 weeks. Of these patients, 3932 received at least one SC dose. The safety of 2.5mg tanezumab SC administration every eight weeks has been investigated in 1604 patients with moderate-to-severe osteoarthritis. Of these, 804 patients were exposed to tanezumab for at least 24 weeks and 374 patients were exposed for at least 56 weeks.

Table 20 reflects the safety population and the number of who (dis)continued the studies. In general, patients  in  the  placebo  arm  completed  the  treatment  phase  more  often  than  the  patients  in  the tanezumab arms.

Table 20 Subject evaluation groups (Safety: OA Controlled Post-2015 Studies 1056, 1057, 1058)

|                              | Placebo (N=515) n (%)   | Tanezumab 2.5 mg (N=1537) (%) uI   | Tanezumab 2.5/5 mg (N=219) (%) uI   | Tanezumab 5mg (N=1289) (%) II   | Tanezumab 2.5and5 mg combined (N=3045) n (%)   | NSAID (N=1008) (%) I   |
|------------------------------|-------------------------|------------------------------------|-------------------------------------|---------------------------------|------------------------------------------------|------------------------|
| Randomized                   | 515 (100.0)             | 1537 (100.0)                       | 219 (100.0)                         | 1289 (100.0)                    | 3045 (100.0)                                   | 1008 (100.0)           |
| Treated                      | 514 (99.8)              | 1530 (99.5)                        | 219 (100.0)                         | 1282 (99.5)                     | 3031 (99.5)                                    | 996 (98.8)             |
| Not Treated                  | 1 (0.2)                 | 7 (0.5)                            | 0                                   | 7 (0.5)                         | 14 (0.5)                                       | 12 (1.2)               |
| Safety Population            | 514 (99.8)              | 1530 (99.5)                        | 219 (100.0)                         | 1282 (99.5)                     | 3031 (99.5)                                    | 996 (98.8)             |
| Number of subjects[1]        |                         |                                    |                                     |                                 |                                                |                        |
| Completed TreatmentPhase     | 430 (83.7)              | 912 (59.6)                         | 209 (95.4)                          | 674 (52.6)                      | 1795 (59.2)                                    | 446 (44.8)             |
| Discontinued Treatment Phase | 84 (16.3)               | 618 (40.4)                         | 10 (4.6)                            | 608 (47.4)                      | 1236 (40.8)                                    | 550 (55.2)             |
| Entered Follow-Up            | 482 (93.8)              | 1377 (90.0)                        | 215 (98.2)                          | 1151 (89.8)                     | 2743 (90.5)                                    | 887 (89.1)             |
| Completed Follow-Up          | 433 (84.2)              | 1189 (77.7)                        | 188 (85.8)                          | 968 (75.5)                      | 2345 (77.4)                                    | 757 (76.0)             |
| Did not enter Follow-Up      | 32 (6.2)                | 153 (10.0)                         | 4 (1.8)                             | 131 (10.2)                      | 288 (9.5)                                      | 109 (10.9)             |
| Completed Study              | 433 (84.2)              | 1189 (77.7)                        | 188 (85.8)                          | 968 (75.5)                      | 2345 (77.4)                                    | 757 (76.0)             |
| Discontinued Study           | 81 (15.8)               | 341 (22.3)                         | 31 (14.2)                           | 314 (24.5)                      | 686 (22.6)                                     | 239 (24.0)             |

[1] Percentages are based on the number of subjects in the Safety Population.

Source: 5.3.5.3 Integrated Summary of Safety

## Adverse events

The number of patients in all treatment arms with AEs ranges from around 40-60% in the post-2015 OA studies' pools. For study 1058 it seems that the percentage of subjects reporting AEs is slightly higher, ranging from 60.3-67.1%, see Table 22. This is probably due to the fact that the blinded study duration

<div style=\"page-break-after: always\"></div>

is longer (12 months), as compared to the other pivotal studies (16-24 weeks), see Table 21. This is also reflected in the percentages of serious and severe AE's ranging from 4.5-10.3% versus 1.4-4.0%.

In general, in the general SC+IV placebo-controlled pool, the same profile of adverse events is observed as in the SC placebo-controlled pool. A dose relation between the number of AE's and tanezumab dose was not clearly observed in the OA population. However, this was more clearly observed for the CLBP pool, which included a 20mg dose. Though, a dose relationship is more clearly visible in the numbers on discontinuation of study/treatment. Also, time to discontinuation decreases if the dose increases.

Table 21 Treatment-emergent adverse events during the treatment period (All Causalities) (Safety: OA Placebo- Controlled SC Studies 1027, 1056, 1057)

| Number(%)ofSubjects                                                  | Placebo (N=586) (%)   | Tanezumab 2.5mg (N=602) n (%)   | Tanezumab 2.5/5 mg (N=219) n (%)   | Tanezumab 5mg (N=347) n (%)   | Tanezumab 10 mg (N=86) n (%)   | Tanezumab 2.5and5mgcombined (N=1168) (%) u   |
|----------------------------------------------------------------------|-----------------------|---------------------------------|------------------------------------|-------------------------------|--------------------------------|----------------------------------------------|
| Subjectsevaluableforadverseevents                                    | 586                   | 602                             | 219                                | 347                           | 86                             | 1168                                         |
| Numberofadverseevents                                                | 647                   | 684                             | 209                                | 482                           | 78                             | 1375                                         |
| Subjectswithadverseevents                                            | 303 (51.7)            | 315 (52.3)                      | 103 (47.0)                         | 190 (54.8)                    | 34 (39.5)                      | 608 (52.1)                                   |
| Subjectswithseriousadverseevents                                     | 9 (1.5)               | 13 (2.2)                        | 3 (1.4)                            | 9 (2.6)                       | 0                              | 25 (2.1)                                     |
| Subjectswithsevere adverseevents                                     | 10 (1.7)              | 13 (2.2)                        | 6(2.7)                             | 13 (3.7)                      | 0                              | 32 (2.7)                                     |
| Subjectsdiscontinuedfromtreatmentduetoadverseevents(a)               | 12 (2.0)              | 8 (1.3)                         | 1 (0.5)                            | 4 (1.2)                       | 0                              | 13 (1.1)                                     |
| Subjectsdiscontinuedfromstudyduetoadverse events(b)                  | 5 (0.9)               | 8 (1.3)                         | 0                                  | 1 (0.3)                       | 0                              | 9 (0.8)                                      |
| Subjectsdiscontinuedfromtreatmentand/orshudyduetoadverseevents       | 13 (2.2)              | 11 (1.8)                        | 1 (0.5)                            | 5 (1.4)                       | 0                              | 17 (1.5)                                     |
| Subjectswithdosereducedortemporarydiscontinuationduetoadverse events | 1 (0.2)               | 1 (0.2)                         | 1 (0.5)                            | 1 (0.3)                       | 0                              | 3 (0.3)                                      |

(a) Subjects who have an adverse event record that indicates that the adverse event caused the subject to be discontinued from the treatment.

(b) Subjects who have an adverse event record that indicates that the adverse event caused the subject to be discontinued from the study.

Table 22 Treatment-emergent adverse events during the treatment period (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| Number (%) of Subjects                                              | Tanezumab 2.5 mg (N=1002) (%) uI   | Tanezumab 5mg (N=998) (%) uI   | Tanezumab 2.5 and 5 mg combined (N=2000) (%) I   | NSAID (N=996) n (%)   |
|---------------------------------------------------------------------|------------------------------------|--------------------------------|--------------------------------------------------|-----------------------|
| Subjects evaluablefor adverse events                                | 1002                               | 998                            | 2000                                             | 996                   |
| Number of adverse events                                            | 1723                               | 2031                           | 3754                                             | 1498                  |
| Subjects with adverse events                                        | 629 (62.8)                         | 670 (67.1)                     | 1299 (65.0)                                      | 601 (60.3)            |
| Subjects with serious adverse events                                | 51 (5.1)                           | 80 (8.0)                       | 131 (6.6)                                        | 46 (4.6)              |
| Subjectswith severe adverseevents                                   | 45 (4.5)                           | 68 (6.8)                       | 113 (5.7)                                        | 45 (4.5)              |
| Subjects discontinued from treatment due to adverse events (a)      | 74 (7.4)                           | 103 (10.3)                     | 177 (8.9)                                        | 58 (5.8)              |
| Subjectsdiscontinued from study due to adverseevents(b)             | 23 (2.3)                           | 20 (2.0)                       | 43 (2.2)                                         | 7 (0.7)               |
| Subjectsdiscontinuedfromtreatmentand/orstudyduetoadverseevents      | 75 (7.5)                           | 105 (10.5)                     | 180 (9.0)                                        | 59 (5.9)              |
| Subjectswithdosereducedortemporarydiscontinuationduetoadverseevents | 17 (1.7)                           | 22 (2.2)                       | 39 (2.0)                                         | 22 (2.2)              |

(a)Subjectswhohave anadverseeventrecord thatindicates that the adverse event caused thesubjecttobe discontinued from the treatment.

(b) Subjects who have an adverse event record that indicates that the adverse event caused the subject to be discontinued from the study.

MedDRA v21.1 coding dictionary applied.

In  general,  the  adverse  drug-related  events  of  tanezumab  which  more  commonly  occurred  than placebo/active control were joint damage (arthralgia, osteoarthritis, joint swelling, RPOA), peripheral neurological  damage  (hypoaesthesia,  paraesthesia,  burning  sensation  and  carpal  tunnel  syndrome), falls, headache, injection reactions and peripheral oedema, see Table 23Table 23  and Table 24.

<div style=\"page-break-after: always\"></div>

Joint  swelling,  OA,  paraesthesia  and  hypoaesthesia  was  increased  in  the  5mg  tanezumab  group compared to the 2.5mg tanezumab group. This was also a reason for the applicant to propose the 2.5mg dose SC for MAA.

In  the  active-controlled  SC  study,  arthralgia,  nasopharyngitis,  fall,  headache,  osteoarthritis,  joint swelling, RPOA, hypoaesthesia, and carpal tunnel syndrome were more reported in the tanezumab arms compared  to  the  NSAIDs  arm,  see  Table  25.  Patients  in  the  tanezumab  5mg  arm  reported  most treatment-related AEs. This was primarily due to an increased incidence of arthralgia, osteoarthritis, RPOA and carpal tunnel syndrome. Treatment-related AEs of OA, RPOA, and paraesthesia were also reported more frequently in the tanezumab 2.5 mg group than in the NSAID group, see Table 26.

During the follow-up period of the active-controlled SC study, OA and RPOA were higher in both of the tanezumab treatment groups compared to the NSAID group. Arthralgia, joint effusion and musculoskeletal pain were more present in the tanezumab 5 mg group compared to the NSAID group. Up to the end of the study, more patients reported rotator cuff syndrome and subchondral insufficiency fracture in the tanezumab groups than in the NSAID group.

No  apparent  differences  occurred  in  other  domains  (infections  and  infestations,  psychiatric  events). Nausea was less than for NSAIDs and opioids, whereas for opioids, somnolence and constipation were more common -as could be expected.

Table 23 Incidence of treatment-emergent adverse events by SOC during the treatment period (All Causalities)(Safety: OA Placebo-Controlled SC Studies 1027, 1056, 1057)

| Number (%) of Subjects: by SYSTEM ORGAN CLASS                    | Placebo (N=586) n (%)   | Tanezumab 2.5 mg (N=602) (%) uI   | Tanezumab 2.5/5 mg (N=219) (%) u   | Tanezumab 5mg (N=347) n (%)   | Tanezumab 10 mg (N=S6) (%) u   | Tanezumab 2.5and5mg combined (N=1168) (%) u   |
|------------------------------------------------------------------|-------------------------|-----------------------------------|------------------------------------|-------------------------------|--------------------------------|-----------------------------------------------|
| With Any adverse event                                           | 303 (51.7)              | 315 (52.3)                        | 103 (47.0)                         | 190 (54.8)                    | 34 (39.5)                      | 608 (52.1)                                    |
| Blood andlymphaticsystemdisorders                                | 0                       | 3 (0.5)                           | 0                                  | 5 (1.4)                       | 1(1.2)                         | 8 (0.7)                                       |
| Cardiac disorders                                                | 13 (2.2)                | 10 (1.7)                          | 5 (2.3)                            | 14 (4.0)                      | 0                              | (57)67                                        |
| Ear andlabyrinthdisorders                                        | 6 (1.0)                 | 2 (0.3)                           | 0                                  | 4(1.2)                        | 2 (2.3)                        | 6 (0.5)                                       |
| Endocrine disorders                                              | 0                       | 0                                 | 1 (0.5)                            | 2 (0.6)                       | 2 (2.3)                        | 3 (0.3)                                       |
| Eye disorders                                                    | 11 (1.9)                | 8 (1.3)                           | 1 (0.5)                            | 11 (3.2)                      | 0                              | 20 (1.7)                                      |
| Gastrointestinaldisorders                                        | 35 (6.0)                | 36 (6.0)                          | 15 (6.8)                           | 23 (6.6)                      | 2 (2.3)                        | 74 (6.3)                                      |
| General disorders and administration site conditions             | 32 (5.5)                | 28 (4.7)                          | 14 (6.4)                           | (TL) St                       | 8 (9.3)                        | 67 (5.7)                                      |
| Hepatobiliary disorders                                          | 2 (0.3)                 | 3 (0.5)                           | 0                                  | 3 (0.9)                       | 0                              | 6 (0.5)                                       |
| Immune system disorders                                          | 0                       | 1 (0.2)                           | 0                                  | 0                             | 0                              | 1 (0.1)                                       |
| Infections and infestations                                      | 90 (15.4)               | 112 (18.6)                        | 28 (12.8)                          | 60 (17.3)                     | 6 (7.0)                        | 200 (17.1)                                    |
| Injuy, poisoning and procedual complications                     | 40 (6.8)                | 48 (8.0)                          | 12 (5.5)                           | 23 (6.6)                      | 5 (5.8)                        | 83 (7.1)                                      |
| Investigations                                                   | 14 (2.4)                | 12 (2.0)                          | 4 (1.8)                            | 11 (3.2)                      | 4 (4.7)                        | 27 (2.3)                                      |
| Metabolism and nutritiondisorders                                | 8 (1.4)                 | 5 (0.8)                           | 2 (0.9)                            | 5 (1.4)                       | 1(1.2)                         | 12 (1.0)                                      |
| Musculoskeletalandconnectivetissuedisorders                      | 135 (23.0)              | 134 (22.3)                        | 48 (21.9)                          | 89 (25.6)                     | 13 (15.1)                      | 271 (23.2)                                    |
| Neoplasms benign,malignant and uspecified(incl cysts and (sdkpod | 5 (0.9)                 | 5 (0.8)                           | 1 (0.5)                            | 2 (0.6)                       | 0                              | 8 (0.7)                                       |
| Nervous system disorders                                         | 49 (8.4)                | 71 (11.8)                         | 15 (6.8)                           | 39 (11.2)                     | 18 (20.9)                      | 125 (10.7)                                    |
| Psychiatmic disorders                                            | 11 (1.9)                | 3 (0.5)                           | 4 (1.8)                            | 7 (2.0)                       | 1(1.2)                         | 14 (1.2)                                      |
| Renalandurinarydisorders                                         | 6 (1.0)                 | 8 (1.3)                           | 1 (0.5)                            | 6(1.7)                        | 0                              | 15 (1.3)                                      |
| Reproductive system andbreast disorders                          | 5 (0.9)                 | 2 (0.3)                           | 0                                  | 5 (1.4)                       | 0                              | 7 (0.6)                                       |
| Respiratory,thoracic andmediastinal disorders                    | 21 (3.6)                | 21 (3.5)                          | 8 (3.7)                            | 14 (4.0)                      | 0                              | 43 (3.7)                                      |
| Skin and subcutaneoustissue disorders                            | 18 (3.1)                | 24 (4.0)                          | 7 (3.2)                            | 12 (3.5)                      | 1 (1.2)                        | 43 (3.7)                                      |
| Suugicaland medicalproceduues                                    | 1 (0.2)                 | 0                                 | 5 (2.3)                            | 0                             | 0                              | 5 (0.4)                                       |
| Vascular disorders                                               | 15 (2.6)                | 10 (1.7)                          | 7 (3.2)                            | 21 (6.1)                      | 2 (2.3)                        | 38 (3.3)                                      |

<div style=\"page-break-after: always\"></div>

Table 24 Incidence of treatment-emergent adverse e vents (≥2%) during the treatment period (Treatment Related) (Safety: OA Placebo-Controlled SC Studies 1027, 1056, 1057)

| Number of subjects evaluableforadverse events   | Placebo (N=586)   | Tanezumab 2.5 mg. (N=602)   | Tanezumab 2.5/5 mg (N=219)   | Tanezumab 5 mg (N=347)   | Tanezumab 10 mg (N=86)   | Tanezumab 2.5 and5mg combined (N=1168)   |
|-------------------------------------------------|-------------------|-----------------------------|------------------------------|--------------------------|--------------------------|------------------------------------------|
| Number (%o) of subjects: bvPreferred Term       | 11 (%)            | 1 (%6)                      | 11 (%)                       | 11 (%)                   | (%)                      | 11 (%6)                                  |
| With any adverse event                          | 71 ( 12.1)        | 82 (13.6)                   | 21 (9.6)                     | 56 ( 16.1)               | 12 ( 14.0)               | 159 (13.6)                               |
| Arthralgia                                      | 14 (2.4)          | 11 (1.8)                    | 4 (1.8)                      | 7 (2.0)                  | 0                        | 22 (1.9)                                 |
| Paraesthesia                                    | 4 (0.7)           | 12 (2.0)                    | 2 (0.9)                      | 7 (2.0)                  | 4 (4.7)                  | 21 (1.8)                                 |
| Hypoaesthesia                                   | 2(0.3)            | 6 (1.0)                     | 1 (0.5)                      | 3 (0.9)                  | 3 (3.5)                  | 10 (0.9)                                 |

Table 25 Incidence of treatment-emergent adverse events ( ≥ 2%) during the treatment period (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| Number of subjects evaluable for Adverse Events Nunber (%o) of subjects: by Preferred Term   | Tanezumab 2.5 mg (N=1002) (%) uI   | Tanezumab 5mg (N=998) n (%)   | Tanezumab 2.5 and 5 mg combined (N=2000) (%) uI   | NSAID (N=996) (%) I   |
|----------------------------------------------------------------------------------------------|------------------------------------|-------------------------------|---------------------------------------------------|-----------------------|
| With Any Adverse Event                                                                       | 629 (62.8)                         | 670 (67.1)                    | 1299 (65.0)                                       | 601 (60.3)            |
| Arthralgia                                                                                   | 133 (13.3)                         | 165 (16.5)                    | 298 (14.9)                                        | 117 (11.7)            |
| Nasopharyngitis                                                                              | 57 (5.7)                           | 67 (6.7)                      | 124 (6.2)                                         | 40 (4.0)              |
| Fall                                                                                         | 65 (6.5)                           | 53 (5.3)                      | 118 (5.9)                                         | 46 (4.6)              |
| Upper respiratory tract infection                                                            | 57 (5.7)                           | 45 (4.5)                      | 102 (5.1)                                         | 59 (5.9)              |
| Headache                                                                                     | 56 (5.6)                           | 45 (4.5)                      | 101 (5.1)                                         | 25 (2.5)              |
| Osteoarthritis                                                                               | 39 (3.9)                           | 54 (5.4)                      | 93 (4.7)                                          | 23 (2.3)              |
| Joint swelling                                                                               | 43 (4.3)                           | 48 (4.8)                      | 91(4.6)                                           | 10 (1.0)              |
| Back pain                                                                                    | 34 (3.4)                           | 55 (5.5)                      | 89 (4.5)                                          | 35 (3.5)              |
| Musculoskeletal pain                                                                         | 43 (4.3)                           | 41 (4.1)                      | 84 (4.2)                                          | 37 (3.7)              |
| Pain in extremity                                                                            | 31 (3.1)                           | 37 (3.7)                      | 68 (3.4)                                          | 28 (2.8)              |
| Oedema peripheral                                                                            | 19 (1.9)                           | 43 (4.3)                      | 62 (3.1)                                          | 17 (1.7)              |
| Rapidly progressive osteoarthritis                                                           | 18 (1.8)                           | 41 (4.1)                      | 59 (3.0)                                          | 4 (0.4)               |
| Hypoaesthesia                                                                                | 27 (2.7)                           | 28 (2.8)                      | 55 (2.8)                                          | 18 (1.8)              |
| Bronchitis                                                                                   | 22 (2.2)                           | 28 (2.8)                      | 50 (2.5)                                          | 13 (1.3)              |
| Paraesthesia                                                                                 | 18 (1.8)                           | 30 (3.0)                      | 48 (2.4)                                          | 13 (1.3)              |
| Carpal tunel syndrome                                                                        | 16 (1.6)                           | 27 (2.7)                      | 43 (2.2)                                          | 6 (0.6)               |
| Influenza                                                                                    | 20 (2.0)                           | 21 (2.1)                      | 41 (2.1)                                          | 26 (2.6)              |
| Cough                                                                                        | 13 (1.3)                           | 26 (2.6)                      | 39 (2.0)                                          | 7 (0.7)               |
| Muscle spasms                                                                                | 15 (1.5)                           | 20 (2.0)                      | 35 (1.8)                                          | 19 (1.9)              |
| Urinary tract infection                                                                      | 12 (1.2)                           | 20 (2.0)                      | 32 (1.6)                                          | 15 (1.5)              |
| Joint effusion                                                                               | 8 (0.8)                            | 21 (2.1)                      | 29 (1.5)                                          | 5 (0.5)               |
| Hypertension                                                                                 | 16 (1.6)                           | 11 (1.1)                      | 27 (1.4)                                          | 25 (2.5)              |
| Nausea                                                                                       | 14 (1.4)                           | 11 (1.1)                      | 25 (1.3)                                          | 21 (2.1)              |

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

<div style=\"page-break-after: always\"></div>

Table 26 Incidence of treatment-emergent adverse events ( ≥ 2%) during the treatment period (Treatment Related) (Safety: OA Active-Controlled SC Study 1058)

| Numberofsubjectsevaluablefor AdverseEvents   | Tanezunab 2.5mg (N=1002)   | Tanezumab 5mg (N=998)   | Tanezumab 2.5and5mg combined (N=2000)   | NSAID (N=996)   |
|----------------------------------------------|----------------------------|-------------------------|-----------------------------------------|-----------------|
| Number（9o)ofsubjects: byPreferredTerm        | Ⅱ (%)                      | n  (%)                  | (%)                                     | (%)             |
| WithAnyAdverseEvent                          | 165 (16.5)                 | 208 (20.8)              | 373(18.7)                               | 158 (15.9)      |
| Arthralgia                                   | 22 ( 2.2)                  | 44 (4.4)                | 66 (3.3)                                | 24 (2.4)        |
| Rapidllyprogressive osteoarthritis           | 12 (1.2)                   | 22 ( 2.2)               | 34 (1.7)                                | 3 (0.3)         |

## Serious adverse events and deaths

During the treatment period arthralgia, OA and RPOA were serious AEs (SAEs) that were more seen in the tanezumab treatment groups compared to the placebo/NSAID groups in the OA studies, see Table 27 and Table 28. These SAEs were considered treatment-related by the applicant. The incidence of OA and RPOA was also higher during the follow-up period. GI haemorrhage was more frequently reported for the NSAID comparator arm in Study 1058.

Table 27 Incidence of treatment-emergent serious adverse events ( ≥ 2 subjects in any treatment group) during the treatment period (All Causalities) (Safety: OA PlaceboControlled SC Studies 1027, 1056, 1057)

| Numberofsubjectsevaluableforadverseevents Number(%6)ofsubjects: byPreferredTerm   | Placebo (N=586) (%) u   | Tanezumab 2.5mg (N=602) (%)   | Tanezumab 2.5/5mg (N=219) (%) u   | Tanezumab 5mg (N=347) (%) u   |   Tanezumab 10 mg (N=86) (%) | Tanezumab 2.5and5mgcombined (N=1168) (%) u   |
|-----------------------------------------------------------------------------------|-------------------------|-------------------------------|-----------------------------------|-------------------------------|------------------------------|----------------------------------------------|
| Withanyadverseevent                                                               | 9 (1.5)                 | 13 (2.2)                      | 3 (1.4)                           | 9 (2.6)                       |                            0 | 25 (2.1)                                     |
| Osteoarthritis                                                                    | 2 (0.3)                 | 2 (0.3)                       | 0                                 | 2 (0.6)                       |                            0 | 4 (0.3)                                      |
| Arthralgia                                                                        | 0                       | 0                             | 1 (0.5)                           | 1 (0.3)                       |                            0 | 2 (0.2)                                      |

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

<div style=\"page-break-after: always\"></div>

Table 28 Incidence of treatment-emergent serious adverse events ( ≥ 2 subjects in any treatment group) during the treatment period (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| NumberofsubjectsevaluableforAdverseEvents   | Tanezumab 2.5 mg (N=1002)   | Tanezumab 5 mg (N=998)   | Tanezumab 2.5 and 5 mg combined (N=2000)   | NSAID (N=996)   |
|---------------------------------------------|-----------------------------|--------------------------|--------------------------------------------|-----------------|
| Number (%) of subjects: by Preferred Term   | (%) uI                      | (%) uI                   | (%) uI                                     | (%) uI          |
| With Any Adverse Event                      | 51 (5.1)                    | 80 (8.0)                 | 131 (6.6)                                  | 46 (4.6)        |
| Osteoarthritis                              | 9 (0.9)                     | 17 (1.7)                 | 26 (1.3)                                   | 4 (0.4)         |
| Rapidly progressive osteoarthritis          | 3 (0.3)                     | 11 (1.1)                 | 14 (0.7)                                   | 0               |
| Arthralgia                                  | 4 (0.4)                     | 9 (0.9)                  | 13 (0.7)                                   | 0               |
| Subchondral insufficiency fracture          | 1 (0.1)                     | 4 (0.4)                  | 5 (0.3)                                    | 2 (0.2)         |
| Meniscus injuy                              | 1 (0.1)                     | 3 (0.3)                  | 4 (0.2)                                    | 1 (0.1)         |
| Pneumonia                                   | 1 (0.1)                     | 2 (0.2)                  | 3 (0.2)                                    | 1 (0.1)         |
| Acute kidney injuy                          | 0                           | 2 (0.2)                  | 2 (0.1)                                    | 0               |
| Acute myocardialinfarction                  | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 3 (0.3)         |
| Appendicitis                                | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 1 (0.1)         |
| Atial fibrllation                           | 1 (0.1)                     | 1(0.1)                   | 2 (0.1)                                    | 1(0.1)          |
| Cellulitis                                  | 0                           | 2 (0.2)                  | 2 (0.1)                                    | 0               |
| Cerebrovascular accident                    | 2 (0.2)                     | 0                        | 2 (0.1)                                    | 0               |
| Cholelithiasis                              | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 1 (0.1)         |
| Chronic obstructivepulmonary disease        | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 1 (0.1)         |
| Intervertebral disc protusion               | 0                           | 2 (0.2)                  | 2 (0.1)                                    | 1 (0.1)         |
| Lumbar spinal stenosis                      | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 1 (0.1)         |
| Myocardial infarction                       | 1 (0.1)                     | 1(0.1)                   | 2 (0.1)                                    | 0               |
| Osteonecrosis                               | 0                           | 2 (0.2)                  | 2 (0.1)                                    | 0               |
| Prostate cancer                             | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 0               |
| Pulmonary embolism                          | 1 (0.1)                     | 1 (0.1)                  | 2 (0.1)                                    | 0               |
| Gastrointestinal haemonhage                 | 0                           | 0                        | 0                                          | 2 (0.2)         |

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

## Deaths

Over all pools of controlled data a higher incidence of observation time-adjusted deaths was observed for the tanezumab treatment groups (ranging from 2.5-12.3/1000 patient-years) compared to placebo (2.8/1000 patient-years) and NSAIDS (0.5/1000 patient-years) during treatment and up to the end of the study and post-study, Table 29. Fourteen of the deaths were included in the post-2015 studies.

Most deaths (11 out of 24) in the tanezumab treatment arms (2.5-20mg) were cardiovascularly related, see Table 30.

MACE Table 31 reflects the incidence rate for potential MACE for placebo and tanezumab treatment arms, and the most frequently reported events in the tanezumab treatment groups were a cerebrovascular accident, acute myocardial infarction and myocardial infarction. MACE cases as assigned by a committee of experts post-hoc were also summarised. A trend was observed for higher incidence of MACE versus placebo,  with  the  highest  incidence  for  the  10  mg  dose.  Sudden  cardiac  death  was  reported  for tanezumab, but not for placebo. There was no clear correlation with baseline risk factors for tanezumab MACE cases at the proposed dose regimen (2.5 mg). This in contrast to the MACE cases of NSAIDs comparator arm, which were clearly related to baseline cardiovascular diseases.

<div style=\"page-break-after: always\"></div>

Table 29 Observation time-adjusted deaths up to end of study and post-study (All Causalities) (Safety: OA Controlled Studies 1011, 1014, 1015, 1018, 1026, 1027, 1030, 1056, 1057, 1017, 1025, 1058)

|                                                                       | 3)           | N=154b2.5mg (N=1931)   | PlaceboTanezumaTanezumaTanezumaTanezuma b2.5/5mg (N=219)   | b5mg (N=2863)   | b10mg (N=1684)   | Tanezuma b2.5and 5mg combined (N=5013)   | A Monothera Ad (N=6697)   | TanezumaTanezuma Tanezumabb2.5mg+ NSAD (N=157)   | b5mg+ NSAID (N=680)   | Tanezuma b10mg+ NSAD (N=687)   | NSAID N=210 4   | Orycodon eCR10- 40 mg HZIO (N=158)   | A Comparato (N=3805)   |
|-----------------------------------------------------------------------|--------------|------------------------|------------------------------------------------------------|-----------------|------------------|------------------------------------------|---------------------------|--------------------------------------------------|-----------------------|--------------------------------|-----------------|--------------------------------------|------------------------|
| Observation Time (subject- years)                                     | 709.4        | 1600.9                 | 162.6                                                      | 2041.2          | 798.1            | 3804.7                                   | 4602.8                    | 86.7                                             | 502.9                 | 493.7                          | 1630.8          | 46.1                                 | 2386.3                 |
| Numberof Subjects (observation time-adjusted rate/1000 subject-years) |              |                        |                                                            |                 |                  |                                          |                           |                                                  |                       |                                |                 |                                      |                        |
| Death                                                                 | 2(2.8)5(3.1) |                        | 2 (12.3)                                                   | 10 (4.9)        | 2(2.5)           | 17 (4.5)                                 | 19 (4.1)                  | 2 (23.1)                                         | 2 (4.0)               | 1 (2.0)                        | 1(0.0 0(0)      |                                      |                        |

Observation time defined as: a) If subject experienced the event: Time from first IV/SC dose to the date of death.

b) If the subject did not experience the event: Time from first IV/SC dose to the end of study.

All Tanezumab Monotherapy is combined group of tanezumab 2.5, 2.5/5, 5 and 10 mg.

All comparators is combined group of placebo, NSAID and oxycodone.

Table 30 Observation time-adjusted deaths up to end of study and post-study (All Causalities) (Safety: OA Controlled Post-2015 Studies 1056, 1057, 1058)

|                                                                       | Placebo (N=514)   | Tanezumab 2.5 mg (N=1530)   | Tanezumab 2.5/5 mg (N=219)   | mg (N=1282)   | Tanezumab5Tanezumab2.5and5 mg combined (N=3031)   | All Tanezumab Monotherapy (N=3031)   | NSAID (N=996   | AlI ）Comparators (N=1510)   |
|-----------------------------------------------------------------------|-------------------|-----------------------------|------------------------------|---------------|---------------------------------------------------|--------------------------------------|----------------|-----------------------------|
| Observation Time (subject-years)                                      | 396.1             | 1444.9                      | 162.6                        | 1255.2        | 2862.6                                            | 2862.6                               | 1016.1         | 1412.2                      |
| Number of Subjects (observation time- adjustedrate/1000subject-years) |                   |                             |                              |               |                                                   |                                      |                |                             |
| Death                                                                 | (0)               | 5 (3.5)                     | 2 (12.3)                     | 7(5.6)        | 14 (4.9)                                          | 14 (4.9)                             |                | 1(1.0) 1(0.7)               |
| Cause of Death Preferred Tenm                                         |                   |                             |                              |               |                                                   |                                      |                |                             |
| Cardiac arrest                                                        | 0(0)              | 1 (0.7)                     | (0)                          | 1 (0.8)       | 2 (0.7)                                           | 2 (0.7)                              | (0)            | (0)                         |
| Acute myocardial infarction                                           | 0(0)              | 0(0)                        | (0)0                         | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | ()             | (0)                         |
| Acute respiratory failure                                             | 0(0)              | 0(0)                        | ①)0                          | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | (0)            | 0(0)                        |
| Adenocarcinoma                                                        | 0(0)              | 1 (0.7)                     |                              |               | 1 (0.3)                                           | 1 (0.3)                              | 0(0)           | ()                          |
| Cerebrovascular accident                                              | 0(0)              | 1 (0.7)                     | ①)0                          |               | 1 (0.3)                                           | 1 (0.3)                              | (0)            | ()                          |
| Completed suicide                                                     | 0(0)              | 0(0)                        | 1 (6.2)                      | 0(0)          | 1 (0.3)                                           | 1 (0.3)                              | (0)            | 0(0)                        |
| Diabetes mellitus                                                     | 0(0)              | (0)                         | ①)0                          | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | (0)            |                             |
| Disease progression                                                   | (0)               | (0)                         | 1 (6.2)                      | (0)           | 1 (0.3)                                           | 1 (0.3)                              |                | 0(0)                        |
| Myocardial infarction                                                 | 0(0)              | 1(0.7)                      |                              |               | 1 (0.3)                                           | 1 (0.3)                              | (0)            | 0(0)                        |
| Nasopharyngitis                                                       | 0(0)              | (0)                         | ①)0                          | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | (0)            | 0(0)                        |
| Pulmonary embolism                                                    | 0(0)              | (0)                         | 0)0                          | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | (0)            |                             |
| Sudden death                                                          | 0(0)              | (0)                         | (0)                          | 1 (0.8)       | 1 (0.3)                                           | 1 (0.3)                              | (0)            | (0                          |
| Toxicity to various agents                                            | 0(0)              | 1(0.7)                      | (0)                          | (0)           | 1 (0.3)                                           | 1 (0.3)                              | (0)            | (0)                         |
| Cardio-respiratory arrest                                             | (0)               | (0)                         |                              | ()            | 0(0)                                              | 0)0                                  | 1 (1.0)        | 1(0.7)                      |

Observation time defined as: a) If subject experienced the event: Time from first IV/SC dose to the date of death.

b) If the subject did not experience the event: Time from first IV/SC dose to the end of study.

All Tanezumab Monotherapy is combined group of tanezumab 2.5, 2.5/5 and 5 mg.

All comparators is combined group of placebo and NSAID.

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

<div style=\"page-break-after: always\"></div>

Table 31 Exposure-adjusted treatment-emergent serious major adverse cardiovascular events (MACE) during the treatment period (All Causalities) (Safety: OA Controlled Studies 1011, 1014, 1015, 1018, 1026, 1027, 1030, 1056, 1057, 1017, 1025, 1058); Investigator reported MACE

|                                                                          |                  | Tanezumab treatment arms   | Tanezumab treatment arms   | Tanezumab treatment arms   | Tanezumab treatment arms   | Tanezumab treatment arms     | Tanezumab treatment arms   |
|--------------------------------------------------------------------------|------------------|----------------------------|----------------------------|----------------------------|----------------------------|------------------------------|----------------------------|
| Number of Subjects/Exposure (rate per 1000 subject-years) Preferred Term | Placebo (N=1543) | 2.5 mg (N=1931)            | 2.5/5 mg (N=219)           | 5 mg (N=2863)              | 10 mg (N=1684)             | 2.5 & 5 mg combined (N=5013) | All Monotherapy (N=6697    |
| With Any MACE adverse event                                              | 2/468.9 (4.3)    | 7/1045.7 (6.7)             | 0/67.9 (0)                 | 5/1570.7 (3.2)             | 5/749.8 (6.7)              | 12/2684.3 (4.5)              | 17/3434.1 (5)              |
| Cerebrovascular accident                                                 | 0/469.2 (0)      | 3/1046 (2.9)               | 0/67.9 (0)                 | 1/1570.8 (0.6)             | 1/750.5 (1.3)              | 4/2684.7 (1.5)               | 5/3435.2 (1.5)             |
| Acute myocardial infarction                                              | 0/469.2 (0)      | 2/1046.4 (1.9)             | 0/67.9 (0)                 | 1/1571 (0.6)               | 0/750.6 (0)                | 3/2685.2 (1.1)               | 3/3435.8 (0.9)             |
| Myocardial infarction                                                    | 1/469 (2.1)      | 1/1046.5 (1)               | 0/67.9 (0)                 | 1/1571 (0.6)               | 0/750.6 (0)                | 2/2685.4 (0.7)               | 2/3436 (0.6)               |

Exposure defined as: a) If subject experienced the event: Time from first IV/SC dose to the date of first occurrence of the event.

b) If the subject did not experience the event: Time from first IV/SC dose to the end of treatment visit date for subjects who completed the treatment period or up to the withdrawal from treatment date for subjects who withdrew early from the treatment period.

All Tanezumab Monotherapy is combined group of tanezumab 2.5, 2.5/5, 5 and 10 mg.

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

Table made by assessor and includes the most relevant parts of the original table 1.7.5.1.y.

Table 32 Association of baseline CV risk factors with observation time-adjusted treatment-emergent MACE up to end of study and post-study (All Causalities) in the OA controlled studies (post-hoc Analysis #1 and Analysis #2)

|                                                                                    | Placebo N=1543                                                      | Placebo N=1543                                                      | Tanezumab 2.5 mg N=1931                                             | Tanezumab 2.5 mg N=1931                                             | All Tanezumab Monotherap y N=6697                                   | All Tanezumab Monotherap y N=6697                                   | NSAID N=2104                                                        | NSAID N=2104                                                        | All Comparat ors N=3805                                             | All Comparat ors N=3805                                             |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| At Least One Baseline CV Risk Factor                                               | Yes                                                                 | No                                                                  | Yes                                                                 | No                                                                  | Yes                                                                 | No                                                                  | Yes                                                                 | No                                                                  | Yes                                                                 | No                                                                  |
| Number of Patients                                                                 | 110 1                                                               | 442                                                                 | 1375                                                                | 556                                                                 | 4761                                                                | 1936                                                                | 1502                                                                | 602                                                                 | 2716                                                                | 108 9                                                               |
| Analysis Based on Investigator-Reported PTs - Analysis #1                          | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           | Analysis Based on Investigator-Reported PTs - Analysis #1           |
| Number of Patients with Any Composite MACE/Observation Time (rate per 1000 pt-yrs) | 2/49 6.2 (4)                                                        | 1/21 1.8 (4.7)                                                      | 7/113 1.3 (6.2)                                                     | 3/46 7.6 (6.4)                                                      | 22/32 61.9 (6.7)                                                    | 5/133 6.4 (3.7)                                                     | 9/116 4.5 (7.7)                                                     | 0/46 3.3 (0)                                                        | 11/16 93.7 (6.5)                                                    | 1/6 88. 2 (1.5 )                                                    |
| Analysis Based on External Adjudication at C5Research - Analysis #2                | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 | Analysis Based on External Adjudication at C5Research - Analysis #2 |
| Number of Patients with Any Composite MACE/Observation Time (rate per 1000 pt-yrs) | 1/49 6.2 (2)                                                        | 1/21 1.8 (4.7)                                                      | 6/113 1.2 (5.3)                                                     | 3/46 7.6 (6.4)                                                      | 18/32 61.8 (5.5)                                                    | 5/133 6.4 (3.7)                                                     | 7/116 5.2 (6)                                                       | 0/46 3.3 (0)                                                        | 8/169 4.4 (4.7)                                                     | 1/6 88. 2 (1.5 )                                                    |

pt-yrs = patient-years

OA Controlled Studies: 1011, 1014, 1015, 1018, 1026, 1030, 1056, 1057, 1017, 1025, 1058.

The following treatment groups are not shown: tanezumab 2.5/5 mg; tanezumab 5 mg; tanezumab 10 mg; tanezumab 2.5 mg + NSAID; tanezumab 5 mg + NSAID; tanezumab 10 mg + NSAID; all tanezumab + NSAID; oxycodone CR 10-40 mg Q12H; all active comparators.

Observation time defined as: a) If subject experienced the event: Time from first IV/SC dose to the date of first occurrence of the event b) If the subject did not experience the event: Time from first IV/SC dose to the end of Study.

Baseline CV risk factors include medical history term from CV-related SMQ or PTs, diabetes (medical history and/or HbA1c&gt;=6.5%), BMI&gt;=35 kg/m 2 , and/or current smoker.

Source: Table 6.4.y (Analysis #1) and Table 6.4.y (Analysis #2)

<div style=\"page-break-after: always\"></div>

## Joint safety

Joint safety is mainly assessed on the post-2015 studies, since these studies take all the measures that were taken after the potential safety findings of osteonecrosis (ON) in the pre-2015 studies into account.

Joint-related  safety  primarily  includes  analyses  of  adjudicated  joint  safety  endpoints,  total  joint replacements  (TJRs), joint space  width (JSW),  osteonecrosis, rapidly  progressive  OA  (RPOA), subchondral insufficiency fracture (SIF), or pathologic fracture.

RPOA is further classified as RPOA1 or RPOA2 by the applicant:

- RPOA1 events were those that the Adjudication Committee considered having significant loss of JSW ( ≥ 2 mm) within approximately one year without gross structural failure.

- RPOA2 events were those considered to have abnormal loss/destruction of bone including the limited or total collapse of at least one subchondral surface (e.g. medial femoral condyle) that is not normally present in conventional end-stage OA.

In the post-2015 OA controlled studies, the incidence of RPOA was the highest in the tanezumab 5 mg treatment  group;  5.5  and  2.7  in  the  2.5mg  treatment  group.  In  the  placebo  group,  no  RPOA  was observed. The incidence in the NSAID group was 1.1. The incidence of RPOA in this pool of post-2015 studies as confirmed by the Adjudication Committee in patients with possible or probable joint-related safety events was the highest in the tanezumab 5 mg treatment group; 31.1 and 24.3 in the 2.5mg treatment group. In the placebo group, no RPOA was observed. The incidence in the NSAID group was 21.1, see Table 33. A dose-response relation for tanezumab and the incidence and observation timeadjusted  and  exposure-adjusted  rates  of  RPOA1  and  RPOA2  was  found.  This  indicates  causality. Particularly for the 5 mg dose, the risk of RPOA1 was higher than for patients treated with NSAIDs. Time to event was shorter with increasing tanezumab dose, see Figure 26.

Tanezumab Integrated Safety Analysis Plot of Time to Adjudicated Joint Safety Outcome -- SubjectLevel: Rapidly Progressive OA Type 1 (Safety: OA Placebo-Controlled Post-2015 Studies 1056, 1057) 0.04 0.03 0.02 0.01 0.00 0 50 100 150 200 250 300 350 400 450 Response Time (Days) Placebo: Tanezumab 5 mg: Treatment Tanezumab 2.5 mg: Tanezumab 2.5/5 mg

Table 33 Adjudicated joint safety outcomes - joint-level (Safety: OA Controlled Post-2015 Studies 1056, 1057, 1058)

|                                                                              | (N=514)   | mg (N=1530)   | PlaceboTanezumab2.5Tanezumab2.5/5Tanezumab5 mg (N=219)   | mg (N=1282)   | Tanezumab2.5and5mg Combined (A=3031)   | NSAD (N=996)   |
|------------------------------------------------------------------------------|-----------|---------------|----------------------------------------------------------|---------------|----------------------------------------|----------------|
| Potential eventsanalyzedby theAdjudicationCommittee [回]                      | 28        | 173           | 19                                                       | 246           | 438                                    | 57             |
| Joint safety events                                                          |           |               |                                                          |               |                                        |                |
| Rapidly Progressive OA[n(96)]                                                | 0         | 42(24.3)      | 1(5.3)                                                   | 77 (31.3)     | 120 (27.4)                             | 12 (21.1)      |
| Rapidly Progressive OA type 1[n(9)]                                          | 0         | 36 (20.8)     | 1(5.3)                                                   | 58 (23.0)     | 95 (21.7)                              | 11 (19.3)      |
| Rapidly Progressive OA type 2[n(%)]                                          | 0         | 6(3.5)        |                                                          | 19 (7.7)      | 25 (5.7)                               | 1(1.8)         |
| PrimaryOsteonecrosis[n(96)]                                                  | 0         | 1(0.0)        |                                                          | 3(1.2)        | 4(0.9)                                 |                |
| Pathological Fracture [n(96)]                                                | 0         | 0             | 0                                                        | 0             | 0                                      | 0              |
| Subchondral Insuffciency Fracture[n(%6)]                                     | 0         | 7(4.0)        |                                                          | 7(2.8)        | 14 (3.2)                               | 4(7.0)         |
| Not Enough Imformation to Detemine Rapid vs.Nommal Progression of OA[n (96)] | 0         | 2(1.2)        | 0                                                        | 0             | 2 (0.5)                                | 0              |
| Normal Progression of OA [n(9%)]                                             | 24 (85.7) | 108 (62.4)    | 18 (94.7)                                                | 128 (52.0)    | 254(58.0)                              | 31(54.4)       |
| OtherJoint Outcome[n(9)]                                                     | 4(14.3)   | 13 (7.5)      | 0                                                        | 31 (12.0)     | 44 (10.0)                              | 10(17.5)       |

The denominator is number of potential events.

<div style=\"page-break-after: always\"></div>

Includes TJR or adjudicated event up to the end of the follow-up period or 26 weeks after the end of the treatment period, whichever is later.

Figure 26 Plot of time to adjudicated primary composite joint safety outcome -- subjectlevel, primary outcome (Safety: OA Controlled Post-2015 Studies 1056, 1057, 1058)

<!-- image -->

Study 1058 had the longest duration, and as such the most (7) administrations of tanezumab, therefore this study is considered important for the relationship between the number of tanezumab administrations and RPOA. In this study, most joint safety events were observed. This was particularly the case for the patients who received 4-7 SC administrations of 5mg tanezumab. Thus the risk of serious joint damage increased with treatment duration of tanezumab.

<div style=\"page-break-after: always\"></div>

## Figure 27

Figure 28 b Tanezumab Integrated Safety Analysis Plot of Time to Adjudicated Joint Safety Outcome -- Subject-Level: Rapidly Progressive OA Type 1 (Safety: OA Placebo-Controlled Post-2015 Studies 1056, 1057)

<!-- image -->

## Total Joint Replacements

In total, across the treatment groups for all three post-2015 studies, 248 patients had at least one total joint replacement (TJR). The incidence ranged from 2.6% in the NSAID treatment group to 7.8% in the tanezumab 5 mg treatment group, see Table 34.

The incidence of at least one total joint replacement (TJR) is higher in the tanezumab groups (5.5-6.8%) than in placebo (4.5%). The incidence rate per 1000 PY was overlapping for the low dose tanezumab and placebo (58.4 (47.2-72.3) vs 58.2 (38.7-87.5)). However, the incidence is lowest in the NSAID group (2.6%, incidence rate 25.7 (17.5-37.7) per 1000 PY).

The  incidence  of  elective  TJRs  was  highest  in  the  placebo  group  (78%)  compared  to  34%  for  the tanezumab 5mg and 67% of the 2.5mg groups. For NSAIDs this was 54%. This indicates that the reason for surgery in placebo was mainly driven by pain which was left untreated, whereas for tanezumab, the reason for surgery was more driven by rapidly progressive OA and bone damage -in a dose-dependent way, which underlines causality.

For the NSAID treatment comparisons in Study 1058, both the tanezumab 2.5 mg and 5 mg treatment groups had an earlier time to TJR. The largest increase in TJR occurred after Study Day 350, which corresponded to the end of the treatment period for Study 1058.

<div style=\"page-break-after: always\"></div>

Table 34 Total joint replacements - subject-level (Safety: OA Controlled Post-2015 Studies 1056, 1057, 1058)

|                                                                               | Placebo (N=514)   | mg (N=1530)   | Tanezumab2.5Tanezumab2.5/5 mg (N=219)   | Tanezumab5 mg (N=1282)   | Tanezumab2.5and5mg Combined (N=3031)   | NSAID (N=996)   |
|-------------------------------------------------------------------------------|-------------------|---------------|-----------------------------------------|--------------------------|----------------------------------------|-----------------|
| Number (%) of subjects with at least one reported TJR                         | 23 (4.5)          | 84 (5.5)      | 15 (6.8)                                | 100 (7.8)                | 199 (6.6)                              | 26 (2.6)        |
| [95% confidence interval]                                                     | [2.9, 6.6]        | [4.4, 6.8]    | [3.9, 11.0]                             | [6.4, 9.4]               | [5.7, 7.5]                             | [1.7, 3.8]      |
| ObservationTime-adjusted incidence of subjects with at least one reported TJR |                   |               |                                         |                          |                                        |                 |
| Observation Time (subj-years)                                                 | 395.4             | 1438.0        | 161.4                                   | 1245.2                   | 2844.7                                 | 1012.6          |
| n (x/1000 subj-yrs)                                                           | 23 (58.2)         | 84 (58.4)     | 15 (92.9)                               | 100 (80.3)               | 199 (70.0)                             | 26 (25.7)       |
| [95% confidence interval]                                                     | [38.7, 87.5]      | [47.2, 72.3]  | [56.0, 154.1]                           | [66.0, 97.7]             | [60.9, 80.4]                           | [17.5, 37.7]    |
| Exposure Time-adjusted incidence of subjects with at least one reported TJR   |                   |               |                                         |                          |                                        |                 |
| Exposure Time (subj-years)                                                    | 187.2             | 901.4         | 67.9                                    | 821.2                    | 1790.5                                 | 684.7           |
| n (x/1000 subj-yrs)                                                           | 23 (122.8)        | 84 (93.2)     | 15 (220.9)                              | 100 (121.8)              | 199 (111.1)                            | 26 (38.0)       |
| [95% confidence interval]                                                     | [81.6, 184.9]     | [75.2,115.4]  | [133.2,366.4]                           | [100.1, 148.1]           | [96.7, 127.7]                          | [25.9, 55.8]    |

Observation time is defined as the start day of first SC study medication until either the (i) date of completion of or withdrawal from study, if a subject has no TJR, or (ii) date of TJR (earliest TJR within each subject in the case of multiple TJRs).

Includes TJR or adjudicated event up to the end of the follow-up period or 26 weeks after the end of the treatment period, whichever is later.

Exposure is defined as the start day of first SC study medication until either the (i) date of completion of or withdrawal from the treatment period, if a subject has no TJR or a

TJR after the end of the treatment period, or (ii) date of TJR (earliest TJR within each subject in the case of multiple TJRs).

<div style=\"page-break-after: always\"></div>

Figure 28 Plot of time to total joint replacement -- subject-level (Safety: OA placebocontrolled Post-2015 Studies 1056, 1057)

Figure 1. Plot of Time to Total Joint Replacement - Subject-Level in OA PlaceboControlled Post-2015 Studies 1056, 1057

<!-- image -->

Source: 2.7.4 SCS Appendix Figure 3.38.1.c1

Figure 29 Plot of time to total joint replacement -- subject-level (Safety: OA Controlled Post2015 Studies 1056, 1057, 1058)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

It is agreed that a higher degree of surveillance, as applied in the post-2015 studies, in general, will lead to more observed adverse events.

However, the patient population that was included in the studies was different from the earlier included population as patients with evidence of risk factors for RPOA were excluded, so a less at-risk population entered the studies. However, the increased rate of RPOA2 and TJR surgery of tanezumab versus active control of NSAIDs in this selected population was observed, see Table 35.

In the placebo group, the incidence of TJRs is also higher in the post-2015 studies than pre-2015. The pre-2015 population included all-cause TJRs or patients with reported ON without TJR. This also accounts for the patients in the tanezumab treatment groups, see Table 36.

Table 35 Summary of adjudicated joint safety events for pre-2015 phase 3 OA studies and post-2015 phase 3 OA studies

|                            | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   | Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]   |
|----------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
|                            | Pre-2015 Phase 3 OA                                                                                               | Pre-2015 Phase 3 OA                                                                                               | Pre-2015 Phase 3 OA                                                                                               | Pre-2015 Phase 3 OA                                                                                               | Post-2015 Phase 3 OA Studies b                                                                                    | Post-2015 Phase 3 OA Studies b                                                                                    | Post-2015 Phase 3 OA Studies b                                                                                    | Post-2015 Phase 3 OA Studies b                                                                                    |
|                            | Tan 2.5 mg N=604 373 pt- years                                                                                    | Tan 5 mg N=1771 1116 pt- years                                                                                    | Tan 2.5 mg + NSAID N=587 381 pt- years                                                                            | Tan 5 mg +NSAID N=1249 877 pt- years                                                                              | Active Comparator c N=1266 661 pt- years                                                                          | Tan 2.5 mg N=1530 1432 pt- years                                                                                  | Tan 5 mg N=1282 1233 pt- years                                                                                    | NSAID N=996 1011 pt- years                                                                                        |
| Primary Composite Endpoint | 0 (0)                                                                                                             | 8 (0.5) 7.2 [3.6, 14.3]                                                                                           | 7 (1.2) 18.4 [8.7, 38.5]                                                                                          | 19 (1.2) 21.7 [13.8, 34.0]                                                                                        | 2 (0.2) 3.0 [0.8, 12.1]                                                                                           | 49 (3.2) d 34.2 [25.9, 45.3]                                                                                      | 80 (6.2) 64.9 [52.1, 80.8]                                                                                        | 15 (1.5) 14.8 [8.9, 24.6]                                                                                         |
| RPOA                       | 0 (0)                                                                                                             | 7 (0.4) 6.3 [3.0, 13.2]                                                                                           | 6 (1.0) 15.7 [7.1,35.0]                                                                                           | 16 (1.3) 18.2 [11.2,29.8]                                                                                         | 1 (0.1) 1.5 [0.2, 10.7]                                                                                           | 41 (2.7) 28.6 [21.1, 38.8]                                                                                        | 71 (5.5) 57.5 [45.6, 72.5]                                                                                        | 11 (1.1) 10.9 [6.0, 19.6]                                                                                         |
| RPOA1                      | 0 (0)                                                                                                             | 2 (0.1) 1.8 [0.4, 7.2]                                                                                            | 2 (0.3) 5.2 [1.3, 21.0]                                                                                           | 1 (0.1) 1.1 [0.2, 8.1]                                                                                            | 0 (0)                                                                                                             | 35 (2.3) 24.4 [17.5, 34.0]                                                                                        | 54 (4.2) 43.6 [33.4, 56.9]                                                                                        | 10 (1.0) 9.9 [5.3, 18.4]                                                                                          |
| RPOA2                      | 0 (0)                                                                                                             | 5 (0.3) 4.5 [1.9, 10.8]                                                                                           | 4 (0.7) 10.5 [3.9, 28.0]                                                                                          | 15 (1.2) 17.1 [10.3, 28.4]                                                                                        | 1 (0.1) 1.5 [0.2, 10.7]                                                                                           | 6 (0.4) 4.2 [1.9, 9.3]                                                                                            | 17 (1.3) 13.6 [8.4, 21.9]                                                                                         | 1 (0.1) 1.0 [0.1, 7.0]                                                                                            |
| Primary ON                 | 0 (0)                                                                                                             | 1 (0.1) 0.9 [0.1, 6.4]                                                                                            | 0 (0)                                                                                                             | 0 (0)                                                                                                             | 0 (0)                                                                                                             | 1 (0.1) d 0.7 [0.1, 4.9]                                                                                          | 2 (0.2) 1.6 [0.4, 6.4]                                                                                            | 0 (0)                                                                                                             |

<div style=\"page-break-after: always\"></div>

Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years) [95% Confidence Intervals]

|     | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Post-2015 Phase 3 OA Studies b   | Post-2015 Phase 3 OA Studies b   | Post-2015 Phase 3 OA Studies b   |
|-----|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
| SIF | 0 (0)                           | 0 (0)                           | 1 (0.2) 2.6 [0.4, 18.6]         | 3 (0.2) 3.4 [1.1, 10.6]         | 1 (0.1) 1.5 [0.2, 10.7]         | 7 (0.5) 4.9 [2.3, 10.2]          | 7 (0.5) 5.6 [2.7, 11.7]          | 4 (0.4) 3.9 [1.5, 10.5]          |
|     | 0 (0)                           | 0 (0)                           | 0 (0)                           | 0 (0)                           | 0 (0)                           | 0 (0)                            | 0 (0)                            | 0 (0)                            |

a Includes Studies 1011, 1014, 1015, 1016, 1017, 1018, 1025, 1026, 1027, 1030, 1043; did not include prospectively scheduled radiographic assessments b Includes Studies 1056, 1057, 1058; included prospectively scheduled radiographic assessments

c Includes naproxen, celecoxib, diclofenac SR or oxycodone CR

d Additional primary ON event from Study 1058 added to primary composite endpoint and primary ON categories No joint safety endpoints were observed in the placebo treatment groups

Table 36 Summary of all-cause TJRs for pre-2015 phase 3 OA studies and TJRs for post2015 phase 3 OA studies

## Incidence Observation-Time Adjusted Rates N (%) Events/1000 patient-years (pt-years)

[95% Confidence Intervals]

|                  | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a   | Pre-2015 Phase 3 OA Studies a             | Post-2015 Phase 3 OA Studies b   | Post-2015 Phase 3 OA Studies b   | Post-2015 Phase 3 OA Studies b   | Post-2015 Phase 3 OA Studies b   |
|------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                  | Placebo N=1029 313 pt- years    | Tan 2.5 mg N=604 373 pt- years  | Tan 5 mg N=1771 1116 pt- years  | Active Compar ator c N=1266 661 pt- years | Placebo N=514 395 pt- years      | Tan 2.5 mg N=1530 1438 pt- years | Tan 5 mg N=1282 1245 pt- years   | NSAID N=996 1013 pt- years       |
| All- Cause TJR d | 10 (1.0) 31.9 [17.2, 59.3]      | 15 (2.5) 40.2 [24.2, 66.7]      | 52 (2.9) 46.6 [35.5, 61.2]      | 28 (2.2) 42.4 [29.3, 61.4]                |                                  |                                  |                                  |                                  |
| TJR e            |                                 |                                 |                                 |                                           | 23 (4.5) 58.2 [38.7, 87.5]       | 84 (5.5) 58.4 [47.2, 72.3]       | 100 (7.8) 80.3 [66.0, 97.7]      | 26 (2.6) 25.7 [17.5, 37.7]       |

b Includes Studies 1056, 1057, 1058; included prospectively scheduled radiographic assessments

c Includes naproxen, celecoxib, diclofenac SR or oxycodone CR

d Total joint replacement (all cause) includes patients with TJR (regardless of causality) or patients with reported ON without TJR

e TJR includes patients with TJR (regardless of adjudication outcome)

## Peripheral Neurological Safety

A dose-response was observed for tanezumab and peripheral AEs. Paraesthesia and hypoaesthesia were the most frequently reported events in the tanezumab-treated patients compared to placebo/NSAIDS, see Table 37 and Table 38. Also, radiculopathy, including carpal tunnel syndrome, was more frequently reported. Most, but not all, events resolved and the number of discontinuations because of AEs was low. The incidence of AEs was higher in the Study 1058, which has a longer duration than the other two post2015 studies. Also, after IV administration, the incidence, duration and discontinuation because of AEs

<div style=\"page-break-after: always\"></div>

was  higher  than  after  SC  administration.  From  this  perspective,  the  choice  of  SC  administration  is understood.

Table 37 Incidence of treatment-emergent adverse events of abnormal peripheral sensation during the treatment period (All Causalities) (Safety: OA Placebo-Controlled SC Studies 1027, 1056, 1057)

| Number (96) of Subiects: by Preferred Term   | Placebo (N=580) n (96)   | Tanezumab 2.5 mg (N=602) n (%6)   | Tanezumab 2.5/5 mg (N=219) n (96)   | Tanezumab (N=347) n(%6)   | Tanezumab 10 mg (N=86) n (%6)   | Tanezumab 2.5 and 5 mg combined (N=1168) n (%6)   |
|----------------------------------------------|--------------------------|-----------------------------------|-------------------------------------|---------------------------|---------------------------------|---------------------------------------------------|
| With Any adverse event                       | 13 (2.2)                 | 31 (5.1)                          | 7 (3.2)                             | 21 (6.1)                  | 11 (12.8)                       | 59 (5.1)                                          |
| With Any Adverse Event Excluding Sciatica    | 12 (2.0)                 | 29 (4.8)                          | 7 (3.2)                             | 20 (5.8)                  | 11 (12.8)                       | 56 (4.8)                                          |
| Paraesthesia                                 | 6 (1.0)                  | 14 (2.3)                          | 3 (1.4)                             | 14 (4.0)                  | 6 (7.0)                         | 31 (2.7)                                          |
| Hypoaesthesia                                | 5 (0.9)                  | 11 (1.8)                          | 3 (1.4)                             | 8 (2.3)                   | 5 (5.8)                         | 22 (1.9)                                          |
| Carpal tumnel syndrome                       | 0                        | 3 (0.5)                           | 0                                   | 1 (0.3)                   | 0                               | 4 (0.3)                                           |
| Sciatica                                     | 1 (0.2)                  | 3 (0.5)                           | 0                                   | 1 (0.3)                   | 0                               | 4 (0.3)                                           |
| Buming sensation                             | 1 (0.2)                  | 1 (0.2)                           | 0                                   | 2 (0.6)                   | 0                               | 3 (0.3)                                           |
| Decreased vibratory sense                    | 3 (0.5)                  | 1 (0.2)                           | 1 (0.5)                             | 1 (0.3)                   | 1 (1.2)                         | 3 (0.3)                                           |
| Neuallgia                                    | 0                        | 1 (0.2)                           | 0                                   | 1 (0.3)                   | 0                               | 2 (0.2)                                           |
| Neuropathy peripheral                        | 0                        | 0                                 | 0                                   | 1 (0.3)                   | 1 (1.2)                         | 1 (0.1)                                           |
| Paraesthesia oral                            | 0                        |                                   | 0                                   | 1 (0.3)                   | 0                               | 1 (0.1)                                           |
| Hypoaesthesia oral                           | 1 (0.2)                  |                                   | 0                                   | 0                         | 0                               | 0                                                 |
| Sensory dishubance                           | 0                        |                                   | 0                                   | 0                         | 1 (1.2)                         | 0                                                 |

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

Abnormal  Peripheral  Sensation  includes  Allodynia,  Axonal  neuropathy,  Burning  sensation,  Carpal  tunnel  syndrome,  Decreased vibratory sense, Demyelinating polyneuropathy, Dysaesthesia, Formication, Hyperaesthesia, Hyperpathia, Hypoaesthesia, Hypoaesthesia oral, Intercostal neuralgia, Neuralgia, Neuritis, Neuropathy

peripheral,  Paraesthesia,  Paraesthesia  oral,  Peripheral  sensorimotor  neuropathy,  Peripheral  sensory  neuropathy,  Polyneuropathy, Polyneuropathy chronic, Sciatica,

Sensory disturbance, Sensory loss, Tarsal tunnel syndrome, Thermohypoaesthesia.

<div style=\"page-break-after: always\"></div>

Table 38 Incidence of treatment-emergent adverse events of abnormal peripheral sensation during the treatment period (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| Number (%6) of Subjects: by Preferred Term   | Tanezumab 2.5 mg (N=1002) n (96)   | Tanezumab (N=998) n (96)   | Tanezumab 2.5 and 5 mg combined (N=2000) n (%)   | NSAID (N=996) n (%6)   |
|----------------------------------------------|------------------------------------|----------------------------|--------------------------------------------------|------------------------|
| With Any Adverse Event                       | 62 (6.2)                           | 90 (9.0)                   | 152 (7.6)                                        | 46 (4.6)               |
| With Any Adverse Event Excluding Sciatica    | 59 (5.9)                           | 85 (8.5)                   | 144 (7.2)                                        | 42 (4.2)               |
| Hypoaesthesia                                | 27 (2.7)                           | 28 (2.8)                   | 55 (2.8)                                         | 18 (1.8)               |
| Paraesthesia                                 | 18 (1.8)                           | 30 (3.0)                   | 48 (2.4)                                         | 13 (1.3)               |
| Carpal tumnel syndrome                       | 16 (1.6)                           | 27 (2.7)                   | 43 (2.2)                                         | 6 (0.6)                |
| Decreased vibratory sense                    | 8 (0.8)                            | 5 (0.5)                    | 13 (0.7)                                         | 7 (0.7)                |
| Sciatica                                     | 3 (0.3)                            | 8 (0.8)                    | 11 (0.6)                                         | 4 (0.4)                |
| Neuropathy peripheral                        | 2 (0.2)                            | 3 (0.3)                    | 5 (0.3)                                          | 0                      |
| Buming sensation                             | 1 (0.1)                            | 3 (0.3)                    | 4 (0.2)                                          | 3 (0.3)                |
| Dysaesthesia                                 | 0                                  | 3 (0.3)                    | 3 (0.2)                                          | 1 (0.1)                |
| Allodymia                                    | 0                                  | 1 (0.1)                    | 1 (0.1)                                          | 0                      |
| Hypoaesthesia oral                           | 0                                  | 1 (0.1)                    | 1 (0.1)                                          | 0                      |
| Peripheral sensory neuropathy                | 1 (0.1)                            | 0                          | 1 (0.1)                                          | 0                      |
| Sensory loss                                 | 0                                  | 1 (0.1)                    | 1 (0.1)                                          | 1 (0.1)                |
| Hyperaesthesia                               | 0                                  | 0                          | 0                                                | 1 (0.1)                |
| Neuralgia                                    | 0                                  | 0                          | 0                                                | 1 (0.1)                |
| Sensory dishurbance                          | 0                                  | 0                          | 0                                                | 1 (0.1)                |

Adverse events are shown by descending frequency by the tanezumab 2.5 and 5 mg combined group.

Abnormal  Peripheral  Sensation  includes  Allodynia,  Axonal  neuropathy,  Burning  sensation,  Carpal  tunnel  syndrome,  Decreased vibratory sense,

Demyelinating  polyneuropathy,  Dysaesthesia,  Formication,  Hyperaesthesia,  Hyperpathia,  Hypoaesthesia,  Hypoaesthesia  oral, Intercostal neuralgia,

Neuralgia, Neuritis, Neuropathy peripheral, Paraesthesia, Paraesthesia oral, Peripheral sensorimotor neuropathy, Peripheral sensory neuropathy,

Polyneuropathy, Polyneuropathy chronic, Sciatica, Sensory disturbance, Sensory loss, Tarsal tunnel syndrome, Thermohypoaesthesia.

## Sympathetic neurological safety

From  December  2012  through  20  March  2015  due  to  concerns  of  possible  adverse  effects  on  the sympathetic nervous system based on findings from nonclinical studies.

The  incidence  of  treatment-related  sympathetic  nervous  system  AE  is  largely  comparable  between tanezumab treatment and placebo/NSAIDs. Diarrhoea, bradycardia, nausea, and orthostatic hypotension were the most commonly reported events. The majority of events was mild.

The exposure-adjusted rates for any Tier 1 sympathetic AE (bradycardia and orthostatic hypotension) in the tanezumab treatment groups were higher compared to the placebo treatment group, see Table 39 and Table 40.

<div style=\"page-break-after: always\"></div>

Table 39 Exposure-adjusted tier 1 treatment-emergent adverse events during the treatment period (All Causalities) (Safety: OA Placebo-Controlled Post-2015 Studies 1056, 1057)

| NumberofSubjects/Exposure (rateper1000subject-years) PreferredTerm   | Placebo (N=514)   | Tanezumab2.5 mg (N=528)   | Tanezumab2.5/5 mg (N=219)   | Tanezumab5mg (N=284)   | Tanezumab2.5 and5mg combined (N=1031)   |
|----------------------------------------------------------------------|-------------------|---------------------------|-----------------------------|------------------------|-----------------------------------------|
| With Any Adverse Event                                               | 4/187.1 (21.4)    | 8/198 (40.4)              | 1/67.8 (14.7)               | 8/126.6 (63.2)         | 17/392.5 (43.3)                         |
| Bradycardia                                                          | 3/187.2 (16)      | 4/198.7 (20.1)            | 0 /67.9 (0)                 | 4/127.5 (31.4)         | 8/394.1 (20.3)                          |
| Orthostatichypotension                                               | 1/187.1 (5.3)     | 3/198.2 (15.1)            | 1/67.8 (14.7)               | 3/126.6 (23.7)         | 7/392.7 (17.8)                          |
| Hypohidrosis                                                         | 0 /187.2 (0)      | 1/198.8 (5)               | 0 /67.9 (0)                 | 0 /127.5 (0)           | 1/394.2 (2.5)                           |
| Syncope                                                              | 0/187.2 0         | 0 /198.8 (0)              | 0 /67.9 (0)                 | 1/127.5 (7.8)          | 1/394.2 (2.5)                           |

Exposure defined as: a) If subject experienced the event: time from first IV/SC dose to the date of first occurrence of the event. b) If the subject did not experience the event: Time from first IV/SC dose to the end of treatment visit date for subjects who completed the treatment period or up to the withdrawal from treatment date for subjects who withdrew early from the treatment period. Tier 1 Adverse Events: Anhidrosis, Bradycardia, Hypohidrosis, Orthostatic hypotension, Syncope.

Table 40 Exposure-adjusted tier 1 treatment-emergent adverse events during the Treatment period (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| NumberofSubjects/Exposure (rateper1000subject-years) PreferredTern   | Tanezumab2.5mg (N=1002)   | Tanezumab5mg (N=998)   | Tanezumab2.5and5mg combined (N=2000)   | NSAID (N=996)   |
|----------------------------------------------------------------------|---------------------------|------------------------|----------------------------------------|-----------------|
| WithAnyAdverseEvent                                                  | 18/696.9 (25.8)           | 23/687.9 (33.4)        | 41/1384.8 (29.6)                       | 29/680.5 (42.6) |
| Orthostatichypotension                                               | 10/698.2(14.3)            | 12/688.1 (17.4)        | 22/1386.3 (15.9)                       | 9/681.6 (13.2)  |
| Bradycardia                                                          | 7/702.8 (10)              | 9/694.6 (13)           | 16/1397.4 (11.4)                       | 16/685 (23.4)   |
| Syncope                                                              | 2/701.5 (2.9)             | 1/694.6 (1.4)          | 3/1396.2 (2.1)                         | 4/684 (5.8)     |
| Hypohidrosis                                                         | 0/702.9 (0                | 1/694.5 (1.4)          | 1/1397.4 (0.7)                         | 0/685 0         |

Exposure defined as: a) If subject experienced the event: time from first IV/SC dose to the date of first occurrence of the event. b) If the subject did not experience the event: Time from first IV/SC dose to the end of treatment visit date for subjects who completed the treatment period or up to the withdrawal from treatment date for subjects who withdrew early from the treatment period. Tier 1 Adverse Events: Anhidrosis, Bradycardia, Hypohidrosis, Orthostatic hypotension, Syncope.

## Laboratory findings

The laboratory evaluations (haematology, clinical chemistry and urinalysis parameters) and vital signs were determined in the broader OA placebo- and active-controlled (SC + IV) pools. In general, the median changes in laboratory test data, from baseline to last observation during the treatment period were generally minimal and not notably different across treatment groups. However, a small, dosedependent increase in the median change from baseline for alkaline phosphatase in the tanezumab treatment groups compared to the placebo and NSAIDs groups was observed.

Tanezumab has no adverse effect on renal function, based on evaluation of renal adverse events and changes  in  estimated  glomerular  filtration  rate  (eGFR).  Tanezumab  treatment  did  not  lead  to  an increased risk for drug-induced renal injury and was not associated with clinically concerning decreases in eGFR during the treatment period in the study population overall or in patients with baseline risk factors for NSAID-related renal impairment or moderate renal impairment at baseline.

Hepatic AEs were rare. The incidence of hepatic AEs was similar across treatment groups in all safety pools evaluated. The incidence of transaminase elevations at ≥ 3x ULN during tanezumab monotherapy was less than 1%. These transaminase elevations were not associated with increases in bilirubin. After administration of tanezumab to over 9700 patients for up to 56 weeks, there is no evidence of DILI meeting Hy's law at any tanezumab dose.

The proportion of patients with categorical decreases from baseline reflective of large decreases in blood pressure (change ≤ 20 mmHg in diastolic blood pressure or change ≤ 30 mmHg in systolic blood pressure) were not notably different across treatment groups (see Table 41 below). Tanezumab treatment led to a dose-dependent mean decrease from baseline in systolic and diastolic blood pressure that was greater

<div style=\"page-break-after: always\"></div>

than the decreases seen with placebo (~1 to 3 mmHg) or NSAID treatment (~1 to 2 mmHg) These differences were not considered clinically meaningful by the applicant.

Table 41

Table 4. Maximum decrease from Baseline for Blood Pressure During the Treatment Period: OA Placebo-Controlled SC Studies

| n (%)                                               | placebo N=586   | tanezumab 2.5 mg N=602   | tanezumab 5 mg N=347   | tanezumab 10 mg N=86   |
|-----------------------------------------------------|-----------------|--------------------------|------------------------|------------------------|
| Sitting Systolic Blood Pressure (mmHg) Change <-30  | 19 (3.3)        | 21 (3.5)                 | 15 (4.4)               | 3 (3.6)                |
| Sitting Diastolic Blood Pressure (mmHg) Change <-20 | 14 (2.4)        | 25 (4.2)                 | 14 (4.1)               | 6 (7.2)                |

Source: 2.7.4 SCS Appendix Table 1.10.3.c

Table 42 Observation time-adjusted adjudicated MACE events up to end of study and poststudy (All Causalities) in the OA controlled post-2015 studies in the restricted patient population

|                                                                   | Placebo       | Tanezumab      | Tanezumab      | Tanezumab     | Tanezumab                        | NSAID         |
|-------------------------------------------------------------------|---------------|----------------|----------------|---------------|----------------------------------|---------------|
| Number of Patients/Observation Time (rate per 1000 patient-years) | N=388         | 2.5 mg N=1104  | 2.5/5 mg N=162 | 5 mg N=909    | All Tanezumab Monotherapy N=2175 | N=697         |
| With any Composite MACE Event                                     | 2/294.5 (6.8) | 6/1042.9 (5.8) | 0/119.4 (0)    | 3/873.1 (3.4) | 9/2035.3 (4.4)                   | 2/715.7 (2.8) |
| CV death                                                          | 0/295.7 (0)   | 2/1044.4 (1.9) | 0/119.4 (0)    | 1/873.5 (1.1) | 3/2037.3 (1.5)                   | 1/716 (1.4)   |
| Non-Fatal MI                                                      | 1/295 (3.4)   | 2/1043.6 (1.9) | 0/119.4 (0)    | 1/873.3 (1.1) | 3/2036.2 (1.5)                   | 1/715.4 (1.4) |
| Non-Fatal Stroke                                                  | 1/295.2 (3.4) | 2/1043.7 (1.9) | 0/119.4 (0)    | 1/873 (1.1)   | 3/2036 (1.5)                     | 0/715.8 (0)   |

OA Controlled Post-2015 Studies 1056, 1057, 1058.

Restricted patient population: Safety patients with KL Grade 3 or 4 in Index Joint and Baseline WOMAC Pain ≥5 Observation  time  defined  as:  a)  If  patient  experienced  the  event:  Time  from  first  SC  dose  to  the  date  of  first occurrence of the event. b) If the patient did not experience the event: Time from first SC dose to the end of Study. All Tanezumab Monotherapy is combined group of tanezumab 2.5, 2.5/5 and 5 mg.

Source: Table 1.4.t.sp

## Safety in special populations

Tanezumab safety data were analysed in discrete patient populations based on age ( ≥ 65 and ≥ 75 years old),  gender,  race,  ethnicity,  body  mass  index,  baseline  eGFR  category,  geographic  region  and concomitant (intermittent) NSAID use. There was a tendency for increased incidence of fall related AEs

<div style=\"page-break-after: always\"></div>

and cardiac/vascular disorders in the tanezumab treatment arms for (very) elderly versus placebo. See Table 43 below. The subgroup analyses did not indicate increased risks in the other special populations.

Table 43 Summary of tanezumab general safety in patient subgroups (Intrinsic Factors) for the OA placebo-controlled, OA placebo-controlled SC, OA active-controlled and OA activecontrolled SC studies

<!-- image -->

|                                                                                                     | Placebo (N=1543)                                     | Placebo (N=1543)                                     | Placebo (N=1543)                                     | Placebo (N=1543)                                     |
|-----------------------------------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Nunber(%) of Subjects with:                                                                         | Age <65 (N=970) n  (%)                               | Age 65-74 (N=440) (%)                                | Age 75-84 (N=125) (%)                                | Age 85+ (N=8) n  (%)                                 |
| Any AE                                                                                              | 461 ( 47.5)                                          | 189 ( 43.0)                                          | 60 ( 48.0)                                           | 7 ( 87.5)                                            |
| Serious AE - Total                                                                                  | 14 (1.4)                                             | 7 (1.6)                                              | 8 (6.4)                                              | 0                                                    |
| - Fatal                                                                                             | 1( ( 0.1)                                            | 0                                                    | 1 (0.8)                                              | 0                                                    |
| -Hospitalization/prolong existinghospitalization                                                    | 14 ( 1.4)                                            | 7( 1.6)                                              | 4 (3.2)                                              | 0                                                    |
| - Life-threatening                                                                                  | 0                                                    | 1( 0.2)                                              | 0                                                    | 0                                                    |
| - Disability/incapacity                                                                             | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
| - Other (medically significant)                                                                     | 3（( 0.3)                                             | 1( 0.2)                                              | 3 (2.4)                                              | 0                                                    |
| -N/A                                                                                                | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
| AE leading to drop-out                                                                              | 25 (2.6)                                             | 11 ( 2.5)                                            | 4 (3.2)                                              | 1 ( 12.5)                                            |
| Psychiatric disorders                                                                               | 20 (  2.1)                                           | 6 ( 1.4)                                             | 2 (1.6)                                              | 0                                                    |
| Nervous system disorders                                                                            | 99 (10.2)                                            | 41 ( 9.3)                                            | 12 (9 9.6                                            | 1 (12.5)                                             |
| Accidents and injuries                                                                              | 71 (7.3)                                             | 16（ 3.6)                                             | 5( 4.0)                                              | 1 ( 12.5)                                            |
| Cardiac disorders                                                                                   | 17 (1.8)                                             | 9( 2.0)                                              | 2( 1.6)                                              | 0                                                    |
| Vascular disorders                                                                                  | 23 (2.4)                                             | 11 ( 2.5)                                            |                                                      | 0                                                    |
| Cerebrovascular disorders                                                                           | 1( 0.1)                                              | 0                                                    | 3 ( 2.4) 1 ( 0.8)                                    | 0                                                    |
| Infections and infestations                                                                         | 143 ( 14.7)                                          | 58 ( 13.2)                                           | 14 ( 11.2)                                           |                                                      |
| Anticholinergicsyndrome                                                                             | 0                                                    | 0                                                    | 0                                                    | 3 ( 37.5) 0                                          |
| Quality of lifedecreased                                                                            | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
|                                                                                                     | 49 ( 5.1)                                            |                                                      |                                                      |                                                      |
| Sumofposturalhypotensionfallsblackoutssyncopedizziness,ataxiafractures                              | 13 (3.0) 3 (2.4) 2 ( 25.0) Tanezumab 2.5 mg. (N=929) | 13 (3.0) 3 (2.4) 2 ( 25.0) Tanezumab 2.5 mg. (N=929) | 13 (3.0) 3 (2.4) 2 ( 25.0) Tanezumab 2.5 mg. (N=929) | 13 (3.0) 3 (2.4) 2 ( 25.0) Tanezumab 2.5 mg. (N=929) |
| Nunber (%) of Subjects with:                                                                        | Age<65 (N=549) n (%)                                 | Age 65-74 (N=288) n (%)                              | Age 75-84 (N=87) n (%)                               | Age 85+ (N=5) n (%)                                  |
| Any AE                                                                                              | 309 ( 56.3)                                          | 149 ( 51.7)                                          | 46 ( 52.9)                                           | 1 ( 20.0)                                            |
| Serious AE-Total                                                                                    | 10 ( 1.8)                                            | 8 (2.8)                                              | 2 (2.3)                                              | 1 ( 20.0)                                            |
| -Fatal                                                                                              | 1(( 0.2)                                             | 0                                                    | 0                                                    | 0                                                    |
| -Hospitalization/prolong existing hospitalization                                                   | )6 1.6)                                              | 8 (2.8)                                              | 2 (2.3)                                              | 1 ( 20.0)                                            |
| - Life-threatening                                                                                  | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
| - Disability/incapacity                                                                             | 1( 0.2)                                              | 0                                                    | 0                                                    | 0                                                    |
| - Other (medically significant)                                                                     | 1 ( 0.2)                                             | 2( 0.7)                                              | 0                                                    | 0                                                    |
| -N/A                                                                                                | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
| AE leading to drop-out                                                                              | 9 ( 1.6)                                             | 9( 3.1)                                              | 3 (3.4)                                              | 1 ( 20.0)                                            |
| Psychiatric disorders                                                                               | 6 ( 1.1)                                             | 2( 0.7)                                              | 0                                                    | 0                                                    |
| Nervous system disorders                                                                            | 87 ( 15.8)                                           | 24 ( 8.3)                                            | 10 ( 11.5)                                           | 0                                                    |
| Accidents and injuries                                                                              | 55 ( 10.0)                                           | 20 ( 6.9)                                            | 6 (6.9)                                              | 0                                                    |
| Cardiac disorders Vascular disorders                                                                | 8 (1.5) 10 ( 1.8)                                    | 8( 2.8) 3 (                                          | 1 ( 1.1)                                             | 0 0                                                  |
| Cerebrovascular disorders                                                                           | 2 (0.4)                                              | 1.0) 2 (0.7)                                         | 4 ( 4.6) 0                                           | 1 ( 20.0)                                            |
| Infections and infestations                                                                         |                                                      |                                                      |                                                      | 0                                                    |
|                                                                                                     | 106 ( 19.3)                                          | 60 ( 20.8)                                           | 16 ( 18.4)                                           |                                                      |
| Anticholinergic syndrome                                                                            | 0                                                    | 0                                                    | 0                                                    | 0                                                    |
| Quality of life decreased Sumofposturalhypotension,fallsblackouts,syncope,dizziness,ataxiafractures | 0 35 ( 6.4)                                          | 16 (5.6)                                             | 0 7( 8.0)                                            | 0 0                                                  |

<div style=\"page-break-after: always\"></div>

|                                                                               | Tanezumab 5mg (N=1324)                                     | Tanezumab 5mg (N=1324)                                     | Tanezumab 5mg (N=1324)                                     | Tanezumab 5mg (N=1324)                                     |
|-------------------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Number (%) of Subjects with:                                                  | Age<65 (N=815) n (%)                                       | Age 65-74 (N=383) n (%)                                    | Age 75-84 (N=112) n (%)                                    | Age 85+ (N=14) n (%)                                       |
| Any AE                                                                        | 400 ( 49.1)                                                | 208 ( 54.3)                                                | 61 ( 54.5)                                                 | 9 ( 64.3)                                                  |
| Serious AE - Total                                                            | 13 ( 1.6)                                                  | 9 (2.3)                                                    | 7 (6.3)                                                    | 0                                                          |
| -Fatal                                                                        | 0                                                          | 0                                                          | 2 (1.8)                                                    | 0                                                          |
| -Hospitalization/prolong existing hospitalization                             | 12 (1.5)                                                   | 7 (1.8)                                                    | 5 ( 4.5)                                                   | 0                                                          |
| - Life-threatening                                                            | 0                                                          | 1( 0.3)                                                    | 0                                                          | 0                                                          |
| - Disability/incapacity                                                       | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| - Other (medically significant)                                               | 2 (0.2)                                                    | 4( 1.0)                                                    | 0                                                          | 0                                                          |
| -N/A                                                                          | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| AE leading to drop-out                                                        | 21 ( 2.6)                                                  | 10 (2.6)                                                   | 3 ( 2.7)                                                   | 1 ( 7.1)                                                   |
| Psychiatric disorders                                                         | 20 (2.5)                                                   | 10 (2.6)                                                   | 4 (3.6)                                                    | 1 ( 7.1)                                                   |
| Nervous system disorders                                                      | 109 ( 13.4)                                                | 55 ( 14.4)                                                 | 12 ( 10.7)                                                 | 2 ( 14.3)                                                  |
| Accidents and injuries                                                        | 61 ( 7.5)                                                  | 24 (6.3)                                                   | 7 (6.3)                                                    | 2 ( 14.3)                                                  |
| Cardiac disorders                                                             |                                                            | 10 (2.6)                                                   | 4 (3.6)                                                    |                                                            |
|                                                                               | 12 (1.5)                                                   |                                                            |                                                            | 0                                                          |
| Vascular disorders Cerebrovascular disorders                                  | 20 ( 2.5) 0                                                | 19 (5.0) 1( 0.3)                                           | 4 ( 3.6) 1 ( 0.9)                                          | 0 0                                                        |
|                                                                               | 138 ( 16.9)                                                | 65 ( 17.0)                                                 |                                                            |                                                            |
| Infections and infestations Anticholinergicsyndrome                           | 0                                                          | 0                                                          | 25 ( 22.3) 0                                               | 5 ( 35.7) 0                                                |
| Quality of life decreased                                                     | 0                                                          | 0                                                          |                                                            | 0                                                          |
|                                                                               | 39(                                                        |                                                            |                                                            |                                                            |
| Sum ofposturalhypotension,falls,black outs,syncope,dizziness,ataxia,fractures | 0 4.8) 19 (5.0) 6 (5.4) 2 ( 14.3) Tanezumab 10 mg (N=1142) | 0 4.8) 19 (5.0) 6 (5.4) 2 ( 14.3) Tanezumab 10 mg (N=1142) | 0 4.8) 19 (5.0) 6 (5.4) 2 ( 14.3) Tanezumab 10 mg (N=1142) | 0 4.8) 19 (5.0) 6 (5.4) 2 ( 14.3) Tanezumab 10 mg (N=1142) |
| Number (%) of Subjects with:                                                  | Age<65 (N=772) n (%)                                       | Age 65-74 (N=266) n (%)                                    | Age 75-84 (N=94) n (%)                                     | Age 85+ (N=10) n(%)                                        |
| Any AE                                                                        | 390 ( 50.5)                                                | 148 ( 55.6) 11 ( 4.1)                                      | 48 ( 51.1)                                                 | 5 ( 50.0)                                                  |
| SeriousAE-Total                                                               | 8( 1.0)                                                    |                                                            | 4 (4.3)                                                    | 0                                                          |
| - Fatal                                                                       | 1( 0.1)                                                    | 1( 0.4)                                                    | 0                                                          | 0                                                          |
| - Hospitalization/prolong existing hospitalization                            | 5( 0.6)                                                    | 9 (3.4)                                                    | 4 ( 4.3)                                                   | 0                                                          |
| - Life-threatening                                                            | 0                                                          | 0                                                          | 1( 1.1)                                                    | 0                                                          |
| - Disability/incapacity                                                       | 1( 0.1)                                                    | 0                                                          | 0                                                          | 0                                                          |
| - Other (medically significant)                                               | 2( 0.3)                                                    | 1 (0.4)                                                    | 0                                                          | 0                                                          |
| -N/A                                                                          | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| AE leading to drop-out                                                        | 34 ( 4.4)                                                  | 15 (5.6)                                                   | 7 (7.4)                                                    | 0                                                          |
| Psychiatric disorders                                                         | 16 ( 2.1)                                                  | 8 (3.0)                                                    | 2 ( 2.1)                                                   | 0                                                          |
| Nervous system disorders                                                      | 134 ( 17.4)                                                | 54 ( 20.3)                                                 | 17 ( 18.1)                                                 | 0                                                          |
| Accidents and injuries                                                        | 70 (9.1)                                                   | 18 (6.8)                                                   | 10 ( 10.6)                                                 | 1 ( 10.0)                                                  |
| Cardiac disorders                                                             | 4( 0.5)                                                    | 6 (2.3)                                                    | 2 (2.1)                                                    | 1 (10.0)                                                   |
| Vascular disorders Cerebrovascular disorders                                  | 16 (2.1) 0                                                 | 6 (2.3) 2 (0.8)                                            | 3 (3.2) 0                                                  | 0 0                                                        |
| Infections andinfestations                                                    |                                                            |                                                            | 16 ( 17.0)                                                 |                                                            |
|                                                                               | 107 ( 13.9)                                                | 27 ( 10.2)                                                 |                                                            | 2 ( 20.0)                                                  |
| Anticholinergic syndrome                                                      | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| Sumofposturalhypotension,falls,blackouts,syncope,dizziness,ataxia,fractures   | 36 (4.7)                                                   | 15 (5.6)                                                   | 7 (7.4)                                                    | 1 ( 10.0)                                                  |

## Pregnancy

Based on pre-clinical findings, a contra-indication of pregnancy is included in the SmPC. For women with an active pregnancy whish in 4.6 guidance is provided to discontinue tanezumab and wait for at least 16 weeks after the last dose of tanezumab.

A total of 12 female patients became pregnant while receiving tanezumab in the pre-2015 and post2015 clinical studies. Exposure to tanezumab occurred during the first trimester of pregnancy in all 12 cases. Of the 12 pregnancies, 8 resulted in live births, 2 had spontaneous abortions, one elected to terminate the pregnancy and the outcome of one pregnancy is unknown. For four out of the 7 infants that were exposed to tanezumab in-utero and from whom post-natal screening data were available, a delay of language development was reported (one of these was temporarily). In one case at the age of 30 months, speech therapy was recommended. It remained unclear how the further development of this case was.

<div style=\"page-break-after: always\"></div>

## Immunological events

Overall  incidence  of  anti-drug  antibody  (ADA)  formation  was  modest,  see  Table  44.  At  long-term exposure,  the  overall  incidence  of  ADA  formation  was  about  8-10%,  of  which  about  80%  were neutralising.

No apparent associations were observed between the presence of (neutralising) antibodies to tanezumab and  treatment-related  adverse  events,  including  hypersensitivity,  nor  was  their  interference  with efficacy.

Table 44 Incidence (%) of TE ADA+ patients vs. treatment grouped by pooling strategy

| Study                                        | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          | Tanezumab Dose (mg)                          |
|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Number                                       | Placebo                                      | 2.5                                          | 2.5/5                                        | P->5                                         | 5                                            | p->10                                        | 10                                           | Tramadol                                     |
|                                              | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        | Individual Studies by Protocol Number        |
| 1056                                         | 4/223 (1.8%)                                 | 14/223 (6.3%)                                | 26/224 (11.6%)                               | N/A                                          | N/A                                          | N/A.                                         | N/A                                          | N/A                                          |
| 1057                                         | 12/275 (4.4%)                                | 22/278 (7.9%)                                | N/A                                          | N/A                                          | 28/279 (10%)                                 | N/A                                          | N/A                                          | N/A                                          |
| 1058                                         |                                              | 84/953 (8.8%)                                | N/A                                          | N/A                                          | 91/960 (9.5%)                                | N/A.                                         | N/A                                          | N/A                                          |
| 1059                                         | 8/365 (2.2%)                                 | N/A                                          | N/A                                          | 11/87 (12.6%)                                | 29/371 (7.8%)                                | 6/92 (6.5%)                                  | 55/375 (14.7%)                               | 9/556 (1.6%)                                 |
| Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   | Pooled Placebo-Controlled Studies; OA Only   |
| 1056, 1057                                   | 16/498 (3.2%)                                | 36/509 (7.1%)                                | 26/216 (12%)                                 | N/A                                          | 28/279 (10.0%)                               | N/A.                                         | N/A                                          | N/A                                          |
| Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP | Pooled Placebo-Controlled Studies; OA + CLBP |
| 1056, 1057, 1059                             | 24/863 (2.8%)                                | 36/509 (7.1%)                                | 26/216 (12%)                                 | N/A                                          | 44/649 (6.8%)                                | N/A                                          | 31/375 (8.3%)                                | N/A                                          |
| Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  | Pooled Active-Controlled Studies; OA + CLBP  |
| 1058, 1059                                   |                                              | 84/953 (8.8%)                                | N/A                                          | N/A                                          | 131/1418 (9.2%)                              |                                              | 61/467 (13.1%)                               | 9/556 (1.6%)                                 |

OA = osteoarthritis; CLBP = chronic low back pain.

P-&gt;5 = Patients first randomised to placebo treatment then received 5 mg tanezumab after 16 weeks.

P-&gt;10 = Patients first randomised to placebo treatment then received 10 mg tanezumab after 16 weeks.

## Injection Site Reactions

The overall incidence of tanezumab injection site reaction AEs in OA clinical studies was low ( ≤ 0.5%) and was not different from placebo injections at the intended dose and regimen of 2.5 mg SC given every 8 weeks. Injection site pain and erythema were the most frequently reported preferred terms. None were serious or severe injection site reactions. Most of the injection site reactions occurred soon after the first injection of study medication. The duration of injection site reaction AEs during the treatment period was generally short (median duration was two days for the tanezumab 2.5, and 5 mg combined treatment group). No meaningful difference was observed in the incidence of Treatment-Emergent Injection Site Reactions (ISR) between patients with or without treatment-emergent ADA to tanezumab.

## Safety related to drug-drug interactions and other interactions

Drug-drug interaction (DDI) studies have not been conducted with tanezumab.

As observed in the totality of safety data, the incidence of adverse events, particular RPOA, increases when tanezumab is used in combination with chronic use of NSAIDs, but not at short term NSAIDs use

<div style=\"page-break-after: always\"></div>

(less  than  maximal  10  days  during  the  8  weeks  treatment  course).  It  is  recommended  not  to  use tanezumab concomitantly with NSAIDs.

## Discontinuation due to AES

Patients in the tanezumab arms discontinued more often from the study (22.3% and 24.5%) than patient in  the  placebo  arm  (15.8%),  except  for  the  2.5/5mg  group  (14.2%).  During  SC  administration,  the incidence of AEs leading to discontinuation of study medication was low and not notably different in the tanezumab treatment groups compared to the placebo group.

The percentage of patients on NSAIDs who discontinued was comparable with the tanezumab treatment arms. In the active-controlled post-2015 Study 1058, treatment with tanezumab was associated with a higher incidence of discontinuation because of SAEs in the treatment period. The most-reported AEs were osteoarthritis, RPOA and arthralgia, see Table 45. These numbers fit in the overall picture of serious joint safety AEs that are associated with tanezumab treatment compared to NSAID treatment.

Table 45 Incidence of treatment-emergent serious musculoskeletal and connective tissue disorder adverse events during the treatment period leading to discontinuation (All Causalities) (Safety: OA Active-Controlled SC Study 1058)

| Number of Subjects Evaluable for AEs                                | Tanezumab 2.5 mg (N=1002)   | Tanezumab 2.5 mg (N=1002)   | Tanezumab 5g (N=998)   | Tanezumab 5g (N=998)   | Tanezumab 2.5 and 5 mg combined (N=2000)   | Tanezumab 2.5 and 5 mg combined (N=2000)   | NSAID (N=996)   | NSAID (N=996)   |
|---------------------------------------------------------------------|-----------------------------|-----------------------------|------------------------|------------------------|--------------------------------------------|--------------------------------------------|-----------------|-----------------|
| Nunber (%o) of Subjects: bySYSTEM ORGAN CLASS and by Preferred Tern | n (%)                       | n (%)                       | n (%)                  | n (%)                  | n (%)                                      | n (%)                                      | n (%)           | n (%)           |
| With Any Adverse Event                                              | 20 (2.0)                    |                             |                        | 37 (3.7)               | 57 (                                       | 2.9)                                       | 21 (            | 2.1)            |
| Musculoskeletal and connective tissue disorders                     | 11                          | 1.1)                        | 25 (2.5)               |                        | 36 (                                       | 1.8)                                       |                 | 7 ( 0.7)        |
| Arthralgia                                                          | 2 (0.2)                     |                             |                        | 5 (0.5)                | 7(                                         | 0.4)                                       | 0               |                 |
| Intervertebral disc protrusion                                      | 0                           |                             | 1(                     | 0.1)                   | 1 (                                        | 0.1)                                       | 0               |                 |
| Lumbar spinal stenosis                                              | 1 (0.1)                     |                             | 0                      |                        | 1                                          | 0.1)                                       | 0               |                 |
| Musculoskeletal pain                                                | 0                           |                             | 1                      | 0.1)                   | 1                                          | 0.1)                                       |                 | 0.1)            |
| Osteoarthritis                                                      | 6(                          | 0.6)                        | 9                      | 0.9)                   | 15                                         | 0.8)                                       | 4(              | 0.4)            |
| Rapidly progressive osteoarthritis                                  | 3(                          | 0.3)                        | 5(                     | 0.5)                   |                                            | 0.4)                                       | 0               |                 |
| Rotator cuff syndrome                                               | 0                           |                             | 0                      |                        | 0                                          |                                            |                 | 1 ( 0.1)        |
| Spondylolisthesis                                                   | 0                           |                             | 1(                     | 0.1)                   | 1(                                         | 0.1)                                       | 0               |                 |
| Subchondral insufficiency fracture                                  | 0                           |                             | 3(                     | 0.3)                   | 3(                                         | 0.2)                                       |                 | 2 (0.2)         |
| Thoracic spinal stenosis                                            | 0                           |                             |                        | 1 ( 0.1)               |                                            | 1 (0.1)                                    | 0               |                 |

Original table (1.7.2.20.m) compressed by assessor in order to reflect Musculoskeletal and connective tissue disorder SAEs.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

Tanezumab is not currently marketed in any country/region.

## 2.5.1. Discussion on clinical safety

The safety database for tanezumab is extensive. It consists of studies in osteoarthritis (OA) but also of studies  in  chronic  low  back  pain  (CLBP)  and  healthy  volunteers.  The  data  from  the  latter  study populations are considered as supportive. The safety database in OA is considered sufficiently large to establish common adverse events associated with tanezumab treatment and to compare the long-term safety profile of tanezumab with non-steroidal anti-inflammatory drugs (NSAIDs) which are standard of care for pain in OA.

The safety of tanezumab in the treatment of pain by OA was investigated in 9732 patients who received at least one dose of tanezumab (SC or IV; 2.5 or 5 mg tanezumab) every 8 weeks. The safety of the proposed dose of 2.5mg tanezumab SC administration every eight weeks has been investigated in 1604 patients with moderate-to-severe OA. Of these, 804 patients were exposed to tanezumab for at least 24 weeks and 374 patients were exposed for at least 56 weeks.

The 'post-2015' phase III OA studies 1056, 1057 and 1058, included the proposed dose and patient population that is in the sought indication: moderate to severe chronic pain associated with (OA) in adult patients for whom treatment with NSAIDs and/or an opioid is ineffective, not tolerated or inappropriate. Furthermore, these post-2015 studies were not affected by the partial clinical  holds.  In  study  1058 patients were not NSAID intolerant, as NSAIDs were the active comparator. Studies 1056 and 1057 are placebo-controlled studies. Study 1058 is a long-term active-controlled study and allows comparison of the safety profiles of tanezumab with NSAIDs. In addition, this study is also considered relevant for the assessment of long-term safety since its duration was 56 weeks. Altogether, the psost-2015 pivotal studies 1056, 1057 and 1058 are considered most relevant for safety analyses.

The AEs were mainly in the domain of Musculoskeletal and connective tissue disorders and Nervous system  disorders.  No  relevant  signals  were  observed  regarding  infections,  psychiatric  events  and injection reactions.

In  the  tanezumab  treatment  arms  the  incidence  of  the  following  AEs  was  higher,  compared  to placebo/NSAID: arthralgia, nasopharyngitis, fall, headache, OA, joint swelling, rapidly progressive OA (RPOA),  peripheral  oedema,  hypoaesthesia,  paraesthesia,  burning  sensation  and  carpal  tunnel syndrome. The incidence of joint swelling, OA, paraesthesia and hypoaesthesia increased with increase in tanezumab dose. In larger pools, this profile was consistent with the findings in the 'post-2015' studies. The occurrence of peripheral oedema was correlated with the abnormal peripheral sensations.

Serious adverse events (SAEs) that were more seen in the tanezumab treatment groups compared to the placebo/NSAID groups during the treatment period were arthralgia, OA and RPOA, and MACE. The incidence of OA and RPOA was also higher during the follow-up period.

A warning should be considered regarding falls, as this impact the elderly, an important part of the target population.

The following AE's are of special interest:

## Joint Safety

The potential safety findings of osteonecrosis (ON) in the pre-2015 studies, led to several adjustments in the study programme: e.g. surveillance on joint safety, adjustment of inclusion criteria: severe OA who were unresponsive to or intolerant of multiple standards of care analgesics, exclusion of patients

<div style=\"page-break-after: always\"></div>

with evidence of risk factors for RPOA, maximum dose of 5mg tanezumab was administrated, restricted duration of concomitant NSAID use. Assessment of joint safety is mainly based on the post-2015 studies.

Despite these precautionary measures, there was still an increased risk of RPOA in the post-2015 studies, although less than reported before in the studies where NSAIDs were used add-on on a chronic basis. A clear dose-response in the incidence of RPOA was observed in the post-2015 pooled studies; 2.7% for tanezumab 2.5mg; 5.5% for tanezumab 5 mg; 0% in the placebo group and 1.1% in the NSAID group, indicating  causality.  The  incidence  of  RPOA  in  this  post-2015  pool  as  confirmed  by  the  Adjudication Committee in patients with possible or probable joint-related safety events was 24.3% for tanezumab 2.5mg; 31.1% for tanezumab 5 mg; 0% in the placebo group and 21.1% in the NSAID group. However, the joint-related damage was more severe for tanezumab as compared to oral NSAIDs, and led to higher rate of surgical interventions (TJR, total joint replacement).

Study 1058 had the longest duration (56 weeks in the controlled phase + longer follow-up of 24 weeks) and thus the largest number of tanezumab dosages (7 injections). In this study, most (serious) joint safety  events  were  observed.  This  was  particularly  the  case  for  the  patients  who  received  4-7  SC administrations of 5mg tanezumab. Thus at treatment continuation, the risk of RPOA increases. This is unfavourable for a treatment in a chronic disorder as OA.

A  restriction  of  NSAID  use  is  recommended  in  the  SmPC,  which  is  supported.  However,  although  a restriction of NSAIDs was successfully applied in the trial setting, this may be difficult to realize in clinical practice, particularly since the treatment effect on the reduction of pain was not complete and NSAIDs are  available  OTC.  A  DUS  is  planned  to  evaluate  the  compliance  to  the  proposed  risk  minimisation measures in clinical practice, including longer-term concomitant NSAIDs use.

No biomarkers could be identified that predict the risk of RPOA (see Pharmacodynamics section of this report).  The  applicant  proposes  a  warning  that  patients  with  (X-ray)  signs  of  pre-existing  rapidly progressive OA, subchondral insufficiency fracture, osteonecrosis, or atrophic OA should be treated with care. However, these patients were excluded from the pivotal post-2015 trials, but this measure did not successfully prevent the occurrence of tanezumab-induced RPOA and TJR. As there are insufficient data for this population at increased risk, these joint-level risk factors is a contra-indication for tanezumab treatment.

No safety data are available from patients with hand OA. As patients with hand OA are excluded from the indication, this is considered acceptable.

## Total Joint Replacement

The incidence of ≥1 total joint replacement (TJR) seems somewhat high er in the tanezumab groups than in placebo. But the incidence of elective TJRs was higher in the placebo group than in the tanezumab groups. This indicates that the reason for surgery in placebo was mainly driven by pain which was left untreated, whereas, for tanezumab, the reason for surgery was more driven by rapidly progressive OA and bone damage -in a dose-dependent way, which underlines causality-. On the long-term, more TJRs were observed for tanezumab treatment. The incidence of TJRs is lowest in the NSAID groups. Most TJRS were in the knee, followed by the hip.

In the long-term Study 1058 approximately 5% of total patients had a TJR, with a higher incidence in the  tanezumab  treatment  groups.  Patients  treated  with  tanezumab  had  approximately  2  times (tanezumab 2.5 mg) or 3 times (tanezumab 5 mg) the risk of having a TJR compared to NSAID-treated patients.

The post-2015 studies had a higher degree of surveillance, which will lead to more observed adverse events. However, the patient population that was included in these studies was different as patients with evidence of risk factors for RPOA were excluded, so a less at-risk population entered the studies.

<div style=\"page-break-after: always\"></div>

Thus, the totality of the findings on joint safety, including TJR, are of great concern, also at the low 2.5 mg dose, which is the current posology. This is particularly worrisome since chronic treatment with tanezumab is foreseen. TJR surgeries are not without risk (blood loss, post-surgical immobility, wound infections). Moreover, TJR is to be postponed as much as possible, since the artificial joints are not durable.

Despite  of  the  demonstrated  benefits  and  feasibility  of  a  symptomatic  treatment,  it  was  considered unacceptable that this would justify the observed risk for progression of the underlying disease. The proposal to restrict  the  indication  to  those  patients  who  are  intolerant  or  irresponsive  to  NSAIDs  or opioids was also considered, but, given the potential risk of surgery, this does not sufficient to justify a positive Benefit/Risk balance.

## Neurological Safety

A dose-response was observed for tanezumab and peripheral AEs. Paraesthesia and hypoaesthesia were the most frequently reported events in the tanezumab-treated patients compared to placebo/NSAIDS. Most events resolved and the number of discontinuation because of AE's was low. These events are listed as common ADRs in section 4.8 of the SmPC. Adequate warnings are also included in section 4.4 of the SmPC. Non-clinically, no effect on learning and memory was observed after tanezumab administration, and this was neither observed at routine monitoring of these outcomes in the clinical studies.

## Neurological Safety - Sympathetic neurological safety

On  14  December  2012,  the  FDA  placed  a  partial  clinical  hold  (PCH)  on  the  tanezumab  clinical development programme due to concerns about adverse changes in the SNS of mature animals from multiple anti-NGF mAb development programs.

For tanezumab treatment, the incidence of treatment-related sympathetic nervous system AE is largely comparable with placebo/NSAIDs. Diarrhoea, bradycardia, nausea, and orthostatic hypotension were the most commonly reported events. The majority of events was mild. The exposure-adjusted rates for any Tier 1 sympathetic AE (bradycardia and orthostatic hypotension) in the tanezumab treatment groups were higher compared to the placebo treatment group. The PD effect of tanezumab on heart rate and blood pressure are included in the SmPC section 5.1.

## Mortality including MACE

A total of 33 deaths have been reported; 30 on tanezumab treatment, one on NSAID treatment and two on placebo. Fourteen of the deaths were included in the post-2015 studies.

Over all pools of controlled data, a higher incidence of observation time-adjusted deaths was observed for the tanezumab treatment groups (ranging from 2.5-12.3/1000 patient-years) compared to placebo (2.8/1000 patient-years) and NSAIDS (0.5/1000 patient-years) during treatment and up to the end of the study and post-study.

Most  deaths  (11  out  of  24)  in  the  controlled  tanezumab  treatment  arms  (2.5-20mg)  were  due  to cardiovascular disease.

In response to a Safety MO at Day120 of the procedure, the applicant reviewed the MACE data, also after  post-hoc  adjudication  by  a  cardiology  experts  group.  A  signal  cannot  be  excluded  from  the adjudicated data. The occurrence of adjudicated MACE appears to be higher in the tanezumab 2.5 mg arm (5.6/1000 PY) and the pooled monotherapy arms (5.0/1000 PY) and NSAID arm (4.3/1000 PY), as compared to placebo (2.8/1000 PY). The risk was highest in the group treated with tanezumab 10 mg (7.5/1000 PY). The risk difference (95%CI) for tanezumab 2.5 mg versus placebo is 2.8 (-2.6 - 8.2), and versus NSAID this is 1.3 (-3.5 - 6.2) in favour of NSAID. Also the adjudicated fatal MACE cases were

<div style=\"page-break-after: always\"></div>

numerically higher for tanezumab as compared to placebo and NSAIDs. Of all 6 CV deaths that occurred on tanezumab, there were 5 cases of sudden cardiac death and 1 myocardial infarction.

It is noted that the numbers are small, and no such signal was observed in non-clinical studies. However, the  signal  was  very  consistent  over  the  different  pooled  analyses.  The  findings  in  the  OA  (IV+SC) tanezumab monotherapy trials are in line with the findings in the OA+CLBP data, the tanezumab SC studies,  other  post-hoc  analyses  using  Investigator-reported  outcomes,  and  when  looking  at  events during the study/during the study and follow-up. The signal for the occurrence of MACE comes from the tanezumab 2.5 mg arm, but it is also found in the 5 mg and 10 mg arms, which supports pooling of these data to increase precision. The highest occurrences in the highest dose (10 mg) suggest a doseresponse relationship.

Presence/absence of CV risk factors at baseline did not well stratify patients for occurrence of CV death and MACE if on tanezumab. Therefore, risk minimisation by the selection of patients without CV risk factors seems not possible.

Remarkably, the occurrence of CV events and deaths in the NSAID arms were lower than expected as compared to (meta-analysis of) trials with NSAIDs performed in OA. The applicant suggests that positive selection may have occurred favoring safety of NSAID treatment (included patients must have 'survived' past  NSAID  treatment).  This  possibility  is  acknowledged.  It  however  is  uncertain  whether  positive selection may have led to this size of differential effect. More importantly, it is considered that the study population matches the proposed target population of patient irresponsive to prior NSAIDs. Therefore, the contrast between tanezumab and NSAID is considered of clinical relevance for future patients, also where it considers MACE and death.

MACE is included as an important potential risk in the safety specifications. Also, it is included as an endpoint  in  the  Post  Authorisation  Safety  Study  (PASS).  However,  the  uncertainty  regarding  MACE remains despite its inclusion in the RMP and its effect on the B/R balance of the product remains negative.

## Post-hoc selected population

Safety data were provided for the post-hoc selected population (72% of original population) consisting of patients who were candidates or scheduled for TJR. The overall safety profile of tanezumab in the post-hoc selected population is largely comparable to the overall patient population in the pivotal studies (1056, 1057 and 1058).

The  incidence  of  RPOA1  and  RPOA2  is  higher  for  tanezumab  than  for  the  comparators  (placebo  or NSAIDs) in the post-hoc analyses, to a similar extent as was observed in the full analysis dataset. The incidence of TJR's is, however, higher among all the subgroups of the post-hoc analyses (i.e. tanezumab and the comparator arms). This may be expected as the post-hoc analyses were performed in a subgroup of patients with more severe pain and joint damage at baseline, and these factors are important reasons for TJR surgery.

However, 18% of the tanezumab-related TJR's cases involved the non-index joint, which is not elected for surgery a-priori in the newly defined target population. Joint damage to the non-index joints was more frequent for tanezumab than placebo or NSAIDS, and this forms an additional and structural harm, as in contrast to the index-joint, these joints are not planned to be removed. The applicant also proposed to  limit  the  duration  of  treatment  to  a  maximum  of  seven  doses  or  two  doses  in  non-responders. However, even long after the withdrawal of short-term tanezumab treatment (16-24 weeks), still cases of RPOA emerged, while this was not reported for placebo and less frequently for NSAIDs. Carry-over effects are thus observed after short-term treatment (2-3 administrations of tanezumab every 8-week).

Furthermore, it is unclear what will be the impact of tanezumab-induced joint damage on TJR surgery outcomes due to limited data. Study 1064 is a long-term observational study of subjects from the three

<div style=\"page-break-after: always\"></div>

pivotal tanezumab studies who underwent a total knee, hip or shoulder replacement. 52 Patients were included after tanezumab 2.5mg treatment, 20 after placebo and 17 after NSAIDs. 5 Cases of (mild) surgical procedure complications were reported, all for tanezumab. Six post-surgical complications were reported for tanezumab, and one for a patient assigned to NSAIDs. The impact of RPOA2 on the success of TJR surgery is currently unknown in this restricted indication. It should be avoided that surgery is more  complex  due  to  additional  RPOA2  caused  by  tanezumab  treatment.  Also,  as  NSAIDs  are  not recommended concomitantly with, and 16 weeks after, tanezumab. This interferes with the usual preand post-surgical use of NSAIDs.

The incidence of MACE is comparable for tanezumab in this selected population compared to the overall population. For NSAIDs this is lower and for placebo this is higher. Two of the 6 tanezumab MACE events were fatal. None of the 2 cases in the placebo group were fatal and 1 out of 2 cases in the NSAID group was fatal.

## Pregnancy

Based on pre-clinical findings, a contra-indication of pregnancy is included in the SmPC. For women with an active pregnancy whish in 4.6, guidance is provided to discontinue tanezumab and wait for at least 16 weeks after the last dose of tanezumab. This is considered adequate.

Causality of exposure in uterus and impact on cognitive development is not established. Based on nonclinical studies, it was argued that tanezumab is not expected to pass the BBB of the developing fetus and that in early pregnancy, the transplacental transfer of monoclonal antibodies like tanezumab would be low. The issue is not pursued as there is already a contra-indication for the use of tanezumab in pregnancy included in the SmPC.

## 2.5.2. Conclusions on clinical safety

The overall safety profile of tanezumab is primarily characterised by the serious risks of joint safety (rapid  progressive  OA  (RPOA)  and  total  joint  replacements  (TJR),  MACE,  peripheral  neurological symptoms  and  (non-severe)  reduction  of  blood  pressure,  peripheral  oedema  (possibly  related  to peripheral  nerve  damage)  and  orthostatic  hypotension.  An  increased  risk  of  falling  in  elderly  is  not excluded.

Unfortunately, the precautionary measures to prevent RPOA and TJR such as exclusion of patients with pre-existing RPOA, subchondral insufficiency fracture (SIF), osteonecrosis (ON), or atrophic OA , and the restriction of NSAIDs use in the post-2015 studies (after the clinical holds), could not prevent that the risk is still present for tanezumab, as compared to placebo and NSAIDs. No other prognostic factors that could  potentially  mitigate  the  risk  could  be  identified.  This  contributes  negatively  to  the  benefit-risk balance.

A higher rate of mortality due to MACE is observed in the tanezumab treated population, including sudden cardiac death. Unfortunately, no clear prognostic factors were identified, making it difficult to handle this in clinical practice. This has a negative impact on the B-R balance. The risk might be higher in nonselected patients outside the clinical trial settings. MACE is included as an important potential risk in the RMP  and  is  included  as  an  endpoint  in  the  Post-Authorisation  Safety  Study  (PASS),  however  the uncertainty regarding MACE remains, and contributes to the negative B/R balance of the product.

Although the peripheral neurological damage is a matter of concern, most cases at the low 2.5 mg dose -that is proposed as posology- were non-serious. self-limiting, or reported to be reversible at treatment withdrawal. A warning in the SmPC section 4.4 regarding Abnormal Peripheral Sensations was included. Moreover,  a  warning  was  included  that  there  is  limited  experience  in  patients  with  pre-existing

<div style=\"page-break-after: always\"></div>

neuropathic disorders and patients with MS were excluded. A warning regarding the risk of falling was proposed in the SmPC, since tanezumab treatment may increase the risk for fall in the elderly.

For the selected population of patients who are candidates or scheduled for TJR, the conclusions on safety are comparable to those of the originally proposed population. However, the possible impact of RPOA2 on TJR surgery in the index joint and the observed RPOA in non-index joints are of concern. Furthermore, the limitations of concomitant NSAIDs use interferes with the usual pre- and post-surgical use of NSAIDs.

## 2.6. Risk Management Plan

The CHMP, having considered the data submitted by the applicant, were of the opinion that, due to the concerns identified with this application, as above outlined, the RMP cannot be agreed at this stage.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The CHMP and PRAC, having considered the data submitted by the applicant, were of the opinion that, due to the concerns identified with this application, as above outlined, the pharmacovigilance system summary cannot be agreed at this stage.

## Periodic Safety Update Reports submission requirements

Not Applicable.

## 2.8. Product information

Due to the aforementioned concerns a satisfactory summary of product characteristics, labelling and package leaflet cannot be agreed at this stage.

## 2.8.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9. New substance status

The CHMP, based on the available data, considers tanezumab to be a NAS as it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The applicant proposed the indication for tanezumab as: '…for treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal  anti-inflammatory  drugs  (NSAIDs)  and/or  an  opioid  is  ineffective,  not  tolerated  or inappropriate.'

OA  is  a  progressive  degenerative  joint  disease  precipitated  by  the  loss  of  cartilage  leading  to compensatory hypertrophy (osteophytes or bone spurs) of bone structure at the joint margins, areas of abnormal  bone  hardening  (subchondral  sclerosis),  and  fluid-filled  pockets  in  the  marrow  known  as subchondral cysts. The hallmark signs and symptoms of OA are joint pain, stiffness, and reduced range of motion. As the cartilage is not innervated, pain from OA is the result of nociception in other joint tissues and from tissues surrounding the joints (ligaments, tendons, muscle).

The course of OA varies widely between patients, according to the joints affected and the degree of erosiveness (EULAR Textbook 2018). Clinically defined, the knee is the most common site of OA, followed by the hand and hip (Hunter 2019). Many patients have OA in more than one joint.

## 3.1.1. Available therapies and unmet medical need

International  treatment  guidelines  are  in  line  with  each  other  regarding  the  recommendations  for management (OARSI, Bannuru et al. 2019; ACR, Kolansinski et al. 2020; EULAR, Kloppenburg et al. 2019; www.Up-to-date.com).

Currently, there are no pharmacological treatment options with univocally established disease-modifying properties; thus, the pharmacological treatment of osteoarthritis is essentially symptomatic. Exercise and self-management are common elements of OA therapy. Surgery is reserved for patients for whom non-pharmacological and pharmacological treatments are not helpful or no option.

The  most  relevant  pharmacological  treatment  options  to  discuss  for  the  symptomatic  treatment  of osteoarthritis  are  paracetamol,  topical  and  oral  NSAIDs,  intra-articular  corticosteroids,  and  (weak) opioids.

This  means  that  for  patients  for  whom  topical  and  oral  NSAIDs  are  insufficiently  effective  or  not appropriate due to contra-indications or tolerability issues, tramadol may be considered as 'last resort' systemic treatment option available, but it appears not to be a very effective option. Stronger opioids cannot be recommended for the treatment of OA.

Altogether, there is an unmet medical need for safe and effective pharmacological treatment options of OA. With the ageing of the European population, the prevalence of OA increases.

## 3.1.2. Main clinical studies

The clinical development of tanezumab was twice interrupted by the FDA due to emerging safety issues: first  between  2010  -  2012  due  to  the  occurrence  of  severe  adverse  effects  to  synovial  joints (osteonecrosis, RPOA), and further from 2012 - 2015,  because of signals of sympathetic nervous system damage from non-clinical studies. After the clinical hold, the applicant proceeded in 2015 with a new set of three clinical studies using tanezumab SC instead of IV and implementing precautionary measures, such as: the avoidance of concurrent chronic NSAIDs use (which appeared as a risk factor of rapidly

<div style=\"page-break-after: always\"></div>

progressive  OA  with  tanezumab),  exclusion  of  patients  with  signs  of  RPOA  and  some  related  joint conditions on X-ray images (in two of the three studies), and annual monitoring using X-ray images.

The  three  main  clinical  studies  were  all  performed  'post-2015'  while  using  the  SC  administration, including the 2.5 mg dose, in the intended target population of patients with moderate to severe OA for whom  standard pharmacological treatments (paracetamol, NSAIDs, or tramadol/opioids) were insufficient or inappropriate (Table 46).

These were all  multi-centre  randomised,  double-blind  controlled  trials.  Study 1056 and 1057 were placebo-controlled of 16 weeks (2 doses) and 24 weeks (3 doses) duration, followed by a safety followup in  which tanezumab was not given. Study 1058 was  NSAID controlled  (celecoxib,  diclofenac,  or naproxen) blinded using double dummies, of 56 weeks duration with additional safety follow-up, with an efficacy endpoint at week 16. After week 16, only patients with at least some response could continue. Patients in this study had no contra-indications for NSAIDs.

Table 46 Design of the 'post-2015' studies including tanezumab 2.5 mg SC

| Study ID Locations                                  | Design                                                                                                                                                                                                | Subjects                                                                                                                                                                                                                                                                   | Treatment groups                                                                                                | N (included/ completed)    | Primary Endpoints                                                                                                         |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------------------------------------------|
| 1056 North America                                  | Phase 3 (16- week treatment) Randomised, DB, PBO- controlled, multicentre study of the analgesic efficacy and safety of a dose up-titration regimen of TAN SC in subjects with OA of the hip or knee. | Moderate to severe hip/knee OA, with: 1) APAP: insufficient pain relief; and 2) NSAIDs: insufficient pain relief/ contra-indication/ intolerance; and 3) TRA or opioids: insufficient pain relief/ contraindication/ intolerance (or for opioids only, unwilling to take). | TAN 2.5 mg SC (2 doses: Day 1 and WK 8) TAN 2.5 mg SC (Day 1), TAN 5 mg SC (wk8) PBO SC (Day 1 and wk8)         | 231/ 208 233/ 209 232/ 192 | Co-primary efficacy endpoints were change from baseline to Week 16 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |
| 1057 Europe, Japan                                  | Phase 3 (24- week treatment) randomised, DB, PBO- controlled, multicentre study of the analgesic efficacy and safety of TAN SC in subjects with OA of the hip or knee.                                | Moderate to severe hip/knee OA, with: 1) APAP: insufficient pain relief; and 2) NSAIDs: insufficient pain relief/ contra-indication/ intolerance; and 3) TRA or opioids: insufficient pain relief/ contraindication/ intolerance (or for opioids only, unwilling to take). | TAN 2.5 mg SC Every-8-wks (3 doses) TAN 5 mg SC every-8-wks (3 doses) PBO SC every-8-wks (3 doses)              | 283/ 257 284/ 255 282/ 283 | Co-primary efficacy endpoints were change from baseline to Week 24 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |
| 1058 North/South America, Asia, Australasia, Europe | Phase 3 (56- Week treatment), Randomised, DB, Active- Controlled Multicentre Study of the long term Safety and Efficacy of                                                                            | Moderate to severe hip/knee OA, and: 1) tolerating and on a stable NSAID dose regimen; and 2) APAP: insufficient pain relief; and at least 1 of the following: a) TRA: inadequate pain relief/contra- indication/intolerable;                                              | TAN 2.5 mg SC every-8-wks (7 doses) + PBO to match NSAID TAN 5 mg SC every-8-wks (7 doses) + PBO to match NSAID | 1002/ 447 998/ 419         | Co-primary efficacy endpoints were change from baseline to Week 16 in: - WOMAC Pain - WOMAC Physical Function - PGA of OA |

<div style=\"page-break-after: always\"></div>

| SC Administration of TAN in Subjects with OA of the Hip or Knee   | b) Opioid: inadequate pain relief/contra- indication/intolerance/unwilli ng to take.   | NSAID PO (NAP 500 mg BID, CEL 100 mg BID, or DIC 75 mg BID) + SC PBO (to match TAN)   | 996/ 446   |
|-------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------|

TAN=Tanezumab; NAP=Naproxen; CEL=Celecoxib; DIC=Diclofenac; APAP=paracetamol; TRA=tramadol; PBO=placebo; SC=subcutaneous; PO=oral.

## 3.2. Favourable effects

The primary objective of study 1056 was met for all three co-primary outcomes (WOMAC Pain, WOMAC Physical  Function,  Patient  Global  Assessment  (PGA).  The  changes  from  baseline  to  week  16  were statistically significantly different (p&lt;0.05) from placebo for both dose regimens (2.5 mg and 2.5/5 mg).

The primary objective of study 1057 was not fully met for the 2.5 mg dose, although it was met for the 5 mg dose. For tanezumab 2.5 mg, two of the three co-primary outcomes (WOMAC Pain, WOMAC Physical Function) were statistically significantly different (p&lt;0.05) from placebo, although not for the third coprimary endpoint, PGA.

## WOMAC Pain

- At week 16 in study 1056 , the mean (SE) change in WOMAC Pain in the tanezumab 2.5 mg group was -3.2 (0.2) versus -2.6 (0.2) in the placebo group; which was statistically significant with a mean (95%CI) difference of -0.6 (-1.1 - -0.1) and p=0.0129. The proportion with an improvement in WOMAC Pain ≥ 50% (secondary endpoint) was 55% in the tanezumab 2.5 mg and 38% in the placebo group (p ≤ 0.001), which is a difference of 17%.
- At week 24 in study 1057 , the mean (SE) change in WOMAC Pain in the tanezumab 2.5 mg group was -2.7 (0.2) versus -2.2 (0.2) in the placebo group; which was statistically significant with a mean (95%CI) difference of -0.5 (-0.8 - -0.1) and p=0.0088. The proportion with an improvement in WOMAC Pain ≥ 50% (secondary endpoint) was 45% in the tanezumab 2.5 mg group and 34% in the placebo group (p&lt;0.05), which is a difference of 11%.
- At week 16 in study 1058 , the mean (SE) change in WOMAC Pain in the tanezumab 2.5 mg group was -3.2 (0.1) versus -3.1 (0.1) in the NSAID group; the mean (95%CI) difference of tanezumab against NSAID was -0.15 (-0.4 - 0.06) for 2.5 mg (p=0.16). The proportion with an improvement in WOMAC Pain ≥ 50% was 55% in the tanezumab 2.5 mg as compared to 52% in placebo (p&gt;0.05).

The effects in WOMAC physical function were largely similar to the changes in WOMAC pain. Only in study 1056 , the treatment effect in PGA was statistically significant in favour of tanezumab 2.5 mg as compared to placebo.

## Other secondary outcomes

For responses in WOMAC Physical Function (30% or 50% improvement), similar patterns are seen as with  response  in  WOMAC  Pain,  with  responder  rates  for  tanezumab  2.5  mg  that  were  statistically significantly higher than placebo, in both studies 1056 and 1057 .

## Onset of effect

In all three studies, the largest improvements in WOMAC Pain, WOMAC Physical Function, and PGA, in the tanezumab groups, as well as the placebo group, were seen in the first 2 weeks, with a similar

<div style=\"page-break-after: always\"></div>

response in the two tanezumab groups (2.5 and 5 mg) that was larger than placebo. After the first 2 4 weeks, responses remained stable through the treatment periods.

## Maintenance

In study 1057 , the maximum effect was achieved at week 16 (2 doses) and remained stable till 8 weeks after the third (last) dose (Week 24). The treatment effect on pain was shown to be highest in-between the 8 weeks dose intervals, using the pain NRS on the e-diary which was more densely assessed.

In study 1058 the levels of WOMAC pain scores remained more or less stable after 24 weeks with a slight tendency to increase up to week 56.

## Pooled results

The pooled IV (6 placebo-controlled studies pre-2015) and pooled SC (2 placebo-controlled studies post2015)  results  of  the  primary  outcomes  showed  that  the  size  of  the  treatment  effects  on  WOMAC pain/Physical Function and PGA were similar for the 2.5 mg dose over all studies. The steady-state exposure of IV is 1.6 to 1.7 times higher than SC

## Subgroups

There is no indication from subgroup analyses that the treatment effect would be relevantly different in subgroups for age, gender, knee/hip OA, disease severity, or region.

## 3.3. Uncertainties and limitations about favourable effects

## Treatment effect

In study 1057 at week 24, treatment effects for tanezumab 2.5 mg were not statistically significantly different from placebo for one of the three co-primary outcomes (PGA), which was the reason that the primary endpoint was not met.

The primary objective of study 1058 , superiority of both tanezumab doses in three co-primary outcomes (WOMAC Pain, WOMAC Physical Function and PGA) at week 16 versus continuation of prior treatment with oral NSAIDs, was not met. The changes from baseline up to week 16 of the co-primary outcomes were not statistically significantly different for tanezumab 2.5 mg from NSAIDs (p&gt;0.05). The treatment effects of tanezumab 2.5 mg and of NSAIDs were similar for both treatments, and in line what was observed in the active treatment tanezumab 2.5 mg arm in the two placebo-controlled confirmatory trials  (1056  and  1057).  As  there  is  no  placebo  arm  in  Study  1058,  it  is  difficult  to  draw  definite conclusions  regarding  assay  sensitivity,  though  for  tanezumab  5  mg  in  two  of  the  three  co-primary outcomes  (WOMAC  Pain,  WOMAC  Physical  Function)  the  changes  from  baseline  to  week  16  were statistically significantly superior (p&lt;0.05) to NSAIDs.

According to the results of NSAID-controlled study 1058, the effect of tanezumab 2.5 mg appears to be similar to what could be reached with continuing NSAIDs, in patients with an inadequate response to prior  NSAIDs  treatment.  However,  study  1058  was  designed  as  a  superiority  study  and  not  as equivalence or non-inferiority trial. It therefore is impossible to claim that the results of this study can be used to support the proposed broad third-line indication, including patients with insufficient response to NSAIDs.

## 3.4. Unfavourable effects

The safety of tanezumab is studied in a large number of patients with OA, Chronic Low Back pain and healthy volunteers. Of the 9732 patients included, 3932 received at least one SC dose. The safety of 2.5mg tanezumab SC every eight weeks has been investigated in 1604 patients with moderate-to-severe

<div style=\"page-break-after: always\"></div>

OA.  The  safety  database  in  OA  is  considered  sufficiently  large  to  establish  common  adverse  events associated with tanezumab treatment and to compare the long-term safety profile of tanezumab with non-steroidal anti-inflammatory drugs (NSAIDs) which are standard of care for pain in OA.

The  AEs  that  were  more  frequently  reported  for  tanezumab  compared  to  placebo  or  NSAIDs  were arthralgia, nasopharyngitis, fall, headache, OA, joint swelling, rapidly progressive OA (RPOA), peripheral oedema, hypoaesthesia, paraesthesia, burning sensation and carpal tunnel syndrome.

Serious adverse events (SAEs) that were more seen in the tanezumab treatment groups compared to the placebo or NSAID groups during the treatment period were arthralgia, OA and RPOA. The incidence of OA and RPOA was also higher during the follow-up period. Incidence of discontinuation was higher for tanezumab treated patients than for placebo/NSAID treated patients.

## Joint safety

A clear dose-dependent response in the incidence of RPOA was observed in the post-2015 pooled studies; 2.7% for tanezumab 2.5mg; 5.5% for tanezumab 5 mg; 0% in the placebo group, indicating causality. The occurrence of RPOA of this post-2015 pool was 24.3% for tanezumab 2.5mg; 31.1% for  tanezumab 5 mg; 0% in the placebo group and 21.1% in the NSAID group. Also, in the NSAIDs comparator group, the  incidence  of  RPOA  events  was  higher  than  for  placebo  (1.1%)  in  the  pooled  dataset  (indirect comparisons, follow-up for placebo was shorter, 16-24 weeks).

In the long-term active controlled study (1058), the incidence of TJR was 5.3% for tanezumab 2.5 mg, 8% for tanezumab 5 mg, and 2.6% for NSAIDs after approximately one year on-treatment.

In the pooled analyses of the two short-term placebo-controlled studies (study treatment duration 1624 weeks (2 and 3 doses), the incidence of Total Joint Replacement (TJR) was 4.4% for placebo and 5.8% for tanezumab 2.5 mg. These high incidences of TJR in the pooled dataset of the two short-term placebocontrolled studies were mainly drawn by Study 1057 (7.8% in tanezumab 2.5 mg arm and placebo 6.7% in Study 1057, versus 3.5% and 1.7% in the Study 1056, respectively). Patients assigned to placebo, the incidence of TJR also increased in the long-term extension phase. However, for the placebo group, the reason for surgery was elective because of untreated pain, whereas for tanezumab, this was often due to RPOA and bone damage. Most TJR cases in these placebo-controlled studies occurred after the study treatments were discontinued, making it difficult to draw conclusions on causality, in contrast to the long-term treatment Study 1058.

## Nervous system

A dose-dependent response was observed for tanezumab with peripheral abnormal sensations (APS). Paraesthesia and hypoaesthesia were the most frequently reported events in the tanezumab-treated patients compared to placebo/NSAIDS. The number of discontinuations because of peripheral AE's was low, and most cases were self-limiting or resolved after treatment withdrawal. The incidence of AE's was higher in the long-term study compared to the two shorter studies. At week 24, the incidence of APS was about 4-5% for the 2.5 and 5 mg dose. Till Week 56, the incidence of APS increased further to 6.2% for the 2.5 mg dose, and 9.0% for the 5 mg dose

From pre-clinical studies, a signal was found that tanezumab suppresses the orthosympathetic nervous system. Diarrhoea, bradycardia, nausea, and orthostatic hypotension were the most commonly reported events that might be related to a suppressive effect on the orthosympathetic nervous system in the clinical trials. The majority of events was mild. The rates for bradycardia and orthostatic hypotension in the tanezumab treatment groups were slightly higher compared to the placebo treatment group. In placebo-controlled studies with tanezumab SC, the incidence of orthostatic hypotension was 0.2% for placebo, 0.6% for tanezumab 2.5 mg, and 1.1 % for tanezumab 5 mg.

<div style=\"page-break-after: always\"></div>

A total of 33 deaths have been reported (30 on tanezumab treatment, one on NSAID treatment and two on placebo). Over all pools of controlled data, a higher incidence of observation time-adjusted deaths was  observed  for  the  tanezumab  treatment  groups  (ranging  from  2.5-12.3/1000  patient-years) compared to placebo (2.8/1000 patient-years) and NSAIDS (0.5/1000 patient-years) during treatment and up to the end of the study and post-study. Most common cause of deaths in the controlled tanezumab treatment arms (2.5-20mg) were Major Adverse Cardiovascular Events (MACE) (11 out of 24).

## Special populations

Based  on  pre-clinical  findings  on  CNS  development  in  the  offspring,  tanezumab  treatment  is contraindicated during pregnancy. Women with an active pregnancy whish are advised to discontinue tanezumab timely. This is reflected in the SmPC.

## 3.5. Uncertainties and limitations about unfavourable effects

## Joint safety

The clinical development programme has been affected by two partial clinical holds imposed by the FDA due  to  investigator-reported  AEs  of  osteonecrosis  (ON)  and  to  concerns  of  possible  AEs  on  the sympathetic nervous system based on preclinical toxicology findings. Because of the findings of ON, several risk minimisation measures were applied in the post-2015 studies, such as the restriction of concurrent  NSAID  use  (this  increased  the  risk  of  RPOA  significantly  in  the  pre-2015  studies),  the exclusion  of  patients  with  a  high  risk  of  RPOA  and  intense  monitoring  of  structural  joint  damage. However,  these  measures  did  not  prevent  the  occurrence  of  joint  damage  and  rescue  surgery  at tanezumab treatment and this may be difficult to handle in daily practice.

## Mortality and Major Adverse Cardiovascular Events (MACE)

Over all pools of controlled data, a higher incidence of observation time-adjusted deaths was observed for the tanezumab treatment groups compared to placebo/NSAIDs during treatment and up to the end of the study and post-study. MACE cases apparently led to a more fatal course in tanezumab arms, notably due to sudden cardiac death. Cardiovascular compromised patients with NYHA class III and IV were  excluded  from  the  trials,  and  safety  of  tanezumab  is  unclear  in  these  patients.  However,  CV diseases are common in the target population of OA patients.

## Nervous system

Patients with peripheral neuropathy or MS (multiple sclerosis) were excluded from the pivotal trial of tanezumab for osteoarthritis.

## Falls

The rate of falls tended to be higher for tanezumab versus NSAIDs (TNZ 2.5 mg; 6.5%, TNZ 5 mg: 5.3%, NSAIDs: 4.6%) in long-term Study 1058 (56 weeks).

About  one  third  of  the  study  population  consisted  of  elderly  (65  years).  In  pooled  analyses,  for  a composite endpoint consisting of hypotension, falls, black-outs, syncope dizziness, ataxia and fractures, the incidences were the highest for the very elderly (≥75 years) treated with tanezumab 2.5 mg (8%) versus placebo (2.4%) and younger age groups (&lt;65 years) treated with tanezumab 2.5 mg (5.6 6.4%).

There was no clear explanation for the falls. There was no clear relationship between the reported falls and hypostatic hypotension of peripheral neuropathy symptoms. Nevertheless, the increased rates of falling for tanezumab is a concern, particularly in elderly.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 47 Effects Table for tanezumab 2.5 mg administered SC every 8 weeks by a healthcare professional for the treatment of moderate to severe chronic pain associated with OA in adult patients for whom treatment with NSAIDs and/or an opioid is ineffective, not tolerated, or inappropriate

|                      | Short Description                                                                    | Unit                    | Plac                 | Ta 2.5 mg            | Ta 5 mg              | NSAID                | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                        | References                  |
|----------------------|--------------------------------------------------------------------------------------|-------------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Favourable Effects   | Favourable Effects                                                                   | Favourable Effects      | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                                                                                                                                                                                         | Favourable Effects          |
| Pain                 | ≥ 50% improved WOMAC pain bl-w16                                                     | %                       | 37                   | 52                   | 52                   |                      | SoE: p<0.05 against placebo in Pain and Function, size of treatment effects against placebo reproducible and also seen in IV studies. Unc: Difference in WOMAC Pain≥50% response at week 16 is small, with 16% for tanezumab 2.5 mg against placebo; p>0.05 for PGA outcome in study 1057. | 1056 and 1057 pooled        |
| Pain                 | ≥ 50% improved WOMAC pain bl-w16                                                     | %                       |                      | 55                   | 57                   | 52                   | Unc: Study 1058 failed to meet superiority hypothesis in patients with inadequate response to prior treatment with NSAIDs.                                                                                                                                                                 | 1058                        |
| Unfavourable Effects | Unfavourable Effects                                                                 | Unfavourable Effects    | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                       | Unfavourable Effects        |
| RPOA - type 1**      | Loss of Joint Space Width (≥2 mm) within appr. 52W without gross structural failure  | %                       | 0                    | 2.3                  | 4.2                  | 1.0                  | SoE : RPOA not observed with placebo, occurrence increases with dose Unc: Irreversible, suspected sign of more damage                                                                                                                                                                      | 1056, 1057 & 1058 pool (SC) |
| RPOA - type 2***     | Abnormal loss/ destruction of bone normally not present in conventional end-stage OA | %                       | 0                    | 0.4                  | 1.3                  | 0.1                  | SoE: RPOA not observed with placebo, occurrence increases with dose Irreversible joint damage, 50% had TJR in/after studies                                                                                                                                                                | 1056, 1057 & 1058 pool (SC) |
| TJR                  | At least one Total Joint Replacement (95%CI)                                         | %                       | 4.5 (2.9-6.6)        | 5.5 (4.4-6.8)        | 7.8 (6.4-9.4)        | 2.6 (1.7-3.8)        | SoE: Occurrence increases with dose. Unc: high incidences of TJR in the pooled dataset of the two placebo-controlled studies were mainly drawn by Study 1057 (placebo 6.7% and 7.8% in tanezumab 2.5 mg arm, versus 1.7% and 3.5% in the 1056 study, respectively).                        | 1056, 1057 & 1058 pool (SC) |
| MACE                 | Adjudicated Major adverse cardiovascular events                                      | n/N (n per 1000 pt-yrs) | 2/708 (2.8)          | 9/1599 (5.6)         | 8/2039 (3.9)         | 7/1628 (4.3)         | Unc: low risks, possible causality is not clear                                                                                                                                                                                                                                            | OA Controlled studies pool  |

<div style=\"page-break-after: always\"></div>

Abbreviations:

JSW = Joint Space Width, ISS = Integrated Summary of Safety, MACE = Major Adverse Cardiovascular Events, RPOA = Rapidly Progressive Osteoarthritis, 2 mm) within approximately one year according to adjudication committee, RPOA2= abnormal loss/destruction of subchondral bone according to adjudication committee, SC =  Subcutaneous,  SCE = Summary of Clinical Efficacy, TJR = Total Joint Replacements,  WOMAC = Western Ontario

RPOA1= loss of JSW ( ≥ and McMaster Universities Osteoarthritis Index. Notes: RPOA1/RPOA2/TJR: Includes TJR or adjudicated event up to the end of the follow-up period or 26 weeks after the end of the treatment period, whichever is later. * p &lt; .05 ** Incidence of RPOA1 as confirmed by the Adjudication Committee in patients with possible or probable joint related safety events, was 20.8 for tanezumab 2.5 mg, 23.6 for the 5mg treatment group and 19.3 for NSAIDs. *** Incidence of RPOA2 as confirmed by the Adjudication Committee in patients with possible or probable joint related safety events, was 3.5 for tanezumab 2.5 mg, 7.7 for the 5mg treatment group and 1.8 for NSAIDs. MACE: Exposure defined as: a) If subject experienced the event: Time from first IV/SC dose to the date of first occurrence of the event. b) If the subject did not experience the event: Time from first IV/SC dose to the end of treatment visit date for subjects who completed the treatment period or up to the withdrawal from treatment date for subjects who withdrew early from the treatment period. OA Controlled studies pool includes studies: 1011, 1014, 1015, 1018, 1026, 1027, 1030, 1056, 1057, 1017, 1025, 1058 # Neurological Adverse Events are pooled differently by the applicant. Study 1027 is a pre-2015 study which included SC administration of 2.5mg, 5mg and 10mg tanezumab, and is pooled with post-2015 placebo-controlled SC studies 1056 and 1057.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The inclusion criteria are in line with a target population as proposed in the indication regarding disease severity and regarding treatment history.

According to the results of the 16-week (2 doses) and the 24-week (3 doses) placebo-controlled studies and the 16-week results of the NSAID-controlled study, there is evidence that tanezumab 2.5 mg SC has a statistically significant, though small, effect on pain and function, presumably similar in size as the treatment effect of NSAIDs in the third-line population. Because the size of the treatment effect in coprimary outcomes was similar over SC and IV trials, usually significant in all three co-primary outcomes, with a reproducible dose-effect relationship, it is considered that the size of the treatment effects is estimated with sufficient precision and robustness. Statistically significant effects in favour of tanezumab 2.5  mg,  versus  placebo,  were  also  found  in  secondary  endpoints  like  the  WOMAC  Stiffness  and  in averaged daily  pain  ratings,  which  is  considered  supportive.  The  5  mg  dose  was  only  slightly  more effective than the 2.5 mg dose in the placebo-controlled studies, and in the NSAID-controlled study. Given that the risk of joint damage that is associated with tanezumab increased with the dose, the choice of the low 2.5 mg dose in the posology is supported.

## Treatment effects

In study 1057 at week 24, treatment effects for 2.5 mg were not statistically significantly different in PGA, which was the reason that the primary endpoint was formally not met. However, of the three coprimary outcomes, pain and physical function may be considered more important than PGA, according to the EMA guideline for OA. Since PGA is an ordinal scale from 1-5, it may be less sensitive to detect change as compared to the WOMAC scales. Overall, the treatment effects in PGA were of the same magnitude, and statistically significant at week 16, in studies 1056 and 1057. Therefore, it is considered that 'failure' of PGA at week 24 in study 1057 is rather related to the overall small treatment effects in pain, than pointing to no effect, of tanezumab 2.5 mg.

Despite statistical significant treatment effects in Pain and Physical Function, primarily based on the number of patients who become responders according to a change in WOMAC pain ≥ 50% after 16 weeks or 24 weeks of treatment, the clinical relevance of the treatment effects of tanezumab is limited: between 11% and 17% of patients on 2.5 mg in the placebo-controlled studies had a reduction in WOMAC pain ≥ 50%. The differences between placebo and tanezumab were similarly in size for the lower cut-off of ≥30% and similar for response in WOMAC Physical Function. The clinical relevance is considered to be limited. Placed in a framework of NNT, this means that about 7 to 8 patients have to be treated with tanezumab 2.5 mg, instead of placebo, to have one additional patient having a pain response ≥50%.

In a large randomised long-term study in patients with an inadequate response to NSAIDS at inclusion, none of the three co-primary outcomes (WOMAC pain, WOMAC Physical Function, PGA) were statistically significantly superior for tanezumab 2.5 mg over continuation of NSAID treatment. For a good response of at least 50% in pain, 33 patients have to be treated with tanezumab, instead of NSAID, for 1 additional patient with a good response.

Consequently, solely from the efficacy point of view, tanezumab 2.5 mg SC could be preferred over placebo (no treatment) in the target 3rd line population, but there is no clear efficacy advantage of tanezumab over continuation with NSAIDs. It is not totally clear how the (16 week) results of study 1058 comparing  continuation  with  NSAIDs  to  switch  to  tanezumab  do  support  the  proposed  third-line

<div style=\"page-break-after: always\"></div>

indication,  including  patients  with  insufficient  response  to  NSAIDs.  Given  the  limited  benefits  of tanezumab, the appreciation of benefit/risk also relies on valuing the main risks (RPOA, TJR and MACE).

## Posology

The choice for 2.5mg as the proposed dose was driven by safety issues and also justified from an efficacy perspective as the treatment effect of tanezumab 5 mg is only incrementally higher than 2.5 mg.

The proposed dose interval is 8 weeks. From the individual studies, it appears that the dose response curve is 'U' shaped with a length of 8 weeks, with the effect largest in the middle of the dosing interval, and - by 8 weeks on average - the start value has been reached again. This means that the proposed dose interval is appropriate. From the 16-week efficacy follow-up after treatment stop, no meaningful rebound effect is currently apparent.

## Maintenance

Treatment effects of tanezumab appear to be maintained over time, according to the results of study 1058 up to week 56. Because the baseline characteristics and treatment history of the three pivotal studies are similar, it is considered that the long-term results apply to the total target population.

## Clinical relevance

Rescue  medication  (paracetamol)  and  occasional  NSAIDs  for  non-OA  purpose  was  used  by  a  large proportion of patients, but the amounts taken in days of use were limited. Overall there was a tendency for more paracetamol use in the placebo groups. If of any influence, it may have diluted differences of tanezumab  with  the  control  group,  which  is  conservative  and  therefore  not  an  issue  to  be  further addressed.

## Importance of unfavourable effects and the associated uncertainties

The safety of tanezumab was investigated in a large number of patients. The safety profile of tanezumab is characterised by serious adverse events of RPOA, OA, arthralgia and TJR. Given that the risk of severe AEs increases with tanezumab dose the choice for the 2.5mg dose is understood. The safety profiles of the active comparators (NSAIDs, opioids) were in line with the known safety profiles of these substances, supporting the validity of the ADR registration during the trials. The main uncertainty about the safety profile of tanezumab is a signal for MACE, including CV death. Occurrence of RPOA and joint safety risks are certain.

## Joint Safety

The incidence of TJRs is higher in tanezumab treated patients. This is particularly worrisome since chronic treatment with tanezumab is foreseen. The reason for surgery in placebo was mainly elective, driven by untreated pain, whereas for tanezumab, the reason for surgery was more driven by RPOA and bone damage. It should be noted that TJR is not an unlikely outcome for patients with hip or knee OA, with or without tanezumab. However, it must also be considered that it is worthwhile to avoid TJR, or at least delay the operation when possible. Although TJR is a routine surgery, peri-operative complications and septic loosening of the prothesis may occur, however serious complications are rare. Also, joint protheses have a limited life span.

In  the  pre-2015  studies,  concomitant  NSAID  use  with  tanezumab  was  studied.  The  pre-2015  data showed  that  there  was  a  dose-response  between  the  rate  of  RPOA  and  tanezumab  treatment. Concomitant use of tanezumab and NSAIDs further increased the risk (by greater than threefold) of RPOA. This led to several adjustments in the study designs. It was proposed that concomitant NSAID use is restricted to short term use for non-OA reasons.

<div style=\"page-break-after: always\"></div>

In the post-2015 studies, the incidence of RPOA and TJRs was higher in the tanezumab treated patients than in the pre-2015 studies. The post-2015 studies had a higher degree of surveillance, which will naturally lead to more observed adverse events. However, the patient population included in the post2015  studies  was  different,  as  patients  with  evidence  of  risk  factors  for  RPOA  were  excluded,  and therefore less at risk. Strikingly, for NSAIDs treatment, the incidence of joint safety AEs was comparable between the pre- and post-2015 studies, indicating that the preventive measures were not sufficient. The applicant proposed a PASS study for monitoring the development of joint safety. Because of the risk and the lack of data, the presence of X-ray signs of RPOA and joint-level risk factors was considered a contra-indication for tanezumab treatment. No further risk factors were identified, that could be suited for risk-minimisation.

The totality of the findings on joint safety, including TJR, are of great concern, also at the low 2.5 mg dose,  the  proposed  posology.  The  benefits  of  a  chronic  symptomatic  treatment,  which  potentially progresses  the  underlying  disease,  are  not  considered  sufficient  to  counterbalance  the  observed beneficial effects.

## Mortality and MACE

The higher incidence of observation time-adjusted deaths in the tanezumab treatment group compared to placebo/NSAIDS is of concern. The majority of death cases were due to MACE. Although the incidence was  low,  the  signal  was  consistent,  and  the  studies  were  highly  powered.  MACE  is  included  as  an important potential risk. In addition, it is proposed as an endpoint in the PASS to further characterise the potential risk in the general target population.

Although the PASS could be supported, there is a small but consistent signal of MACE in the studies, which cannot be ignored in establishing the B-R balance. The selected study populations were not fully representative for the general target population which might be at higher risk (e.g. patients with NYHA Class III and IV were excluded). The proposed indication includes of patients with a contra-indication for NSAIDs -and who may be candidates for opioids which are neither warranted- are not considered a good option to mitigate risks, as this will select patients at higher risk for MACE. Thus, potential risk of MACE impacts negatively on B/R assessment.

## Nervous system

Adverse events of abnormal peripheral sensations were commonly reported for tanezumab treatment, which could be expected given the nature of the drug, targeting NGF. In general, these AEs were mildmoderate and reversible, and rarely lead to treatment withdrawal in the trials. Nevertheless, a warning and guidance is provided in the SmPC, because of the novelty of this drug, particularly regarding the course of these events and when recovery is to be expected after treatment withdrawal. A warning is included not to use the product in patients with pre-existing peripheral neuropathy or MS, due to limited experience in these patients at risk.

## 3.7.2. Balance of benefits and risks

The unmet medical need to treat pain in osteoarthritis is recognised, especially for patients for whom NSAIDS or tramadol are insufficiently effective or not appropriate. The proposed indication (moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal  anti-inflammatory  drugs  (NSAIDs)  and/or  any  opioid  is  ineffective,  not tolerated or inappropriate) indicates a third-line treatment after NSAIDs or opioids.

The study populations were in line with the target population as proposed in the indication, regarding hip/knee OA, disease severity, and treatment history.

<div style=\"page-break-after: always\"></div>

Tanezumab 2.5 mg SC was shown to have a statistically significant, though limited, effect on pain and function  versus  placebo.  There  was  no  subgroup  for  whom  the  treatment  effect  would  be  larger. Moreover,  given  absence  of  superiority  of  tanezumab  treatment  as  compared  to  continuation  with NSAIDs in patients with inadequate response to NSAIDs at inclusion, it is unclear how these results support the proposed broad third-line indication.

The increased risk of joint damage (RPOA) for tanezumab, including higher incidence of TJR and an earlier need for TJR surgery, is of great concern, even at the low 2.5 mg dose. Surgery is reserved for patients for whom non-pharmacological and pharmacological treatments are not helpful or no option. Also due to the limited life-span of joint prothesis, it is important to try to postpone this surgery.

Compared with NSAIDs, the safety profile of tanezumab is less favourable regarding the risks of RPOA and TJR. In addition, a risk of MACE including fatalities could not be excluded for tanezumab either. The benefit/risk balance of tanezumab for special patients' groups with limited treatment options, such as a contra-indication for NSAIDs, is also not favourable as this will select patients at higher risk for MACE.

Figure 30 Numbers needed to treat and numbers needed to harm, tanezumab versus placebo and Tanezumab versus NSAID (made by assessors)

|           | Tanezumab vs Placebo            | Tanezumab vs Placebo            | Tanezumab vs Placebo   | TanezumabvsNSAiD   | TanezumabvsNSAiD   |
|-----------|---------------------------------|---------------------------------|------------------------|--------------------|--------------------|
|           |                                 | Per 100 pts                     | Per 1000 pts           | Per 100 pts        | Per 1000 pts       |
| NNT       | 7-8                             | 13                              | 133 33                 | 3                  | 30                 |
| NNH (JS)  | 32                              | 3 30                            | 56                     | 2                  | 20                 |
| NNH (TJR) | Could not bereliablecalculated* | Could not bereliablecalculated* | 37                     | 3                  | 30                 |

To conclude, the benefit-risk balance of tanezumab in the treatment of 'moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with nonsteroidal anti-inflammatory drugs  (NSAIDs)  and/or  any  opioid  is ineffective, not tolerated or inappropriate'  is  considered  to  be negative .  The  small  positive  effect  of  tanezumab  in  this  patient population on joint pain, physical function, and patient global assessment of OA does not outweigh the safety risks  in terms of an increased risk of developing rapidly progressive osteoarthritis, which may lead to joint replacement, and a probable higher risk for major adverse cardiovascular event.

This  is  considered  for  both  the  comparisons  of  tanezumab  versus  placebo,  and  tanezumab  versus NSAIDs. This also means that benefit/risk is not positive in a subgroup of patients, such as those with contra-indications to NSAIDs.

## 3.7.3. Additional considerations on the benefit-risk balance

## Patient preference study

The applicant has performed a patient preference study (discrete choice experiment) that, together with clinical data from the SC studies, was input to a quantified Benefit/Risk assessment (multicriteria decision analysis). Participants were patients with OA and Chronic low back pain from the US and the UK. Central

<div style=\"page-break-after: always\"></div>

treatment attributes were pain relief and key adverse events: severe joint problems that may require total joint replacement (tanezumab risk), heart attack (NSAID risk), and dependence (opioids risk).

According to the patient preference study, the participants preferred better pain/symptom control and avoiding the risk of dependence over avoiding severe joint problems or heart attack. (Achieving pain and symptom control was 10 times more important than avoiding severe joint safety problems. Avoiding dependency was ~7.4 times more important than avoiding severe joint problems.) Given the relatively large  weight  participants  placed  on  pain/symptom  relief  and  on  avoiding  dependence  of  opioids, treatment with tanezumab was preferred (higher weighted net BR score) over NSAID, no treatment (placebo) and opioids, in that order (Figure 31).

Figure 31

<!-- image -->

Figure 6 from Pfizer's Quantitative Benefit-Risk analysis of tanezumab for moderate to severe osteoarthritis report.

According to the net Benefit/Risk analysis using the patient preferences (Figure 31), the net B/R score was rated higher for tanezumab than for NSAID and rated lowest for opioids. The difference between tanezumab and NSAID in net B/R score appears as small and is explained by an advantage for tanezumab in CV safety (blue) and the small contribution of RPOA (yellow). The contribution of joint safety/avoidance of RPOA (yellow) was relatively low, due to the combination of low preference and low occurrence. The differences in CV safety contribution in disadvantage of NSAID is in line with non-fatal MI a priori being the main safety AE of NSAIDs in general.

The above analysis did not consider a higher incidence for MACE, including sudden death, for tanezumab as compared to NSAID. The applicant has therefore submitted a sensitivity analysis of the previously submitted Quantitative Benefit/Risk analysis using patient preferences. The occurrence of non-fatal MI was replaced by the occurrence of MACE, and analysis was performed using patient preferences of the subgroup of patients with contra-indications or medical inappropriateness of NSAID. It is considered that according  to  these  sensitivity  analyses,  from  the  patient  perspective  there  appears  to  be  rather  an indifference in weighted net Benefit/Risk between tanezumab and placebo, and tanezumab and NSAIDs.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Raylumis is negative.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Raylumis in the treatment of osteoarthritis, the CHMP considers by consensus that

[a] safety and efficacy of the above-mentioned medicinal product is not sufficiently demonstrated, and, therefore recommends the refusal of the granting of the marketing authorisation for the abovementioned medicinal product. The CHMP considers that:

Whereas

- The increased risk of joint damage (rapid progressive osteoarthritis, and a higher incidence of total joint replacement with an earlier need for total joint replacement) is of great concern. Furthermore,  a  risk  of  MACE,  including  fatalities,  cannot  be  excluded.  Risk  minimisation measures, such as a contra-indication for patients with X-ray signs of RPOA and limited use of concomitant NSAIDs, are not considered sufficient to minimize the identified risk for RPOA. Restriction of the indication to a subgroup with limited treatment options, such as a contraindication for NSAIDs, is not considered acceptable, as this will select patients at higher risk for  MACE. Therefore, the safety of Raylumis in the claimed indication was not sufficiently demonstrated.
- Tanezumab 2.5 mg SC was shown to have a statistically significant, though small, effect on pain and function versus placebo. However, the effect was of limited clinical relevance. Also, there  was  no  patients'  subgroup  identified  for  whom  a  larger  treatment  effect  was demonstrated. Moreover, given the absence of superiority of tanezumab treatment compared to continuation with NSAIDs in patients with insufficient response to NSAIDs at inclusion, the proposed third-line indication is not supported.

The modest positive effect size of tanezumab in the claimed indication, or a subset of the patient population from the claimed indication, does not outweigh the medicinal product's joint related safety risks and a potential identified risk for MACE.

In conclusion, the benefit-risk balance of tanezumab in the treatment of 'moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal  anti-inflammatory  drugs  (NSAIDs)  and/or  any  opioid  is  ineffective,  not  tolerated  or inappropriate' is considered to be negative.

Due to the aforementioned concerns a satisfactory summary of product characteristics, labelling, package leaflet, pharmacovigilance system, risk management plan and follow-up measures to address other concerns as outlined in the list of outstanding issues cannot be agreed at this stage.

Furthermore, following review of the available data in the context of the applicant's claim of new active substance status, the CHMP position at the time of this report is reflected in section 2.9 (new active substance). However, in light of the negative recommendation, the CHMP is of the opinion that it is not appropriate to conclude on the new active substance status.